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Summary
Beside the well-known role of CRH and CRH-related peptides in controlling HPA axis,
the peptides have been implicated as important mediators various physiological
processes including reproduction, endocrinology of pregnancy, energy homeostasis.
Diverse functions of CRH and UCNs are governed via activation of two types of CRH
receptors, R1 and R2.
Since tissue sensitivity to agonists is determined by the availability of receptor in the
plasma membrane and how fast the signal is terminated, one of goals of this project
was to investigate the cellular expression of CRH-R1 variants (α, β, d and β/d), and 
internalization characteristics of the receptors following homologous and heterologous
activation of the receptor. Also, I investigated the structural and functional
characteristics of the CRH-R1d receptor, a splice variant that contains deletion of 14
amino acids within the 7th TMD. The co-expression studies utilizing HEK293 cells
expressing CRH-R1d and CRH-R2β demonstrated attenuation of CRH-R2β mediated 
cAMP production and MAPK activation in the presence of CRH-R1d. This could be of
potential importance in human peripheral tissues which express both types of CRH
receptors, such is uterus. Additionally, I investigated the signalling and internalization
characteristics of CRH-R2β and explore the possible link between the CRH-R2 
internalization and MAPK activation. The analysis of the spatio-temporal
characteristics of MAPK activation revealed important differences between CRH-R1
and R2 mediated signalling cascades. Immunofluorescence analysis demonstrated that
activation of both type of CRH receptors led to a recruitment of β-arrestin to the plasma 
membrane; however the internalization pathways of the receptors were different.
Since human pregnancy is associated with changes in the myometrial CRH-R variant
expression profile and functional activity, as a part of the study, I characterised the
effect of IL-1β (an important mediator of the onset of labour) on the regulation of CRH-
R1 gene expression and the functional properties of the CRH-R. Data showed that IL-1β 
can potentially target CRH-R1 gene transcription and splicing mechanisms of the CRH-
R1 gene; these interactions appeared to involve two members of the MAPK family of
proteins, ERK1/2 and p38 MAPK and NF-κB activation. Interestingly, increased CRH-
R1 gene transcription and generation of receptor splice variants was not associated with
increased CRH-R protein levels and CRH signalling activity. Furthermore, the
signalling characteristics of CRH-R activated by UCN-II (CRH-R2 specific agonist)
were investigated. The data showed that activation of CRH-R2 did not lead to cAMP
production which is associated with the quiescent state of uterus, but the MAPK
signalling cascade was activated, which have been implicated in mediating pathways
that promote contractility.
During the course of this project biological role of CRH receptors was investigated in
T37i cells. RT-PCR analysis showed the presence of CRH-R1 and R2 mRNA in mice
brown adipose tissue and T37i cells. Immunofluorescence and western blot analysis
demonstrated the presence of CRH-Rs in T37i cells. The functional capacity of adipose
CRH-Rs to activate adenylyl cyclase and MAPK signalling cascade was assessed. Low
concentration of agonists (close to receptors Kd=1 nM) stimulated activation of
adenylyl cyclase/cAMP/PKA signalling cascade resulting in lipolysis. However; higher
concentration (10-10 nM) of agonists activated MAPK signalling cascades.
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1 INTRODUCTION
1.1 The corticotropin-releasing hormone (CRH)
Since the discovery of corticotropin releasing hormone or factor (CRH or CRF),
a 41-amino acid peptide, in the early 1980s (Vale W et al, 1981), it has become evident
that physiological role of CRH is much wider than initially thought. Primary function
of CRH is to stimulate the secretion of adrenocorticotropinc hormone (ACTH) from the
anterior pituitary, which induces the release of adrenal glucocorticoids. The release of
glucocorticoids represents the final stage in the hypothalamic-pituitary-adrenal axis
(HPA axis) which mediates the endocrine response to stress (Swanson LW et al.,
1986). Furthermore, CRH has been linked with chronic anxiety disorder, melancholic
and atypical depression, chronic pain and fatigue states, sleep disorders, addictive
behaviour, acute and chronic neurodegeneration, allergic and autoimmune
inflammatory disorders, the metabolic syndrome, gastrointestinal diseases, and pre-
term labour (Grammatopoulos DK & Chrousos G, 2002).
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1.1.1 The family of CRH-related peptides
Since the early 1980s, the family of CRH-related peptides has rapidly expanded
to include mammalian urocortin (UCN), urocortin II (UCNII) (also known as
stresscopin-related peptide-SRP), and urocortin III (UCNIII) (also known as
stresscopin-SCP), as well as fish urotensin I and frog sauvagine (Svg) (Vaughan J et
al., 1995; Reyes TM et al., 2001; Lewis K et al., 2001; Hsu SY & Hsueh AJ, 2001). All
of these peptides appear to share an ancestral peptide precursor. Mammalian CRH
shares approximately 50% homology to sauvagine and urotensin I. UCN is a 40 amino
acid peptide with 45% homology in amino acid sequence to CRH, 63% to urotensin,
and 35% to sauvagine. Additionally, UCNII shows 34% homology to human/rat CRH
(h/r CRH) and urotensin, 43% homology to human UCN (hUCN), 37-40% homology
to UCNIII, and minimal homology to sauvagine (15%) (Dautzenberg F & Hauger R,
2002).
Both UCNs and CRH are synthesised as precursors and are subsequently
processed to the mature bioactive peptides (Vale W et al., 1997). CRH derives from a
196-amino acid precursor highly conserved among mammalian species. The CRH gene
contains only two exons separated by a short intron. The mature peptide sequence is
entirely encoded by the second exon (Hillhouse EW & Grammatopoulos DK, 2006).
CRH and CRH-related peptides are differently distributed in the brain and
periphery highlighting the importance of the peptides in different physiological
processes such as stress adaptation, learning, memory, glucose metabolism and energy
balance (Dautzenberg F & Hauger R, 2002; Hsu SY & Hsueh AJ, 2001).
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1.1.2 CRH and CRH-related peptides action
1.1.2.1 The pituitary and extrapituitary action of CRH and CRH-related
peptides
The core of the neuroendocrine system is represented by the hypothalamic-
pituitary complex. CRH was isolated for the very first time from ovine hypothalamic
extracts in 1981 by Vale (Vale W et al., 1981). Produced in the hypothalamus CRH,
reaches the pituitary gland via the portal vessels, where it controls the secretion of
peptides derived from pro-opiomelanocortin (POMC). POMC, a 241 amino acid
precursor polypeptide, can be enzymatucally cleaved into: ATCH and β-lipotropin (β-
LPH) in the anterior pituitary gland; and corticotropin-like intermediate lobe peptide
(CLIP), γ-LPH, α-MSH and β-endorphin in the intermediate lobe. Each of these 
peptides is packaged in large dense-core vesicles that are released from the cells by
egocytosis in response to appropriate stimulus. ACTH, released upon CRH stimulation,
induces the release of adrenal glucocorticoids; this represents the final stage in the
activation of hypothalamic-pituitary-adrenal axis (HPA), which mediates the endocrine
response to stress.
Figure 1. 1 Schematic representation of POMC prohormone. (Adapted from
Copper JR et al., 1991)
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However, the action of CRH does not stop here; CRH and related peptides play
a fundamental role in the coordination of behavioural, endocrine, autonomic,
cardiovascular and immune responses to stress. Independently from the stimulatory
effects on glucocorticoid secretion, CRH also induces anxiogenic effects, increases
cardiovascular activity, induces anorexia, and inhibits luteinizing hormone-releasing
hormone (LHRH) secretion (Ojeda SR, 2004). The extrapituitary action of UCN is in
influencing feeding, anxiety, and auditory processing. Moreover, UCN is a more potent
suppressor of feeding behaviour than CRH; additionally, it also has more potent effects
on the cardiovascular system than CRH, suggesting that UCN might play a crucial role
in the cardiovascular response to stress possibly through involvement of the CRH type
2 receptor (CRH-R2). On the other hand, UCNII decreases feeding behaviour and
appears to play a role in delaying gastric emptying (Ojeda SR 2004).
The CRH action on the immune response to stress is very complex. As
mentioned above, CRH POMC production in the pituitary; the release ATCH and
ATCH-induced cortisol have anti-inflammatory action on circulating immune cells. In
contrast, when CRH is released into local tissue beds, from either peripheral nerve
endings or immune cells, the action of CRH is pro-inflammatory; it stimulates the
production of IL-1, TNF-α and other pro-inflammatory cytokines, promotes neutrophil 
influx, but also acting through β-endorphin can enhance natural killer cells activity and 
reduce pain. This distinctive CRH action in different tissues is called “context-
dependent” action, quite common phenomenon among cytokines and neurohormones
(Munford RS, 2004).
INTRODUCTION
5
1.1.2.2 CRH and CRH-related peptides action in pregnancy
CRH and related peptides play an important role in implantation and
endocrinology of pregnancy. CRH, produced by the trophoblast, promotes blastocyst
implantation and facilitates immune tolerance of the early pregnancy by killing
maternal activated T cells (Carr, BR and Rehman, KS, 2004). Placentaly derived CRH
increases in maternal serum throughout pregnancy and peaks during labour and
delivery. Levels of CRH at term may be 50- to 100-fold higher than those in non
pregnant women. There is also an increase in carrier protein, CRH-binding protein
(CRH-BP), which binds CRH and may blunt the increase in CRH biological activity.
Elevated levels of maternal plasma CRH have been found in women in preterm labour
who are destined to deliver within 24-48 hours, compared with those who continued
pregnancy despite threatened preterm labour (McLean, M et al, 1995). Although the
biological role of CRH remains enigmatic, the presence of functional CRH receptors in
the myometrium suggests that CRH might modulate myometrial contractility and hence
parturition. CRH action is mediated via multiple receptor subtypes, these receptors are
primarily coupled to adenylyl cyclase second messenger system, which promotes
quiescence. CRH can exert further actions such as inhibition of prostaglandin
production to prevent contractions. Grammatopoulos and Hillhouse have postulated a
hypothesis that at term under the influence of oxytocin, there is a modification in the
coupling mechanism that leads to a decrease in the biological activity of the CRH-R
and in the generation of cAMP favours myometrial contractility. Additionally, CRH,
via distinct receptor subtype, is then able to enhance the contractile response of the
myometrium (Grammatopoulos DK & Hillhouse EW, 1999). Moreover, the findings
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that pregnant and non-pregnant myometrium have a different CRH receptors profile
supports this hypothesis (Sec. 1.3.1). Also, in favour of this hypothesis, there is a
founding that UCNII action via CRH-R2 promotes phosphorylation of myosin light
chain (MLC) leading to increased contractility (Karteris E et al, 2004).
1.1.2.3 CRH and CRH-related peptides action in metabolism and energy
homeostasis
Beside the well-known role of CRH and CRH-related peptides in controlling
HPA axis, the peptides have been implicated as important mediators of metabolism and
energy homeostasis. Administration of CRH into the paraventricular nucleus, promotes
state of negative energy balance and weight loss (Schwartz MW et al., 1999), including
suppression of food intake (Arase K et al., 1988), coupled with stimulation of sympatic
nervous system (SNS) outflow (Arase K et al., 1988; Egawa H et al., 1990), which
increases lipolysis (Egawa H et al., 1990) and activates brown adipose tissue (BAT)
lipolysis (Rothwell N, 1989). Additionally, chronic central CRH administration reduces
food intake and body mass in normal rats (Arase K et al., 1988), genetically obese rats
(Arase K et al., 1989), and primates (Glowa J & Gold P, 1991). Recently, Kotz and
colleges have demonstrated that during food restriction, UCN in the paraventricular
nucleus (PVN) increases plasma leptin and uncoupling protein 1 (UCP-1) in brown
adipose tissue and decreases UCP-3 gene expression in muscles, which might have
important consequences for thermogenesis (Kotz CM et al., 2002), suggesting that the
CRH system could be a potential target for anti-obesity drugs. Additionally, it has been
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reported that CRH receptors are expressed in human adipose tissue (Seres J et al.,
2004), and that adipocytes synthesize UCNII and UCNIII (“natural” ligands of CRH-
R2). A resent report by Wellhoner and colleges (Wellhoner P et al., 2006) highlighted
the in vivo effects of CRH on femoral adipose tissue metabolism. They have found that
the administration of iv CRH leads to increased levels of interstitial and plasma
glycerol suggesting stimulated lipolysis. Additionally, the report describes the effect of
CRH on glucose levels, which do not change in plasma, but the interstitial glucose
increase biphasically; suggesting potential effects of CRH on glucose transport
(Wellhoner P et al., 2006).
Moreover, the CRH system is present in the pancreas and could modulate the
insulin and glucagons secretion, thus controlling glucose blood levels. Also it has been
demonstrated that UCNII null mice display increased glucose uptake in skeletal muscle
through the removal of UCNII-mediated inhibition on insulin signalling (Chen, A. et
al. 2006). Since UCNs have higher affinity for CRH-R2 than CRH and from the fact
that UCNIII does not bind to CRH-R1, it is likely that these metabolic and homeostatic
actions could be mediated via actions of CRH-R2 (section 1.3.2)
1.2 CRH-Binding Protein (CRH-BP)
CRH-BP, a 37 kDa binding protein for CRH, was purified from human plasma in
the late 1980s (Orth DN & Mount CD, 1987; Behan DP et al., 1989). The human CRH-
BP has been cloned and mapped to the distal region of chromosome 13 and locus 5q in
the mouse and human genomes (Behan DP et al., 1993). The CRH-BP three-
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dimensional structure has not yet been identified. Photoaffinity labelling experiments
indicated that, although the human CRH-BP had previously been observed to dimerize
after association with the ligand, the rCRH-BP was found to dimerize, in part, and be
exclusively bound to the ligand as a monomer (Woods RJ et al., 1996). Additionally,
the sequence of 23-36 amino acid residues of CRH-BP was found to be involved in
ligand-binding site of human/rat CRH (h/rCRH) (Woods RJ et al., 1996).
CRH-BP has the ability to modulate the bioactivity of CRH suggesting that this
protein may be an important regulator of the HPA axis (Linton EA et al., 1990). A
CRH-BP cleavage product, with molecular weight of 27 kDa, has been identified in the
synovial fluid (Woods RJ et al., 1999), which binds with the same affinity as the intact
CRH-BP to CRH. However, the role of this cleavage product has not yet been
determined.
Urocortin is also bound to CRH-BP (Vaughan J et al., 1995). Interestingly, CRH-
BP binds CRH and UCN-I with picomolar affinity, approximately 5-fold higher the
affinity of either peptide for the CRH-Rs (Huising MO et al., 2007). It has been
reported that the two arginines Arg-23 and Arg-36 are the sites of photoincorporation
of mono- and bifunctional probes, suggesting that these residues are involved in ligand
binding (Jahn O et al., 2002). However, a resent report suggested that the mutation of
Arg-23 and Arg-36 to alanine did not have an effect on CRH nor UCN-I binding to
CRH-BP (Huising MO et al., 2007). In addition, it has reported that CRH-BP binding
affinity for CRH and sauvagine (Svg) differs by two orders of magnitude and if a single
amino acid residue on both peptides was identified as a responsible for different
binding affinities (Eckart K et al., 2001). The authors demonstrated that Ala-22 of CRH
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was responsible for this peptide high affinity binding, and that Glu-21 located on the
equivalent position of Svg prevented high affinity binding to CRH-BP. Additionally, it
has been demonstrated that exchange of these two amino acids serve as a switch
enhancing or preventing the binding of the h/rCRH and sauvagine, to the CRH-BP and
the receptor (Eckart K et al., 2001).
1.3 The CRH receptor (CRH-R)
Signals from CRH and CRH-related peptides are transduced across cell
membrane via activation of the two types of CRH-receptors (CRH-R), termed R1 and
R2, which are encoded by different genes (Hillhouse EW et al., 2002). A third type of
CRH receptor was identified in fish (Arai M et al., 2001). CRH-R1 gene is located on
the long arm of chromosome 17 at 17q12-q22 (Vamvakopoulos NC & Sioutopoulou
TO, 1994) whereas the CRH-R2 gene is located on the short arm of chromosome 7 at
7p21-p15 (Meyer AH et al., 1997). Structurally, CRH-R1 and R2 are approximately
70% identical at the amino acid level, but exhibit considerable divergence at the N-
terminus, consistent with their distinct pharmacological properties. The CRH receptor
sequence contains multiple potential phosporylation sites for second messenger
kinases, casein kinase II, identical in both receptor types (Chen R et al., 1993).
Modulation of CRH receptor function by G-protein coupled receptor kinase (GRK3)
has been recently showed (Dautzenberg F, 2001).
The receptors belong to the class II (B) superfamily of G-protein coupled
receptors (GPCR), which all contain seven transmembrane helical domains and share
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considerable sequence identity with one another especially in the transmembrane
domains and intracellular loops. All class B receptors possess a large extracellular
domain (ECD) with which they bind with high affinity to the C-terminal regions of
their peptide ligands. This interaction on its own is not sufficient to stimulate coupling
of the receptor to G-proteins, but, a second interaction between the juxtamembrane
domain of the receptor and the first few residues within N-terminal portion of the
ligand has to occur (Perry SJ et al., 2005). Upon agonist binding, GPCRs change their
structural conformation and transduce signals across cells mainly through activation of
heterotrimeric G-proteins, which regulate a diverse network of intracellular systems
(Hillhouse EW and Grammatopoulos DK, 2006). Beside CRH receptor other members
of the B superfamily are the calcitonin, parathyroid hormone (PTH), pituitary adenylyl-
cyclase-activating peptide (PACAP), growth-hormone-releasing hormone (GHRH),
glucagon, glucagone-like peptide (GLP), and secretin receptors.
CRH-R are widely distributed in the central nervous system and in a variety of
peripheral tissues, including the immune, cardiovascular and reproductive systems,
adrenals, lungs, liver, pancreas, small intestine, stomach, skin, and also in some types
of human tumours such as melanomas and corticotrope tumours (Suda T et al. 1993;
Hillhouse EW & Grammatopoulos DK, 2006) .
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1.3.1 The CRH-R type 1 (CRH-R1)
The CRH receptor type 1α (CRH-R1α), cloned from human pituitary cell 
tumour, is a 415-amino acid protein (Chen, R. et al. 1993). On the bases of the cDNA
sequence coding for the CRH-R1α, the receptor is predicted to have a molecular weight 
of approximately 44 kDa (Chen R et al., 1993). There appear to be five putative N-
glycosylation sites (Asn-Xaa-Ser/Thr) in the N-terminus (Chen R et al., 1993).
Differential post-translational glycosylation events might be responsible for the
differences shown between CRH-R molecular weight. CRH-R1 in pituitary and human
reproductive tissues was detected as 75 kDa (Hillhouse EW et al., 1993), fetoplacental
receptor as 55 kDa (Karteris E et al., 1998), while human, monkey and rat cerebral
cortex receptor as 58 kDa protein (Grigoriadis DE and DeSouza EB, 1989).
In most mammals, the fully active CRH-R1 protein arises from transcription of
all 13 exons present within the CRH-R1 gene sequence. However, only in humans the
CRH-R1 gene contains 14 exons and the complete gene product is 444-amino acid
protein; this isoforms is termed R1β. This insertion interferes with the signal 
transduction and reduces the coupling efficiency to adenylyl cyclase by 100-fold
(Xiong Y et al., 1995). However, this receptor isoform is still able to internalize
(unpublished data). Moreover, several other splice variants of the mRNA for this
receptor have been identified, which might encode different isoforms, termed R1c-n
(Grammatopoulos DK & Chrousos G, 2002) (Table 1.1 and Figure 1.2). The protein
sequence of splice variants predicts receptors with amino acid inserts or various
deletions in the N-terminus, C-terminus, intracellular loops, or transmembrane
domains. Moreover, CRH-R1e1 and R1h are predicted to be soluble isoforms
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(Pisarchik A & Slominski A, 2002). These different isoforms would be expected to
show different degrees in the efficiency of agonist-binding and varying signalling
capability.
Regarding the receptor pharmacology, CRH-R1 binds CRH, UCN, urotensin I
and sauvagine, with approximately equal affinity, but does not recognize UCN II or III.
CRH-R1 mRNA was found in high levels in the forebrain, cerebellum, septum, and
amygdale, the anterior and intermediate lob of the rat pituitary, and with only low
expression levels in thalamic and hypothalamic nuclei (Potter E et al., 1994; Chalmers
DT et al., 1995). There is also evidence suggesting the presence of functional CRH
receptors in the mouse spleen (Webster EL et al., 1989). CRH receptor binding sites
were localised on resident spleenic macrophages but not T or B lymphocytes (Webster
EL & DeSouza EB, 1988). These findings suggest that CRH may play a
physiologically significant role in regulating immune responses mediated by
macrophages, such as chemotaxis, phagocytosis, and antigen presentation.
Additionally, CRH-R1 expression was found in the mouse and human skin (Slominski
A et al., 1995; Ermak G and Slominski, 1997), human leukemic mast cells, rat
mammary carcinoma and melanocarcinoma cells, suggesting a possible explanation for
the CRH proinflammatory effects (Tjuvajev J et al., 1998; Sato H et al., 2002).
Furthermore, the CRH-R1, R1d and splice variants- e, f, h, j, k, m, and n- were found
to be differentially expressed in hamster pituitary, eye, spleen, heart, human and mouse
skin, and four human melanoma cell lines (Pisarchik A & Slominski AT, 2001).
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CRH-R1 subtype Structural characteristics References
R1α (415 aa) Contains 13 exons Chen R et al, 1993
R1β (444 aa) Exon insertion after exon 5,
CRH-R1 with extra 29 aa in the
first IC loop
Chen R et al, 1993
R1c (375 aa) Exon 3 deletion, CRH-R1 with
40 aa missing from the N-
terminus
Ross PC et al, 1994
R1d (401 aa) Exon 12 deletion, CRH-R1 with
14 aa missing from the seventh
TMD
Grammatopoulos DK et
al, 1999
R1e (194 aa and
240 aa)
Exon 3 and 4 deletion, frame
shift, two potential reading
frames
Pisarchik A et al, 2001
R1f (370 aa) Exon 11 deletion, frame shift Pisarchik A et al, 2001
R1g (341 aa) Exon 10, 27bp of exon 9 and
28bp of exon 11 deletion
Pisarchik A et al, 2001
R1h (145 aa) Cryptic exon insertion after
exon 4, translation terminator
Pisarchik A et al, 2001
Table 1.1. Structural and splicing characteristics of CRH-R1 subtypes
Figure 1.2 CRH-R1 isoforms. The presented receptor is CRH-R1α, and the 
other isoforms are compared to CRH-R1α (adapted from Grammatopoulos DK 
& Chrousos G, 2002).
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Furthermore, CRH specific binding sites have also been demonstrated in the
male reproductive system. In the female reproductive system, CRH receptor expression
has been shown in a number of tissues, reinforcing the evidence for a significant CRH
function during pregnancy and other reproductive events. In particular, it has been
shown that CRH-R1 receptors are expressed in the human endometrial epithelial
(Papadopoulou N et al., 1998) and stromal cells (Di Blasio AM et al., 1997), indicating
a role for locally produced CRH in the physiological events of the endometrium. The
CRH-R1 mRNA has also been found in the human ovary, located exclusively in the
thecae cells of mature follicles and moderately in small antral follicles, suggesting an
autocrine and paracrine regulatory role for CRH in steroidogenesis and a possible
implication in the aseptic inflammatory processes of ovulatory events (Asakura H et
al., 1997). The specific receptor subtype CRH-R1 mRNA and protein were detected in
the human placenta and fetal membranes (Karteris E et al., 1998). Two CRH-R1
isoforms, R1 and the C splice variant, were identified in the syncytiotrophoblasts of
the placenta and the amniotic epithelial cells of the foetal membranes. Additionally,
the presence of CRH R1d splice variant expression has been found in the foetal
membranes (Grammatopoulos DK et al., 1999d). Furthermore, seven subtypes of the
CRH receptors were found in the human pregnant myometrium at term before the onset
of labor, R1, R1, R1c, R2, R2, and R (Grammatopoulos DK et al., 1998a), and
the splice variant R1d (Grammatopoulos DK et al., 1999d), whereas only three
subtypes, R1, R1 and R2were found in the non-pregnant myometrium. This data
demonstrates a differential expression pattern of the CRH receptor during pregnancy
and suggests that CRH acting via different receptor subtypes might be able to exert
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distinct actions on the human myometrium in the pregnant, compared to the non-
pregnant state (Grammatopoulos DK et al., 1998a).
1.3.2 The CRH-R type 2 (CRH-R2)
A distinct gene encodes the type 2 CRH receptor. There are very large regions
of amino acid identity between the CRH-R1 and CRH-R2 particularly between the
transmembrane domains (TMDs) five and six. This similarity underlies the
conservation of second messenger function, since this 3rd intracellular loop region is
presumed to play an important role in G protein coupling (Chalmers DT et al., 1996).
However, the CRH-R2 gene exhibits a completely different splicing pattern compared
to CRH-R1. This gene has three mRNA splice variants, termed R2α, R2β, and R2γ. All 
three variant mRNA are produced by the use of an alternative 5’ exon 1 that splice onto
a common set of downstream exons, resulting in R2 variants, with identical
transmembrane and C-terminus domains. Therefore, the variants differ only in their N-
terminal expracellular domains; CRH-R2α has 34-amino acids at the N-terminus, 
which are replaced by 61-amino acids to form the CRH-R2β or 20-amino acids to form 
the CRH-R2γ (Hillhouse, EW & Grammatopoulos DK, 2006) (Figure 1.3). Both CRH-
R2α and R2β have five potential glycosylation sites, which are analogous to those 
found in CRH-R1. The third splice variant, CRH-R2γ, has only four potential 
glycosylation sites (Kostich WA et al., 1998). In adenylyl cyclase activation assay,
urocortin and sauvagine, appeared 10-fold more potent at the CRH-R2β than R2α or 
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R2γ, suggesting that the N-terminus of the receptor is responsible for the ligand-
receptor interaction (Kostich WA et al., 1998).
Interestingly, by contrast to CRH-R1, CRH-R2 binds UCN, UCN II, UCN III,
sauvagine and urotensin I with significantly higher binding affinity than it does CRH,
suggesting that these peptides might be its natural ligands (Perrin MH et al., 1999;
Reyes TM et al., 2001; Lewis K et al., 2001). The CRH R2 was detected in the rat and
mouse subcortical structures of the brain: in the lateral septal nucleus, ventromedial
hypothalamic nucleus, olfactory bulb, amygdala and the choroid plexus (Sawchenko
PE & Arias C 1995; Chalmers DT et al., 1995). Additionally, CRH R2 mRNA was
also identified in the paraventricular nucleus and supra-optic nucleus, as well as within
the cerebral arterioles.
Figure 1.3 CRH-R2 isoforms. The presented receptor is CRH-R2α, and the 
other isoforms are compared to it (adapted from Grammatopoulos DK &
Chrousos G, 2002).
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CRH R2 appeared to be the predominant CRH-R2 isoform, which is expressed
on neuronal tissue, where CRH-R2 is localised to the non-neuronal elements such as
the choroid plexus and cerebral arterioles (Chalmers DT et al., 1995). CRH-R2
subtypes are highly expressed in the heart and skeletal muscle (Perrin M et al., 1995).
In rodents, it appears that CRH-R2 is mainly a peripheral receptor produced in the
heart and in blood vessels, whereas CRH-R2 has been found only in the central
nervous system (CNS) (Lovenberg TW et al., 1995a; Lovenberg TW et al., 1995b;
Turnbull AV & Rivier C, 1997). In contrast to rodents, both human CRH-R2 and
CRH-R2are co-expressed in peripheral organs and the CNS (Valdenaire O et al.,
1997; Ardati A et al., 1999); however, CRH-R2, isolated only from human, was found
only in the brain (Kostich WA et al., 1998). Additionally, CRH-R2 appears to be the
predominant CRH receptor subtype present in the human heart (Hillhouse EW &
Karteris E, 2002). Also, it has been shown that CRH-R2 mRNA was detected in human
umbilical vein endothelial cells (HUVEC) (Simoncini T et al.) suggesting another
action for placentally derived CRH during pregnancy. In pregnant myometrium CRH-
R2β and R2γ mRNA was detected, while in non pregnant myometrium only CRH-R2β 
mRNA was present (Grammatopoulos DK et al., 1998a).
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1.4 Intracellular signalling of GPCRs
Binding of a ligand to GPCR causes conformational changes of the receptor,
resulting in the positional changes of transmembrane domains and transduction of the
signal from the extracellular environment to the inside of the cell. Initiation of signal
transduction pathways mediated by guanine nucleotide binding proteins (G-proteins)
lead to generation of second messengers cAMP, inositol 1,4,5-triphosphate (IP3),
diacylglycerol (DAG), and calcium (Wettschureck N & Offermanns S, 2005).
G-proteins are dependent on the guanyl nucleotide guanosine triphosphate
(GTP) for their regulatory actions. They are located in the cell membrane and
composed of three subunits:  (36-52 kDa),  (35-36 kDa),  (8-10 kDa) encoded by
distinct genes. The - and - subunits are assembled into dimmers that function as one
unit and are only separable under strongly denaturing conditions. In an inactive state,
the Gα-subunit is bound to GDP.  GPCR’s conformational change upon hormone 
binding stimulates GDP-GTP exchange on the Gα-subunit. The activated GTP bound 
-subunit dissociates into -GTP and  components. G-protein activation and subunit
dissociation is accompanied by separation from the receptor, which reverts to the low-
affinity agonist binding state.  Free α-GTP and βγ dimers then modulate activities 
associated with a range of effector enzymes or ion channels. The slow intrinsic GTPase
activity of the Gα-subunit promotes reassociation of GDP-bound Gα-subunit with ,
thus ending the interaction of with its effector system and also terminating the -
mediated signalling (Cerione RA et al., 1984) (Figure 1.4).
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Figure 1.4 The G-protein cycle. When the ligand binds to its receptor (1), the
receptor activates a G-protein by causing the Gα subunit to release GDP and 
bind GTP (2). The Gα and βγ subunits than dissociate (3), and initiate signal 
transduction events with wide range of effectors (4). The Gα’s intrinsic 
GTPase activity leads to hydrolysis of its bound GTP to GDP (5). The Gα-
GDP subunit associates with βγ to form inactive G-heterotrimer (adapted from 
Cerione RA et al., 1984).
An individual G protein is primarily distinguished by the identity of the α 
subunits. More than 100 Gα subunits have been cloned from various species (Simon 
MI et al., 1991). According to their sequence homology and differential coupling to
their effectors these proteins are classified in four distinct families: Gs, Gi, Gq/11, and
G12/13.
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1.4.1 CRH-R coupling to G-proteins, second messengers and downstream signals
In many tissues, endogenously expressing CRH-R (i.e. brain, heart, and
myometrium), stimulation of the receptor by CRH or CRH-related peptides leads to the
activation of adenylyl cyclase (AC) and increases cAMP levels (Grammatopoulos D. et
al. 1994). However, in some tissues like testis and placenta, CRH is unable to activate
the AC pathway, but it stimulates hydrolysis of phosphoinositols. Such distinct
response of CRH-R activation has been attributed to differential and multiple G-protein
activation. Several studies investigating CRH-R in native tissue and overexpressed in
cellular systems have demonstrated multiple G-protein activation, with an order of
potency Gs≥Go>Gq/11>Gi1/2>Gz. Interestingly, in native tissues, the pattern of G-protein
activation by endogenous CRH-Rs appears to be unique for each tissue
(Grammatopoulos D et al. 1999, Grammatopoulos D et al. 2001). Additionally, studies
utilizing yeast cells (Sz. Pombe) containing Gα-transplants that enable exogenous 
CRH-Rs to couple to the yeast signalling pathways demonstrated that CRH-Rs couple
to various G-proteins in agonist specific manner (Ladds G et al., 2003). The authors
reported that CRH-activated CRH-R1α coupled to Gs, Gi2, Gi3 and G16, while UCN
activated receptor coupled to Gq and G16 (Ladds G et al., 2003). Moreover, CRH
activated CRH-R2β coupled only to Gs and Gi2; however, UCN-activated receptor
interacted with Gi2, Gi3 and G16, but not to Gs. While UCN-II and UCN-III stimulation
of cells expressing CRH-R1α did not lead to any coupling of the receptor to G-proteins; 
these two agonists induced CRH-R2β interaction with Gs, Gi2, Gi3 and G16, and with
Gs, Gi3, and Gq, respectively (Ladds G et al., 2003).
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Due to its promiscuous coupling to diverse G-proteins, CRH-Rs can activate a
plethora of intracellular protein kinases, such as PKA, PKC, PKB /Akt, and the
p42/p44 and p38 MAPKs, by generating a number of second messengers (cAMP,
cGMP, Ca2+, DAG, IP3). Moreover, in a tissue-specific manner, signalling through
CRH-R can activate other important molecules, such as steroidogenic enzymes and Fas
ligand (Grammatopoulos DK and Chrousos G, 2002). In immune cells, the local effects
of CRH are complex since CRH can potentially inhibit and stimulate production of the
proinflammatory cytokines (IL-1 and IL-6) by peripheral blood mononuclear cells. In
reproductive tissues, CRH-R activation leads to prostaglandin production in human
foetal membranes and placenta, and induces vasodilatation in the human foetal-
placental circulation via a NO/cGMP-mediated pathway (Karteris E et al. 2000;
Karteris E et al. 2005). The complexity and tissue specific diversity of CRH-R
signalling in different types of cells is best illustrated by reports describing CRH as an
inhibitor and stimulator of NF-κB pathway in human HaCaT keratinocytes and 
epidermal keratinocytes, respectively (Zbytek B et al. 2003; Zbytek B et al. 2004).
In majority of cells, activation of CRH-Rs with CRH or UCNs leads to coupling
of the receptors to the Gαs proteins and subsequent activation of adenylyl cyclase, 
resulting in cAMP production and PKA activation (Hillhouse EW & Grammatopoulos
DK, 2006). The initiation of this signalling cascade modulates many cytoplasmic as
well as nuclear target proteins. In a tissue-specific manner, the physiological results of
activation of this cascade result in vasodilatation of aortas and renal arteries (Sanz E et
al., 2003; Maki I et al., 2004), possible glycerol release from adipose depose
(Wellhoner P et al., 2007), upregulation of genes having CREB transcription site
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(cAMP responsive element-binding protein) such as c-fos (Boutillier AL et al., 1991)
and Mif (macrophage mitogen-inhibitory factor gene) in pituitary cells (Waeber G et
al., 2004), activation of the inflammatory responses in synovial tissue (McEvoy AN et
al., 2002).
1.5 Termination of GPCRs signalling
After ligands bind GPCRs and trigger signal transduction cascades, there are
many steps that occur over seconds, minutes and hours that work to terminate the
activation. An obvious termination mechanism is the dissociation of the ligand from the
receptor, but this is dependent upon the affinity of the interaction. However, the waning
of GPCR signalling in the continued presence of agonist is accomplished by a
coordination of series of events:
 Receptor desensitization
 Internalization
 Down-regulation
 Resensitization
These mechanisms include the uncoupling of the receptor from heterotrimeric G
proteins in response to receptor phosphorylation by both second messenger-dependent
kinases and GPCR kinases (GRKs), binding of β-arrestins to the receptor, the 
internalization of cell surface receptors to intracellular membranous compartments, and
the down-regulation of the total cellular complement of receptors due to reduced
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receptor mRNA and protein synthesis, as well as both the lysosomal and plasma
membrane degradation of pre-existing receptors (Ferguson SS, 2001).
1.5.1 Receptor desensitization
The exposure of GPCRs to agonists often results in a rapid attenuation of
receptor responsiveness. This process, termed desensitization, begins within seconds of
agonist exposure. Desensitization is initiated by phosphorylation of the receptor on
serine and threonine residues within the intracellular loops and C-terminal tail of many
GPCRs (Luttrell LM & Lefkowitz RJ, 2002). There are two types of desensitization:
heterologous and homologous. During heterologous desensitization the agonist
occupancy of the target GPCR in not required; the receptor can be phosphoralated and
desensitized by the activation of second messenger dependent protein kinases such as
cAMP-dependent kinase (PKA) and protein kinase C (PKC). On the other hand,
homologous desensitization is a consequence of conformational changes of the receptor
upon ligand binding, and further phosphorylation of the receptor by G-protein coupled
receptor kinases (GRKs) and subsequent binding of β-arrestin. These events lead to the 
uncoupling of receptors from their heterotrimeric G-proteins.
1.5.1.1 G-protein coupled receptor kinases (GRKs)
The GRK family of serine/threonine kinases is comprised of seven family
members that phosphorylate agonist-occupied or activated GPCRs as their primary
targets. GRKs identified up to date include: GRK1 (also known as rhodopsin kinase)
(Lorenz W et al., 1991), GRK2 (β-adrenergic receptor kinase-1) (Benovic JL et al.,
1989), GRK3 (β-adrenergic receptor kinase-2) (Benovic JL et al., 1991), GRK4 (IT-11)
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(Ambrose et al., 1992), GRK5 (Kunapuil P & Benovic JL, 1993, Premont RT et al.,
1994), GRK6 (Benovic JL and Gomez J, 1993), and GRK7 (Hisatomi O et al., 1998).
In unstimulated cells, GRK1-3 are localized in the cytosol; upon the agonist
activation of their GPCR targets GRK1-3 translocate to the plasma membrane. Since
membrane targeting of all of the GRKs is crucial to their function, the mechanisms of
this translocation were topic of many studies. Examining the structure of GRKs
revealed that NH2-terminal domain contains a conserved RGS domain responsible for
binding to GPCRs, while distinct covalent modification of C-terminus are essential for
membrane targeting (Stoffel RH et al., 1997). GRK1 and GRK7 are farnesylated at
CAAX motifs (Inglese J et al., 1992), while GRK2 and GRK3 contain a βγ-subunit 
binding domain within their C-tails (Pitcher JA et al., 1992; Touhara K et al., 1994).
The GRK5 C-terminus contains a starch of 46 basic amino acids that mediate plasma
membrane phospholipid interactions (Kunapuil P et al., 1994b; Premont RT et al.,
1994). GRK4 and GRK6 are palmiotoylated at cystein residues which keeps them on
the plasma membrane even in unstimulated cells (Stoffel RH et al., 1994; Stoffel RH et
al., 1998).
GRKs phosphorylate GPCRs on Ser and Thr residues in their third intracellular
loop and C-terminal domains; these phosphorylation increase affinity of receptor for
arrestins. However, GRKs phosphorylation of GPCRs alone has little effect on receptor
and G-protein coupling in the absence of arrestins (Lohse MJ, 1993). It is the binding
of arrestin to receptor domains involved in G-protein coupling, rather than GRK
phosphorylation, that leads to homologous desensitization of receptor (Luttrell LM &
Lefkowitz RJ, 2002).
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1.5.1.2 The arrestin family
The arrestins constitute a small gene family with four members, all of which
interact with activated and GRKs phosphorylated GPCRs. Aresstin1 and arrestin4 are
found exclusively in retinal rods and cones, respectively, where they regulate rhodopsin
and colour opsins (Shinohara T et al., 1987; Murakami A et al., 1993). By contrast,
arestin2 and arrestin3 (Lohse MJ et al., 1990), commonly known as β-arrestin1 and β-
arrestin2, are expressed in all tissues where they regulate most GPCRs. There are
reports suggesting existence of two more arrestins, D-arrestin and E-arrestin (Craft CM
et al., 1994). However, only partial cDNA clones for these two arrestins have been
found in a broad range of tissues, but it sill remains uncertain whether full length D-
and E-arrestin protein exist.
The crystal structure of visual arrestin indicates that the protein contains two
major domains, an N-domain (residues 8-180) and a C-domain (residues 188-362),
each of which is composed of a seven stranded β-sheets (Granzin J et al., 1998). Based
upon mutagenesis studies, the β-arrestins are composed of two major functional 
domains an N-terminal (A) domain which is important in recognition of activated
receptor, and C-terminal (B) domain which is responsible for secondary receptor
recognition. These two domains are separated by a phosphate sensor domain (P-
domain). N (R1)- and C (R2)-terminal regulatory domains reside at either end of the
protein. The R2 domain contains the primary site of β-arrestin phosphorylation (S412) 
as well as the LIEF binding motif for clathrin and the RXR binding domain for β2-
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adaptin (AP2). The recognition domain for inositol phospholipids as well as JNK3 and
possibly other MAP kinases recognition sequence reside within the B domain (Luttrell
LM & Lefkowitz RJ, 2002).
Beside their role in the specific uncoupling of agonist-bound GPCR from their
cognate G proteins, numerous studies suggested that β-arrestins have an important role 
as adaptors and scaffolding proteins that link the receptors to the clathrin-coated pit
endocytosis machinery (Goodman OB et al., 1996; Laporte SA et al., 1999) as well as
to a variety of signaling systems such as ERK1/2 (Tohgo A et al., 2002), JNK3
(McDonald PH et al., 2000) and p38 (Sun Y et al., 2002).
Moreover, a mechanism by which β-arrestins attend to the degradation of 
cAMP has been suggested via acting as adaptors for the translocation of
phosphodiesterase (PDE4) to activated β2-adrenergic receptors to sites of localized 
PKA activity at the plasma membrane (Perry SJ et al., 2002). As such, β-arrestins 
coordinate both receptor desensitization and the quenching of PKA activity.
Figure 1.5 Structural and functional domains of β-arestin1 and β-arrestin2 
(adapted from Luttrell LM & Lefkowitz RJ, 2002).
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1.5.2 Receptor internalization
Internalization of GPCRs, also known as receptor sequestration or endocytosis,
occurs more slowly than desensitization, happening over a period of several minutes
after agonist exposure (Ferguson SS, 2001). GRK-mediated GPCR phosphorylation
and binding of β-arrestin to the receptor facilitates the agonist-promoted endocytosis of 
many GPCRs. The extent of β-arrestin involvement appears to vary depending on the 
receptor, agonist and cell type.  As mentioned earlier, β-arrestins contain two motifs 
that allow them to function as adapter proteins that link the GPCRs to components of
the clathrin-dependent endocytic machinery. β-arrestins have high affinity for clathrin 
in vivo (Goodman OR et al., 1996). In addition, β-arrestins bind directly to AP-2 
(Laporte SA et al., 1999). AP-2 complex links many receptors to the clathrin endocytic
machinery by binding clathrin, dynamin and EPS-15, and is involved in the initiation of
clathrin-coated pit formation (Kirchhausen T, 1999).
The phosphorylation state of β-arrestin1 is crucial in its endocytic function. 
Cytoplasmic β-arrestin1 is phosphorylated on S412 (Lin FT et al., 1997) by ERK1 and
ERK2 (Lin FT et al., 1999). However, upon translocation to the membrane, β-arrestin1 
is rapidly dephosphorylated. On the other hand, β-arrestin2 is not phosphorylated at its 
C-terminus, but its endocytic function is regulated by post-translational modification
after binding to the receptor. Shenoy has demonstrated that β-arrestin2 and β2 
adrenergic receptors undergo rapid, β-arrestin-dependent ubiquitination in response to 
agonist binding (Shenoy SK et al., 2001). β-arrestin ubiquitination is required for 
receptor internalization, whereas the receptor ubiquitination is involved in degradation
of the receptor but not its internalization (Luttrell LM & Lefkowitz RJ, 2002).
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Based on the β-arrestin involvement in the internalization GPCRs are grouped 
into two distinct classes (Oakley RH et al., 2000). Class A receptors bind to β-arrestin2 
with higher affinity than β-arrestin1 and do not bind visual arrestin. Their interaction 
with β-arrestin is transient. β-arrestin is recruited to the receptor and translocates to 
clathrin-coated pits; but the receptor-β-arrestin complex dissociates upon 
internalization of the receptor, and the receptor proceeds into an endosomal pool, while
β-arrestin translocates back to the plasma membrane (Zhang J et al., 1999). The
members of this class include β2 and α1B adrenergic, μ opioid, endothelin A, and 
dopamine D1A receptors. Class B receptors, such as neurotensin 1, vasopressin 2, and
angiotensin AT1a receptors, bind to β-arrestin1 and β-arrestin2 with equal affinity and 
also interact with visual arrestin. The complex receptor-β-arrestin is stable and it 
internalizes as a unit that is targeted to endosomes (Luttrell LM & Lefkowitz RJ, 2002).
The stability of receptor-β-arrestin complex is dictated by the specific clusters of Ser 
and Thr residues in the C-terminal tail of the receptor as well as the C-terminus of β-
arrestin (Oakley RH et al., 2001).
The precise mechanism by which all GPCRs internalize is still controversial
topic. It is now thought that not all GPCRs internalize in β-arrestin and clathrin-
dependent manner (Ferguson SS, 2001). As an example of this case is that both
angiotensin II type 1A receptor and m2 muscarinic acetylcholine receptor seem to
internalize normally in the presence of dominant-negative β-arrestin and dynamin 
mutants, however the internalization of both these GPCR subtypes seems to be
dependent on receptor phosphorylation (Smith RD et al., 1998; Lee KB et al., 1998).
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1.5.3 Receptor down-regulation
Down-regulation of GPCRs is defined as the persistent loss of cell surface
receptors that occurs over a period of hours to days. Control of cell surface receptor
density occurs at least partially at the transcriptional level, but the removal of agonist-
occupied receptor from the surface and their sorting for either degradation or recycling
is important, at least in the early stages of down-regulation (Luttrell LM & Lefkowitz,
RJ, 2002).  As mentioned earlier the complexes between receptor and β-arrestin have 
different stability. As a matter of fact, the stability of those complexes might dictate the
fate of internalized receptor. Class A receptors are rapidly dephosphorylated and
recycled back to the plasma membrane; whereas the stable complex of class B
receptors and β-arrestin retards resensitization and might favour the receptor for 
degradation.
1.5.4 Receptor resensitization
In order for an internalized GPCR becomes resensitized, not only that β-
arrestin-dependent targeting of receptors to clathrin-coated pits and their subsequent
endocytosis to endosomes is required, but also the receptors have to release β-arrestin, 
become dephosphorylated, sorted and recycled back to the cell surface. It was found
that involvement of small RabGTPases is essential for these processes (Ferguson SS,
2001). Rab5 (GTPase Rab5) is involved in formation of receptor-bearing vesicles at the
cell surface (Seachrist JL et al., 2000), their trafficking and fusion with early
endosome. The dephosphorylation of receptor occurs during the receptor transition
between Rab5- and Rab4-positive endosomal compartments (Seachrist JL et al., 2000).
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The low pH in endosomes could contribute to ligand dissociation as well as
conformational changes in the receptor. It has been reported that protein phosphatases
(PP2A) are capable of dephosphorylating GPCRs in acidic conditions (Sibley DR et al.,
1986; Pitcher JA et al., 1995) Rab4 also regulates the recycling of the receptor back to
the plasma membrane. All these events lead to receptor resensitization.
1.5.5 CRH-R desensitization and internalization
In most tissues, CRH actions are dependent on the adequate expression of
CRH-R in the plasma membrane. The exposure of CRH-R to CRH and other agonists
results in rapid attenuation of CRH-R responses, through a mechanism of receptor
desensitization. In recent years, CRH-R1 desensitization and internalization have been
extensively studied (Teli T et al. 2004; Rasmussen TN et al. 2004; Perry SJ et al.,
2005, Holmes KD et al., 2006, Markovic D et al., 2006). Teli et al (2004) has
demonstrated that half-maximal desensitization of CRH-R1α occurred after 
approximately 40 min of pre-treatment and full recovery of the receptor’s functional
response was within 2h of removal of CRH pre-treatment. In HEK293 cells,
desensitization of CRH-R1α was associated with receptor phosphorylation and 
subsequent endocytosis (Teli T et al., 2004). Moreover, it has been shown that the
mechanism leading to the desensitization of CRH-R1α involves GRK3 and GRK6 as 
the main isoforms that interact with the receptor, and that recruitment of GRK3
requires Gβγ-subunits as well as β-arrestin. Site-directed mutagenesis of Ser and The 
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clusters within the C-tail of CRH-R1α, pointed toward Thr399 as an important residue 
for GRK-induced receptor phosphorylation and desensitization (Teli T et al., 2004).
Further internalization studies demonstrated that β-arrestin was recruited toward 
the plasma membrane of HEK293 over-expressing CRH-R1α, upon the stimulation 
with CRH (Rasmussen TN et al., 2004; Perry SJ et al., 2005; Holmes KD et al., 2006).
Perry and Holmes pin-pointed β-areestin2 as a major isoforms involved in CRH-R1α 
sequestration, but further fate of the receptor is still controversial. Holmes (2006)
defines CRH-R1α as a class A receptor regarding the lack of β-arrestin2 co-localisation 
with the receptor in the endosome structure in HEK293, whereas Perry (2004) has
demonstrated co-localisation of the two in the cytoplasm. However, Holmes (2006) has
demonstrated that CRH-R1α indeed co-localise with β-arrestin2 in the cytoplasm of 
primary cortical neurons. Moreover, it has been shown that following the endocytosis,
the receptor transited from Rab5-positive early endosome to Rab4-positive recycling
endosome, and that the receptor was not targeted for degradation in lysosomes in
HEK293 overexpresing CRH-R1α and in primary cortical neurons (Holmes KD et al.,
2006). In contrast, CHO-K1 stably expressing CRH-R1 challenged with CRH for 1h
had 83% of the receptor remain, but after 24h treatment only 38% the total CRH-R1
proteins were detected, clearly showing the receptor down-regulation (Perry SJ et al.,
2005). Taken together these findings suggest that different cellular systems might have
distinct patterns of CRH-R1 endocytosis.
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1.6 GTPase Rho and Rho-dependent response
Currently around 100 members of the small GTPase superfamily ranging from
20-30 kDa have been identified. These are broadly divided into five subfamilies: Ras,
Rho/Rac/cdc42, Rab, Sar1/Arf and Ran. The functions of many small G-proteins are
still unknown. In general, Ras family of GTPases regulates cell signalling events that
lead to alterations in gene transcription; Rho family GTPases function as regulators of
actin cytoskeleton and can also influence gene transcription (one of possible
mechanisms is through activation of NF-κB pathway (Perona R et al. 1997)); Rab and
Arf family GTPases control the formation, fusion and movement of vesicular traffic
between different membrane compartments of the cell; and Ran GTPase regulates both
microtubule organisation and nucleo-cytoplasamic protein transport (Bhattacharya M
et al., 2004).
The small GTPase Rho have been reported to regulate many cellular functions
such as cell adhesion, cell contraction, cell migration and tumour cell invasion, growth
control and survival responses, phospholipids metabolism, MAP kinase activation and
gene transcription, endocytosis, exocytosis, glucose transport and ion channels
(Wettschureck N & Offermanns S, 2002). RhoA is the best characterized member of
Rho family. All members of the Rho family of proteins, like any other small GTPases,
function as molecular switches, cycling between an inactive GDP-bound state and an
active GTP-bound state (Somlyo AP & Somlyo AV, 2003). In the resting state, RhoA-
GDP exists in the cytosol tightly associated with its partner, GDP dissociation inhibitor
(RhoGDI). Activation of receptors coupled to certain trimeric G proteins such as Gαq,
Gα12,13, and receptor tyrosine kinases lead, through activity of guanine nucleotide
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exchange factors (GEFs), to the exchange of GDP for GTP on RhoA. This causes
RhoGDI dissociation and “free” RhoA-GTP translocation to the membrane where it
interacts with Rho-kinase (ROCK) to initiate a number of signalling events. The GTP-
bound form of RhoA is converted in the GDP-bound form due to its intrinsic GTPase
activity, which is stimulated by GTPase-activating proteins (Rho-GAPs) (Figure 1.6).
It is well documented that GPCR signalling through heterotrimeric G-proteins
can lead to the activation of Ras and Rho-GTPases. Most GPCRs can couple to
multiple G proteins, making it difficult to pin point which specific G protein is
involved in the activation of RhoA. It has been shown that the stimulation of
heterologously expressed α2-adrenergic receptor in preadipocytes leading to Rho-
mediated changes in cell morphology is pertussis toxin sensitive (Betuing S et al.,
1998). Paradoxically, βγ subunits isolated from Gi/o were shown to bind to Rho and
inhibit Rho-GTPγS binding, suggesting a possible additional inhibitory effect of Gi/o
proteins on Rho (Harhammer R et al., 1996).
Figure 1.6 RhoA activation cycle. Upon stimulation, cytoplasmic RhoA-GDP
is activated by GEF. RhoA-GTP translocates to the plasma membrane where it
interacts with ROCK. RhoA-GTP is inactivated by GAP which hydrolyses
GTP to GDP. Inactive RhoA is reunited with its cytoplasmic partner (GDI).
(Adapted from Somlyo AP & Somlyo AV, 2003).
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Most of the GPCRs shown to activate Rho are coupled to Gq/11. In spite of this,
accumulating evidence suggest that Gq/11 proteins might be insufficient activators of
Rho-mediated responses, but that an additional interaction with other proteins such as
β-arrestins is required for the activation. Recently, it has been demonstrated in the case 
of angiotensin II type 1A receptor (AT1AR) that neither β-arrestin1 nor Gαq/11 activation
alone are sufficient to robustly activate RhoA, but that the concurrent recruitment of β-
arrestin1 and activation of Gαq/11 leads to full activation of RhoA and to the subsequent
formation of stress fibres (Barnes WG et al., 2005).
There is increasing evidence showing that in some cellular systems activation of
Rho is primarily mediated via G proteins of the G12/13 family. G12/13 can bind to and
activate Rho-specific GEFs (p115RhoGEF, LARG, PDZ-RhoGEF) (Kozasa T et al.,
1998) providing a possible mechanism by which GPCRs could activate Rho and its
downstream responses. However, it has been demonstrated that these two G-proteins
activate Rho via distinct mechanisms (Gohla A et al., 1998; Diviani D et al., 2001).
Although most of current evidence suggest that Gα12/13 can interact directly with
RhoGEFs, it is likely that second messenger pathways and kinase cascades also
regulate Rho activity. Phosphorylation of Rho or its regulators (GAPs, GDIs and GEFs)
by MAP kinase, PKC, PKG, and PKA (Murthy KS et al., 2003), is likely to provide
additional mechanisms by which GPCRs can modulate Rho signalling pathways.
Once activated, Rho can bind to a large number of proteins. The best
characterized Rho effectors are the serine/threonine-directed Rho kinases (Rho kinase/
ROKα/ROCK II and p160ROCK/ROCKβ, generically known as Rho kinase). The 
development of a selective inhibitor, Y27632 (Uehata M et al.,1997), has made
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possible monitoring the involvement of Rho kinase in cellular responses. Much less is
known about the specific function of other groups of Rho effectors, which are PKC-
related serine/threonine kinases (PKN/PRK1 and PRK2), citron kinase, p140mDia,
rhophilin and rhotekin.
1.7 Nuclear factor kappa B (NF-κB) 
NF-κB was first discovered as a constitutive protein in the nuclei of mature 
murine B-lymphocytes that bound to a ten-base pair DNA motif (GGGACTTTCC) in
the κ immunoglobulin light chain enhancer (Sen R & Baltimore D, 1986). NF-κB is 
now known to be an inducible transcription factor widely distributed in eukaryotic cells
(Lenardo MJ & Baltimore D, 1989; Sen R & Baltimore D, 1986). This ubiquitous
transcription factor modulates many gene products involved in inflammation and acute
phase responses (Baeuerle PA & Henkel T, 1994;). NF-κB also plays an important part 
in immune responses, thymus development, apoptosis, embryonic development, growth
control, malignant transformation and viral gene expression (Beg AA et al., 1995;
Kopp  EB & Ghosh S, 1995). Over 150 stimuli are known to activate NF-κB (Pahl, 
1999). These include multiple bacterial and viral infections, as well as bacterial and
viral products and because of this NF-κB has often been termed “the central mediator 
in the immune system”. In addition, NF-κB is also activated by numerous other stimuli 
that are not derived from bacterial and viral infections, including, various cellular and
environmental stresses such as irradiation, osmotic shock, oxidative stress,
hyperglycaemia, the ER overload response, and haemorrhage (Pahl HL, 1999).
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Upon activation, NF-κB promotes transcription of over 150 genes many of which 
are involved in the host immune/inflammatory responses. These include cytokines,
chemokines, immunoreceptors, adhesion molecules, stress response genes, apoptotic
regulators, growth factors, transcription factors, and inflammatory enzymes known to
be active in inflammatory diseases (Barnes PJ & Karin M, 1997; Pahl HL, 1999).
  NF-κB is a homo- or heterodimeric protein composed of different combinations 
of members of the Rel family of transcriptional factors. This family shares an N-
terminal domain of approximately 300-amino acid, known as the Rel homology domain
(RHD). The N-terminal part of the RHD contains the DNA-binding domain, whereas
the dimerization domain is located in the C-terminal region of the RHD. Close to the C-
terminal end of the RHD is the nuclear localization signal (NLS), which is essential for
the transport of active NF-κB complex into the nucleus. Also RHD is responsible for 
binding to inhibitor of Kappa B (IκB) (Chen FE & Ghosh G, 1999).  
Five mammalian NF-κB family members have been characterised; these are p65 
(RelA), RelB, c-Rel, NF-κB1 (p50 and its precursor p105) and NF-κB2 (p52 and its 
precursor p100) (Bonizzi G & Karin M, 2004). The NF-κB proteins are divided into 
two groups based on sequence C-terminal to the RHD. Members of the first group
(p105, p100, and Drosophila Relish) have long C-terminal domain that contain
multiple copies of ankyrin repeats, which act to inhibit these molecules. These proteins
become active by either limited proteolyisis or arrested translation (p105 to p50, and
p100 to p52) (Gilmore TD, 1999). As such, members of this group are generally not
activators of transcription, except when they form dimmers with the members of the
second group. The second group includes p65 (RelA), RelB and c-Rel as well as Dorsal
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and Dif. These proteins are not synthesised as precursors and they possess one or more
C-terminal transactivation domains (TD), in addition to RHD (Gilmore TD, 1999).
RelB, c-Rel and p65 do not bind DNA efficiently, but they are good transactivators.
However, p50 and p52 are the main DNA-binding subunits with poor transactivation
abilities unless in a dimmer with RelB, c-Rel or p65 (Siebenlist U et al., 1994). The
most abundant of the complexes is NF-κB which consists of p65/p50 heterodimers. 
There are currently eight members of the IκB family including IκBα, IκBβ, 
IκBγ, IκBε IκBζ, Bcl-3, p105, p100 and the Drosophila protein cactus (Ghosh S et al.,
1998; Yamazaki S et al., 2001). The proteins p105 and p100 are the pre-cursors of
(p50) and (p52) respectively. All IκBs contain 6 or 7 ankyrin repeats which bind the 
RHD of NF-κB (Karin & Ben-Neriah, 2000). Little is known about the functional 
significance of the different IκBs. However, IκBα, IκBβ and IκBε are the only IκBs to 
possess the N-terminus regulatory regions required for stimulus induced NF-κB 
activation (Karin M & Ben-Neriah Y, 2000). In the majority of cells, the p65/p50
heterodimer form of NF-κB is found complexed with IκBα, which is targeted by IKK-
dependent phosphorylation of serines 32 and 36 (Hayden and Ghosh, 2004; Karin and
Ben-Neriah, 2000). The phosphorylated IκBα proteins are recognised by ubiquitin 
ligases, which polyubiquitinate IκBα at lysines 21 and 22 leading to the degradation of 
IκBα by the 26S proteosome (Hayden MS & Ghosh S, 2004; Karin M & Ben-Neriah Y, 
2000).
The IκB kinase was first identified by biochemical methods as a 700 kDa 
complex with IκB kinase activity (Chen ZJ et al., 1996). To date three proteins have
been confirmed as components of the IKK complex (Chen ZJ et al., 1996), IKKα, 
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IKKβ and NF-B essential modulator (NEMO) or IKKγ (Karin M and Ben-Neriah Y, 
2000). Recent reports have shown that the IKK complex might contain two additional
proteins, Hsp90 and Cdc37 (Chen F et al., 2002; Krappmann D et al., 2000). According
to these reports, the IKK complex contains a heterodimer of IKKα and IKKβ, a 
homodimer of Hsp90 and two or three molecules of IKKγ and Cdc37 giving an 
approximate molecular weight of 800 kDa (Chen F et al., 2002; Krappmann D et al.,
2000). The IKK complex is the convergence point where the numerous pathways that
leads to IB-degradation dependent NF-κB activation. 
1.7.1 NF-κB activation  
There are two NF-κB activation pathways: classical and alternative. In the 
classical pathway, the activated IκB kinase (IKK) complex, predominantly acting 
through IKKβ in an IKKγ-dependent manner, catalyzes the phosphorylation of IκBs (at 
the sites equivalent to Ser32 and Ser36 of IκBα), polyubiquitination (at the sites 
equivalent to Lys21 and Lys22 of IκBα) and subsequent degradation by the 26S 
proteosome. The released NF-κB dimmers (most commonly p65/p50) translocate to the 
nucleus, bind DNA and activate gene transcription, including IκBα (Ghosh S and Karin 
M, 2002). After re-synthesis, IκBα enters the nucleus through its nuclear localisation 
signal (NLS) and removes NF-κB from the κB binding sites. IκBα is able to do this 
because NF-κB has a greater affinity for IκBα binding than it does for DNA binding 
(Arenzana-Seisdedos F et al., 1997).  Once bound the IκBα/NF-κB complex is exported 
back into the cytoplasm through the IκBα nuclear export signal (NES). Thus, the 
resynthesis of IκBα acts as a negative feedback loop and limits the duration of NF-κB 
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activity (Arenzana-Seisdedos F et al., 1997). The alternative pathway is independent of
IKKβ and IKKγ. The target for IKKα homodimers in this pathway is NF-κB/p100, 
which is phosphorylated at two C-terminal sites, leading to processing of p100 to p52
(Xiao G et al., 2001).
Figure 1.7 NF-κB activation pathway. Activation of various receptors leads to
phosphortlation of IκB (1), and subsequent ubiqutination and degradation (2). 
RelA is than phosphorylated (3) which enhances its translocation to the nucleus
(4), where it binds to the DNA leading to the NF-κB dependent transcription. 
One of the transcribed genes is IκBα. Newly synthesised IκBα enter in the 
nucleus (5), where it binds to RelA/p50. The complex than leaves the nucleus
(6). (Adapted from Bonizzi G & Karin M, 2004)
A number of kinases, including NF-κB inducing kinase (NIK), MEKK-3, NF-
κB activating kinase (NAK) (also known as TANK binding kinase (TBK) or T2K), 
MAPK and Akt have been implicated in NF-κB activation via the IKK complex 
(Pomerantz JL & Baltimore D, 1999; Romashkova JA and Makarov SS, 1999; Bonnard
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M et al., 2000). Nevertheless, it has proved difficult to unambiguously confirm that any
of these kinases activate the IKKs and it is likely that activation of the IKKs is a
complex process involving multiple kinases and adapter proteins.
1.8 Brown adipose tissue
Mammalian adipose tissue is characterised into white adipose tissue (WAT) and
brown adipose tissue (BAT), according to their colour and distinct function. The
presence, amount and distribution of each varies depending on the species (Albright
AL & Stern JS, 1998). Until recently it was believed that the function of WAT was heat
isolation, mechanical cushion and energy storage. Moreover, WAT is an endocrine
organ able to produce many adipocytokines or adipokines such are leptin, adiponektin,
resistin, plasminogen activator inhibitor-1 (PAI-1), tumor necrosis factor α (TNF-α), 
visfatin, retinol binding protein 4 (RBP4). The role of these peptides involved in
modifying appetite, insulin resistance and artheriosclerosis is under vigorous
investigation. Morphologically, BAT differs from WAT by its rich vascularisation and
numerous unmyelinated nerves which provide sympatic stimulation to the adipocytes
(Nnodim JO & Lever JD, 1988) Additionally, in contrast to white adipocytes which
contain a single, large lipid droplet, brown adipocytes contain numerous smaller lipid
droplets and extraordinary number of mitochondria (Weber WA, 2004). The function
of BAT is to transfer energy from stored energy into heat. A mitochondrial protein,
uncoupling protein 1 (UCP-1) is responsible for this unique function of BAT. UCP-1
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gives the mitochondria an ability to uncouple oxidative phosphorylation and utilize
substrates to generate heat rather than ATP. The development of BAT and UCP-1 was
probably determinative for the evolutionary success of mammals, as its thermogenesis
enhances hibernating animals and neonates survival and allows active life even in cold
environment (Cannon B & Nedergaard J, 2004). BAT is most predominant in newborn
animals. In human babies it comprises up to 5% of body weight and it is present in the
neck and interscapular area.
1.8.1 Lipolysis and proteins involved in lipolysis
The information on body temperature, energy reserves and feeding status are
coordinated in the ventromedial hypothalamic nucleus (VMN) of the brain. When there
is a need to increase the rate of heat production, a signal (norepinephrine) is transmitted
via sympathic nervous system to the individual brown adipocytes (Cannon B &
Nedergaard J, 2004). The released norepinephrine binds to its receptor (β3-adrenergic 
receptor) on the plasma membrane of the brown adipocyte. Activation of β3-adrenergic 
receptor leads to increased cAMP production, which is followed by activation of PKA
and subsequent phosphorylation of hormone sensitive lipase (HSL) and perilipin,
resulting in triglycerides and diglycerides breakdown to free fatty acids (FFA) and
glycerol (Egan JJ et al., 1992) (Figure 1.8).
The rate limiting step of lipolysis is controlled by the actions of HSL. There are
three isoforms of the enzyme ranging from 84 to 130 kDa. (Carmen GY & Victor SM,
2006). Beside acylglycerols, HSL can hydrolyse cholesteryl esters, retinyl esters,
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steroid esters and p-nitrophenyl esters (Holm C et al., 2000). This enzyme has three
domains, a catalytic domain, a regularory domain with several phosphorylation sites
and an N-terminal domain involved in protein-protein and protein-lipid interactions
(Yeaman SJ, 2004). It has been demonstrated that upon lipolytic stimulation of fat cells
and 3T3-L1 adipocytes, HSL translocates from cytoplasmic compartments to the lipid
droplets, the site of its action (Egan JJ et al., 1992; Londos C et al., 1995).
Figure 1.8.PKA-stimulated lipolysis in adipocytes. Activation of β3-
adrenergic receptor (1) leads to activation of adenylyl cyclase (AC) and
subsequent elevation of cAMP levels and activation of PKA (2). PKA
phosphorylates perilipin (prlp) and HSL; perilipin undergoes conformational
changes in order to make space on the droplet surface for activated HSL (3).
Once on the droplet surface, HSL mediates hydrolysis of triacylglycerol (TG)
and diacylglycerol (DG) to DG and MG (monoacylglycerol), respectively.
Released FFAs (free fatty acids) than enter mitochondria. (Adapted from
Tansey J et al., 2004)
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PKA phosphorylates HSL at Ser-563, Ser-659 and Ser-660 stimulating the
activity of the lipase (Degerman E et al., 1990; Anthonsen MW et al., 1998). On the
other hand, AMP-dependent protein kinase (AMPK) phosphorylates HSL at Ser-565
and the phosphorylation of this site prevents the phosphorylation of Ser-563, thus
decreasing the lipase activity (Garton AJ & Yeaman SJ, 1990). Recently, It has been
demonstrated that phosphorylation at Ser-600 ERK enhances the enzymatic activity of
HSL (Greenberg AS et al., 2001).
The perilipins are hydrophobic lipid droplet-associated phosphoproteins that can
be phosphorylated by PKA in multiple residues. It has been proposed that in
nonstimulated cells perilipin may deter HSL interaction with the droplet by forming a
barrier around it (Clifford GM et al., 2000). However, upon HSL translocation to the
lipid droplet, perilipin are phosphorylated by PKA and lose their blocking capability,
possibly through translocation from the droplets (Carmen GY & Victor SM, 2006).
Adipocyte lipid binding proteins (ALBP) are cytosolic proteins that interact with
HSL favouring the translocation from the cytosol to lipid droplets (Shen WJ et al.,
1999). ALBP form 1:1 complex with fatty acids and other hydrophobic ligands,
sequestering fatty acids inside the cytosol to protect the cell from its harmful effect
(Bernlohr DA et al., 1997).
1.8.2 Thermogenesis in BAT
The product of lipolysis, FFA are activated to acyl-CoAs (CoenzymeA) by
acyl-CoA synthetase are transferred to acyl-carnitine by carnitine palmitoyltransferase I
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(CPT-I). The acyl-carnitine probably enters the mitochondria through the carnitine
transporter and it is probably reconverted to acyl-CoA by CPT-II. The ensuring β-
oxidation of the acyl-CoA and the activity of the citric acid cycle lead to formation of
the reduced electron carrier FADH and NADH, which are then oxidized by the electron
transport chain (respiratory chain), ultimately though oxygen consumption. This results
in a pumping out protons from the mitochondria and the formation of a proton-motive
force. In cells other than brown adipocytes, protons re-enter mitochondria via ATP
syntheses. If ADP is unavailable, protons are unable to re-enter mitochondria,
increasing the proton gradient and limiting further electron transfer and fuel oxidation
(Lowel BB & Flier JS, 1997). On the other hand, mitochondria of brown adipocytes
have UCP-1 in the innter membrane, which dissipates the proton gradient by driving
protons back into the mitochondrial matrix, thereby uncoupling fuel oxidation from the
availability of ADP. Thus, the physiological consequence of UCP-1 activity is
unrestrained oxidation of fuels with the generation of heat (Cannon B & Nedergaard J,
2004) (Figure 1.9).
The proton transport mediated by UCP-1 is highly regulated. Fatty acids are the
main physiologically relevant intracellular regulator of UCP-1 activity (Locke RM et
al., 1982). Studies utilising isolated brown adipocyte mitochondria have demonstrated
that proton transport is significantly stimulated by increasing concentration of fatty
acids (Cannon B & Nedergaard J, 2004). It has been suggested that UCP-1 is a FFA
anion transporter and not a proton transporter (Jezek P et al., 1994; Jezek P et al.,
1996). Membrane impermeable FFA anions are transported out of the mitochondria by
UCP-1. Theses FFA anions become protonated and, in this permeable state, re-enter the
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mitochondria, with the net result being transport of protons onto the mitochondria
(Lowel BB & Flier JS, 1997).
Figure 1.9.Thermogenesis in brown adipocytes. Lipolysis generated FFA
are activated to acyl-CoAs and as such they are transported into mitochondria
(1) where the fatty acids enter β-oxidation (β-ox) (2) followed by the citric acid 
cycle (3). Products of these processes are the reduced FADH and NADH,
which are oxidized by the respiratory chain (blue boxes) (4). This leads to
pumping protons out of mitochondria and the formation of proton gradient
which drives proton back to mitochondrial matrix through UCN-1 (5). The
energy stored in this proton-motive force is released as heat. (Adapted from
Cannon B & Nedergaard J, 2004).
1.8.3 BAT and regulation of total body fat
Beside to its thermoregulatory role, BAT plays an important role in regulating
total body fat, at least in rodents. Transgenic mice with decreased BAT have glucose
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intolerance and insulin resistance as well as enhanced susceptibility to diet-induced
obesity and diabetes (Hamann A et al., 1993; Hamann A et al., 1995). This suggests
that BAT protects against obesity caused by high calorie diet.
As newborns, we have relatively large deposits of BAT. The heat produced in
BAT can be imaged using a thermal-infrared camera. If such pictures are taken of an
unwrapped infant sleeping at room temperature, “hot spots” can be seen in the skin
overlying BAT deposits in the neck and interscapular area (Austgen L 2002). It is
believed that with age, but probably more with size, our relative functionality of BAT
decreases and disappears. Recently, it has been reported that within WAT depots in
adult humans, islets of BAT may be found; additionally UCP-1 mRNA is detectable in
WAT and its levels can be increased in vitro by norepinephrine (Cannon B &
Nedergaard J, 2004). However, the evidence for adaptive adrenergic nonshivering
thermogenesis in humans are limited. There are two positive reports, suggesting the
recruitment of an adaptive adrenergic nonshivering thermogenesis in adult humans, but
only to the levels of 15% above basal (Cannon B & Nedergaard J, 2004). In adults with
pheochromocytomas (catecholamine secreting tumors) abundant BAT depots were
detected, indicating that BAT in human adults has marked capacity for expansion
(Ricquier D et al., 1982). However, due to the diffuse distribution of BAT in adults, the
analysis of BAT function in lean versus obese people is hard to perform. Moreover, it
has been suggested that because to its capacity for expansion, BAT is a reasonable
target for anti-obesity drugs (Lowel BB & Flier JS, 1997).
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1.9 Aim of the study
Due to the fact that the CRH system is expressed in various tissues where it can
mediate diverse cellular functions, this research project was designed to investigate a
broad spectrum of CRH-Rs properties in overexpressing as well as in endogenous
cellular systems. In particular, the project was set up:
 to investigate expression and internalization properties of CRH-R1 splice
variants
 to study structural and functional characteristics of CRH-R1d, a splice variant
with impaired signalling characteristics
 to characterise signalling and internalization characteristics of CRH-R2β 
 to investigate the regulation of CRH-R1 gene expression and signalling
characteristics of endogenous CRH-Rs in human pregnant myometrial smooth
muscle cells
 to characterise CRH-R signalling in brown adipocytes
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1
2 MATERIAL AND METHODS
2.1 LIST OF BUFFERS AND CHEMICALS
 Dulbecco’s PBS
0.132 g CaCl-2H2O, 0.2 g KCl, KH2PO4, 0.1 g MgCl2-6H2O, 8.0 g NaCl, 1.15 g
Na2PO4, up to 1000 ml in distilled water.
 Stimulation buffer for cAMP assay
1mM 3-isobutyl-1-methylxanthine (IBMX), 1M MgCl2 in DMEM
 HBSS with 2mM CaCl2 and 30mM HEPES
0.294 g CaCl2 x 2H2O , 0.4 g KCl, 0.06g KH2PO4, 0.1 g MgCl2 x 6H2O, 0.1 g MgSO2 x
7H2O, 8 g NaCl, 0.35 g NaHCO3, 0.048 g Na2HPO4, 1 g D-glucose, 7.149 g HEPES up
to 1000ml in distilled water.
 HBSS without CaCl2 and 30mM HEPES
0.4 g KCl, 0.06g KH2PO4, 0.1 g MgCl2 x 6H2O, 0.1 g MgSO2 x 7H2O, 8 g NaCl, 0.35 g
NaHCO3, 0.048 g Na2HPO4, 1 g D-glucose, 7.149 g HEPES up to 1000ml in distilled
water.
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 Trypsin-EDTA in HBSS without Ca+2 and Mg+2
0.4 g KCl, 0.06g KH2PO4, 8 g NaCl, 0.35 g NaHCO3, 0.048 g Na2HPO4, 1 g D-
glucose, 10 ml phenol red 0.1 %, 2.5 g trypsin (1:250), 0.38g EDTA up to 1000ml in
distilled water.
 RIPA buffer
50 mM Tris-HCl (pH 7.4), 150 nM NaCl, 1mM PMSF, 1 mM EDTA, 5μg/ml 
aprotinin, 5 μg/ml leucopeptin, 1% Triton X-100, 1% sodium deoxycholade, 0.1% SDS 
 DNA loading buffer
1mM Tris-HCl pH 7.5, 40% glycerol (v/v), 0.1% bromphenol blue (w/v)
 L-Broth
5 g Tryptone, 2.5 g yeast extract, 5 g NaCl in 500ml destilled water, autoclaved
 L-agar plates
5 g Tryptone, 2.5 g yeast extract, 5 g NaCl, 1.5% agar (w/v) in 500ml destilled water,
autoclaved, when warm ampicillin was added to final concentration of 100μg/ml. The 
mix was poured in plates.
 L-Broth low salt
5 g Tryptone, 2.5 g yeast extract, 2.5 g NaCl in 500ml destilled water, autoclaved
 L-agar plates (low salt)
5 g Tryptone, 2.5 g yeast extract, 2.5 g NaCl, 1.5% agar (w/v) in 500ml destilled water,
autoclaved, when warm Zeocin was added to final concentration of 50μg/ml. The 
mixture was poured in plates. The plates were kept in dark at 4oC for a week.
 Buffer A
1mM EDTA, 1mM MgCl2, 1mM PMFA (phenylmethylsulfonylfluoride), 0.1% BSA,
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0.1% bacitricin in Dulbbeco’s PBS (without MgCl2 and CaCl2), pH 7.2
 Buffer B
1mM EDTA, 1mM MgCl2, 1mM PMFA (phenylmethylsulfonylfluoride), 0.1% BSA,
0.1% bacitricin in 10mM TRIS pH 7.2
 Buffer D
10mM TRIS pH 7.4, 1% Triton X-100, 1% Na-deoxycholate, 0.5% SDS, 150mM
NaCl, 1mM DTT, 1mM EDTA, 0.2mM PMSF, 10μg/ml aprotinin 
SDS-PAGE & Western Blot:
 Resolving gel (10%)
4ml Acrylamide(30% 37.5:1), 3ml 1.5 TRIS pH 8.8, 120l 10% SDS, 4.84ml water,
40l 10% ammonium persulphate, 10l TEMED
 Stacking gel (4.5%)
1.5ml Acrylamide(30% 37.5:1), 2.5ml 0.5 TRIS pH 6.8, 100l 10% SDS, 5.8ml
water, 100l 10% ammonium persulphate, 10l TEMED
 2X SDS-PAGE Loading buffer (stock)
6% SDS, 20% glycerol in 0.12M TRIS pH 6.8
 SDS-PAGE Loading buffer (working solution)
900l 2X SDS-PAGE loading buffer, 100l β-mercapto-ethanol, 50l 0.08%
bromphenol blue
 10X Electrode Buffer
30g TRIS, 144g glycine, 10g SDS and distilled water to 1000ml
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 Transfer Buffer
7.575g TRIS, 36g glycine, 500ml methanol, distilled water to 2500ml
 10X TBS
24.2 g Tris base, 80 g NaCl, up to 1000ml distilled water, pH 7.6
 Wash Buffer TBS/T (500 ml)
50 ml 10X TBS in 450 ml distilled water, add 0.5 ml Tween-20.
 Blocking Buffer
1X TBS, 0.1% Tween-20 with 5% w/v nonfat dry milk or BSA
 10% Ammonium persulphate (APS)
0.1 g ammonium persulphate in 1 ml distilled water, made up prior to use and stored at
4oC for a week
 Coomassie blue staining solution
0.1% (w/v) Coomassie blue G-250, 40% (v/v) methanol, 7% (v/v) acetic acid in
distilled water
 De-staining solution
40% (v/v) methanol, 7% (v/v) acetic acid in distilled water
 Ponceau-S staining solution
0.5% (w/v) Ponceau-S, 1% (v/v) acetic acid in distilled water
Glycerol-PAGE
 10X Running buffer
7.575g TRIS, 36g glycine (20mM Tris-glycine)
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 Urea sample buffer
4.8g urea (8M), 1ml 10X transfer buffer (20mM Tris-glycine pH~8.8), 0.5ml glycerol
(5%), 10μl DTT stock (10mM),water to 10ml 
 Resolving gel
1ml Tris-glycine (20mM Tris-glycine pH8.6), 4ml glycerol (40%) ,3ml 30%
acrylamide/bis 19:1 (10%), 10μl TEMED, 40μl (10%)APS, 2ml water 
 Stacking gel
1ml Tris-glycine (20mM Tris-glycine pH8.6), 4ml glycerol (40%), 1.16ml 30%
acrylamide/bis 19:1 (3.5%), 10μl TEMED, 40μl (10%)APS, 3.84ml water 
2.2 PATIENTS
Pregnant myometrial biopsies were obtained from women undergoing elective
caesarean section at term (39/40 weeks) before the onset of labour for nonmaternal
problems at the Women’s Hospital, Walsgrave Hospital, Coventry, UK. The biopsy
was standardised to the upper margin of the lower segment of the uterus in the midline.
This provides the closest approximation to the upper segment of the uterus. The study
was approved by the local Ethics Committee and informed consent was obtained from
all participating patients prior to operation.
The myometrial biopsy was collected in ice-cold Hank’s balanced salt solution
(HBSS) (Gibco-Europe, Uxbridge, UK) containing penicillin and streptomycin
(100g/ml) (prepared in our laboratories) and used for cell culture.
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2.3 TISSUE CULTURE METHODS
2.3.1 Primary myometrial cell cultures
All cell culture techniques presented in this project were carried out under a
flow cabinet (sterile conditions) assigned for handling animal tissues or human
material, and using sterile dissecting tools to avoid any kind of contamination.
2.3.1.1 Digestion and primary culture
Each biopsy (100-300 mg) was washed several times in HBSS (without Ca+2) in order
to remove any excess blood. The tissue was placed this in the shallow lid of the
petridish and chopped into 2 mm3 pieces with sterile round edged scalpel. The tissue
was transferred in 10mL HBSS to be washed (repeat if necessary to get rid of excess
blood cells). Finally the tissue pieces were placed in a 50 ml Falcon tube containing
10ml of enzyme solution (1% pen/strep, 1mg/ml collagenase IAS, 1mg/ml collagenase
XI, 0.5% BSA (fatty acid free) in HBSS (without Ca+2)). Tissue was incubated in the
enzyme solution for 30-40 minutes at 37oC. Meanwhile, the cells were dissociated by
pipetting through sterile plastic pipette (more than 100 times).1-2 malls of supernatant
(containing dissociated cells) was removed and put through a cell sieve (Falcon, 70
μm), and collected in the normal growth media (DMEM containing 10% FCS, 1% 
glutamine, 0.3% Pen/Strep). Gradually all digest was put through the sieve. The cells
were span at 1000rpm for 10-20min. The supernatant was removed, the cells were
washed 1-2 times, and resuspended in the normal growth media, and transferred into a
25cm2 tissue culture flask. The cells were incubated at 37oC in atmosphere of 95% : 5%
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(air : CO2). After 1-2 hours, unattached cells (smooth muscle cells) were removed and
left to grow in the fresh culture medium. For a week the medium was changed every
day.
2.3.1.2 Subculture of primary myometrial cells
When cells were 85-95 % confluent, the medium was removed by aspiration
and monolayers were washed twice with PBS, pre-warmed at 37oC, to remove any
debris and traces of FCS which would inhibit the action of trypsin. 3mls of
trypsin/EDTA solution per 75 cm2 flask were added and cells were incubated for 5min
at 37oC. Detachment of cells was monitored using light microscopy. The action of
trypsin was stopped by addition of 15 ml the normal growth media medium, pre-
warmed at 37oC. Cells were span at 1000rpm for 5min, and resuspended in the normal
growth media. The total volume of culture medium added was enough to distribute
cells in 3 75cm2 flasks, or 9 six-well plates. In the most of experiments cells of passage
4 were used.
2.3.2 Culture of HEK 293 cell line
Human Embryonic Kidney (HEK) 293 cells were obtained from the European
Collection of Animal Cell Cultures (EACCC). HEK 293 cells were routinely
maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) with Glutamax (Gibco-
Europe, Uxbridge, UK) containing 10% fetal calf serum (FCS), 100 U/ml penicillin
and 100 g/ml streptomycin. The media was replaced every 2-3 days. Confluent cells
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cultures grown in vented flasks were washed with PBS and subcultured using
trypsin/ETDA made up in Hank’s salt balanced solution (without calcium and
magnesium). 3mls of trypsin/EDTA solution per 75 cm2 flask were added and cells
were incubated for 1-2 min at 37oC. Detachment of cells was monitored using light
microscopy. The action of trypsin was stopped by addition of 15 ml the normal growth
media medium, pre-warmed at 37oC. Cells were span at 1000rpm for 5min. The pellet
was diluted in culture medium to the total volume required and distributed among
several flasks. To freeze stocks of cells for future use, cells were trypsinized as
described above. The pellet from one medium flask was resuspended in 4.5mls freezing
medium containing 90% FCS and 10% MDSO. 1.0 ml of cell suspension was place in a
cryovial, and stored at –70oC for not longer than 24 hours, and then transferred and
stored in liquid nitrogen.
To revive frozen cells, each cryovial was warmed at 37oC and the contents were
transferred in a 25 cm2 vented flask containing 5-7 ml pre-warmed normal growth
media. The cells were incubated at 37oC in atmosphere of 95% : 5% (air : CO2). The
following day the medium was replaced.
2.3.3 Transient transfection in HEK293 cells
The Lipofectamin2000 (Invitrogen) was used for transfection in HEK293 cells.
Transient transfection was carried out in 50-70% confluent cells seeded in 25cm2 or
75cm2 vented flasks. 5μg or 10μg DNA was transfected in 25cm2 or 75cm2 vented
flask, with 5μl or 10μl ipofectamin2000 reagent, respectively in 5 ml or 10ml of 
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OptiMEM+GlutaMax (Gibco), for overnight according to manufacturer’s instructions.
Following morning the transfection mixture was replaced with normal growth media.
The same evening cells were transferred onto poly-D-lysine (sigma) coated plates (6,
12 or 24-well plates) or on coated glass cover slips (for confocal microscopy studies).
The experiments were carried out 48-96h after transfection. Expression was verified by
immunoblotting and confocal microscopy analysis.
2.3.4 Stable transfection in HEK293 cells (st293 R2β) 
For stable transfection 10μg pcDNA3.1(+) CRH-R2β plasmid was transfected 
into HEK293 cells grown in 75cm2 vented flasks using Lipofectamine2000, as above.
After 3 days non-selective growth in normal growth media, followed by 15 days of
growth in the same media with 500μg/ml gentamicin (G418, Gibco), clones were 
selected by serial dilution of surviving foci and maintained in 250μg/ml gentamicin. 
The optimal concentration of gentimcin and the length of cell growth before cloning
out was determined by growing non-transfected HEK293 cells in media containing
different concentrations of the antibiotic (50-1000μg/ml) for 21 days and performing a 
cell viability MTT (thioazolyl blue) assay (as described later). After 2 months the
expression of CRH-R2β was verified by PCR, immunoblotting, confocal microscopy 
analysis, and functional assays (including cAMP production and ERK activation). A
clone that had shown the most desirable properties was used in further studies. The
stables were maintained in DMED with Glutamax containing 10% FCS, 100 U/ml
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penicillin and 100 g/ml streptomycin and 250 g/ml gentamicin, until reaching
passage 18, when a fresh frozen stock of the same clone was revived.
2.3.4.1 MTT assay
Cells were seeded in 24-well plates. After the treatments, the media was removed,
and 200μl of 1mg/ml MTT in HBSS was added in each well. The cells were incubated 
at 37oC for 20-30min or until the cells show purple tinge. The MTT solution was
aspirated off. Add 200μl of DMSO, collect samples into a 96-well plate and measure 
absorbance at 550nm.
2.3.5 Culture of T37i cells
The T37i cell line was derived from a hibernoma (malignant brown fat tumor) of
the transgenic mouse founder 37 carrying a hybrid gene composed of the human MR
proximal promoter linked to the SV40 large T antigen. T37i cells were cultured in
DMEM-Ham’s F12 medium supplemented with 10% FCS, 2mM glutamine, 100 U/ml
penicillin and 100 g/ml streptomycin, and 20nM HEPES (containing 1g/l glucose)
and were grown in at 37oC in a humidified atmosphere with 5%CO2. Differentiation
into adipocytes was achieved under standard conditions by incubating subconfluent
undifferentiated T37i cells with 2nM triiodothyronine (T3) and 20nM insulin for 10-13
days. The differentiation process was monitored by examining cells for lipid droplet
formation under light microscope, and staining cells with oil-O-red (Sigma). 18h prior
to treatment the cells were washed and starved, in DMEM-Ham’s F12 medium
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supplemented with 0.5% fatty acids free BSA, 2mM glutamine, 100 U/ml penicillin
and 100 g/ml streptomycin, and 20nM HEPES. 2h prior to treatments the cells were
washed and incubated in plain DMEM-Ham’s F12.
2.3.5.1 Cell proliferation assay
T37i were grown in a 96-well plate until 50% confluent. The cells were treated
with 1-100nM UCNII and CRH for 24 and 48h. Promega’s CellTiter 96® AQueous
One Solution Cell Proliferation Assay was used according to manufacturer’s
instruction. The assay is colorimetric method for determining the number of viable
cells in proliferation or cytotoxicity assays. The assay contains tetrazolium compound
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphenyl)-2H-
tetrazoliun, inert salt, MTS] and an electron coupling reagent (phenazine ethosulfate,
PES). The MTS tetrazolium compound is bioreduced by cells into a coloured formazan
product that is soluble in tissue culture medium. This conversion is accomplished by
NADPH or NADH produced by dehydrogenase enzymes in metabolically active cells.
Assays are performed by adding 20μl of the supplied reagent directly to culture wells, 
incubating for 1-4 hours and reading the absorbance at 490nm. One row of a 96-well
plate did not have cells, it contained only media, and the absorbance from that row was
used as a background absorbance.
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2.4 SECOND MESSANGER STUDIES: cAMP PRODUCTION
2.4.1 Stimulation of cells
The assay was performed on myometrial smooth muscle cells, transiently and
stably transfected HEK293 cell, T37i cells. The cells were plated in 12 well plates.
When 70-80% confluent the media was aspirated from the cells and the cells were
washed with plain DMEM. The stimulation buffer (with 10mM MgCl2 and 0.1mg/ml
IBMX) was placed on the cells for 20 min at 37oC. The buffer was removed, cells
washed with plain DMEM, and stimulated with 1-100nM UCNII, CRH and UCN for
15min, as a positive control 10μM forskolin was used. The reaction was stopped by 
adding 10μl of concentrated HCl. After 15-20 min most of the cells have burst. The 
cells were scraped and the transferred in 1.5ml tube. After a brief spin, the cells and
media were stored at -20oC.
In some instances, myometrial smooth muscle cells were incubated with IL-1β 
(1ng/ml) for 2h and 18h before the stimulation buffer was placed on the cells.
2.4.2 Receptor desensitization/ cAMP production
When 80% confluent st293-R2β (in 12-well plates) the media was aspirated 
from the cells and the cells were washed with plain DMEM. The stimulation buffer
(with 10mM MgCl2 and 0.1mg/ml IBMX) was placed on the cells for 20 min at 37oC.
The buffer was removed, cells washed with plain DMEM, and pre-treated for various
time intervals (0-30min) at 37oC with 100nM UCN-II or CRH, following a brief wash
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the cells were stimulated with 100nM UCN-II for 15min. The reaction is stopped with
addition of 10μl concentrated HCl, as described above.  
2.4.3 cAMP measurement
The cAMP levels were determined by commercially available ELISA Direct
Cyclic AMP Enzyme Immunoassay Kit (Assay Designs Ins., Ann Arbor, MI, USA) or
cAMP low pH ELISA kit (R&D systems, Minneapolis, MN, USA). The supernatant of
HEK293 cells transiently or stably expressing CRH-R was diluted two times (except
the basal, not diluted); however supernatant of myometrial smooth muscle cells and
T37i were used neat. All of the treatments have been done in duplicates or triplicates,
and all experiments have been repeated at least three times. The assay was performed
according to the manufacturer’s instructions.
2.5 MOLECULAR BIOLOGY TECHNIQUES
2.5.1 Gel electrophoresis of DNA and RNA
Vertical gel electrophoresis was routinely used to analyze DNA and RNA.
Agarose concentration was 1.5-2% in TBE, depending on the fragment to be analyzed.
DNA and RNA were visualized by ethidium bromide (0.25μg/ml) present in gels. 
Samples were loaded in a volume 10-20μl with 1/5 volume of loading buffer. 
Electrophoresis was carried in 1X TBE, at 80-120V for 1-2 hours. The nucleic acids
were visualized under UV light of GenDoc system.
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2.5.2 Gel purification of DNA fragments
Agarose gels were exposed to UV light and the DNA fragments were cut out with
a clean razor blade. The DNA was purified from the agarose slice using a Qiagen gel
purification kit, according to the manufacturer’s guidelines.
2.5.3 RNA isolation
70-80% confluent cells from a well of 6 well plates were used for RNA
extraction. After a treatment cells were washed with ice cold PBS, and left in a lysis
buffer (from Sigma GenElute Mammalian Total RNA Kit) for 10 min or until the
solution becomes viscose. The extraction was done by using Sigma GenElute
Mammalian Total RNA Kit, according to the manufacturer’s guidelines.
2.5.4 Determination of DNA and RNA concentration
DNA and RNA concentration was determined on a NanoDrop system. 1.5μl of 
sample was loaded in a chamber.
2.5.5 RT-PCR (reverse transcription polymerase chain reaction)
0.2-1μg RNA (1-3μl), 1.5μl random hexamers and up to 16.5μ of molecular 
biology grade water, were mixed in a sterile ependorf tube, and heat at 70oC for 5min,
and then cooled slowly to the room temperature. Once at room temperature the RNA
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was span down and the following mixture was added in: 3l dNTP (10mM), 6l of 5 x
buffer, 1.5l RNasin, 0.5l AMV(25u/l), and 2.5l water. The mixture was span
and set to the following cycle: 37oC for 60 mins (reverse transcription), 95oC for 5 mins
(inactivates AMV and separates the 2 cDNA strands), ice for 5 mins (prevents the
cDNA reanniling, this step should eliminate the use for ‘hot start’ PCR). cDNA was
stored at -20oC.
2.5.6 Primers design
cDNA sequence was found using NCBI database. The sequence was loaded in
Primer3 Input (primer3_www.cgi v 0.2). The product size was chosen to be 250-350bp,
Tm was set 57-63 oC, and the primer size 18-24bp. The resulting primers were checked
for specificity by nucleotide-nucleotide BLAST. The primer sequences for PCR were
given in Methods section of each results chapter
2.5.7 Polymerase chain reaction (PCR)
The PCR mixture was prepared as in the table 2.1:
MgCl2 (50mM) 0.6l
NH+4 buffer (x10) 2.0l
dNTP(10mM each) 0.4l
PrimerA(0.1g/l) 1.0l
PrimerB(0.1g/l) 1.0l
Taq 0.2l
cDNA 4.0l (can vary)
water up to 20l
Table 2.1: PCR reaction components used for majority of PCR reaction
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After the brief spin, the PCR reactions were set according to the program as
described in a table 2.2
1. 95oC 5min
2. 95oC 15-60sec (denaturation of ds
DNA)
3. 55-60oC 30-60sec (temperature depends
on primers Tm. Since majority of
the primers have Tm around
60oC, this step is usually done at
58oC. If there is no band then
temperature should be lower, if
there are too many bands then
temperature should be higher.)
(annealing of primers to ssDNA)
4. 72oC 30-60sec (DNA polymerisation)
5. go to 2 repeat N times ( 15<N<35, start with 30 cycles, then
change if needed)
6. 72oC 7min
7. hold on 4oC
Table 2.2: Standard PCR conditions
The products were stored at -20oC until run on an agarose gel (as described in
2.4.1)
2.5.8 Real time PCR performed on a Light Cycler system
Quantitative (real time) PCR of cox-2 (PGHS-2) was performed on a Roche
Light CyclerTM system (Roche Molecular Biochemicals, Germany). The PCR reaction
was carried in a 10 μl reaction mixture containing 5μl of PCR 2x Mastermix with 2mM 
MgCl2, 0.5μl of Light Cycler DNA Master SYBER®Green I, 1μl of each primer 
(2ng/μl), and 1μl of cDNA. The PCR protocol consisted of a denaturation step at 95oC
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for 15 secs, followed by 40 cycles of amplification at 95oC for 5 secs, 58oC for 10 secs,
and 72oC for 15 secs, and finally by a melting curve analysis step at 95oC for 0 secs,
56oC for 15 secs and 99oC for 0 secs. For analysis, quantitative amounts of gene of
interest were standardised against the house-keeping gene β-actin. As negative 
controls, preparations lacking RNA or reverse transcriptase were used. RNA
expression was tested in four independent experiments. The mRNA levels were
expressed as a ratio, using the “Delta-delta method” for comparing relative expression
between treatments. The PCR products were sequenced in an automated DNA
sequencer (Dept of Biological Sciences, The University of Warwick, UK) and the
sequence data was analyzed using Blast Nucleic Acid Database Searches from the
National Centre for Biotechnology Information (NCBI).
2.5.9 Real time PCR performed on a TaqMan System
Dr. Mei Gu performed quantitative PCR on a TaqMan Gene Expression Assay
(Applied Biosystems, UK) to determine expression levels of various CRH-R1 mRNA
variants in human gestational myometrium and human primary myometrial cells.
Briefly, four sets of oligonucleotide primers and four TaqMan probes specific for
various human CRH-R1 mRNAs were designed from the GenBank database by
mySciences (Applied Biosystems, UK). Real-time RT-PCRs were performed using the
ABI PRISM 7000 Sequence Detection System (Applied Biosystems) in a total volume
of 30 µl reaction mixture following the manufacturer’s protocol, using the SYBR
Green Universal 2x PCR Master Mix (Applied Biosystems) and 0.1 µM of each primer
using the dissociation protocol for the amplification of CRH-R1 mRNA variants.
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Negative controls contained water instead of first-strand cDNA were also used. Each
sample was normalized on the basis of its 18S ribosomal RNA content (house keeping
gene). The 18S quantification was performed with a TaqMan ribosomal RNA reagent
kit (Applied Biosystems) using the manufacturer’s protocol. All samples were run in
triplicate and results were calculated with reference to the amplification of 18S rRNA
using comparative Ct method for relative quantitation (ABI Prism 7000 SDS v1.1
software). Results were calculated with the Ct method; they were expressed as the
n-fold differences in gene expression relative to 18S rRNA and calibrator and were
determined as follows: n-fold = 2 – (Ct sample – Ct calibrator), where the parameter Ct
(threshold cycle) is defined as the fractional cycle number at which the PCR reporter
signal passes a fixed threshold. Ct values of the sample and calibrator were
determined by subtracting the average Ct value of the transcript under investigation
from the average Ct value of the 18S rRNA gene for each sample.
2.6 MUTAGENESIS AND CLONING TECHNIQUES
2.6.1 PCR mutagenesis of 14 amino acids within the 7th TMD of CRH-R1
The CRH-R1d isoform lacks 14 amino acids encoded by 13th exon. In order to
see which amino acids are required for CRH-R1 to be expressed in the plasma
membrane, the series of CRH-R1α and CRH-R1d mutants were made containing 3 
amino acids deletion or insertion. Primers that have mismatched sequences to template
DNA were used to introduce a mutation through the process of PCR amplification as
described by Higuchi in 1988 (Higuchi R et al., 1988). Overlap extension PCR (OE-
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PCR) utilizes four primers in two sequential PCR reactions to introduce an internal
mutation into the target sequence (Figure 2.1). Two separate PCR reactions are run,
using primers F (forward primer containing a sequence for HindIII restriction site
adjacent to the 5’-of the receptor sequence 5’-
CCCAAGCTTGGGATGGGAGGGCACCCGCAGCTCCGTCT-3’) and RM (reverse
primer that contain a mutation), and primers R (reverse primer containing 3’-end of the
receptor sequence and a sequence for XbaII restriction site 5’-
TGCTCTAGAGCATCAGACTGCTGTGGACTGCTTGATGC-3’) and FM (forward
primer that contain a mutation) to amplify separate, overlapping sequences of the
template DNA. Primers RM and FM have overlapping homologous regions containing
the required mutation (reverse complement sequences). The fragments were run on a
2% agarose gel, purified and combined, denatured, reannealed and amplified by third
PCR reaction using primers F and R, the outer, conserved primers. The PCR conditions
were empirically established. The reaction was performed on a Hybaid Thermal
Reactor. The reaction mixture were run on 2% agarose gel and visualized by ethidium
bromide staining, cut and purified from a gel as described above. In order to estimate
the band size 1Kb DNA ladder (Bioline) was used. A representative agarose gel with
PCR products from reaction 1, 2 and 3 is shown on Figure 2.2.
The PCR components are shown in the table 2.4, the PCR program is shown in
the table 2.5, and the nucleotide sequences of primers used to create mutant CRH-R1α 
and CRH-R1d receptors are given in the table 2.6.
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Figure 2.1. Schematic representation of OE-PCR. Desired mutations
(deletion or insertion) were introduced with three separate PCR reactions. RM-
reverse mutation containing primer and conserved forward, F, primer were
used in the reaction 1. In the reaction 2, FM-forward mutation containing
primer and conserved reversed, R, primer were used. The PCR products were
separated on 2% agarose gel and purified. The resulting products were used as
templates for the PCR reaction 3 with F and R primers.
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Figure 2.2. Products of PCR reactions. A representative agarose gel with
PCR products from reaction 1, 2 and 3.
PCR reaction buffer                              2 μl 
Pfu polymerase (1.5u/μl)                       0.5 μl 
Each primer(0.1g/l) 1.0l
DNA tamplate 5ng
dNTP (10μM each)                                0.4μl            
water up to 20l
Table 2.4: PCR reaction components used to generate CRH-R1α and CRH-
R1d mutants.
Temp (oC) Time (min) Number of
cycles
Initial
denaturation
95 5 1
Denaturation 95 0.45 35
Annealing 48 0.45 35
Extension 72 1.5 35
Final extension 72 7 1
Table 2.5: PCR conditions used for the two first rounds of the overlap
extension PCR and for the overlapping PCR.
ladder
No
water
Reaction
1
Reaction
2
Reaction
3
1221 bp1005 bp
216 bp
Non-spec. product
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CRH-R1α 
Δ(356-358) 
FM: 5’GGAATCCTTCCAGGTGTCTGTGTTCTACTGTTTCC
RM:5’GGAAACAGTAGAACACAGACACCTGGAAGGATTCC
CRH-R1α 
Δ(359-361) 
FM:5’GGAATCCTTCCAGGTCTACTGTTTCCTCAATAGTGAGG
RM:5’CCTCACTATTGAGGAAACAGTAGACCTGGAAGGATTC
C
CRH-R1d
+(356-358)
FM:5’GGAATCCTTCCAGGGCTTCTTTGTCCGTTCTGCCATCC
RM:5’GGATGGCAGAACGGACAAAGAAGCCCTGGAAGGATT
CC
CRH-R1d
+(356-361)
FM:5’ CCTTCCAGGGCTTCTTTGTGTCTGTGTTCCGTTCTGCC
RM:5’GGCAGAACGGAACACAGACACAAAGAAGCCCTGGAA
GG
CRH-R1d
+(356-364)
FM:5’CCAGGGCTTCTTTGTGTCTGTGTTCTACTGTTTCCGTTC
TGCC
RM:5’GGCAGAACGGAAACAGTAGAACACAGACACAAAGAA
GCCCTGG
Table 2.6: Nucleotide sequences of primers used to created CRH-R1α and 
CRH-R1d mutants.
2.6.2 Digestion and ligation of CRH-R1α and CRH-R1d mutant inserts into 
pcDNA.3.1(+)
The purified fragments were digested with HindIII and XbaII at 37oC overnight.
The following mix was prepared:
HindIII             1μl 
XbaI             1μl 
Tango buffer    2μl 
DNA                 4μl (can vary) 
Water                up to 20μl  
The digested inserts were run on 2% agarose gel, cut and purified. The Ligation was
performed with FastLiga System from Promega. The vector and the insert DNA were
mixed in a 3:1 molar ratio of insert to vector in 10μl containing 1μl T4 ligase and 5μl of 
accompanying buffer and incubated at room temperature for 5minutes.
The amount of insert was determined using the following formula:
Insert (ng)= (100ng (vector) x A Kb (insert) x 3)/ B Kb (vector)
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After transformation into E.coli DH-α and purification of plasmid (described 
later), the resulting plasmid were digested with HindIII and XbaII at 37oC for 2h to
determine the presence of inserts. The plasmids containing the inserts were sequenced
(Molecular Biology Service of the Biology Department, University of Warwick).
2.6.3 PCR mutagenesis of 4 amino acids in the C-terminus of CRH-R2β 
The amino acid homology of CRH-R2β and CRH-R1α is ~70%. The C-terminus 
of CRH-R2β has the following sequence: Thr-Ala-Ala-Val (TAAV), and CRH-R1α has 
this sequence Ser-Thr-Ala-Val (STAV). CRH-R2β receptor was mutated that way that 
it contains the STAV instead of TAAV in the C-terminus. Also two other mutants were
created: Ala mutant, which has four alanines instead of the TAAV sequence, and Del
mutant, which contained a deletion of the last four amino acids from the C-terminus.
These mutants were created using one PCR round. The forward primer (common)
contained a sequence for EcoRI restriction site adjacent to the 5’-of the receptor
sequence, while the reverse primer was specific for each mutant and contained the
sequence for XhoI restriction site (chapter 5). PCR mixture and PCR conditions were
same as described in 1.6.1.
2.7 DUAL EXPRESSION VECTOR
pBudCE4.1 expression vector contains two promoter sites (CMV and EF-1α). 
The expression of CRH-R1α or CRH-R1d (with or without stop codons)  was driven 
from CMV promote. These receptors were ligated into the vector on HindIII and XbaI
sites. The receptors that lacked stop codon had C-tagged myc. The expression of CRH-
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R2β was driven from EF-1α promoter. The insert was ligated into the vector on KpnI
and BglII sites. CRH-R2β was V5 tagged at the C-terminus (Figure 2.3). 
The receptors cDNA was cut from constructs already available in the lab. The
restriction sites at the 5’ and 3’ end of the cDNA were introduced with sets of primers
(Table 2.7).
R2β-rev 5’GAAGATCTTCTCACACAGCGGCCGTCTGCTTGATG3’ 
R2β-rev(no 
stop codon)
5’GAAGATCTTCCACAGCGGCCGTCTGCTTGATG3’
R2β-for 5’CGGGGTACCCCGATGAGGGGTCCCTCAGGGCCCCCAGG3 
R1α/d-rev 5’TGCTCTAGAGCATCAGACTGCTGCTGTGGACTGCTTGAT
GC3’
R1α/d-rev(no 
stop codon)
5’TGCTCTAGAGCAGACTGCTGCTGTGGACTGCTTGATGC3’
R1α/d-for 5’CCCAAGCTTGGGATGGGAGGGCACCCGCAGCTCCGTCT3’
Table 2.7. Primer sequences used to insert CRH-Rs cDNA into pBudCE4.1.
Figure 2.3. Map of pBudCE4.1. CRH-R2β cDNA was inserted between 
KpnI and BglII restriction sites. CRH-R1α or R1d cDNA was inserted between 
HindIII and XbaI restriction sites (adapted from www.invitrogen.com).
CRH-R2 CRH-R1d or
CRH-R1
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2.8 BACTERIAL METHODS
2.8.1 Transformation of E.coli DH5-α with pcDNA based plasmids 
100μl of competent cells (E. coli DH5-α, Invitrogen), were transferred into a pre-
cooled 15ml Falcon tube. Then 1-10ng of plasmid DNA was added to the cells, by
moving the pipette through the cells while dispensing. After the incubation of 30 min
on ice, the cells were heat-shocked at 42oC for 45 sec. The tube was placed on ice for 2
min, then 0.9 ml of LB was added and the cells were incubated at 37oC for 1h with
shaking.  After 1h, the cells were diluted 1:100 with LB, and 100μl (or 200μl) was 
spread on an LB100amp plate (containing ampicilin). The plate was incubated at 37oC
overnight.
2.8.2 Transformation of E.coli DH5-α with pBUD ce4.1 based plasmids 
100μl of competent cells (E. coli DH5-α, Invitrogen), were transferred into a 
pre-cooled 15ml Falcon tube. Then 1-10ng of plasmid DNA was added to the cells, by
moving the pipette through the cells while dispensing. After the incubation of 30 min
on ice, the cells were heat-shocked at 42oC for 45 sec. The tube was placed on ice for 2
min, then 0.9 ml of LB (low NaCl) was added and the cells were incubated at 37oC for
1h with shaking.  After 1h, the cells were diluted 1:100 with LB (low NaCl), and 100μl 
(or 200μl) was spread on a LB (low NaCl) containing 100μg/ml Zeocine (Gibco). The 
plate was incubated at 37oC overnight.
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2.8.3 Mini-prep of plasmid DNA
Single colony was picked up and grown in 4-5ml of LB 100μg/ml ampicillin (if 
insert in pcDNA3.1) or in low salt LB 100μl Zeocine (if inserts in pBUD ce4.1). The 
cells were incubated at 37oC overnight with shaking. The following morning, the cells
were harvested at 4000rpm for 5min. The Qiagen miniprep kit was used for the DNA
preparation following the manufacturer’s instructions.
2.8.4 Midi-prep of plasmid DNA
Single colony from a plate was used to inoculate a 100mls of LB Broth with the
selective antibiotic (100μg/ml ampicillin if insert in pcDNA3.1 or in low salt LB 100μl 
Zeocine if inserts in pBUD ce4.1), and was cultured at 37oC overnight with shaking.
The cells were harvested by centrifugation and the DNA was prepared with the Qiagen
HiSpeed Plasmid midiprep kit according to the manufacturer’s instructions.
2.9 BIOCHEMICAL TECHNIQUES
2.9.1 Preparation of membrane fraction from cultured cells
Membrane and membrane associated proteins were extracted with
ProteoExtract® native Membrane Protein Extraction Kit (M-PEK) from Calbiochem.
The proteins were extracted in the mild and non-denaturating conditions, making it
suitable for variety of assays (co-immunoprecipitation, kinase assays, non-denaturating
gel electrophoresis; also for SDS-PAGE). The extraction is based on a robust yet mild
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differential extraction procedure. In contrast to the two phase partitioning techniques,
where detergents are used to separate membrane proteins based on their
hydrophobicity, the kit’s uses differential extraction procedure selectively extracts
integral and membrane-associated proteins based on their actual association with
cellular membranes.
Cells (st-293-R2β) were grown in poly-D-lysine coated 60mm cell culture 
dishes. When 60-70% confluent, cells were deprived of FCS for 1h, and treated with
100nM UCNII and CRH for 2, 10 and 15min. Media was removed, dishes placed on
ice, and cells were washed twice with 2ml wash buffer. 10μl of protease inhibitors was 
added on the well of the dish and 2ml of extraction bufferI was added in the dish. The
dish was gently swirl that buffer and protease inhibitors can mix, and the dish was
placed on an agitation rotor in the cold room for 15min. The extraction bufferI was
removed and collected since it contained soluble proteins. 5μl of protease inhibitors 
was added on the well of the dish and 1ml of extraction bufferII was added in the dish.
The dish was gently swirl that buffer and protease inhibitors can mix, the cells were
scraped and transferred in 2ml ependorff tube. The tube was placed in a rotary shaker
in the cold room for 15min. The proteins were spun down at 16,000xg at 4oC for
15min. The supernatant containing membrane proteins was collected, aliqoted and
stored at -20oC. The protein concentration was determined as described later. 5μg of 
proteins was used for SDS-PAGE.
For some experiments, plasma membranes were made by homogenizing cells
in the extraction buffer A. Unbroken cells and nuclei were removed by a spin at 600g
for 30 min at 4oC. The supernatant was collected and centriguged at 40,000g for 60 min
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at 4oC. The pellet was washed twice with the buffer B. After the final spin, the pellet
was resuspended in buffer B. The proteins were aliqoted and store at -80oC.
2.9.2 Preparation of total cellular proteins from cultured cells
60-70% confluent cells were serum starved overnight. The following morning
fresh media was placed on cells for 1h before the treatments were added. After the
treatments, the media was removed, cells were briefly washed with ice-cold PBS, and
75-200μl of 2X Sample buffer (sigma) was added on the cells. The cells were kept on 
ice and total proteins were collected by scraping the cells with a blue tip and placing
the proteins in 1.5 ml ependorf tubes. The proteins were sonicated for 20sec, boiled for
5min, briefly span down, and stored at -20oC until used. Alternativly, instead of lysing
cells in 2X Sample buffer, the cells were lysed in 75-200μl of RIPA buffer containing 
protease and phosphatase inhibitors. The cells were scraped in RIPA buffer, transferred
in 1.5 ml ependorf tubes and left on ice for 15 min, then the suspension was sonicated
for 10 secs, and left on ice for 30 min. The resulting lysates were centrifuged for 10
min at 4oC at 10,000g. The supernatant was collected, protein concentration was
determined, and the proteins were stored at -20oC.
2.9.3 Determination of protein concentration
To determine the protein concentration from the cell lysate the bicinchoninic
acid (BCA) protein assay (Pierce) was used. The principle of this method is based on
the reduction of Cu+2 to Cu+1 by protein in an alkaline medium (the biuter reaction) and
the highly sensitive and selective colorimetric detection of the cuprous cation using
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BCA containing reagent. The purple-colored reaction product of this assay is formed
by the chelation of two molecules of BCA with one cuprous ion. This complex has a
strong absorbance at 562 nm which is nearly linear with increasing protein
concentration over a broad concentration range (20-2000μg/ml). The advantage of this 
assay is a detergent-compatibility. The assay was performed according to the
manufacturer’s instructions. Briefly, the standards were prepared as described in the
table 2.8. The unknown protein concentration was determine by using two different
dilution (1:5 and 1:10) of proteins from cell lysates.
vial Volume of
diluent (µl)
Volume and source of
BSA (µl)
Final BSA
concentration
A 0 300μl of stock 2000 μg/ml 
B 125 375 μl of stock 1500 μg/ml 
C 325 325 μl of stock 1000 μg/ml 
D 175 175 μl of vial B 750 μg/ml 
E 325 325 μl of vial C 500 μg/ml 
F 325 325 μL of vial E 250 μg/ml 
G 325 325 μL of vial F 125 μg/ml 
H 400 100 μL of vial G 25 μg/ml 
I 400 0 0 μg/ml (blank) 
Table 2.8: Preparation of diluted Albumin (BSA) standards
All vials were vortexed and incubated at 37°C for 30 minutes. The absorbance
of each sample at 562 nm was then determined against blank containing distilled water.
Sample protein concentration was calculated from the standard curve and corrected
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after the subtraction of the standard BSA concentration (1mg/ml) in the protein
extraction buffer (sample medium).
2.9.4 Polyacrylamide gel electrophoresis (SDS-PAGE)
The glass plates of the SDS-PAGE minigel (Mini-Protean III Electrophoresis
Cell) were assembled according to the manufacturer’s instruction (Bio-Rad). The
resolving polyacrylamide solution was poured between clean glass plates, overlaid with
water. The polymetisation usually takes 30-45 mins. After the gel has polymerised, the
overlay was washed off with distilled water and the top of the gel was dried by a filter
paper. Immediately after the stacking gel was poured on the top of the resolving gel,
the 10-well comb was inserted. The stacking gel was allowed to polymerise for 10-
15min at room temperature. When set, the comb was removed and the wells washed
with distilled water. The gels were set up in the tank following the manufacturer’s
instruction. The tank was filled up with 1X SDS-PAGE running buffer. The samples
and the BioRad protein marker were loaded onto the stacking gel wells. The
electrophoresis was run at 200V, until the dye front had migrated to the bottom of the
gel.
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Solution components 10% resolving 4.5% stacking
Gel (ml) gel (ml)
Distilled H2O 4.84 5.80
30% acrylamide mix (37.5:1) 4.00 1.50
1.5 M Tris (pH 8.8) 3.00 -
0.5 M Tris (pH 6.8) - 2.50
10% SDS 0.120 0.100
10% ammonium persulphate 0.04 0.100
TEMED 0.01 ml 0.01
2.9.5 Electrophoretic transfer to PVDF membrane
Western transfer of proteins was performed using a wet electroblotter (BioRad)
onto a PVDF membrane. Just before the gel has finished running 6x10cm pieces of
PVDF membrane were cut and the membranes were activated by soaking in 100%
methanol for 2-5 secs. The membranes were washed in ddH2O for 2mins, and
equilibrated in transfer buffer for 10-15min. Also the chromatography paper was cut (6
sheets/gel), and equilibrated in the transfer buffer, together with the fibre pads, for 10-
15min. Once when the gel has finished running the stacking gel was removed, and the
running gel (with the proteins) was equilibrated in the transfer buffer for 10-15 min.
Then the “transfer sandwich” was assembled on the black side of the cassette as
follows: fibre pad, three filter papers, gel, membrane, three filter papers, fibre pad;
close the cassette. Each layer was wetted with 1-3mls of transfer buffer, and extra care
had to be taken not to trap any air bubbles between the gel and the membrane. The
shut cassette was placed in the tank and ice-cold transfer buffer was added. The transfer
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was run at 100V for 1h, the current should be 150-200mA, (much higher or lower
current means that the transfer buffer is probably not correct.
2.9.6 Immunodetection of transferred proteins using ECL
Following electroblotting the membranes were blocked in TBS-T (TBS
containing 0.1% (v:v) Tween-20) containing 5% (w:v) BSA for 1h at room temperature
with constant shaking. After a brief wash with TBS-T, the membranes are incubated
with primary antibodies (1:250-1:1000) diluted in 5% BSA TBS-T, overnight at 4oC.
In the morning, the membranes were washed three times, 15 minutes each, with TBS-T
at room temperature. Then, the membranes were incubated with secondary horse-radish
peroxidase (HRP)-conjugated immunoglobulin (DAKO) (1:2000) diluted in 5% BSA
TBS-T for 1h at room temperature. After the washes, the antibody complex was
detected by enhanced chemiluminescence (ECL) as described by the Amersham
detection kit.
2.9.7 Stripping membranes following ECL detection
30ml of water based buffer containing 6ml of 10% SDS, 1.875 ml of 1M Tris-
HCl pH6.8, and 233μl of β-mercaptoethanol was used per membrane. The procedure 
was carried out in a fume hood. The buffer was heated to 55oC and poured over a
membrane. The temperature was kept constant for 30min (the membrane was placed in
a carrier in a water bath). Then the membrane was washed 4-5 times with TBS-T, and
immunodetection was carried as described above.
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2.9.8 Immunodetection of transferred proteins using Licor system
After completion of transfer, the PVDF membrane was incubated with 8-10ml
Licor blocking buffer (Licor) for 1h at room temperature with gentle agitation. This
step minimises non-specific binding of antibody to the membrane. After the membrane
was briefly washed TBS-T, it was incubated with primary antibody at 1:1000 dilution
in 10 ml of Licor blocking buffer with gentle agitation overnight at 4oC. This
conditions were used for majority of antibodies. However, the phospho-p44/42 MAP
kinase (Thr202/Tyr204) antibody which detects p42 and p44 MAP kinase only when
catalytically activated by phosphorylation Thr202 and Tyr204 and the p42 MAP kinase
antibody which is phosphorylation-state independent antiserum and detects total p42
MAP kinase levels were used at the same time in the dilutions of 1:1500 and 1:2000,
respectively, in Licor blocking buffer for overnight incubation at room temperature
with gentle agitation. The next day the antiserum was removed and the membrane was
washed 3 times for 10 minutes each with 15 ml of TBS-T. It was then incubated with
secondary antibody conjugated to a fluorescent entity at 1:6000 in 10 ml of blocking
buffer with gentle agitation for 1 hour at room temperature. Finally, the blot was
washed 2 more times each with 15 ml of TBS-T, and once with TBS only. The
membrane was dried between sheets of fine tissue, visualized and analysed on the
Odyssey Infrared Imaging System (LI-COR Biosciences, Cambridge,UK).
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2.9.9 Stripping membranes following Licor system detection
Membranes were placed in a stripping buffer containing 25mM glycin buffer
pH2 and 2% SDS for 15 min at room temperature. Then the membranes were placed in
fresh stripping buffer for another 15 min. Following two TBS washes (15 min each) the
membranes were placed in Licor Blocking buffer for 1h, and re-probed with
appropriate antibody.
2.9.10 Commassie blue staining of SDS-PAGE gels
The gels were stained in Commassie blue stained for 10min, the solution was
replaced with de-stain solution. Once the protein bands become visible the gel was
transferred in distilled water and scanned using Licor.
2.9.11 Glycerol-polyacrylamide gel electrophoresis
The setting was assembled the same way as for SDS-PAGE. The gel was pre-
run for 30-45min at 200V. After the samples were loaded the gel was run at 200-300V
for at least 2-3h, or until the blue dye was completely gone. The proteins were
transferred as described above.
2.9.12 RhoA activation assay
To detect RhoA translocation/activation the commercially available kit was
used (Rho activation assay, Cytoskeleton, Denver, USA). Briefly, the principe of the
assay is to detect Rho-GTP (active form). The Rho Binding Domain (RBD) of
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Rhotekin has been shown to bind specifically to Rho-GTP. This allows one to “pull-
down” Rhotekin-RBD/Rho-GTP complex with glutathione-agarose beads. Before the
treatments, the cells have been starved overnight (since RhoA activation and
translocation are FCS sensitive). The assay was performed according to the
manufacturer’s instruction. The Rhotekin-RBD/Rho-GTP complex with glutathione-
agarose beads were dissolved in 2x sample buffer, boiled for 5min, span down and 10μl 
of supernatant was loaded on a 10% PAGE-SDS gel. A separate gel was loaded with
10μl of total cell lysate to demonstrate equal amount of RhoA protein in all samples. 
Following protein transfer to a PVDF membrane, the membrane was probed with
RhoA-antibody as described above.
2.9.13 On-cell western
st293-R2β were cultured on poly-D-lysine coated 24-well plates. When 80% 
confluent, cells were treated with 100nM UCN-II or CRH for 15-45 min. Cells were
fixed with 4% PFA for 20min, and after three brief washes with PBS, non-specific
binding was blocked with Licor blocking buffer. A rabbit antibody raised against the
N-terminus of CRH-R2 was used in dilution of 1:2000 (Abcam) in Licor blocking
buffer at 4oC overnight. After 3 washes with PBS, cells were incubated with the
secondary anti-rabbit IRDye-800 antibody (dilution) 1:800 for 1h at room temperature.
The signal was detected and analysed using the Odyssey Infrared Imaging System (LI-
COR Biosciences, Cambridge,UK).
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2.10 IMMUNOCYTOCHEMISTRY AND CONFOCAL MYCROSCOPY
2.10.1 Preparation of cover slips
Round glass cover slips were placed in a beaker and treated with concentrated
acetic acid for at least 30min, then with 70% ethanol for 30min, and with the mixture of
10ml acetone containing 200μl  3-(aminopropyl)triethoxy silane (APES). After each 
treatment, the cover slips were washed with approximately 1liter of distilled water. The
cover slips were dried on air, and place in 6 well plates. Prior to use, the plates were
sterilized by UV radiation for 30 min.
2.10.2 Plating cells on the cover slips
The cover slips were coated with 100μg/ml poly-D-lysine in PBS (if HEK293 
cells were seeded). 200μl of poly-D-lysine was plased on a cover slip, and after 10min 
poly-D-lysine was removed, cover slips were washed with filter sterilised PBS (F/S
PBS). Confluent cells were trypsinized as described earlier, and resuspended in 15mls
of media. 100-150μl of cells were left on a cover slip for 20min, and then 4ml of media 
was added. When the cells reached 70-80% confluency, they were treated and fixed.
2.10.3 Fixing the cells
Media was removed from the wells, and cells were briefly washed with F/S
PBS. 0.5ml of 4% PFA in PBS was added and left for 30min. The cells were washed
with F/S PBS, and either stored in sodium azide at 4oC, or immunostained.
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2.10.4 Immunostaining
The fixed cells were washed with F/S PBS. Non-specific binding was blocked
with 3% BSA PBS-Triton x-100 (0.01%). Triton x-100 is used to permeabilize the
cells. After one hour and three 5min washes with F/S PBS, the cells were incubated
with primary antibody (1:50-1:100) overnight at 4oC. The next day, cells were washed,
and incubated with secondary antibody (donkey anti-goat/mouse/rabbit Alexa-Flour
594, Alexa-Flour 488, Alexa-Flour 405, Molecular Probes, Cambridge, UK) for 1h at
room temperature (from now on the cells were protected from the light). Cover slips
were washed with F/S PBS and mounted on microscope slides with hard set mounting
solution (with or without DAPI). The slides were kept in dark at 4oC until the
microscopy was done.
2.10.5 Fixing and immunostaining for RhoA translocation
Cells were fixed with 10% ice cold TCA in PBS for 15 min at 4oC. After three
5min washes with G-PBS (30mM glycerin in PBS) , the cells were permeabilized with
0.2% Triton-x100 in G-PBS for 15min. The cells were washes three times with G-PBS,
and non-specific binding was blocked with 1% BSA for 1h at room temperature. After
a brief wash the cells were incubated overnight with RhoA antibody (1:100) at 4oC.
The following morning, the cells were washed and incubated with donkey anti-mouse
Alexa-Flour 595 or 488.
MATERIAL AND METHODS
85
2.10.6 Confocal microscopy
Cells were examined under an oil immersion objective (x63) using a Leica
model DMRE laser scanning confocal microscope (Leica Microsystems, UK,
Buckinghamshire, Milton, Keynes, UK) with TCS SP2 scan head. Laser 543 nm at 50%
of power and emission filter set at 555-620nm were used to examine AlexaFlour ®594
staining, and Laser 488 nm at 30% of power and emission filter set at 500-535nm was
used to examine AlexaFlour®488 staining. DAPI and AlexaFluor®405 staining was
examined with was examined with Laser 405 at 10% of power and emission filter set at
410-450 nm. Scan speed was 400 Hz, and the format was 1024x1024 pixels.
Increasing pixel number increases the quality of picture, but it bleaches dye. Optical
sections (0.5 µm) were taken, and representative sections corresponding to the middle
of the cells were presented. After indirect immunofluorescent staining, no specific
fluorescence was observed in cells treated with secondary antibody. The images were
manipulated with Leica (5x zoom) and ImageJ software.
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1
2
3 EXPRESSION AND INTERNALIZATION PROPERTIES OF
CRH-R1 SPLICE VARIANTS IN TRANSIENTELY
TRANSFECTED HEK293
3.1 INTRODUCTION
The type 1 CRH receptor (CRH-R1) is widely expressed in central nervous
system as well as in peripheral tissues (Hillhouse EW & Grammatopoulos DK, 2006).
Several splice variants of the receptor have been described, at least at mRNA level.
However a lack of variant-specific antibody makes it impossible to demonstrate protein
expression of variants. In most mammals, the fully active CRH-R1 is transcribed from
all 13 exons present within the CRH-R1 gene. However, in humans the CRH-R1 gene
contains 14 exons encoding a “pro-CRH-R1” receptor isoform which is a 444-amino
acid protein known as CRH-R1β. Compared to the fully active CRH-R1α (which is a 
415-amino acid protein), the CRH-R1β variant contains exon 6 which encodes a 29-
amino acid insert within the first intracellular loop, resulting in a receptor protein with
impaired agonist binding and signalling properties (Chen R et al., 1993). mRNA
studies have demonstrated that CRH-R1β is expressed in the pituitary (Chen R et al.,
1993), myometrium (Grammatopoulos DK et al., 1998), mast cells (Cao J et al., 2005),
and endometrium (Karteris E et al., 2004), but the physiological function of this variant
is unknown. Another CRH-R1 variant investigated in this study was CRH-R1d. This
variant has exon 13 deleted leading to the loss of 14-amino acids from the C-terminal
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end of the putative seventh transmembrane domain. Overexpression studies of
recombinant CRH-R1d have demonstrated that this variant has impaired G protein
coupling and signalling properties, but it was able to bind agonists with intact affinity
(Grammatopoulos DK et al., 1999). CRH-R1d mRNA was found in myometrium of
pregnant women (Grammatopoulos DK et al., 1999) and skin (Pisarchick A &
Slominski AT, 2001). In addition to the expression of CRH-R1α, R1β and R1d, the 
myometrial tissue from pregnant women expresses another variant of the receptor
identified in our laboratory and termed CRH-R1β/d (unpublished data). This variant is 
a “cross” between CRH-R1β and R1d, since it contains exon 6 and lacks exon 13. The 
precise splicing mechanisms controlling the expression of CRH-R1 variants are still
unknown. Studies in keratinocytes suggest that environmental stimuli (UV irradiation)
as well as intracellular messengers (cAMP) and phorbol esters could induce CRH-R1
splicing (Pisarchick A & Slominski AT, 2001).
In most tissues, CRH actions are dependent on the adequate expression of CRH-
R in the plasma membrane. The exposure of CRH-R to CRH and other agonists results
in rapid attenuation of CRH-R responses, through receptor desensitization. Current
evidence suggests that this process is initiated by phosphorylation of the receptor on
serine and threonine residues within the intracellular loops and C-terminal tail of many
GPCRs (Luttrell LM & Lefkowitz RJ, 2002), including the CRH-R1 receptor (Teli T et
al., 2005; Oakley RH et al., 2007). There are two types of desensitization: heterologous
and homologous. During heterologous desensitization agonist occupancy of the target
GPCR in not required; the receptor can be phosphoralated and desensitized by the
activation of second messenger dependent protein kinases such as cAMP-dependent
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kinase (PKA) and protein kinase C (PKC). On the other hand, homologous
desensitization is a consequence of conformational changes of the receptor upon ligand
binding, and further phosphorylation of the receptor by G-protein coupled kinases
(GRKs) and subsequent binding of β-arrestin. These events lead to the uncoupling of 
receptors from their heterotrimeric G-proteins and agonist-promoted endocytosis of
many GPCRs. The extent of β-arrestin involvement appears to vary depending on the 
receptor, agonist and cell type. GPCRs are grouped into two distinct classes according
to β-arrestin involvement in receptor internalization (Oakley RH et al., 2000).
Activated receptors of the class A, bind β-arrestin transiently and with low affinity. β-
arrestin is released after targeting the receptor to clathrin-coated pits; the receptor
proceeds into an endosomal pool, while β-arrestin translocates back to the plasma 
membrane (Zhang et al., 1999). Class A receptors typically undergo rapid recycling to
the plasma membrane. The members of this class include β2 and α1B adrenergic, μ 
opioid, endothelin A, and dopamine D1A receptors. Class B receptors, such as
neurotensin 1, vasopressin 2, and angiotensin AT1a receptors, show a much stronger
and more prolonged binding to β-arrestin. The complex receptor-β-arrestin is stable and 
it internalizes as a unit that is targeted to endosomes (Luttrell LM and Lefkowitz RJ,
2002). The stability of receptor-β-arrestin complex is dictated by the specific clusters of 
Ser and Thr residues in the C-terminal tail of the receptor as well as the C-terminus of
β-arrestin (Oakley RH et al., 2001).
In recent years, CRH-R1α desensitization and internalization have been a topic of 
several studies (Rasmussen TN et al. 2004; Perry SJ et al., 2005; Teli T et al. 2005;
Holmes KD et al., 2006; Markovic D et al., 2006; Oakley RH et al., 2007). However,
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the internalization characteristics of CRH-R1 variants have not been studied. Since
tissue sensitivity to agonists is determined by the availability of receptor in the plasma
membrane and how fast the signal is terminated, the aims of my studies were to
investigate the cellular expression of CRH-R1 variants (α, β, d and β/d), and 
internalization characteristics of the receptors. HEK293 cells over-expressing different
variants (293-R1α, 293-R1β, 293-R1d, 293-R1β/d) were chosen as a model system, 
because the system has been well characterised and validated and used successfully to
investigate various aspects of CRH signalling (Papadopoulou N et al., 2004; Teli T et
al., 2005)
METHODS
3.1.1 Transient transfection of HEK293
The Lipofectamin2000 (Invitrogen) was used for transfection in HEK293 cells.
Transient transfection was carried out in 50-70% confluent cells seeded in 25cm2
vented flasks. 5μg DNA (CRH-R1α, CRH-R1β and CRH-R1d and CRH-R1β/d in 
pcDNA3.1 (-)) and 5μl Lipofectamin2000 reagent, in 5 ml of OptiMEM+GlutaMax 
(Gibco) were used for overnight transfection according to manufacturer’s instructions.
The following morning the transfection mixture was replaced with normal growth
media (DMEM with 10% FBS). The same evening cells were transferred on poly-D-
lysine (Sigma) coated glass cover slips (for confocal microscopy studies). The
experiments were carried out 48h after transfection. Expression was verified by
immunoblotting and confocal microscopy analysis.
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3.1.2 Stimulation of cells
One hour prior to stimulation transiently transfected cells were FBS deprived.
The cells were treated for various times (0-60minutes) with 0.1-100nM CRH, or
200nM PMA (phorbol 12-myristate 13-acetate). At the end of the treatment cell were
placed on ice and washed with ice cold PBS.
For some experiments HEK293 stably transfected with CRH-R1α cDNA (st-
293-R1α) were used. st-293-R1α were established by Dr Teli during her PhD studies 
(Teli T, 2005).
3.1.3 Immunostaining
Cells were seeded on cover slips coated with 100μg/ml poly-D-lysine in PBS. 
When reached 70-80% confluency, the cells were treated and fixed with 4% PFA. Non-
specific binding was blocked with 1% BSA in PBS-Triton x-100 (0.01%) for 1h at
room temperature. Following a 5min wash with PBS, a PBS solution containing 1:75
polyclonal rabbit pan-arrestin antibody were added for overnight incubation at 4oC. The
next morning, the antibody mixture was removed and slides were washed with PBS 3
times for 5min each and polyclonal goat antibody against the C-terminus of CRH-R1/2
(1:100 in PBS) was added for 2h at room temperature. After three PBS washes for
5min each, donkey anti-rabbit AlexaFluor®488 and donkey anti-goat AlexaFluor®594
were added in 1:400 dilution each for 1h at room temperature. Following three 5min
washes with PBS, slides were mounted with VECTASHIELD or with Gold Slowfade
mounting solution with DAPI. When single staining with CRH-R1/2 was employed,
the receptor specific antibody (1:100) was placed on the slides overnight at 4oC. The
CHAPTER 3
91
specificity of antibody employed was demonstrated in the presence of blocking peptide.
The antibody was pre-incubated with 10 fold molar excess of the blocking peptide
overnight at 4oC, before placing on a slide (Figure 3.1). The rest of procedure was done
as described above.
3.1.4 Confocal microscopy
Cells were examined under an oil immersion objective (x63) using a Leica
model DMRE laser scanning confocal microscope (Leica Microsystems, UK,
Buckinghamshire, Milton, Keynes, UK) with TCS SP2 scan head, as described in the
Material and Methods (2.10.6).
Figure 3.1. Characterisation of CRH-R1 and β-arrestin antibodies 
specificity. st-293-R1α cells were grown on cover slips. CRH-R1 and β-
arrestin signal was monitored by indirect immunofluorescence using specific
primary antibodies in the presence and absence of corresponding blocking
peptides (10-fold molar excess) and Alexa-Fluor®594 secondary antibody
for CRH-R1 and Alexa-Fluor®488 secondary antibody for β-arrestin 
visualisation. Cell nuclei were stained using the DNA-specific dye, DAPI.
CRH-R1
immunofluorescence
(-) (+) blocking
peptide
-arrestin
immunofluorescence
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3.1.5 Quantitative analysis of protein movement
For each treatment, between 20-25 individual cells in five random fields of
view were selected and examined. Fluorescence intensity profiles were generated along
a line drawn through the middle of a cell, analysed and quantified using Image J
software developed at the National Institutes of Health (http://rsb.info.nih.gov/ij/).
Relative quantification of intracellular (internalized) CRH-R1 was carried out by
measuring the amount of total fluorescence along the longitudal axis corresponding to
the intracellular space (average 4-18μm). The activated β-arrestin that was translocated 
to the plasma membrane was quantified by measuring fluorescence along the area
corresponding to the cell membrane (1-3μm and 19-21μm). 
3.1.6 Membrane fractionation and western blot analysis
HEK293 cells transiently transfected with CRH-R1α or CRH-R1d were grown in 
75 cm2 flasks. Cells were washed with ice cold PBS and lysed in 0.2% NaCl. Cells
were homogenised in extraction buffer (Dulbbeco’s PBS containing 1mM EDTA,
1mM PMSF, 10mM MgCl2, 0.1% BSA, 0.1% bacitricin. The homogenated cells were
centrifuged for 30min at 600g at 4oC (to remove unbroken cells and nuclei). The
supernatant was collected and centrifuged for 60min at 40,000g at 4oC. The resulting
supernatant was collected (cytoplasmic fraction) and the pellet (membrane fraction)
was resuspended in 10mM Tris-HCl pH 7.4 containing 1% Triton x-100, 1% Na
deoxycholate, 0.5% SDS, 150mM NaCl, 1mM DTT, 1mM EDTA, 0.2mM PMSF,
10μg/ml aprotinin (Karteris E et al., 2004). The protein concentration was determined
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using BCA reagent, and 10μg of proteins were loaded on 10% SDS-PAGE. Following 
electro transfer onto a PVDF membrane, the blot was incubated with 5% milk in TBS-
T for 1h at room temperature, and overnight at 4oC with 1:1000 anti CRH-R1/2
antibody. Following three washes with TBS-T, the blot was incubated with secondary
antibody and visualised using ECL reagent.
3.2 RESULTS
3.2.1 The cellular expression of CRH-R1 variants
HEK293 transiently transfected with recombinant CRH-R1 variants were
examined by a confocal microscope. The expression of CRH-R1α was exclusively on 
the plasma membrane of the cell. The same pattern of expression was observed for
CRH-R1β variants, suggesting that the insertion of 29 amino acids within the first 
intracellular loop does not effect receptor expression in the plasma membrane.
Interestingly, CRH-R1d and R1β/d immunoreactivity was distributed primarily in the 
cytosol although cell membrane expression was also evident, suggesting that the
deletion of 14 amino acids from the seventh transmembrane domain effects the
stability of the receptor in the plasma membrane (Figure 3.2 A). The specificity of the
staining is shown on figure 3.2B. Since the experiment was performed on transiently
transfected cells, a percentage of the cells did not take up DNA those cells did not over-
express CRH-R1, and showed the absence of immunoreactive staining on the
membrane or cytoplasm (Figure 3.2 B)
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Figure 3.2. The cellular expression of CRH-R1 variants visualised by
confocal microscopy. A. HEK293 were transiently transfected with CRH-R1α, 
CRH-R1β, CRH-R1d and CRH-R1β/d. CRH-R1α and R1β are expressed only 
on the plasma membrane of the cell; on the other hand the immunoreactivity
of CRH-R1d and R1β/d was observed in cytoplasm as well as cell membrane. 
B. HEK293 that did not transfect with CRH-R1α cDNA did not show any 
staining on the plasma membrane. The immunofluorescence was monitored
using CRH-R1-specific antiserum and Alexa-Fluor®594 secondary antibody.
The cell nuclei are visualised using DNA-specific dye-DAPI. Identical results
were obtained from five independent experiments.
10 μm
CRH-R1α CRH-R1β
CRH-R1β/dCRH-R1d
A
B
CHAPTER 3
95
3.2.2 Internalization characteristics of CRH-R1α 
In order to investigate homologous internalization, st-293-R1α were stimulated 
with 0.1-100nM CRH for 0-60minutes. The internalization of CRH-R1α showed to be 
an agonist-dose dependent as well as time dependent process. In the absence of CRH,
the receptor was exclusively on the plasma membrane. Treatment of cells with 0.1 nM
CRH 45min did not cause redistribution of the receptor; CRH-R1α staining was still 
very clearly on the plasma membrane. However 1nM CRH treatment for 45minutes led
to a partial reduction of the receptor staining from the cell surface. Treatment of cells
with concentrations of CRH greater than 10nM for 45 minutes led to significant
redistribution of cellular imunoreactivity; the majority of cells had strong punctuated
staining in the cytoplasm, indicative of receptor endocytosis (Figure 3.3). Since
100nM CRH treatment led to the strongest redistribution of the receptor, this
concentration was chosen to investigate further the time-dependent internalization
characteristics. Lower concentrations (0.1-10nM) of CRH were also used in these
experiments for comparison (data not shown). 0.1nM CRH treatment did not lead to
visible redistribution of the receptor even after 60min. Cells treated with 1nM CRH had
some redistribution of CRH-R1α from the membrane, which was observed as 
intracellular staining. 10nM CRH treatment induced internalization was similar to
100nM CRH induced internalisation, though there was a delay of 10-15 minutes. When
st-293-R1α were treated only with vehicle (acetic acid), the receptor was exclusively 
expressed on the plasma membrane. Treatment with 100nM CRH for 15min led to the
appearance of punctuated staining in the near proximity of the plasma membrane,
possibly indicative of early endocytosis. After 30minutes of exposure to 100nM agonist,
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strong immunoreactivity was observed in the cytoplasm. Similar results were seen after
45 minutes. The most dramatic change in the receptor localisation was after 60min of
treatment (Figure 3.4). Also strong presence of the receptor in the perinuclear area was
detected. To demonstrate that the internalization of CRH-R1α was CRH specific, st-
293-R1α cells were treated with 100nM UCNII (CRH-R2 receptor specific agonist) for 
60 min. The plasma membrane distribution of CRH-R1α was not affected with UCNII 
(Teli T et al., 2005).
Figure 3.3. Internalization of CRH-R1α in st-293-R1α- agonist-dose 
dependency. st.293-R1α cells were grown on cover slips and after exposure to 
CRH (0.1–100 nM) for 45 minutes, CRH-R1 distribution was monitored by
indirect immunofluorescence using CRH-R1-specific antiserum and Alexa-
Fluor®594 secondary antibody. Identical results were obtained from four
independent experiments. Magnification x 63. (Teli T et al., 2005)
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Figure 3.4. Internalization of CRH-R1α in st-293-R1α- time course. st.293-
R1α cells were grown on cover slips and exposed to 100nM CRH for various 
time points (0-60min); no apparent internalization was observed when the cells
were challenged with 100nM UCN-II (CRH-R2 specific agonist) for 60min.
CRH-R1 distribution was monitored by indirect immunofluorescence using
CRH-R1-specific antiserum and Alexa-Fluor®594 secondary antibody.
Identical results were obtained from four independent experiments.
Magnification x 63, and optical zoom x 5. (Teli T et al., 2005)
15min CRH(100nM) 30min
CRH(100nM) 0min
CRH(100nM) 30min
CRH(100nM) 45min
0nMCRH(100nM) 60min
10 μm
M CRH(45min) 1nMCRH(100nM) 15min
10 μm
UCNII(100nM) 60min
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3.2.3 Internalization of CRH-R1α is β-arrestin dependent 
The internalization of most GPCR requires recruitment of β-arrestin to the 
plasma membrane (DeWire SM et al., 2007). In the absence of CRH the endogenous β-
arrestin (green) was uniformly distributed through the cytoplasm, whereas the receptor
was exclusively on the plasma membrane (Figure 3.5 top row). Two minutes treatment
with 100nM CRH elicited a significant and rapid translocation of β-arrestin to the 
plasma membrane, as demonstrated by a significant increase (more than 60 fold) in cell
surface immunostaining for β-arrestin signal (Figure 3.5 middle row) and appearance of 
yellow colour, indicative of co-localization of the receptor (red) and β-arrestin (green). 
This was confirmed by quantification of fluorescence that showed an increased green
fluorescence at the point where the line demarcated the cell membrane (1-3 and 19-
21μm) 2min treatment with CRH did not affect cellular distribution of the receptor, 
which was still on the plasma membrane (red). Following 30min treatment with 100nM
CRH, a significant pool of the receptor was internalized. A fraction of internalized
CRH-R1α was co-localized with β-arrestin in the cytoplasm (yellow dots), however 
some vesicles of the receptor (red) were not associated with β-arrestin in the cytosol; 
potentially suggesting more than one pathway of receptor internalization. This was also
evident in the analysis of fluorescent spectra where some (but not all) intensity peaks of
green and red fluorescence could be observed at the same position (Markovic D et al.,
2006).
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Figure 3.5. Internalization of CRH-R1α in st-293-R1α is β-arrestin 
dependent. st.293-R1α cells were grown on cover slips and exposed to 100nM 
CRH for 2 and 30min. CRH-R1 distribution was monitored by indirect
immunofluorescence using CRH-R1-specific antiserum and Alexa-Fluor®594
secondary antibody (red). β-arrestin distribution was monitored by indirect 
immunofluorescence using pan-arrestin antiserum and Alexa-Fluor®488
secondary antibody (green). Identical results were obtained from four
independent experiments. Quantification was done as described in the text
above. Magnification x 63, and optical zoom x 5. (Markovic D et al., 2006).
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3.2.4 Internalization characteristics of CRH-R1β 
In order to determine whether the insertion of 29 amino acids within the first
intracellular loop has an effect on internalization characteristics of CRH-R1β, tr-293-
R1β were stimulated with 0.1-100nM CRH for 0-60minutes. Internalization of CRH-
R1β was shown to be an agonist-dose dependent as well as time dependent. The pattern 
of internalization was similar to the internalization pattern of CRH-R1α (Figure 3.6). 
Figure 3.6. Internalization of CRH-R1β in tr-293-R1β- time course. tr.293-
R1β cells were grown on cover slips and after exposure to 100nM CRH for 
various time points (0-60min). CRH-R1 distribution was monitored by indirect
immunofluorescence using CRH-R1-specific antiserum and Alexa-Fluor®594
secondary antibody. The specificity of CRH-R1 antibody was demonstrated by
lack of staining when antibody was incubated with the corresponding blocking
peptide prior to addition on the slides. Cells nuclei (blue) were stained using
the DNA-specific dye DAPI. Identical results were obtained from four
independent experiments. Magnification x 63, and optical zoom x 5.
CRH(100nM) 0min CRH(100nM) 15min
CRH(100nM) 30min CRH(100nM) 45min
CRH(100nM) 60min Ab+blocking peptide
10 μm
CHAPTER 3
101
3.2.5 Internalization of CRH-R1β is β-arrestin dependent 
To determine whether the internalization of CRH-R1β was β-arrestin dependent, 
the same experimental approach was employed.
Figure 3.7. Internalization of CRH-R1β in tr-293-R1β is β-arrestin 
dependent. tr.293-R1β cells were grown on cover slips and exposed to 100nM 
CRH 2 and 30min. CRH-R1 distribution was monitored by indirect
immunofluorescence using CRH-R1-specific antiserum and Alexa-Fluor®594
secondary antibody (red). β-arrestin distribution was monitored by indirect 
immunofluorescence using pan-arrestin antiserum and Alexa-Fluor®488
secondary antibody (green). Identical results were obtained from four
independent experiments. Quantification was done as described in the text
above. Magnification x 63, and optical zoom x 5. (Markovic D et al., 2006).
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In the absence of agonist treatment the β-arrestin staining (green) was uniformly 
distributed through the cytoplasm, whereas the receptor was exclusively expressed on
the plasma membrane (Figure 3.7 top row). 2min treatment with 100nM CRH caused a
significant and rapid translocation of β-arrestin to the plasma membrane, which 
resulted in 70 fold increase of green fluorescence on the plasma membrane. 30min
exposure to 100nM CRH led to significant accumulation of CRH-R1β in the cytoplasm 
a fraction of the internalized receptor was co-localised with the endogenous β-arrestin 
(Figure 3.7).   These results demonstrated for the first time that CRH-R1β, a signalling 
impaired receptor, retains some of characteristics of a functionally active receptor
(Markovic D et al., 2006).
3.2.6 Internalization characteristics of CRH-R1d
As shown on the figure 3.2 CRH-R1d is predominantly expressed in the
cytoplasm or cellular compartments such is endoplasmatic reticulum of tr-293-R1d.
However there is also a small portion of the receptor that is present on the plasma
membrane, as shown by defined sharp edges of the cell surfaces. The membrane
expression of CRH-R1d receptor protein was confirmed with western blot analysis of
membrane protein fractions from tr-293-R1α and tr-293-R1d (figure 3.8). The 
membrane proteins were prepared as previously described (Karteris E et al., 2004)
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Figure 3.8. Western blot analysis of membrane fraction of HEK293
transiently expressing CRH-R1α and CRH-R1d. Cytoplasmic and
membrane fraction were separated as described in methods. 10μg of proteins 
were loaded and separated on a 10% SDS-PAGE. Following transfer on a
PVDF membrane, the CRH-R band was identified using an antibody that
recognises both CRH-Rs.
In this part of the study, the potential internalization of membrane-expressed
CRH-R1d was investigated. In the absence of CRH, the imunoreactivity of the receptor
was uniformly distributed through the cytoplasm and membrane. Addition of 100nM
CRH for 15min caused redistribution of the receptor, evident as an appearance of
punctuated staining in the cytoplasm. The redistribution of the receptor was more
evident after 60min treatment with 100nM CRH. At this time point there was little or
no immunoreactivity of the receptor on the plasma membrane, however the majority of
intracellular immunoreactivity showed a punctuated staining pattern possibly an
indicative of the receptor in endocytotic vesicles. The specificity of staining was
demonstrated by lack of staining when CRH-R1 antibody was pre-absorbed with the
synthetic blocking peptide (10 fold molar excess) prior to addition on the slides (Figure
3.9).
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Next, the involvement of β-arrestin in the internalization of CRH-R1d was 
investigated. In the absence of agonist stimulation, the endogenous β-arrestin was 
distributed in the cytoplasm. Similarly to the experiments with CRH-R1α and R1β, 
100nM CRH treatment for 2min of tr-293-R1d led to recruitment of β-arrestin to the 
plasma membrane; however after 30min there was no significant co-localisation
between the receptor and β-arrestin (Figure 3.10). This was confirmed with an analysis 
of fluorescent spectra, where majority of intensity peaks of green and red fluorescence
could not be observed at the same position.
Figure 3.9. Internalization of CRH-R1d in tr-293-R1d- time course. tr.293-
R1d cells were grown on cover slips. Following exposure to 100nM CRH for
various time points (0-60min), CRH-R1 distribution was monitored by indirect
immunofluorescence using CRH-R1-specific antiserum and Alexa-Fluor®594
secondary antibody. The specificity of CRH-R1 antibody was demonstrated by
lack of staining when antibody was incubated with the corresponding blocking
peptide prior to addition on the slides. Cells nuclei (blue) were stained using
the DNA-specific dye DAPI. Identical results were obtained from four
independent experiments. Magnification x 63, and optical zoom x 5.
10 μm
CRH(100nM) 15min
CRH(100nM) 30min
CRH(100nM) 60min Ab+blocking peptide
CRH(100nM) 45min
10 μm
CRH(100nM) 0min
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Figure 3.10. The involvement of β-arrestin in CRH-R1d internalization.
tr.293-R1d cells were grown on cover slips and exposed to 100nM CRH for 2
and 30min. CRH-R1 distribution was monitored by indirect
immunofluorescence using CRH-R1-specific antiserum and Alexa-Fluor®594
secondary antibody (red). β-arrestin distribution was monitored by indirect 
immunofluorescence using pan-arrestin antiserum and Alexa-Fluor®488
secondary antibody (green). The cell nuclei were visualised using DNA-
specific dye-DAPI. Identical results were obtained from three independent
experiments. Quantification was done as described in the text above.
Magnification x 63, and optical zoom x 5.
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3.2.7 Heterologous internalization of CRH-R1α and CRH-R1β 
In tissues, such is myometrium that express multiple CRH receptor subtypes,
heterologous activation of protein kinase C (PKC) by oxytocin leads to a differential
CRH binding to the CRH receptor and to the attenuation of CRH induced cAMP
production (Grammatopoulos DK and Hillhouse EW, 1999). Since the CRH receptors
contain multiple putative PKC phosphorylation sites within the first and second
intracellular loops and at the C-terminus, it is possible that the heterologous
phosphorylation of these sites could lead to conformational changes of the receptor
resulting in impaired functionality. In order to further investigate PKC effects on
various subtypes of CRH-R, Drs Teli and Papadopoulou demonstrated that CRH-R1α 
and CRH-R1β exhibited differential functional responses to PKC-induced 
phosphorylation, with only CRH-R1β susceptible to cAMP signalling desensitisation 
(Markovic D et al., 2006). Since the phosphorylation of the receptors could not be
acquitted for the differential functional responses, further investigations focused on
internalisation properties of the receptors. Interestingly, internalization studies
revealed that a challenge with 200nM PMA (phorbol 12-myristate 13-acetate –specific
activator of PKC) for 30min led to differential cellular redistribution of CRH-R1α and 
CRH-R1β. Treatment of tr-293-R1α with 200nM PMA for 30min did not have any 
effect on cellular distribution of the receptor. In contrast, PMA induced CRH-R1β 
internalization demonstrated by a significant redistribution of cellular immunostaining
(Figure 3.11). This observation was confirmed by quantification of intracellular
fluorescence spectra of 15-20 individual cells treated with 100nM CRH for 45min and
200nM PMA for 30min (Figure 3.12).
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Figure 3.11. Effect of PMA on internalization of CRH-R1α and CRH-R1β 
in transiently transfected HEK293. Cells were grown on cover slips and
exposed to 200nM PMA for 30min. CRH-R1 distribution was monitored by
indirect immunofluorescence using CRH-R1-specific antiserum and Alexa-
Fluor®594 secondary antibody. Cells nuclei (blue) were stained using the
DNA-specific dye DAPI. Identical results were obtained from four
independent experiments. Scale bar is 10μm. Representative profile of 
fluorescent intensities is also shown. Magnification x 63, and optical zoom x 5.
(Markovic D et al., 2006)
Figure 3.12. Relative quantification of CRH-R1α and CRH-R1β 
endocytosis following CRH and PMA treatment. Following a treatment,
cells were examined using confocal microscopy and intracellular CRH-R1
fluorescence intensity measurements were generated by summing the spectral
measurement from 20 individual cells (distance 4-18μm) (Markovic D et al.,
2006).
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Next, the involvement of β-arrestin in PMA induced internalization of CRH-R1β 
was investigated. PMA treatment for 2 and 30 min did not affect β-arrestin cellular 
distribution in neither of cellular systems, tr-293-R1α nor tr-293-R1β (Figure 3.13). 
Figure 3.13. The effect of PMA treatment on β-arrestin distribution.
tr.293-R1α and tr-293-R1β cells were grown on cover slips, and treated with 
200nM PMA 2 and 30min. CRH-R1 distribution was monitored by indirect
immunofluorescence using CRH-R1-specific antiserum and Alexa-Fluor®594
secondary antibody (red). β-arrestin distribution was monitored by indirect 
immunofluorescence using pan-arrestin antiserum and Alexa-Fluor®488
secondary antibody (green). Identical results were obtained from four
independent experiments. Quantification was done as described in the text
above. Magnification x 63, and optical zoom x 5. (Markovic D et al., 2006).
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3.3 DISCUSSION
The exposure of CRH-R to CRH and other agonists results in rapid attenuation of
CRH-R responses, through a mechanism of receptor desensitization and internalization.
In recent years, CRH-R1 desensitization and internalization have been extensively
studied by various groups (Rasmussen TN et al. 2004; Teli et al. 2005; Perry SJ et al.,
2005, Holmes KD et al., 2006; Markovic D et al., 2006). In HEK293 cells over-
expressing CRH-R1α, desensitization of the receptor was associated with its 
phosphorylation and subsequent endocytosis (Teli et al., 2005). Further internalization
studies demonstrated that β-arrestin was recruited toward the plasma membrane of 
HEK293 over-expressing CRH-R1α, upon the stimulation with CRH (Rasmussen TN 
et al., 2004; Perry SJ et al., 2005; Holmes KD et al., 2006; Markovic D et al., 2006).
Perry and Holmes pin-pointed β-arrestin2 as a major isoforms involved in CRH-R1α 
sequestration, but the subsequent fate of the receptor still remains controversial.
Holmes et al (2006) defined CRH-R1α as a class A receptor regarding the lack of β-
arrestin2 co-localisation with the receptor in the endosome structure in HEK293,
whereas Perry (2004) has demonstrated co-localisation of the two in the cytoplasm.
These discrepant results could be possibly due to different experimental approaches
that the two groups employed. Although, both groups used CRH-R1-tagged receptors,
Holmes et al monitored the colocalisation of the receptor with β-arrestin in live cells, 
while Perry et al (2005) carried out the experiments in fixed cells. However, Holmes et
al (2006) has demonstrated that CRH-R1α indeed co-localise with β-arrestin2 in the 
cytoplasm of primary cortical neurons, but in a small portion to the total amount of β-
arrestin2-GFP. Moreover, it has been shown that following the endocytosis, the
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receptor transited from Rab5-positive early endosome to Rab4-positive recycling
endosome, and that the receptor was not targeted for degradation in lysosomes in
HEK293 over-expressing CRH-R1α and in primary cortical neurons (Holmes KD et al.,
2006). In contrast, CHO-K1 stably expressing CRH-R1 challenged with CRH for 1h
had 83% of the receptor remaining in the cell, while after 24h treatment only 38% the
total CRH-R1 proteins were detected, clearly showing the receptor down-regulation
(Perry SJ et al., 2005). Taken together these findings suggest that different cellular
systems might have distinct patterns of CRH-R1 endocytosis, possibly depending on
availability of accessory proteins involved in the internalisation and mechanisms
regulating the sensitivity of the target tissue to active CRH.
The evidences shown in this chapter highlight the complexity of CRH-R1
sequestration. I have provided novel evidence that CRH-R1 internalizes in a time and
agonist concentration dependent manner, and that β-arrestin is recruited to the cell 
surface as early as 2min following CRH stimulation. Following 60min treatment with
CRH, CRH-R1α is redistributed from the plasma membrane to the cytoplasm as a 
consequence of receptor endocytosis. A fraction of the internalized receptor is co-
localised with β-arrestin, however another portion of the receptor is not, defining the 
receptor as a member of the both classes of receptors, A and B, regarding interaction
with β-arrestin during internalization. This could suggest the existence of distinct 
pathways (β-arrestin dependent and independent) involved in CRH-R1 trafficking. 
Nevertheless, one has to keep at mind, that the internalization is studied in receptor
over-expression systems, and that the promiscuous behaviour of the CRH-R1α receptor 
could be because of an unbalanced ratio of the receptor and β-arrestin. This limitation 
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could have been overcome using controlled over-expression of the receptor and β-
arrestin by viral vectors in a cellular system that has low expression of endogenous
CRH-R1 and β-arrestin, such are CHO cells.  
In addition, the investigation of CRH-R1α internalization in primary myometrial 
smooth muscle cells overexpressing the receptor, demonstrated that in this system too,
β-arrestin is recruited to the plasma membrane following CRH stimulation. Moreover, 
a longer exposure to CRH (30 min) induced CRH-R1α endocytosis and a partial co-
localization with β-arrestin was detected (Figure 3.14). These data, although 
preliminary, agree with the data obtained from HEK293 cells overexpressing the
receptor.
Figure 3.14. The involvement of β-arrestin in CRH-R1α internalization in 
primary myometrial smooth muscle cells overexpressing the receptor. The
cells were grown on cover slips and exposed to 100nM CRH for 5 and 30min.
CRH-R1 distribution was monitored by indirect immunofluorescence using
CRH-R1-specific antiserum and Alexa-Fluor®594 secondary antibody (red).
β-arrestin distribution was monitored by indirect immunofluorescence using 
pan-arrestin antiserum and Alexa-Fluor®488 secondary antibody (green). The
cell nuclei were visualised using DNA-specific dye-DAPI. The bar scale is
10nm. Magnification x 40, and optical zoom x 5.
CRH-R1 -arrestin merge
basal
CRH
5min
CRH
30min
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The human specific CRH-R1β variant is identical to the fully functional, wild 
type receptor, CRH-R1α except for a 29-amino acid insert within the first intracellular 
loop of the R1β. It has been demonstrated that CRH-R1β has impaired agonist binding 
and G protein coupling (Chen R et al., 1993). Internalization properties of this variant
have not been investigated prior to our report (Markovic D et al., 2006). I have
demonstrated that despite signalling impairment, the CRH-R1β receptor retained the 
same internalization properties as the functional, CRH-R1α, receptor. The initial 
recruitment of β-arrestin to the plasma membrane provides indirect evidence that the 
intracellular mechanisms inducing β-arrestin translocation to the membrane are 
independent of CRH-R1 signalling potency.
Interestingly, a substantial difference between CRH-R1α and R1β was observed 
in response to heterologous desensitisation mediated via PKC. Drs Teli and
Papadopoulou have demonstrated that activation of PKC led to phosphorylation of both
CRH-R1 isoforms (α and β), but only the CRH-R1β variant was susceptible to PKC-
induced desensitization. The reduction in the functional response of CRH-R1β 
following PKC activation, could potentially be explained by the reduction of cell
surface expression of CRH-R1β due to internalisation, but not CRH-R1α following 
activation of PKC. However, PMA-induced internalization was not associated with
recruitment of β-arrestin to the cell surface, suggesting an alternative β-arrestin-
independent pathway that is activated in response to PKC phosphorylation of the CRH-
R1 (Markovic D et al., 2006). These data agree with previous observation showing that
only some CRH-R variants are susceptible to PKC-induced inhibition of CRH binding
possibly due to receptor desensitization (Grammatopulos DK et al., 1999).
CHAPTER 3
113
It has been demonstrated that internalization of some GPCRs in the basal-
unstimulated state can be triggered by direct activation of PKC. PKC-mediated
phosphorylation of CXCR4 induces receptor internalization through a dynamin-
dependent mechanism that is distinct from ligand induced endocytosis (Wolfe BL &
Trejo J, 2007). It is quite likely that such a mechanism drives PKC-induced
internalization of CRH-R1β. This mechanism might be physiologically relevant since it 
suggests that the response of CRH-R1 to PKC and the tissue sensitivity to CRH
depends upon the splicing pattern of the CRH-R1.
Previous mRNA studies carried out on myometrial tissue from pregnant women
identified a splice variant of CRH-R1 receptor that lacks 14-amino acids within the
seventh transmembrane domain, termed CRH-R1d (Grammatopoulos DK et al., 1999).
Recent quantitative RT-PCR studies have shown that CRH-R1d mRNA levels increase
as the uterus switches from a quiescent to labouring state (Markovic D et al., 2007)
suggesting a physiologically important role of this variant at the end of pregnancy and
the onset of labour. CRH-R1d has impaired signalling properties and G protein
coupling, but it is able to bind agonists with high affinity (Grammatopoulos DK et al.,
1999). In this study I demonstrated that CRH-R1d is predominately expressed in the
cytoplasm, with a small portion of receptor on the plasma membrane. The cell surface
portion of the receptor was susceptible to CRH induced internalization in a time
dependent manner. Additionally, the initial recruitment of β-arrestin following receptor 
activation was observed, but in contrast to the CRH-R1α and R1β receptors, there was 
no evidence of co-localisation between CRH-R1d and β-arrestin in the cytoplasm. It is 
tempting to speculate that the deletion of 14-amino acids leads to misfolding of the C-
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terminus orienting it towards extracellular space, which makes the C-terminus
inaccessible to β-arrestin.  The C-terminus of many GPCRs contains 
serine/threonine clusters that can be phosphorylated by GRKs and regulate β-arrestin 
translocation and binding to the receptor (Reiter E & Lefkowitz RJ, 2006; Kohout TA
& Lefkowitz RJ, 2003). A resent study investigating internalization characteristics of
CRH-R1 has revealed that when the last 30 amino acids of the C-terminus were
removed, phosphorylation of the activated receptor and β-arrestin2 recruitment were 
markedly reduced. Although, the truncation of the last four amino acids (STAV) from
the C-terminus, resulted in reduced receptor phosphorylation, did not have an effect on
β-arrestin2 recruitment to the activated receptor (Oakley RH et al., 2007). Also this
report suggests that CRH-R1 contains an arrestin binding domain in one or more of the
intracellular loops which is dependent on receptor activation but independent of GRK
phosphorylation (Oakley RH et al., 2007). The identical arrestin binding domain has
been identified in several GPCRs including vasopressin V2, luetinizing hormone,
parathyroid hormone, substance P and neurotensin receptors and rhodopsin family
GPCRs (Oakley RH et al., 2007). In the light of these studies one can speculated that
the β-arrestin recruitment and possible interaction with the activated membrane CRH-
R1d receptor is established via the arrestin binding domain within the intracellular
loops, since the CRH-R1d C-terminus is not accessible to β-arrestin; additionally, the 
lack of co-localisation of the internalised receptor and β-arrestin in the cytoplasm (in 
our experimental condition) could be due to an “incomplete” association between β-
arrestin and the receptor caused by misfolding of the C-terminus of CRH-R1d. The
investigation of this character would include detailed biochemical study characterising
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possible CRH-R1d/β-arrestin interactions. Also, it would be interesting to determine if 
CRH induces, and if so in which extent, phosphorylation of CRH-R1d. In addition, it
would be extremely important to determine if the second intracellular loop that contains
a few features of arrestin binding motif (His214, Ala216, Ile217, Val218, Leu219- as
identified in Oakley RH et al., 2007) is involved in agonist induced CRH-R1d
internalisation.
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1
2
3
4 STRUCTURAL AND FUNCTIONAL CHARACTERISTICS OF
CRH-R1d
4.1 INTRODUCTION
In humans, the CRH-R1 gene spans over 50.3 kb, and contains 14 exons; one
exon more than in other mammalian species. The CRH-R1 gene contains introns within
its transmembrane domain/cytoplasmic region, highly conserved cysteins in its
extracellular domains, and the first intacellular loop, which is characteristics of the
glucagon/PTH receptor gene family (Hillhouse EW & Grammatopoulos DK, 2006).
The omission of the exon 13 (exon 12 in a case of other species but human) from the
CRH-R1 transcript, results in expression of receptor protein termed CRH-R1d. This
protein lacks 14 amino acids within the seventh transmembrane domain and exhibits
impaired G-protein binding abilities and signalling properties, but it retains agonist
binding characteristics of the wild type receptor (Grammatopoulos DK et al., 1999).
Since the post-translational modifications of most GPCRs as well as docking sites for
signalling proteins are found in the C-terminus of receptors, it is possible that the
deletion of the 14 amino acids from the seventh TDM of CRH-R1d leads to retraction
and distortion of the C-tail altering its signalling and hence function. CRH-R1d is not a
unique example of GPCR splice variant. The exon encoding the C-terminal 14 amino
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acids of the seventh TMD is highly conserved in most class B GPCR genes. The
calcitonin receptor family, members of the class B GPCRs, has also numerous splice
variants, and the splicing profile is identical to the one of CRH-R1. Both receptors have
splice variants that contain inserts in the first intracellular loop (16 and 29 amino acids
in the calcitonin and CRH-R1, respectively) and exon deletion in the seventh TMD
(Grammatopoulos DK et al., 1999). Additionally, cloning of the rabbit calcitonin
receptor identified a variant, identical to CRH-R1d, with a deletion of exon 13, termed
CTRΔe13, which encodes the C-terminal part of the seventh TMD (Shyu et al., 1996).
Activated by calcitonin, this variant has significantly impaired production of inositol
phosphate and cAMP, also it fails to induce ERK phosphorylation; some of these
findings are caused by the fact that the Δe13 variant is poorly expressed on the plasma 
membrane (Seck T et al., 2003). Moreover, splice variants identical to CRH-R1d have
been reported for the vasoactive intestinal peptide receptor (Grinninger C et al., 2003)
and PTH/PTHrP receptor (Ding C et al., 1995).
On the other hand the CRH-R2 gene exhibit a very different splicing pattern
compare with CRH-R1. Mammals express only three known CRH-R2 variants: R2α, 
R2β and R2γ, which differ only in their N-terminus. The different N-termini do not 
significantly alter agonist binding and signalling properties, although the CRH-R2β is 
about 10-fold more potent in second messenger activation that R2α and R2γ (Hillhouse 
EW and Grammatopoulos DK, 2006).
The peripheral expression of CRH-R1 and –R2 exhibits a species dependent
pattern with R2 receptor as the main functional receptor in animal peripheral tissues
(Bale TL et al., 2003; Brar BK et al., 2004). In contrast, most peripheral human tissues
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express both types of CRH receptors, indicating higher levels of complexity and more
subtle roles for CRH and UCNs in human physiology (Hillhouse EW and
Grammatopoulos DK, 2006). Current knowledge suggests that the expression of both
CRH-R1 and R2 in human peripheral tissues allows CRH and its related peptides to
exert diverse and contrasting effects (Hillhouse EW and Grammatopoulos DK, 2006).
Although recent reports have demonstrated homodimerisation of CRH-R1 (Kraetke O
et al., 2007) and heterodimetisation between vasopressin V1b and CRH-R1 receptors
(Young SF et al., 2006), there are no reports investigating the interactions, possible
cross-talk and dimerisation, between two types of the CRH receptors, R1 and R2.
In this part of the project I investigated the structural and functional
characteristics of the CRH-R1d receptor. Since co-expression studies between the
CRH-R1d and CRH-R1α demonstrated that the R1d receptor does not play a role of 
dominant negative receptor for CRH (Grammatopoulos DK et al., 1999), I co-
expressed CRH-R1d and CRH-R2β in HEK293 in order to investigate potential effect 
of this variant on signalling and functional characteristics of CRH-R2β. The generated 
conditions could be used as a simpler model to investigate the potential interactions
between the two receptors, which actually might occur in human peripheral tissues
which express both types of CRH receptors, such is uterus.
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METHODS
4.1.1 Transient transfection of HEK293 and primary myometrial smooth muscle
cells
Lipofectamin2000 reagent (Invitrogen) was used for transfection in HEK293 and
primary myometrial smooth muscle cells. Transient transfection was carried out in 50-
70% confluent cells seeded in 25cm2 vented flasks. 5μg DNA (CRH-R1α and CRH-
R1d in pcDNA3.1 (-)) and 5μl Lipofectamin2000 reagent, in 5 ml of 
OptiMEM+GlutaMax (Gibco) were used for overnight transfection according to
manufacturer’s instructions. Co-expression of CRH-R1 and CRH-R2 was carried using
pBudCE4.1 expression vector. This vector contains CMV and EF-1 promoter sites that
enable independent expression of two genes from a single plasmid in mammalian cells
(See Material and Methods chapter for more details). The transfection of pBudCE4.1
plasmid in HEK293 cells was performed the same way as for pcDNA3.1, however the
transfection efficiency was significantly reduced (Figure 4.1). Only 17±11% of cells
transfected with CRH-R subcloned in pBudCE4.1 expressed the receptor, compared
with 87±8% of cells transfected with CRH subcloned in pcDNA3.1.
Following morning the transfection mixture was replaced with normal growth
media (DMEM with 10% FBS). The same evening cells were transferred on poly-D-
lysine (Sigma) coated glass cover slips (for confocal microscopy studies) or to 12-well
plates for signalling studies (cAMP production and MAPK activation). The
experiments were carried out 48h after transfection. Expression was verified by
confocal microscopy analysis.
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Figure 4.1. Transfection efficiency. HEK293 cells were transiently
transfected with CRH-R2β subcloned into pBudCE4.1 or pcDNA3.1. 24-48 h 
following the transfection the cells were examined under confocal microscope
as described in methods. The transfection efficiency is expressed as a
percentage of cells overexpressing the receptor to the total number of cells.
The results are expressed as mean±SEM. The identical results were obtained
from at least three independent transfections.
In some experiments HEK293 stably expressing CRH-R1α and CRH-R1d were 
used. These cells were generated by Dr Teli.
4.1.2 Stimulation of cells
MAPK activation assay: 18 hours prior to stimulation transiently transfected
cells were FBS deprived. The cells were treated for 5min with 100nM UCNII, and total
cellular proteins were made by lysing cells in 2x SDS-PAGE sample buffer (Sigma).
0
10
20
30
40
50
60
70
80
90
100
pBudCE4.1-R2β-V5 pcDNA3.1-R2β
tr
an
sf
ec
tio
n
ef
fic
ie
nc
y
(%
)
pBudCE4.1-R2β-V5 pcDNA3.1-R2β
tr
an
sf
ec
tio
n
ef
fic
ie
nc
y
(%
)
CHAPTER 4
121
The MAPK phosphorylation was analysed by Western Blotting as described in
Material and Methods.
cAMP assay: 20minutes prior to stimulation transiently transfected HEK293
were equilibrated in the stimulation media (DMEM containing 10mM MgCl2 and
0.1mg/ml 3-isobutyl-1-methylxanthine-IBMX). The cells were stimulated with 100nM
UCN-II or 10μM forskolin for 15min. The reaction was stopped by adding 10μl of 
concentrated HCl for 15-20 min and cells were transferred in 1.5ml tubes. After a brief
spin, the cells and media were stored at -20oC. The cAMP levels were determined by a
commercially available ELISA Direct Cyclic AMP Enzyme Immunoassay Kit (Assay
Designs Ins., Ann Arbor, MI, USA).
Internalisation assay: one hour prior to stimulation transiently transfected
HEK293 were serum deprived. The cells were stimulated for 0-60min with 100nM
UCNII, or CRH.
4.1.3 Immunostaining
The cells were fixed with 4% PFA and imunostained for CRH-R as described in
the Material and Methods. The specificity of used antibody was demonstrated in the
presence of blocking peptide. The antibody was incubated with 10 fold molar excess of
the blocking peptide overnight at 4oC, before placing the solution on a slide. To
visualize the two types of CRH receptors tagged with either V5 or myc, monoclonal
V5-antibody was used together with Alexa-Fluor®488 (green) or Texas-red conjugated
monoclonal myc antibody.
CHAPTER 4
122
4.1.4 Confocal microscopy
Cells were examined under an oil immersion objective (x63) using a Leica model
DMRE laser scanning confocal microscope (Leica Microsystems, UK,
Buckinghamshire, Milton, Keynes, UK) with TCS SP2 scan head, as described in the
Material and methods.
4.2 RESULTS
4.2.1 Expression of CRH-R1d in endogenous and over-expressing systems
Primary myometrial smooth muscle cells originated from a pregnant uterus were
immunostained for CRH-R1/2 and examined for protein expression by a confocal
microscopy. Strong intracellular staining was observed as well as “hot spots” of the
receptor expression on the plasma membrane of myocytes (Figure 4.2A). The
specificity of the signal was confirmed with a pre-absorption of the antibody with the
corresponding blocking peptide when no staining was detected Figure 4.2 B).
Unfortunately, a lack of variant-specific antibody prevented further protein splice
variant characterisation of the expressed CRH-R in the two primary cell systems.
Since, I showed in the previous chapter that the CRH-R1d variant has
intracellular expression and poor expression on the cell surface; it is possible that the
intracellular immunoreactivity in the primary cells is a due to the expression of CRH-
R1d. To confirm that cellular distribution of over-expressed CRH-R1d is not a due to
transcriptional conditions present in HEK293 cells, primary myometrial smooth muscle
cells were transfected with the recombinant CRH-R1d. Parallel transfection of CRH-
CHAPTER 4
123
R1α in the same model systems were used as a control that the intracellular staining 
was specific characteristic of the CRH-R1d receptor. The results shown on Figure 4.3
confirm that the CRH-R1d receptor is expressed predominantly in the cytoplasm of the
both model systems, primary myometrial smooth muscle cells and HEK293, while the
CRH-R1α receptor was exclusively expressed in the plasma membrane. 
Figure 4.2. Visualization of endogenous CRH-R distribution in primary
myometrial cells by indirect immunofluorescent confocal microscopy using
specific primary antibody for CRH-R and Alexa-Fluor®594 (red). A. The
CRH-R receptor in primary myometrial smooth muscle cells was expressed in
the plasma membrane (white arrows indicate “hot spots” of the receptor
expression) and in the cytoplasm (Markovic D et al., 2007). B. The specificity
of CRH-R antibody was demonstrated with a lack of immunoreactivity
following pre-absorption of the antibody with the blocking peptide. The cell
nuclei were visualised using DNA specific dye-DAPI. The identical results
were obtained from three independent experiments.
A
CRH-R1/2 CRH-R1/2+ blocking peptideB
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Figure 4.3. Visualization of over-expressed CRH-R1α and CRH-R1d 
distribution in HEK293 and myometrial smooth muscle cells by indirect
immunofluorescent confocal microscopy using specific primary antibody for
CRH-R and Alexa-Fluor®594 (red). The cell nuclei were stained with a DNA
specific dye-DAPI. The identical results were obtained from three independent
experiments.
4.2.2 Prediction of transmembrane domains and loops using TMHMM
algorithm
Since the deletion of the 14 amino acids from the 7th transmembrane domain
(TMD) leads to significant changes in the receptor cellular distribution; next, I
investigated the possible effects of the deletion on the receptor folding within the
plasma membrane and whether misfolding leads to expression of the intracellular form
of the receptor. The algorithms available at http://workbench.sdsc.edu were used for
CRH-R1α CRH-R1d
20 μm 20 μm
10 μm
HEK293
MSMC
10 μm
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this analysis. Protein sequences of CRH-R1α and CRH-R1d were loaded and compared 
using the TMHMM software. This software predicts localisation of transmembrane
helixes and localisation of inverting loop regions. It scores probability from 0 to 1 (0
means that there is no probability that an event would happen, 1 means that there is a
strong possibility that the event actually occurs). The results obtained from this analysis
are presented in the figure 4.4.
As shown at the top part in the Figure 4.4, CRH-R1α is a classical example of 
seven transmembrane domain protein. However, there is an equal probability (50:50)
for CRH-R1d to be a six or seven TMD protein; and if the receptor is a 6 TMD protein
then it is highly likely that the C-terminus is actually present in the extracellular space.
Figure 4.4. TMHMM prediction of TMD and loops
(http://workbench.sdsc.edu). The protein sequences of CRH-R1α and CRH-
R1d were analysed and compared. The red colour represents TMD, the
intacellular loops are presented in blue and the extracellular in pink.
CRH-R1α
CRH-R1d
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4.2.3 The C-terminus of CRH-R1d is in the extracellular space
Majority of GPCRs have seven transmembrane domains, the N-terminus facing
the extracellular space and the C-terminus in the intacellular area. However, there are
always exemptions; the adiponectin receptor has the N-terminus facing inside of the
cell and the C-terminus in the extracellular side of the cell (Deckert CM et al., 2006).
Also a splice variant of calcitonin receptor, termed CTR eΔ13, is a 6 transmembrane 
domain protein (Seck T et al., 2005). Interestingly, this splice variant is encoded
without exon 13 of calcitonin receptor gene, same as the R1d variant of CRH-R1.
To investigate CRH-R1d C-tail localisation, I used indirect confocal microscopy
and a CRH-R specific antibody raised against the C-terminus of the receptor.
Immunoreactivity would be detected in non-permeabilesed cells only if the C-tail is on
the extracellular side of a cell; if the C-tail is in the intacellular space, it would be
inaccessible to the antibody in not-permeabilised cells, and thus no imunoreactivity
would be detected. HEK-293 cells stably expressing CRH-R1α or CRH-R1d were 
grown on class cover slips, fixed and stained as described in Methods. In Triton x-100
treated CRH-R1α expressing cells the receptor was localised on the membrane and in 
the CRH-R1d expressing cells the receptor was cytosolic too. CRH-R1α over-
expressing cells without treatment with Triton x-100 had no detectable fluorescence.
The lack of signal suggests the C-tail was not accessible to the antibody because of its
extracellular localisation. Interestingly, in the CRH-R1d over-expressing HEK293 cells
substantial fluorescence was detected even without treatment with Triton x-100. This
suggests that the C-terminus of CRH-R1d was accessible to the antibody, possible due
to the C-terminus localization in the extracellular space (Figure 4.5)
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Figure 4.5. Orientation of the C-terminus of CRH-R1.Visualization of
over-expressed CRH-R1α and CRH-R1d distribution in permeabilised (top 
row) and not permeabilsed (bottom row) HEK293 by indirect
immunofluorescent confocal microscopy using specific primary antibody for
the C-terminus of CRH-R and Alexa-Fluor®594 (red).
4.2.4 Identification of amino acids encoded from the exon 13 that are necessary
for the membrane expression of the receptor
The particular characteristics of CRH-R1d cellular localisation and the high
probability to form a 6TMD receptor, most likely resulted from the deletion of 14
amino acids from the 7th TMD of CRH-R1 that as a consequence affects the expression
of a missfolded six TMD receptor with the C-terminus in the extracellular space that is
unstable in the plasma membrane and shuttles between membrane and cytoplasm. To
identify which amino acids are necessary for the membrane expression, a series of
CRH-R1α CRH-R1d
+ Triton x-100
- Triton x-100
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CRH-R1α and CRH-R1d mutant receptors were made. Two CRH-R1α mutant and 
three CRH-R1d mutant receptors were generated with subsequent deletion and
insertion, respectively, of cassette of three amino acids each starting from the N-
terminus encoded by the exon 13 (table 4.1). The mutants were generated as described
in Material and Methods (2.6.1).
Amino acid sequence Name of the receptor
GFFVSVFYCFINSE CRH-R1α 
VSVFYCFINSE CRH-R1α  Δ(356-358) 
GFFFYCCFINSE CRH-R1α Δ(359-361) 
CRH-R1d
GFF CRH-R1d +(356-358)
GFFVSV CRH-R1d +(356-361)
GFFVSVFYC CRH-R1d +(356-364)
      Table 4.1.CRH-R1α and CRH-R1d mutant receptors. 
These mutants were expressed in HEK-293 and the cellular localisation of the
resulting receptors was visualized using indirect confocal microscopy. Deletion of GFF
(Gly356-Phe357-Phe-358) cassette from the 7th TMD of CRH-R1α in the mutant CRH-
R1α Δ(356-358) resulted in transcription of an intracellular receptor or constitutively 
internalized receptor. However, a deletion of VSV cassette (Val359-Ser360-Val361)
from the 7th TMD of CRH-R1α  in the mutant CRH-R1α Δ(359-361) did not have an 
effect on membrane expression of the receptor (Figure 4.6). These results suggest that
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the GFF cassette is necessary for the stability of CRH-R1 in the plasma membrane.
Next, I investigated whether the insertion of the GFF cassette in CRH-R1d would be
sufficient for the membrane expression. As shown on the figure 4.7, the insertion of
GFF did not have an effect on intracellular localisation of CRH-R1d, even the insertion
of GFF-VSV did not result in a transcription of membrane receptor. Only when 9
amino acids (GFFVSVFYC) were inserted, the mutant receptor was expressed
primarily in the plasma membrane.
Figure 4.6. The cellular localisation of CRH-R1α wild type and mutant 
constructs. HEK-293 were transiently transfected with CRH-R1α constructs. 
The receptor was visualized by indirect confocal microscopy using CRH-R
antibody and Alexa-Fluor®594 (red). The cell nuclei were stained with a DNA
specific dye-DAPI. The identical results were obtained from three independent
experiments
FLESFQGFFVSVFYCFINSE
7th transmembrane domain
FLESFQGFFVSVFYCFINSE
FLESFQGFFVSVFYCFINSE
encoded by exon 13
CRH-R1
CRH-R1
(356-358)
CRH-R1
(359-361)
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Figure 4.7. The cellular localisation of CRH-R1d wild type and mutant
constructs. HEK-293 were transiently transfected with CRH-R1α constructs. 
The receptor was visualized by indirect confocal microscopy using CRH-R
antibody and Alexa-Fluor®594 (red). The cell nuclei were stained with a DNA
specific dye-DAPI. The identical results were obtained from three independent
experiments
4.2.5 Co-expression of CRH-R1d and CRH-R2β in HEK293 cells 
Previously it has been demonstrated that although signalling impaired, CRH-
R1d does not act as a “decoy” receptor for CRH-R1α (Grammatopoulos DK et al.,
1999). In order to investigate the effect of CRH-R1d on functional characteristics of
CRH-R2β, both receptors were co-expressed in HEK293 cells as described in Methods. 
FLESFQ
Remaining of the 7th
transmembrane domain
FLESFQGFF
FLESFQGFFVSV
FLESFQGFFVSVFYC
CRH-R1d
CRH-R1d
+(356-358)
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The cellular localisation and internalisation properties of CRH-R2β in the presence of 
CRH-R1d, as well as CRH-R2β mediated MAP kinase activation and cAMP 
production were investigated.
4.2.5.1 Characterisation of cellular localisation of CRH-R2β-V5, CRH-
R1α-myc, and CRH-R1d-myc 
In order to monitor cellular localization and internalization of two types of CRH-
R in one cell, I introduced a tag to the C-terminus of receptors. Firstly, the effect of the
receptor tagging on the cellular localisation of the receptor was examined. CRH-R1α 
was tagged with V5-tag or myc-tag, CRH-R1d was tagged with myc-tag and CRH-R2β 
with V5-tag, as controls the receptors without tags were used. HEK293 cells were
transfected with different constructs and the resulting receptors were visualized by
indirect confocal microscopy (Figure 4.8).
Localisation of the CRH-R1α-myc receptor (red) and CRH-R1α-V5 (green) was 
exclusively/primarily on the membrane (Figure 4.8 A and C), while CRH-R1d-myc
was distributed both in the cytoplasm and plasma membrane (Figure 4.8 E). CRH-R2β-
V5 (green) was expressed exclusively on the plasma membrane (Figure 4.8 G). The
cellular localization the receptors without V5 or myc tag was detected with CRH-R1/2
specific antibody (Figure 4.8 B, D, F, and H). CRH-R1α and CRH-R2β were expressed 
exclusively on the plasma membrane, while CRH-R1d was distributed in the cytoplasm
compartments too. This data demonstrates that the introduction of a myc-tag and V5-
tag to the C-terminus of CRH-R1α or CRH-R1d and CRH-R1α or CRH-R2β, 
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respectively, does not have an effect on the cellular localisation the receptors when
expressed in HEK293 cells.
Figure 4.8. Expression of CRH-R1α-myc, CRH-R1α-V5, CRH-R1d-myc, 
CRH-R2β-V5 in HEK293 cells. HEK293 cells were transiently transfected
with a mammalian expression vector pBudCE4.1 containing CRH-R1α-myc (A), 
CRH-R1α-V5 (C), CRH-R1d-myc (E), CRH-R2β-V5 (G), CRH-R1α-stop (B, 
D), CRH-R1d-stop (F) and CRH-R2β-stop (H). V5-tag was detected using 
mouse monoclonal antibody and secondary anti-mouse Alexa-Fluor®488
(green), myc-tag was detected with mouse monoclonal myc-antibody
conjugated with Texas Red (red) entity. The receptors without tag (labelled as
stop-meaning that they have stop codon) were visualized using CRH-R1/2
antibody and Alexa-Fluor®594 (red). The cell nuclei were stained with a DNA
specific dye-DAPI (blue).The cells were examined using indirect confocal
microscopy.
The plasmids containing CRH-R1α-V5 and CRH-R1d-myc, CRH-R2β-V5 and 
CRH-R1α-myc, CRH-R2β-V5 and CRH-R1d-myc, as well the same combinations of 
the wild type receptors (without tags) were expressed in HEK293 cells and the cellular
localisation of the receptors was visualized using indirect confocal microscopy. CRH-
R1α-V5 (green) and CRH-R1d-myc (red) were distinctively distributed; R1α receptor 
was present only on the plasma membrane, while R1d was present only in the
cytoplasm, without significant co-localisation between the two receptors was detected
(Figure 4.9 A). Immunofluorescent detection of the wild type receptors using CRH-
A B C D
E F G H
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R1/2 antibody and Alexa-Fluor®594 strong plasma membrane staining (possibly from
CRH-R1α) as well as intracellular smeary and punctuated staining (from CRH-R1d) 
(Figure 4.9 B). Co-expression of CRH-R2β-V5 (green) and CRH-R1α-myc (red) 
resulted in a detection of cells with yellow membrane staining indicative of co-
localisation of the two receptors on the plasma membrane (Figure 4.9 C). The
membrane expression of the both receptors was detected also in the cells co-expressing
CRH-R1α and CRH-R2β wild type (without the C-terminus tag) (Figure 4.9 D).  
Figure 4.9. Co-expression of two types of CRH-Rs in HEK293 cells. The
cells were transiently transfected with a mammalian expression vector
pBudCE4.1 containing CRH-R1α-V5 and CRH-R1d-myc (A), CRH-R2β-V5 
and CRH-R1α-myc (C), CRH-R2β-V5 and CRH-R1d-myc (E), CRH-R1α and 
CRH-R1d (B), CRH-R2β and CRH-R1α (D), CRH-R2β and CRH-R1d (F). 
V5-tag was detected using mouse monoclonal antibody and secondary anti-
mouse Alexa-Fluor®488 (green), myc-tag was detected with mouse
monoclonal myc-antibody conjugated with Texas Red (red) entity. The
receptors without tag were visualized using CRH-R1/2 antibody and Alexa-
Fluor®594 (red). The cell nuclei were stained with a DNA specific dye-DAPI
(blue).The cells were examined using indirect confocal microscopy.
A B
C D
E F
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An interesting result was obtained from cells co-expressing CRH-R2β-V5 (green) 
and CRH-R1d-myc (red) (Figure 4.9 E). CRH-R2β-V5 was expressed on the plasma 
membrane; however majority of red signal from CRH-R1d-myc was not coming from
the cytoplasm but from the plasma membrane. A possibility that the introduction of the
myc-tag to the C-tail of CRH-R1d could lead to the membrane expression of the
receptor was eliminated by over-expressing CRH-R1d-myc on its own (Figure 4.8 E).
However, it is possible that co-expression of the two receptors in the same cell could
stabilise CRH-R1d in the plasma membrane, possibly due to a receptor dimerisation.
When CRH-R2β and CRH-R1d (wild types) were co-expressed and detected with 
CRH-R1/2 antibody and Alexa-Fluor®594, only the membrane staining was observed;
eliminating possibility that the introduction of C-tail tags could affect R2β and R1d 
conformation leading to dimerisation of the receptors.
Figure 4.10. The cellular localisation pattern of CRH-R1d is dependent on
the expression levels of CRH-R2β and CRH-R1d. The cells were transiently
transfected with a mammalian expression vector pBudCE4.1 containing CRH-
R2β-V5 and CRH-R1d-myc. V5-tag was detected using mouse monoclonal 
antibody and secondary anti-mouse Alexa-Fluor®488 (green), myc-tag was
detected with mouse monoclonal myc-antibody conjugated with Texas Red
(red) entity. A white arrow points out a cell that has a strong red intracellular
signal (R1d) and weak green membrane signal (R2β). 
CRH-R2β-V5                  CRH-R1d-myc                  merge
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Another interesting observation was that the cellular localisation of CRH-R1d-
myc in a cell co-expressing CRH-R2β-V5 was dependent on levels of over-expressed 
receptors (Figure 4.10). A cell at the bottom of the figure 4.10 (pointed by a white
arrow) expresses smaller amount of the receptors than the other cells on the same
image, that cell has a strong red (R1d) intracellular signal and weaker green (R2β) 
membrane signal, while the rest of the cells have the both signals on the plasma
membrane
4.2.5.2 The effect of CRH-R1d on the CRH-R2β receptor internalization 
properties
The internalization characteristics of CRH-R1α, CRH-R1d and CRH-R2β are 
investigated in detail and described on chapters 3 and 5. In this section I determined
whether over-expression of CRH-R1d has an effect on UCNII induced internalisation
of CRH-R2β. In preliminary experiments, I demonstrated that CRH-R1α does not 
internalise when challenged with UCNII (Figure 3.4), additionally it has been
demonstrated that UCNII does not bind to CRH-R1 (Zorrilla EP et al., 2004). Basted
on these observations it was expected that UCNII induced effects in the R2β/R1d co-
expression system will be mediated exclusively via the CRH-R2β receptor. In figure 
4.11 a time course of CRH-R2β internalisation is shown. As previously demonstrated 
CRH-R2β-V5 was expressed in the plasma membrane; 5min treatment with 100nM 
UCNII did not cause any visible internalisation. However, after 15 minutes of UCNII
or CRH treatment, punctuated staining was detected in the cytoplasm. The amount of
internalised receptor following CRH challenge was lesser than following UCNII
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treatment. 30 minutes after UCNII treatment, the most of CRH-R2β was in the 
cytoplasm, and only partial staining was detected in the plasma membrane (Figure
4.11).
A short, 5min, treatment with 100nM UCNII did not induce internalisation of
CRH-R2β-V5 (Figure 4.11); however, introduction of CRH-R1d accelerated UCNII 
induced CRH-R2β internalisation (Figure 4.12).  Interestingly, both receptors were 
internalised after 5min of UCNII treatment, as shown by the punctuated pattern of
green and red fluorescence in cytoplasm. Additionally, substantial levels of co-
localisation between CRH-R2β and CRH-R1d were detected in the cytoplasm 
following UCNII and CRH treatments (Figure 4.12)
Figure 4.11. Internalisation of CRH-R2β-V5 in HEK293 cells: time course.
HEK293 cells were transiently transfected with a mammalian expression
vector pBudCE4.1 containing CRH-R2β-V5. The cells were treated with 
100nM UCNII for various times (0-30min) and with 100nM CRH for 15min.
V5-tag was detected using mouse monoclonal antibody and secondary anti-
mouse Alexa-Fluor®488 (green), The cell nuclei were stained with a DNA
specific dye-DAPI (blue).The cells were examined using indirect confocal
microscopy. The identical results were obtained from three independent
transfection experiments.
UCNII 5min
UCNII 15min
CRH 15min
Basal
UCNII 30min
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Figure 4.12. Internalisation characteristics of CRH-R2β-V5 co-expressed 
with CRH-R1d-myc in HEK293 cells: time course. HEK293 cells were
transiently transfected with a mammalian expression vector pBudCE4.1
containing CRH-R2β-V5 and CRH-R1d-myc. The cells were treated with 
100nM UCNII for various times (0-30min) and with 100nM CRH for 15min.
V5-tag was detected using mouse monoclonal antibody and secondary anti-
mouse Alexa-Fluor®488 (green), myc-tag was detected with mouse
monoclonal myc-antibody conjugated with Texas Red (red) entity. The cell
nuclei were stained with a DNA specific dye-DAPI (blue).The cells were
examined using indirect confocal microscopy. The identical results were
obtained from three independent transfection experiments.
CRH-R2β-V5  CRH-R1d-myc      merge
basal
100nM UCNII 5min
100nM UCNII 15min
100nM UCNII 30min
100nM CRH 15min
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Figure 4.13. Internalisation characteristics of CRH-R2β-V5 co-expressed 
with CRH-R1α-myc in HEK293 cells: time course. HEK293 cells were
transiently transfected with a mammalian expression vector pBudCE4.1
containing CRH-R2β-V5 and CRH-R1α-myc. The cells were treated with 100nM 
UCNII for various times (0-30min) and with 100nM CRH for 15min. V5-tag was
detected using mouse monoclonal antibody and secondary anti-mouse Alexa-
Fluor®488 (green), myc-tag was detected with mouse monoclonal myc-antibody
conjugated with Texas Red (red) entity. The cell nuclei were stained with a DNA
specific dye-DAPI (blue).The cells were examined using indirect confocal
microscopy. The identical results were obtained from three independent
transfection experiments.
To demonstrate that the enhanced rate of CRH-R2β internalization, in the 
presence of CRH-R1d, was not a due to non-specific events such are increased number
CRH-R2β-V5  CRH-R1α-myc merge
basal
100nM UCNII 5min
100nM UCNII 15min
100nM UCNII 30min
100nM CRH 15min
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of receptors on the membrane or non-specific interaction between receptors, CRH-R2β-
V5 was co-expressed with CRH-R1α-myc. The same internalisation experiment was 
performed and the results shown on the figure 4.13 demonstrate that 5min UCNII
treatment dose not lead to redistribution of CRH-R2β-V5 immunoreactivity from the 
plasma membrane to cytosol, suggesting that accelerated internalization rate of CRH-
R2β in the presence of CRH-R1d is likely to be due to the potential interactions 
between the two receptors.
4.2.5.3 The effect of CRH-R1d on CRH-R2β-medaiated cAMP 
production
The functional characteristics of the CRH-R2β receptor such as cAMP production and 
MAP kinase activation were investigated in detail in the following chapter X, where I
have demonstrated that the treatment of HEK293 stably expressing CRH-R2β with 
various concentration of CRH, UCN-I or UCNII (1-100nM) for 15 min results in a
dose-dependent increase of intracellular cAMP production. In this part of the study,
HEK293 cells were transiently transfected with a mammalian expression vector
pBudCE4.1 containing CRH-R2β and CRH-R1d, CRH-R2β and CRH-R1α, and each of 
receptor cDNA separately. The cells were stimulated with 100nM UCNII for
15minutes and cAMP levels were determined using a commercially available ELISA.
The cells over-expressing CRH-R1α or CRH-R1d did not have any significant 
production of cAMP following UCNII treatment. The cells over-expressing CRH-R2β 
showed a 3.42±0.44 fold increase in cAMP levels compared to not stimulated cells.
The cells co-expressing CRH-R2β and CRH-R1α produced 3.11±0.25 times more 
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cAMP than not stimulated cells; suggesting that CRH-R1α does not have an effect on 
CRH-R2β mediated cAMP production. Interestingly, cells co-expressing CRH-R2β and 
CRH-R1d had only 2.03±0.05 times more cAMP than not stimulates cells; which is
40% less than in cells expressing CRH-R2β only or co-expressing CRH-R2β and CRH-
R1α.  
Figure 4.14. CRH-R2β mediated cAMP production. HEK293 cells
transiently transfected with CRH-Rs, were stimulated with 100nM UCNII for
15min and cAMP production was measured. The stimulations were performed
in triplicates and the identical results were obtained from two independent
transfections
UCNII induced cAMP production
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4.2.5.4 The effect of CRH-R1d on CRH-R2β-medaiated MAP kinase 
activation
HEK293 cells were transiently transfected with a mammalian expression vector
pBudCE4.1 containing CRH-R2β and CRH-R1d, CRH-R2β and CRH-R1α, and each of 
receptor cDNA separately. The cells were stimulated with 100nM UCNII for 5minutes
and total cellular proteins were collected. ERK1/2 and p38 MAPK phosphorylation was
determined using western blot analysis. The cells over-expressing CRH-R1α or CRH-
R1d did not show significant ERK1/2 nor p38 MAPK activation following UCNII
treatment. The cells over-expressing CRH-R2β showed 2.5 and 1.5 fold increase in 
ERK1/2 and p38 MAPK phosphorylation, respectively, compared to not stimulated
cells. The identical MAPK phosphorylation levels were detected in cells co-expressing
CRH-R2β and CRH-R1α; suggesting that CRH-R1α does not have an effect on CRH-
R2β mediated MAPK activation. Interestingly, ERK1/2 phosphorylation was only 1.5 
fold above basal in UCNII stimulated cells co-expressing CRH-R2β and CRH-R1d, 
while p38 MAPK phosphorylation was completely abolished (Figure 4.15).
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Figure 4.15. The effect of CRH-R1d on CRH-R2β mediated MAPK 
activation. HEK293 cells transiently transfected with CRH-Rs, were
stimulated with 100nM UCNII for 5min and total cellular proteins were
assayed for ERK1/2 and p38 MAPK phosphorylation. The stimulations were
performed in duplicates and the identical results were obtained from two
independent transfections.
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4.3 DISCUSSION
In most tissues, CRH actions are dependent on the adequate expression of CRH-
R in the plasma membrane. The existence of multiple splice variants of CRH-R1 with
impaired signalling characteristics raises a question whether the resulting proteins have
a plasma membrane expression or not. I have demonstrated in Chapter 3, that CRH-
R1β is expressed in the plasma membrane, while CRH-R1d is predominantly expressed 
in the cytoplasm or intracellular compartments, with a small portion of receptor present
on the cell surface, suggesting that the deletion of 14 amino acids from the C-terminus
of the seventh TMD leads to inability of the protein to segregate into the lipid
membrane phase.
Due to the lack of CRH-R variant-specific antibody, it is impossible to determine
protein variant expression in endogenous cellular systems or in tissues. Confocal
microscopy studies that I performed on primary myometrial smooth muscle cells and
primary adipocytes have demonstrated a significant expression of CRH-Rs. The CRH
receptors were not uniformly expressed on the plasma membrane, some parts of
smooth muscle cell plasma membrane had higher receptor expression than other parts
of the cell surface, suggesting “hot spots” of CRH mediated signalling. Additionally,
strong intracellular and peri-nuclear staining detected in the native systems could
represent soluble receptor variants (such is CRH-R1d) and the newly synthesised CRH-
R, respectively. It is very possible that the intracellular CRH-R signal was from the
CRH-R1d variant, since other splice variants that might have cytoplasmic expression
(such as CRH-R1e1 and CRH-R1h) do not have the epitope against which the antibody
used was raised. Additional evidence for the CRH-R1d intracellular expression came
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from over-expression studies in HEK293 and primary myometrial smooth muscle cells.
The pattern of CRH-R1d over-expression in myocytes had striking similarity to the
endogenous CRH-R intracellular staining. These data provide a novel insight into the
CRH-R1 protein expression profile in endogenous systems. Of course, one can not
support with certainty that the intracellular immunoreactivity is solely due to CRH-R1d
expression. Further use of siRNA to knock down CRH-R1d or all the other variants
but CRH-R1d would possibly provide more concrete evidence. However, at this point
of time, the lack of variant specific antibody prevents any further analysis of CRH-R
variant protein localisation in endogenous systems.
The exon encoding the C-terminal 14 amino acids of the seventh TMD is highly
conserved in Class B GPCR genes. The splice variants with the deletion of this exon,
beside the CRH-R1d receptor (Grammatopoulos DK et al., 1999) were described for
the calcitonin receptor (Shyu J-F et al., 1996), the PTH/PTHrP receptor (Ding C et al.,
1995) and the vasoactive intestinal peptide receptor (Grinninger C et al., 2004). The
Kyte-Dolittle hydrophobicity analysis of CRH-R1α and CRH-R1d amino acid sequence 
has demonstrated that the deletion of 14 amino acids from the distal part of the seventh
TMD reduces the hydrophobicity of the residual sequence that follows the third
extracellular loop (Grammatopoulos DK et al., 1999). As a consequence, this might
reduce ability of the seventh TMD to anchor in lipid bilayer of the plasma membrane,
leading to a 6-TMD receptor with a extracellular C-terminus, as it has been reported for
the calcitonin splice variant CTRΔe13 (Seck T et al., 2005). The likelihood that CRH-
R1d has the same structural characteristics as CTRΔe13 receptor was assessed by 
indirect confocal microscopy using CRH-R specific antibody raised against the C-tail
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of the receptor. The experimental approach employed was based on the hypothesis that
if the C-terminus of CRH-R1d is in the extracellular space, even in non-permeabilised
over-expressing cells, the antibody would bind to the receptor resulting in detectable
immunoreactivity on the cell surface. Seck et al (Seck T et al., 2005) used different
experimental techniques to investigate the orientation of Δe13 C-terminus. Using a 
NMR analysis they demonstrated that the absence of the sequence encoding exon 13
leads to the loss of a functional seventh TMD and therefore and extracellular C-
terminus of the CTRΔe13 variant, and the extracellular orientation of the C-terminus 
was confirmed using FACS (fluorescence-activated cell sorter) analysis.
After establishing that the extracellular orientation of the C-terminus of CRH-
R1d, which was possibly responsible for the intracellular expression of the receptor, my
studies focused on identifying the sets of amino acids encoded by exon 13 that were
essential for the plasma membrane expression of the receptor. Series of CRH-R1α and 
CRH-R1d mutant constructs were generated and the cellular localisation of the
receptors was investigated by using indirect confocal microscopy (Table 4.1). The
mutagenesis study revealed that the GFF cassette (Gly356-Phe357-Phe-358) within the
seventh TMD of CRH-R1α was required for a stable receptor expression in the plasma 
membrane. The protein structure prediction algorithms (PELE) available at
http://workbench.sdsc.edu were used to investigate whether the GFF cassette is
involved in the start of certain secondary protein structures such are the α-helix, β-
sheets or turns (Figure 4.16). The most of algorithms predict that the GFF cassette or at
least one of amino acids in the cassette could be the start of β-sheet following either α-
helix or coil structure. It is tempting to speculate that the deletion of the GFF cassette
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as in the CRH-R1α Δ(356-358) mutant receptor, prevents the formation of the β-sheet, 
leading to the misfolding of the rest of receptor. However the cell surface expression of
CRH-R1d is not rescued by the insertion of the same cassette into the CRH-R1d protein
sequence. Only addition of 9 amino acids (GFFVSVFYC) to CRH-R1d protein
sequence resulted in the expression of the receptor within plasma membrane. In future
studies, it would be interesting to perform an NMR analysis of the mutant CRH-R1α 
and CRH-R1d receptors, and determine the effects of deletion and insertion on
topological orientation of receptor domains. Since a detailed structural analysis was not
a topic of this project, I focused my attention on the functional interactions between
CRH-R1d and CRH-R2β. 
Figure 4.16. Secondary structure prediction. The algorithms available at the
Biology Workbench web site were used to analyse amino acid sequence of
CRH-R1α for the formation of secondary structures. Amino acid sequence 
encoded by exon 13 is highlighted by the green rectangle.
Previous studies on the CRH-R1d variant have indicated that an intact seventh
TMD is not required for efficient receptor-ligand interaction, but it is crucial for
algorithm
s
algorithm
s
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adequate signal transduction (Grammatopoulos DK et al., 1999). In comparison to
CRH-R1α, the activated CRH-R1d was less potent in mediating cAMP production, and 
fail to induce IP3 production, these was attributed to reduced coupling to G-proteins of
the latter (Grammatopoulos DK et al.,1999). The calcitonin Δe13 receptor 
demonstrated similar signalling impairment (Shyu J-F et al., 1996). However, while
CTRΔe13 exhibited a dominant negative effect on receptor surface expression and 
signalling (Seck T et al., 2005), the CRH-R1d variant did not act as a dominant
negative receptor when co-expressed with CRH-R1α (Grammatopoulos DK et al.,
1999). However, a possible link between two distinct types of the CRH receptors has
not been investigated until now. My experiments have provided novel evidence that
CRH-R1d can heterologously modulate CRH-R2 functional characteristics when co-
expressed with CRH-R1d, CRH-R2β’s signalling abilities are impaired. 
The CRH-R2β receptor is primarily Gs-protein coupled receptor, which 
activation leads to cAMP production and activation of protein kinase A (PKA);
additionally, various studies have demonstrated that this receptor couples to multiple
G-proteins (Gq, Gi and Go) activating diverse kinases (PI3-K, MAPK kinase 1, Raf-1
kinase, tyrosine kinase (Grammatopoulos DK et al.,2000; Brar BK et al., 2004). In
view of recent studies implicating peripheral CRH-R2 in the control of energy balance
and homeostasis (Li C et al., 2003; Chen A et al., 2006), it is of pivotal importance to
establish a potential link between the two types of CRH receptors. There is only one
study investigating the effects of co-expression on the signalling characteristics of
CRH-R1 and R2 (Maya-Nunez G et al., 2005). This study reports that co-expression of
CRH-R1α and CRH-R2α leads to reduced CRH induced cAMP production. 
CHAPTER 4
148
Additionally, the study finds that the co-expression of the two receptors does not effect
ligand binding nor internalisation properties of the receptors. In my study, co-
expression of CRH-R1α and CRH-R2β did not lead to impaired UCNII induced cAMP 
production, MAPK activation nor internalisation kinetics. The different results
regarding cAMP production between these two studies can be attributed to different
agonists. In my study, I purposely used UCN-II because it only binds and activates
CRH-R2, so any effect on signal transduction that I might have seen when co-
expressing the two receptors was not due to activation of the type 1 receptor, but solely
due to activation of CRH-R2 and possible physical interaction between the two
receptors. Another reason for the discrepant result could be that co-transfection was
performed differently, although the same cellular system, HEK293, in my study, I used
pBudCE4.1 plasmid, which was design for the independent but equal expression of two
genes within the same mammalian cell. However, Maya-Nunez et al used two
pcDNA3.1 plasmids for the co-transfection. These experimental conditions do not
guarantee that each transfected cell would up take both plasmids. It is very likely that
the use of pcDNA3.1 for this kind of transfection would lead to creation of mixed
population of cells in which some of the cells express only one type of receptor.
Given that I have not found that co-expression of CRH-R1α and CRH-R2β has an 
effect on UCNII induced cAMP production, MAPK activation nor internalization of
CRH-R2β, I used this co-expression system as a control to study the potential effects of 
CRH-R1d on CRH-R2β functional characteristics.  
Co-expression of CRH-R1d did not effect CRH-R2β membrane expression. 
However, an interesting phenomenon was observed: when the two receptors expressed
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in high number of copies in the same cell, a significant portion of CRH-R1d was
present in the plasma membrane; but in cells with lower levels of receptor expression,
CRH-R2β was expressed only in the plasma membrane and CRH-R1d was detected 
primarily in the cytoplasm. It is possible that CRH-R1d and R2β form a physical 
contact through dimerisation, which leads to the stabilisation of CRH-R1d in the
plasma membrane. To draw concreted conclusion about these data detailed biochemical
experiments (co-immunoprecipitation and BRET analysis) on cells stably expressing
the two types of receptors would be required. These experiments could be a topic of a
future study.
The internalization studies revealed that the presence of CRH-R1d enhances
UCN-II induced CRH-R2β internalisation, and that both types of receptors are co-
localised in the cytoplasm. It is tempting to speculate that formation of dimers is
responsible for this effect. Increasing evidence suggests that GPCRs are more common
as dimmers than monomers, and that heterodimerization can modify receptor
trafficking and signalling compared to the individual homodimers (Gomes JI et al.,
2001). Along these lines is that the CTRΔe13 receptor forms a heterodimer with the 
wild type calcitonin receptor, leading to the retention of the wild type receptor in
intracellular compartments (Seck T et al., 2003). Up to date, there are only two reports
describing dimerization of CRH-R1 (Kraetke O et al., 2005; Young et al., 2007).
Functional cooperativity between the effects of CRH and AVP in the pituitary suggests
that CRH-R1 and vasopressin V1b receptor (V1b-R) form a physical interaction
(Young et al., 2007). Using BRET and co-immunoprecipitation techniques, Young et al
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(2007) reported that V1b-R and CRH-R1formed homo- and heterodimers and this
interaction did not affect the binding abilities of the receptors.
Second messenger studies and MAPK activation assays have shown that the co-
expression of CRH-R1d and CRH-R2β attenuated UCN-II induced cAMP as well as 
ERK1/2 and p38 MAPK phosphorylation. The impaired signal transduction could be
due to quick endocytosis rate of CRH-R2β in the co-expressing system.  Detailed time 
course studies should be able to provide more conclusive evidence for this speculation.
In this part of the project I have provided evidence that the co-expression of
CRH-R1d does have an effect on UCN-II induced CRH-R2β activation. This is of 
potential importance in understanding how the action of urocortins via activation of
CRH-R2 are controlled in peripheral tissues, such are skin, muscle, adipose tissue, that
express both types of receptors.
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2
3
4
5 SIGNALLING AND INTERNALIZATION
CHARACTERISTICS OF CRH-R2β 
5.1 INTRODUCTION
Corticotropin-releasing hormone (CRH), urocortin–I (UCN-I), urocortin–II
(UCN-II and urocortin-III (UCN-III) are members of the CRH-like family of peptides
that play various roles in mammalian development and physiology, especially the
adaptation to stressful stimuli (Bale TL & Vale WW, 2004). Two classes of CRH
receptors termed R1 and R2, mediate the diverse actions of CRH and UCNs in the
brain, pituitary and peripheral tissues (Hillhouse EW & Grammatopoulos DK, 2006).
Mammals express three known CRH-R2 variants: R2α and R2β expressed both 
centrally and peripherally and R2γ which has so far been found only in the limbic 
regions of the human CNS (Hillhouse EW & Grammatopoulos DK, 2006). These
variants have identical transmembrane and C-terminal domains and only differ in their
N-terminal extracellular domains. Pharmacological characterization of the CRH-R2 has
shown that this seven heptahelical G-protein coupled receptor (GPCR) preferentially
binds UCNs rather than CRH (Lewis K et al., 2001). CRH-R2 activation is central in
mediating UCNs diverse physiological actions including anxiolytic and feeding
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reduction effects in the brain as well as cardioprotection, tissue angiogenesis and
gastrointestinal regulatory effects at the periphery (Bale TL et al., 2000; Bale TL et al.,
2002; Carlin KM et al., 2006; Lawrence KM & Latchman DS, 2006). Recent findings
showing involvement of UCNs in the control of glucose utilization and insulin
sensitivity in skeletal muscle as well as stimulation of insulin and glucagon secretion in
pancreatic β-cells, implicate CRH-R2 in the control of energy balance and homeostasis 
(Li C et al., 2003; Chen A et al., 2006).
The CRH-R2, similar to the CRH-R1 receptor, is primarily a Gsα/adenylyl 
cyclase/cAMP-coupled GPCR (Hoare SR et al., 2005). In addition, two members of the
family of mitogen-activated protein kinases (MAPK), extracellular signal regulated
kinase (ERK1/2) and p38 MAPK, have also been implicated as key signalling
intermediates downstream of CRH-R2 activation (Dermitzaki E et al., 2002;
Sananbenesi F et al., 2003; Brar BK et al., 2004; Karteris E et al., 2004). Various
studies (Grammatopoulos D et al., 2000; Brar BK et al., 2004 ) investigating the
mechanisms of CRH-R2-ERK1/2 interactions have shown involvement of multiple G-
proteins (Gq-, Gi- and Go-) and a number of signalling molecules including,
phosphatidylinositol-3 OH kinase (PI3-K), MAPK kinase 1, phospholipase C, Raf-1
kinase, tyrosine kinases, and intracellular Ca2+.
At present, there is little information about the intracellular mechanisms
regulating CRH-R2 signalling efficiency. A characteristic feature of most GPCRs
function is their ability to adjust their biological activity in response to prolonged
agonist stimulation. This is achieved through a series of fine tuned signalling events
involving receptor phosphorylation by protein kinases, β-arrestin recruitment to the 
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plasma membrane and association with the receptor that leads to GPCR signalling
desensitization and uncoupling from G-proteins; this is followed by receptor
endocytosis, sometimes via a clathrin/dynamin-mediated process (Claing A et al.,
2002). Interestingly, for many GPCRs this mechanism also appears to be essential for
activation of the ERK1/2 signalling pathway in a G-protein independent manner
(Lefkowitz RJ & Shenoy SK, 2005).
Previous studies addressing CRH-R1 signalling properties (Perry JS et al., 2005; Teli T
et al., 2005; Markovic D et al., 2006) demonstrated that the CRH-R1 is sensitive to β-
arrestin-dependent signalling desensitization and internalization. Receptor endocytosis
is also one of the mechanisms employed by CRH-R1 to induce ERK1/2 and p38
MAPK phosphorylation and activation (Punn A et al., 2006).
In this part of my project I sought to determine the signalling and internalization
characteristics of CRH-R2β and explore the possible link between the CRH-R2 
internalization and MAPK activation. I also analysed some of the spatio-temporal
characteristics of MAPK activation, and investigated potential receptor structural
domains that are involved in this process. I used recombinant human CRH-R2β stably 
expressed in HEK293 cells.
METHODS
5.1.1 Establishment of HEK293 cells stably expressing CRH-R2β (st.293-R2β) 
For stable transfection 10μg pcDNA3.1(+) CRH-R2β plasmid was transfected 
into HEK293 cells grown in 75cm2 vented flasks using Lipofectamine2000. After 3
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days non-selective growth in normal growth media (DMEM with Glutamax and 10%
FCS), followed by 15 days of growth in the same media with 500μg/ml gentamicin 
(G418, Gibco), clones were selected by serial dilution of surviving foci and maintained
in 250μg/ml gentamicin. The optimal concentration of gentimcin and the length of cell 
growth before cloning out was determined by growing non-transfected HEK293 cells
in media containing different concentrations of the antibiotic (50-1000μg/ml) for 21 
days and performing a cell viability MTT (thioazolyl blue) assay Figure 5.1) as
described in Material and Methods.
Figure 5.1. Cell viability in the presence of G418. HEK293 cells were
grown in normal growth media containing 0-1000μg/ml G418 for 2 weeks. 
The cell viability was determined by a MTT assay. The assay was performed
in quadruplets.
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After 2 months the expression of CRH-R2β was verified by confocal 
microscopy analysis. The clones that showed uniform membrane expression of the
CRH-R2β were subjected to a further verification of the receptor expression by PCR 
and immunoblotting. Those clones were also tested for cAMP production and ERK1/2
activation following 10-100 nM UCN-II treatment to asses the functionality of the
clones. A clone that had shown the most desirable properties was used in further
studies. The stables (st.293-R2β) were maintained in DMED with Glutamax containing 
10% FCS, 100 U/ml penicillin and 100 g/ml streptomycin and 250 g/ml gentamicin,
until reaching passage 18, when a fresh frozen stock of the same clone was revived.
5.1.2 Transient transfection of CRH-R2β and DN β-arrestin to HEK293 cells 
Human wild-type or mutant CRH-R2β or dominant negative (DN) -arrestin
cDNAs subcloned in pcDNA3.1(+) were transfected in HEK293 cells using
Lipofectamine 2000 reagent, according to the manufacturer’s protocol. Briefly, 5 μg 
DNA was mixed with 5μl Lipofectamine 2000 reagent, and added to 50-70% confluent 
cells seeded in 25cm2 flasks in 5 ml of OptiMEM + GlutaMax (Invitrogen/Gibco) for
overnight transfection. The following morning the transfection mixture was replaced
with high-glucose DMEM with Glutamax containing 10% FCS, 100 U/ml penicillin
and 100 μg/ml streptomycin. Eight hours later, cells were transferred onto 12-well 
plates coated with 100μg/ml poly-D-lysine in PBS or on coated glass cover slips (for 
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confocal microscopy studies). All required experiments were carried out 48-96h after
transfection.
5.1.3 CRH-R2β site-directed mutagenesis 
Site-directed mutagenesis was used to create CRH-R2β receptors, in which the 
cassette TAAV at the end of C-tail was replaced by AAAA, STAV, or deleted (DEL)
[CRH-R2β(STAV), CRH-R2β(4A), and CRH-R2β(Del)]. Human CRH-R2β cDNA 
was subcloned into the mammalian cell expression vector pcDNA3.1(+)
(InvitrogenLifeTechnologies) and was used as a template for mutagenesis using Pfu
polymerase. The PCR mixture (20μl) contained 5ng of cDNA, 5ng/μl of each primer, 
1unit of Pfu polymerase and 20 nM of each dNTP. cDNAs were amplified at 48oC in a
total of 35 cycles. The forward primer contained a sequence for EcoRI restriction site
adjacent to the 5’-end of the receptor sequence 5’-ATTCCGATGAGGG
GTCCCTCAGGGCCCCCAGG-3’; while the reverse primer was specific for each
mutant and contained the sequence for XhoI restriction site (Table 5.1)
CRH-
R2β(STAV) 
5’-CCGCTCGAGCGGGTCACACAGCGGTCGACTG
CTTGATGCTGTGGAAGCT-3’
CRH-
R2β(4A) 
5’-CCGCTCGAGCGGGTCACGCAGCGGCCGCCT
GCTTGATGCTGTGGAGCT-3’,
CRH-
R2β(Del) 
5’-TCGAGCGGGTCACTGCTTGATGCTGTGGAA
GCT-3’
Table 5.1. Nucleotide sequences of primers used to create CRH-R2β 
mutant receptors.
The resulting PCR products were run on 1.2% agarose gel, purified using
QIAquick gel extraction kit (Qiagen Ltd, Crawley, West Sussex, UK), digested with
EcoRI and XhoI, purified again and ligated into pcDNA3.1(+) using FastLiga System
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from Promega (Madison, USA) according to manufacturer’s instruction. E.coli DH-5α 
was transformed with the resulting plasmids, and after selective overnight growth on
LB plates containing 100μg/ml ampicillin, five colonies were picked up for further 
analysis. The entire regions amplified by PCR were sequenced to ensure the fidelity of
the mutant cDNAs and confirm presence of mutations. DNA sequence analysis was
performed by the Core facility of the Department of Biological Sciences, University of
Warwick.
5.1.4 Clathrin siRNA transfection to st.293-R2β  
Three sets of clathrin heavy chain Stealth™ RNAi (3216-3241 oligo 1; 3543-
3528 oligo 2; 3928-3953 oligo 3) were obtained from Invitrogen Ltd (Paisley,
UK).  One day before transfection st.293-R2β were plated in 6 well plates in normal 
growth media without any antibiotics. Lipofectamine 2000 was used for the delivery of
0.5 and 1nmol siRNA into cells according to manufacturer’s instructions. Subsequent
experiments were performed 72-96h after transfections.
5.1.5 cAMP studies
Cells were grown in 12-well plates and when reached 70-80% confluency,
media was aspirated and the cells were washed with plain DMEM. Stimulation buffer
(DMEM containing 10mM MgCl2 and 0.1mg/ml 3-isobutyl-1-methylxanthine-IBMX)
was added on the cells for 20 min at 37oC and then cells were washed with plain
DMEM, and stimulated with 1-100 nM UCN-II, CRH or 10μM forskolin for 15 min. 
The reaction was stopped by adding 10μl of concentrated HCl for 15-20 min and cells 
were transferred in 1.5ml tubes. After a brief spin, the cells and media were stored at -
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20oC. The cAMP levels were determined by commercially available ELISA Direct
Cyclic AMP Enzyme Immunoassay Kit (Assay Designs Ins., Ann Arbor, MI, USA).
Receptor desensitization was assessed as previously described (Teli T et al.,
2005). Briefly, cells plated in 12-well plates, were pre-treated for various time intervals
(0-30 min) with 100 nM UCN-II or CRH, and following a brief wash cells were
stimulated with 100 nM UCN-II for 15 min. Intracellular cAMP levels were measured
as described above.
5.1.6 Western blot analysis for detection of ERK1/2 and p38 MAPK
phosphorylation
Cells reached 60-70% confluency were serum starved for or overnight. The
following morning, appropriate inhibitors were added in concentrations previously
optimised during the PhD projects of Drs Teli and Papadpoulou, and from published
work of the other lab members (Drs Punn and Karteris) (concanavalin A 0.25 mg/ml
for 40 min, U0126 10 μM for 1 h, 1 μM PKAi for 30 min, 10 μM st-Ht-31 for 30 min, 
50 μM LY -294002 for 30 min) followed by stimulation of cells with different 
concentrations (1-100 nM) of UCN-II or CRH for various time periods (2 min-60 min).
At the end the stimulation, media was removed, and cells were briefly washed with ice-
cold PBS, and then were lysed by addition of 150μl of 2X SDS-PAGE sample buffer 
(Sigma). Solubulised material was collected, sonicated for 20sec, and boiled for further
5 min. After a brief centrifugation step protein lysates were stored at -20oC until used.
Before electrophoresis, protein extracts were centrifuged at 4,000 rpm for 5 min to
remove insoluble material and 15μl of the supernatant were loaded on 10%SDS-PAGE 
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gels. After completion of transfer, the PVDF membrane was incubated with 8-10ml
Licor blocking buffer (LI-COR Biosciences, Cambridge, UK) for 1 h at room
temperature with gentle agitation. To determine ERK1/2 phosphorylation the
membrane was incubated simultaneously with the phospho-ERK1/2 (Thr204/Tyr202)
antibody and total ERK2 antibody (dilutions 1:1500 and 1:2000, respectively) in 10 ml
of Licor blocking buffer with gentle agitation overnight at room temperature. The
following day the antiserum was removed and the membrane was washed 3 x 10
minutes with 15 ml TBS-T (TBS-0.1% Tween), before addition of secondary antibody
conjugated to a fluorescent entity: IRDye™800-conjugated goat anti-rabbit IgG and/or
Alexa Fluor®680-conjugated goat anti-mouse IgG (dilution 1:6000) in 10 ml of Licor
blocking buffer with gentle agitation for 1 hour at room temperature. At the end of the
incubation period, membranes were washed twice with 15 ml of TBS-T, and once with
15ml of TBS. The membrane was dried, visualized and analysed on the Odyssey
Infrared Imaging System (LI-COR Biosciences, Cambridge,UK).
To monitor p38MARK phosphorylation, membranes were incubated with the
phospho-p38MAPK antibody (1:1000 in Licor buffer) with gentle agitation overnight
at 4oC. Following 3 washes with TBS-T, goat anti-mouse Alexa®Fluor 680 conjugated
IgG (dilution 1:6000 in 10 ml of blocking buffer) was added for 1 hour at room
temperature, before visualization and analysis by the Odyssey Infrared Imaging System
(LI-COR Biosciences, Cambridge,UK). Membranes were then stripped with 25mM
glycine buffer pH 2 containing 2% SDS, and re-probed with total p38MAPK antibody
(dilution 1:500 in Licor blocking buffer) with gentle agitation overnight at room
temperature.
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5.1.7 Western blot analysis for detection of β-arrestin-1 phosphorylation 
Cells reached 60-70% confluency were serum starved for 2 h. The cells were
lysed in 100μl of RIPA buffer containing protease and phosphatase inhibitors cocktail 
(Santa Cruz). Protein concentration was determined with BCATM Protein Assay Kit
(Pierce, Rockford, IL, USA), and 5 or 10μg of proteins were loaded on 10%SDS-
PAGE gels that run at 200V for approximately 1 h. Proteins were electrophoretically
transferred to PVDF membrane at 100V for 1 hr. After completion of transfer, the
PVDF membrane was incubated with 8-10ml Licor blocking buffer (LI-COR
Biosciences, Cambridge, UK) for 1 h at room temperature with gentle agitation. For β-
arrestin1 phosphorylation, membranes were incubated simultaneously with phospho-β-
arrestin1 (Ser412) and total β-arrestin1 antibodies (dilutions 1:500 and 1:1000, 
respectively) in 10 ml of Licor blocking buffer with gentle agitation overnight at 4oC.
The following day the antiserum was removed and the membrane was washed 3 x 10
minutes with 15 ml TBS-T (TBS-0.1% Tween), before addition of secondary antibody
conjugated to a fluorescent entity: IRDye™800-conjugated goat anti-rabbit Gig and/or
Alexi Fluor®680-conjugated goat anti-mouse IgG (dilution 1:6000) in 10 ml of Licor
blocking buffer with gentle agitation for 1 hour at room temperature. At the end of the
incubation period, membranes were washed twice with 15 ml of TBS-T, and once with
15ml of TBS. The membrane was dried, visualized and analysed on the Odyssey
Infrared Imaging System (LI-COR Biosciences, Cambridge,UK).
The specificity of phospho-β-arrestin antibody was confirmed with alkaline 
phosphatase treatment of a PVDF membrane. The membrane was incubated at 37oC
overnight in 10mls of alkaline phosphatase buffer and 1000u of alkaline phosphatase.
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The following morning membrane was washed with TBS-T and probed with the
phospho-β-arrestin1 (Ser412) and total β-arrestin1 antibodies as described above. 
5.1.8 Plasma membrane fractionation and β-arrestin translocation  
For plasma membrane fractionation, 293-R2β were grown in 10cm Petri dishes, 
and when reached 80% confluency, cells were deprived from FCS for 1 h before
treatment with 100 nM UCN-II or CRH for the indicated time intervals. Membrane
proteins were prepared using ProteoExtract® Native Membrane Protein Extraction Kit
(Calbiochem/ Merck Biosciences, Nottingham, UK). Protein concentration was
determined using a BCATM Protein Assay Kit (Pierce, Rockford, IL, USA). Protein
fractions (5μg) were analysed by western blot analysis. Following SDS-PAGE and 
electrophoretic transfer, membranes were incubated overnight at 4oC with pan-arrestin
antibody (recognizes both arrestins β-arrestin1 of 49kDa and β-arrestin2 of 47kDa) 
(dilution 1:500), after 1 h incubation step in TBS-T containing 5% BSA at room
temperature. Following incubation with the secondary horseradish peroxidase-
conjugated anti-rabbit IgG (DAKO UK Ltd, Ely, UK) (1:2000 dilution in TBS-T for 1
h at room temperature), proteins were visualized using ECL reagent from
Amersham/Pharmacia Biotech (GE Healthcare UK Ltd, Little Chalfont, UK). When the
β-arrestin1 specific antibody was used, membranes were blocked in Licor blocking 
buffer for 1 h at room temperature with gentle agitation, following an overnight
incubation with total β-arrestin1 antibody (dilution 1:1000 in Licor blocking buffer) at 
4oC. After 3 washes with TBS-T the membranes were probed with goat anti-rabbit
IRDye™800-conjugated IgG (dilution 1:6000 in 10 ml of blocking buffer) with gentle
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agitation for 1 hour at room temperature and immediately visualized and analysed on
the Odyssey Infrared Imaging System (LI-COR Biosciences, Cambridge,UK).
The purity of membrane fraction was confirmed by a lack of GAPDH and the
presence of pan-cadherin in the fraction. To detect GAPDH, PVDF membranes were
incubated with the GAPDH antibody (1:60,000 in TBS-T) with gentle agitation for 1 h
at room temperature. Following 3 washes with TBS-T, goat anti-mouse Alexa®Fluor
680 conjugated IgG (dilution 1:6000 in 10 ml of blocking buffer) was added for 1 hour
at room temperature, before visualization and analysis by the Odyssey Infrared Imaging
System (LI-COR Biosciences, Cambridge,UK). For detection of pan-cadherin, a
plasma membrane protein marker, PVDF membranes were incubated with the pan-
cadherin antibody (1:500 in TBS-T) with gentle agitation overnight at room
temperature. Following 3 washes with TBS-T, goat anti-mouse Alexa®Fluor 680
conjugated IgG (dilution 1:6000 in 10 ml of blocking buffer) was added for 1 hour at
room temperature, before visualization and analysis by the Odyssey Infrared Imaging
System (LI-COR Biosciences, Cambridge,UK).
5.1.9 Immunofluorescent confocal microscopy
Cells were seeded on cover slips coated with 100μg/ml poly-D-lysine in PBS. 
When reached 70-80% confluency, the cells were treated with various concentration of
agonists and fixed with 4% PFA. Non-specific binding was blocked with 1% BSA in
PBS-Triton x-100 (0.01%) for 1 h at room temperature. Following a 5 min wash with
PBS, a PBS solution containing 1:100 monoclonal mouse antibody against CHC and
1:75 polyclonal rabbit pan-arrestin antibody were added for overnight incubation at 4oC.
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The next morning, the antibody mixture was removed and slides were washed with PBS
3 times for 5 min each and polyclonal goat antibody against the C-terminus of CRH-
R1/2 (1:100 in PBS) was added for 2 h at room temperature. After three PBS washes for
5 min each, donkey anti-rabbit AlexaFluor®488 and donkey anti-goat AlexaFluor®594
were added in 1:400 dilution each for 1 h at room temperature. Following three 5 min
washes with PBS, solution containing 1:400 goat anti-mouse AlexaFluor®405 was
added for 1 h at room temperature. After three final washes with PBS, slides were
mounted with VECTASHIELD Mounting Medium without DAPI after three final
washes with PBS. When double staining was carried out, both primary antibodies 1:100
CRH-R1/2 and 1:75 pan-arrestin or 1:100 CHC or β-arrestin1 or phospho-p38MAPK, 
were placed on slides for overnight incubation at 4oC, whereas incubation with 1:100
CRH-R1/2 and 1:100 phospho-ERK1/2 would take place overnight at room
temperature. After three washes with PBS, slides were incubated with donkey anti-
rabbit (or mouse) AlexaFluor®488 and donkey anti-goat AlexaFluor®594 (1:400),
before mounting with Gold Slowfade mounting solution with DAPI (Molecular Probes).
The slides were examined under an oil immersion objective (x63) using a Leica
model DMRE laser scanning confocal microscope (Leica Microsystems, UK,
Buckinghamshire, Milton, Keynes, UK) with TCS SP2 scan head. Laser 543 nm at 50%
of power and emission filter set at 555-620 nM were used to examine AlexaFluor®594
staining, and Laser 488 nm at 30% of power and emission filter set at 500-535 nm was
used to examine AlexaFluor®488 staining. DAPI or AlexaFluor®405 staining was
examined with Laser 405 at 10% of power and emission filter set at 410-450 nm. The
scan speed was set at 400 Hz, and the format was 1024x1024 pixels. Optical sections
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(0.5 µm) were taken, and representative sections corresponding to the middle of the
cells are presented. After indirect immunofluorescent staining, no specific fluorescence
was observed in cells treated with secondary antibody only, or when blocking peptide
was incubated with the primary antibody prior to incubation on cells. For each
treatment, between 20 and 30 individual cells in five random fields of view were
randomly selected and examined. Fluorescence intensity profiles were generated along
multiple line axes, analyzed, and quantified using ImageJ software developed at the
National Institutes of Health (http://rsb.info.nih.gov/ij/). Relative quantification of
intracellular (internalized) CRH-R2 was carried out by measuring the amount of total
fluorescence along the longitudinal axis corresponding to the intracellular space
(average 4–18μm).  
5.1.10 On-cell western
Cells were cultured on 24-well plates. When 80% confluent, cells were treated
with 100 nM UCN-II or CRH for 15-45 min. Cells were fixed with 4% PFA for 20 min,
and after three brief washes with PBS, non-specific binding was blocked with Licor
blocking buffer. A rabbit antibody raised against the N-terminus of CRH-R2 was used
in dilution of 1:2000 (Abcam) in Licor blocking buffer at 4oC overnight. After 3 washes
with PBS, cells were incubated with the secondary anti-rabbit IRDye-800 antibody
(dilution) 1:800 for 1 h at room temperature. The signal was detected and analysed
using the Odyssey Infrared Imaging System (LI-COR Biosciences, Cambridge,UK).
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5.1.11 Statistics
All experiments were performed in duplicates and repeated at least three times.
Phosphorylated and total levels of ERK1/2 and p38MAPK were quantified using the
Oddyssey Infrared Imaging System (LI-COR Biosciences, Cambridge, UK).
Background was automatically corrected; the first derivatives of the band intensities of
the phosphorylated kinases were divided by the total kinases values to give fold
activation. In order to express the results as a fold above basal (the vehicle-treated
control) the “(treated – not treated)/ not treaded“ formula was used. The means and
SEM were calculated for each treatment. Single-factor one-way ANOVA was
performed for each treatment, and significance was assumed when P<0.05.
5.2 RESULTS
5.2.1 Characterisation of st.293-R2β cells 
Following two months of a selective growth in media containing 500μg/ml 
G418, 49 clones survived. The clones were tested for the receptor expression and
functional activity. Firstly, the clones were screened for the receptor membrane
expression using CRH-R specific antibody and indirect confocal microscopy (Figure
5.2). Weak immunoreactivity was detected in HEK293; some of clones such as 1 and 4
had an even receptor distribution on the plasma membrane; on the other hand not all of
the cells originated from clones 15 and 46 over-expressed CRH-R2β. Clones 9, 10, 17, 
19, 25, 36, and 45 expressed the receptor on the plasma membrane. However, I noted
CHAPTER 5
166
that the proliferation of the clone 10 was faster while the clone 36 was proliferating
slower than the other clones.
Further analysis of mRNA and protein levels of CRH-R2β by RT-PCR (Figure 
5.3) and western blot (Figure 5.4), demonstrated that the clone 10 had a weaker mRNA
and protein expression than the other clones. Additionally, the clone 36 did not express
significant levels of CRH-R2β mRNA and proteins. Clones 9, 17, 19, 25 and 45 
expressed substantial mRNA and protein levels of CRH-R2β. 
Figure 5.2. Characterisation of CRH-R2β cellular expression in HEK293 
stably expressing the receptor by indirect confocal microscopy. Forty nine
clones survive selective growth in media containing 500μg/ml G418. The 
clones were grown on cover slips and the expression of CRH-R2β was 
monitored by indirect confocal microscopy using CRH-R1/2 specific antibody
and Alexa-Fluor®594 secondary antibody. Cell nuclei were visualized using
the DNA specific dye-DAPI.
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Figure 5.3. Characterisation of mRNA CRH-R2β expression in HEK293 
stably expressing the receptor by RT-PCR. RNA and cDNA was made from
the seven clones having membrane expression of the receptor. PCR using
CRH-R2β specific primers was performed, β-actin was used as an internal 
control demonstrating the good quality of cDNA. Two negative controls were
used: to confirm that there was no contamination with genomic DNA in the
RNA prep, in the –RT control, reverse transcriptase was omitted when RNA
was converted to the cDNA; to confirm that the PCR chemicals are “clean” of
contaminants, water was placed instead of cDNA in the PCR reaction in the
water control.
Figure 5.4. Characterisation of protein CRH-R2β expression in HEK293 
stably expressing the receptor by western blot analysis. Total cellular
proteins from the seven clones were made and subjected to the separation by
SDS-PAGE and electrotransfer. The protein expression of the receptor was
detected by CRH-R specific antibody.
The functionality of the over-expressed receptor in the six clones was assessed
by investigating cAMP production and ERK1/2 MAP activation. The clone 25 was
lost due to a fungal infection.
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In order to demonstrate that the over-expression of CRH-R2β does not affect 
the adenylyl cyclase activity, the plasma membrane components were by-passed by
use of forskolin, an adenylyl cyclase activator. The forskolin induced cAMP
production among all of the clones and wild type HEK293 was comparable, 58-65
fold above basal (Figure 5.5A). This demonstrated that the clones retained the
functional adenylyl cyclase system.
Since CRH-R2 is primarily coupled to Gsα/adenylyl cyclase/cAMP system, 
it was of pivotal importance to demonstrate that the generated clones were indeed
able to produce cAMP following UCN-II treatments. Treatment of the cells with 1-
100 nM UCN-II (Figure 5.5B) showed that the endogenous levels of CRH-R2 in
HEK293 were not sufficient to induce a marked cAMP production. In addition, the
clones 10 and 35 failed to produce cAMP following UCN-II treatments; which is
not surprising since the PCR and western blot analysis fail to detect substantial
levels of mRNA and protein expression of CRH-R2β in those clones. The clone 17, 
although able to produce high levels of cAMP following UCN-II stimulation, fail to
demonstrated the agonist dose dependent cAMP production. It is possible that
because of high number of the receptors molecules in the plasma membrane, the
plato of cAMP production was reached. To investigate if this was the case, binding
studies determining the number of receptors on the membrane were needed.
However, since that would side track the project, this clone was eliminated from the
study. Moreover, other clones such as 9, 19 and 45 showed UCN-II dose dependent
cAMP production. The clone 45 had 30% reduced ability of UCN-II induced cAMP
production than the other two clones (9 and 19).
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Another major pathway activated by UCN-II, downstream of CRH-R2β, is the 
mitogen activated protein kinase (MAPK) signalling cascade. To asses the ability of
the selected clone in an activation of this cascade, the cells were treated with 10 and
100 nM UCN-II for 5 min, total cellular proteins were made and ERK1/2
phosphorylation was determined as described in the methods (Figure 5.6).
Stimulation of clone 36 as wild type HEK293 with UCN-II did not led to
significant ERK1/2 activation; UCN-II induced ERK1/2 activation in clone 10 was
not dose dependent as well as in clone 45. Clone 17 demonstrated the highest
ERK1/2 activation following the UCN-II stimulation, however because of
undesirable cAMP production pattern this clone was eliminated from the further
studies. Clone 9 and 19 were equally potent in mediating UCN-II induced ERK1/2
phosphorylation.
As clones for most desirable qualities regarding the membrane receptor
expression and functional characteristics, cAMP production and ERK1/2
phosphorylation, the clones 9 and 19 were used in the further studies.
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Figure 5.5. cAMP production in HEK293 and CRH-R2β clones. (A).1μM 
forskolin for 15 min was used to asses the intactness of adenylyl cyclase
system in the cells. (B) the cells were treated for 15 min with 1-100 nM UCN-
II, supernatants were collected and cAMP levels were determined by a
commercially available ELISA kit. The assay was performed in duplicates.
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Figure 5.6. ERK1/2 phosphorylation in HEK293 and CRH-R2β clones.
The cells were treated for 5 min with 10-100 nM UCN-II and assayed for
ERK1/2 activation as described in the methods. The results represent mean
values of two independent experiments.
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5.2.2 Agonist induced cAMP production in st.293-R2β  
The functional coupling of CRH-R2 to Gsα/adenylyl cyclase/cAMP pathway in 
response to different agonists, was assessed st.293-R2β cells. Treatment of cells with 
various concentrations of CRH, UCN-I or UCN-II (1-100 nM) for 15 min resulted in a
dose-dependent increase of intracellular cAMP accumulation (Figure 5.7). In agreement
with previous studies (Lewis K et al., 2001), both UCN-II and UCN-I were equipotent
in inducing adenylyl cyclase activation and were 40% more potent than CRH.
Figure 5.7. Agonist-induced cAMP production in st.293-R2β cells. Cells
were treated with various concentrations of UCN-II, CRH and UCN-I for 15
min. cAMP production was determined by ELISA. Each sample was analysed
in duplicates or triplicates. Results are expressed as the means±SEM of three
independent experiments (Markovic D et al., 2007).
5.2.3 CRH-R2β desensitization is dependent on the agonist potency 
CRH-R1α is susceptible to agonist-induced desensitization, however little is 
know about the desensitization characteristics of CRH-R2. In order to determine
whether CRH-R2β functional coupling to the cAMP signalling pathway is susceptible 
to agonist-induced (homologous) desensitization, I used UCN-II was because of its
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specificity for CRH-R2 binding and activation. For that purpose, st.293-R2β cells were 
pretreated with 100 nM of UCN-II for various time intervals (0-30 min) and the
maximal UCN-II-induced cAMP stimulation was determined. Results showed (Figure
5.8) that agonist pre-treatment for only 15 min was sufficient to induce a 80% decrease
in CRH-R2β responsiveness, and a 30 min pre-exposure to 100 nM UCN-II almost 
completely abolished subsequent UCN-II (100 nM)-induced cAMP response.
Interestingly, when CRH (100 nM) was used to induced receptor desensitization we
observed a weaker effect on CRH-R2β responsiveness. When CRH (100 nM) was used 
to induce receptor desensitization, we observed a weaker effect on CRH-R2β 
responsiveness; CRH pre-treatment for 15 min caused a 60% decrease only in
subsequent UCN-II (100 nM)-induced cAMP response whereas a 30 min pre-exposure
to 100 nM CRH reduced UCN-II effect on cAMP stimulation by 80%.
Figure 5.8. CRH-R2β desensitization characteristics in st.293-R2β cells. Cells
were pretreated with CRH or UCN-II (100 nM) for various time intervals to
induce desensitization. After extensive washing, cAMP response to a second
UCN-II stimulus (100 nM for 15 min) was determined. Data represent the
mean±SEM of two estimations from three independent experiments. *, P <0.05
compared with cells without pretreatment. +, P <0.05 compared to each other
agonist pretreatment.
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5.2.4 The effect of different growth conditions on UCN-II induced ERK1/2 and
p38 MAPK phosphorylation in st.293-R2β 
Several studies have implicated ERK1/2 and p38 MAPK as key signalling
intermediates downstream of CRH-R2 activation (Dermitzaki E et al., 2002;
Sananbenesi F et al., 2003; Brar BK et al., 2004; Karteris E et al., 2004). In order to
further characterise these signalling cascades, firstly I tested the how different growth
conditions affect the activation of ERK1/2 and p38 MAPK.
18 hours prior to stimulation cells were deprived from FCS. Two hours prior to
stimulation the cells were given fresh DMEM or HBSS. The cells were stimulated with
1-100 nM UCN-II for 5 min, and the MAPK activation was assayed as described in the
methods. Agonist induced ERK1/2 activation was significantly higher when DMEM
was used. The effect was more evident at lower concentration of agonist (1-10 nM)
than when 100 nM UCN-II was used. 1nM UCN-II induced 2-3 fold increase in
ERK1/2 phosphorylation in the cells kept in DMEM and 1-1.5 fold increase in the cells
kept in HBSS. Treatment with 10 nM UCN-II led to 6.5 and 4 fold increase in ERK1/2
activation in cells kept in DMEM and HBSS, respectively; while 100 nM UCN-II
induced ERK1/2 activation was 10±1.7 and 9.5±0.9 in cells kept in DMEM and HBSS,
respectively (Figure 5.9).
On the other hand, in contrast to the cells kept in DMEM, the cells kept in HBSS
fail to show agonist dose dependent p38 MAPK phosphorylation (Figure 5.10). All the
further experiments were performed on the cells kept in DMEM only.
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Figure 5.9. The effect of media on UCNII-induced ERK1/2
phosphorylation. 2 h prior to stimulation with 1-100 nM UCN-II, st.293-R2β 
were transferred in DMEM or HBSS. Following the treatment the total cellular
proteins were harvested and the ERK1/2 phosphorylation was assessed as
described in the methods. Results are expressed as the means±SEM of three
independent experiments.
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Figure 5.10. The effect of media on UCNII-induced p38 MAPK
phosphorylation. 2 h prior to stimulation with 1-100 nM UCN-II, st.293-R2β 
were transferred in DMEM or HBSS. Following the treatment the total cellular
proteins were harvested and the p38 MAPK phosphorylation was assessed as
described in the methods. Results are expressed as the means±SEM of three
independent experiments.
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ERK1/2 activation of 5.6-6.4 fold above basal, while maximal p38 MAPK activation
was 2.5±1.0 fold above basal.
Figure 5.11. Agonist-induced and dose dependent ERK1/2
phosphorylation in st.293-R2β.  The cells were stimulated with 1-100 nM
UCN-II, UCN-I and CRH for 5 min. Total cellular proteins were subjected to
SDS-PAGE and immunoblotted with antibodies for phospho- and total-
ERK1/2 to determine the phosphorylated/activated ERK1/2 and secondary
antibodies conjugated to IRDye™ 800 and Alexa Fluor® 680 [near-infrared
(IR) fluorophore dyes] as described in the methods. Data represent the mean
±SEM from three independent experiments.
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Figure 5.12. Agonist-induced and dose dependent p38 MAPK
phosphorylation in st.293-R2β.  The cells were stimulated with 1-100 nM
UCN-II, UCN-I and CRH for 5 min. Following the treatment the total cellular
proteins were harvested and the p38 MAPK phosphorylation was assessed as
described in the methods. Results are expressed as the means±SEM of three
independent experiments.
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5.2.6 Agonist-induced ERK1/2 and p38 MAPK phosphorylation is transient
UCN-II induced ERK1/2 activation was transient and maximal stimulation was
observed after 5 min of treatment and returned to basal levels after 30 min of treatment
(Figure 5.13). UCN-II effect on p38MAPK phosphorylation showed a similar response
with maximal stimulation after 5-10 min of treatment and return to basal levels after 30
min of treatment (Figure 5.14). The similar pattern was observed when UCN-I and
CRH were used for the simulation (data not shown).
Figure 5.13. Time-dependent ERK1/2 activation by UCN-II in 293-R2β 
cells. Top panels are representative Western blots of cells stimulated with
UCN-II (100 nM) for various time points (2-60 min). Following the treatment
the total cellular proteins were harvested and the ERK1/2 phosphorylation was
assessed as described in the methods. Results are expressed as the
means±SEM of three independent experiments.
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Figure 5.14. Time-dependent p38 MAPK activation by UCN-II in 293-R2β 
cells. Top panels are representative Western blots of cells stimulated with
UCN-II (100 nM) for various time points (2-60 min). Following the treatment
the total cellular proteins were harvested and the p38 MAPK phosphorylation
was assessed as described in the methods. Results are expressed as the
means±SEM of three independent experiments
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5.2.7 The spatio-temporal characteristics of MAPK activation following UCN-II
stimulation
Beside the phosphorylation of plethora of cytoplasmic targets, the MAPK are
important in direct activation of various transcription factors, such as Elk, c-Fos, c-Myc
(Roux PP & Blenis J, 2004) and indirect activation of NF-κB (Markovic D et al., 2007).
In addition, it has been reported that ERK1/2 can translocate to the nucleus in order to
activate downstream targets (Ebner HL et al., 2007)
To examine the spatio-temporal characteristics of MAPK activation in st.293-
R2β, indirect immunofluorescence confocal microscopy was employed with phospho-
specific MAPK antibodies, to monitor the relative subcellular distribution of activated
MAPK and CRH-R2β after agonist stimulation (Figure 5.15).  In unstimulated st.293-
R2β cells, low levels of activated (phosphorylated) ERK1/2 and p38MAPK were found. 
As expected, CRH-R2β was primarily localized in the plasma membrane. UCN-II 
treatment for 5-10 min led to rapid increase in the amount of fluorescent signal for both
phospho-ERK1/2 and p38MAPK indicating increased activity. Phospho-ERK1/2
immunoreactive signal was widespread throughout the intracellular space suggesting
cytoplasmic as well as nuclear localization of activated ERK1/2. In contrast, phospho-
p38MAPK immunoreactivity was present only in the cytoplasm and no phospho-p38
MAPK immunoreactivity was detected in the nucleus. In agreement with the
immunoblotting experiments suggesting transient MAPK activation, prolonged
treatment (15-20 min) with UCN-II (100 nM), caused only a small increase in the
amount of phospho-ERK1/2 and p38MAPK immunofluorescent signal, reflecting
deactivation of the signalling pathway. Interestingly, in contrast to CRH-R1α (Punn A 
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et al., 2006) no co-localization between internalized CRH-R2β and phospho-ERK1/2 or 
p38MAPK was found to be present (Figure 5.15).
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5.2.8 UCN-II induced ERK1/2 phosphorylation, but not p38 MAPK
phosphorylation, is protein kinase A (PKA) dependent
The cAMP and ERK1/2 pathways play crucial roles in controlling a wide range
of diverse cellular responses in different cell types. Accumulating evidence suggest that
there is a cross-talk between those two pathways. It has been documented that in
st.293-R1α, UCN-I induced ERK1/2 phosphorylation was negatively regulated by PKA 
(Papadopoulou N et al., 2004). However, in a different over-expressing system, CHO
cells, the inhibition of PKA led to partial inhibition of UCN-I induced ERK1/2
phosphorylation (Brar BK et al., 2004). Additionally, the latter report provided
evidence that CRH-R2β mediate ERK1/2 activation was also partially dependent of 
PKA.
In order to determine whether PKA activation was important for the ERK1/2
and p38 MAPK phosphorylation in st.293-R2β, I used PKAi, PKA inhibitor peptide 
(14-22) that has been merystoylated at the N-terminus in order to enhance its cell
permeability. The advantage of inhibitor peptides over chemical inhibitors such is H-89
is in the specificity and toxicity. While chemical inhibitors if used in excess could
potentially inhibit activity of other enzymes and be toxic for the cell, the inhibitor
peptides are competing with the endogenous substrate for the active site of the enzyme,
or prevent binding of different subunits to form an active complex. The other inhibitor
used in this project was St-Ht31 inhibitor peptide (St-Ht-31). This peptide has derived
from AKAPs (A Kinase Anchoring Proteins), it has an amphipatic helical structure that
has been shown to interrupt PKA binding to AKAPs (Colledge M & Scott JD, 1999)
and as such prevents further transduction of the signal from PKA.
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UCN-II induced ERK1/2 phosphorylation was reduced by 40% in st.293-R2β 
cells pretreated with PKAi or st-Ht-31, at the same time p38 MAPK phosphorylation
was not affected with the pretreatments (Figure 5.16).
Figure 5.16. The effect of PKA inhibition on UCN-II induced ERK1/2 and
p38 MAPK activation in st.293-R2β cells. Top panels are representative
Western blots of cells stimulated with inhibitors and 100 nM UCN-II for 5 min.
Following the treatment the total cellular proteins were harvested and the
ERK1/2 and p38 MAPK phosphorylation were assessed as described in the
methods. Results are expressed as the means±SEM of three independent
experiments.
However, that the interaction between cAMP/PKA and ERK MAPK pathways
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PKA activity stimulated ERK1/2 phosphorylation by 60 % when the cells were
treated with UCN-II for 2 min. While a longer exposure of the cells to UCN-II for 5
and 10 min in the presence of the PKA inhibitor resulted in attenuation of ERK1/2
phosphorylation (Figure 5.17).
Figure 5.17. Time course: the effect of PKA inhibition on UCN-II induced
ERK1/2 in st.293-R2β cells. Top panels are representative Western blots of
cells stimulated with and without PKA inhibitor and 100 nM UCN-II for 2, 5
and 10 min. Following the treatment the total cellular proteins were harvested
and the ERK1/2 MAPK phosphorylation were assessed as described in the
methods. Results are expressed as the means±SEM of three independent
experiments.
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5.2.9 UCN-II induced ERK1/2 phosphorylation, but not p38 MAPK
phosphorylation, is PI(3) kinase dependent
Another kinase implicated in UCN-I induced ERK1/2 activation in st.293-R1α 
(Punn A et al., 2006) and CHO cells overexpressing CRH-R1α and R2β (Brar BK et al.,
2004) is PI(3)-kinase. However, UCN-I induced p38 MAPK activation in st.293-R1α 
was PI(3)-kinase independent (Punn A et al., 2006). Inhibition of PI(3)-kinase by LY-
294002, revealed that UCNII-induced ERK1/2 phosphorylation in st.293-R2β reduced 
by 90±5% compared to control cells, while p38 MAPK phosphorylation was
insensitive the kinase inhibition (Figure 5.17).
Figure 5.18. The effect of PI(3)-kinase inhibition on UCN-II induced
ERK1/2 and p38 MAPK activation in st.293-R2β cells. Top panels are
representative Western blots of cells stimulated with inhibitors and 100 nM
UCN-II for 5 min. Following the treatment the total cellular proteins were
harvested and the ERK1/2 and p38 MAPK phosphorylation were assessed as
described in the methods. Results are expressed as the means±SEM of three
independent experiments
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5.2.10 Internalisation characteristics of CRH-R2β 
In order to investigate homologous internalization, st-293-R2β were stimulated 
with 0.1-100 nM UCNII, UCN-I and CRH for 0-60 minutes. The internalization of
CRH-R1α showed to be an agonist-dose dependent (due to lack of space, data not 
shown) as well as time dependent process. The UCN-II and UCN-I induced CRH-R2β 
internalization showed the same pattern (results not shown). In the absence of UCN-II
or CRH, the receptor was exclusively on the plasma membrane. Since 100 nM UCN-II
and CRH treatment led to strongest redistribution of the receptor, this concentration
was chosen to investigate the time-dependent internalization characteristics. When st-
293-R2β were treated only with vehicle (acetic acid), the receptor was exclusively 
expressed on the plasma membrane. Treatment with 100 nM UCN-II for 15 min led to
the appearance of punctuated staining in the cytoplasm, possibly indicative of
endocytosis (Figure 5.19). After 30 minutes of exposure to 100 nM agonist, strong
immunoreactivity was observed in the cytoplasm. Similar results were seen after 45
and 60 minutes (data not shown for the latter) (Figure 5.19). CRH was less potent in
inducing early endocytosis, after 15 min of the exposure to 100 nM CRH no significant
receptor redistribution was detected (Figure 5.19). After 30 min and especially 45 min
significant cytoplasmic immunoreactivity was detected, as an indicative of CRH-R2β 
internalization (Figure 5.19).
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Figure 5.19. Internalization of CRH-R2β in st293-R2β is dependent on 
agonist potency. st.293-R2β cells were grown on cover slips and exposed to 
100 nM UCN-II or CRH for various time points (0-45 min). CRH-R2
distribution was monitored by indirect immunofluorescence using CRH-R1/2-
specific antiserum and Alexa-Fluor®594 secondary antibody. Identical results
were obtained from four independent experiments. Magnification x 63, and
optical zoom x 5.
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basal
15min
30min
45min
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The potency of different agonists in inducing CRH-R2β internalization was 
quantitatively determined using On-cell western assay with near IR dyes in non-
permeabilized cells. For that purpose antibodies targeted against the CRH-R2β N-
terminus and the Odyssey infrared (IR) imaging system was employed, as previously
described (Miller JW, 2004). In preliminary experiments the IR signal characteristics
were established; signal intensity was typically 80% higher than signal obtained when
secondary anti-mouse IRDye 800-conjugated IgG was used alone (Table 5.1). The
calculated % specific signal of the antibodies used in this assay was determined to be
between 45-55% of total signal. Results showed that UCN-II (100 nM) treatment for 30
min induced a 58-67% decline in CRH-R2β immunoreactivity from the cell surface of 
293-R2β cells compared to basal, whereas an equimolar concentration of CRH reduced 
CRH-R2β immunoreactivity by only 43-52% (Figure 5.2).  
Table 5.2. The IR signal characteristics. (Markovic D et al., 2007b).
48%% Specific (T-NSB*/ T)
signal
131002nd Ab only
5001st Ab only
400Background
26700Total binding
(1st+2nd Ab)
Signal Intensity
levels (average)
*NSB: combined sum of background, 1st and 2nd
Ab alone signal intensity
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Figure 5.20. Quantification of CRH-R2β endocytosis. CRH-R2β loss from the 
cell-surface following agonist stimulation (UCN-II or CRH, 100 nM) for 30 min,
was quantified by an “On-cell Western” assay with near IR dyes in non-
permeabilized cells, using antibodies against the CRH-R2β N-terminus and the 
Odyssey infrared (IR) imaging system. Data represent the mean±SEM of two
estimations from three independent experiments. *, P <0.05 compared with cells
without pretreatment. +, P <0.05 compared to each other agonist pretreatment
(Markovic D et al., 2007b).
5.2.11 Internalization of CRH-R2β is β-arrestin and clathrin dependent 
The internalization of most GPCR requires recruitments of β-arrestin and 
clathin to the plasma membrane (DeWire SM et al., 2007). The fate of CRH-R2β 
receptors following activation by UCN-II or CRH was investigated by indirect confocal
microscopy to monitor temporal distribution of the receptor. In the absence of agonist,
CRH-R2β receptors were exclusively localized on the cell surface of st.293-R2β cells 
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(Figure 5.21 top row). Immunostaining for β-arrestin (using an antibody that recognises 
both β-arrestin1 and β-arrestin2) and clathrin (heavy chain) demonstrated widespread 
distribution, primarily in the cytoplasm. Treatment of cells with 100 nM UCN-II for 2-
5 min induced a rapid redistribution of β-arrestin and clathrin to the plasma membrane 
that appear to co-localise with CRH-R2β receptors, as demonstrated by a significant 
increase in plasma membrane immunostaining of β-arrestin (green) and clathrin (blue) 
signal and the appearance of white signals, in the overlap images (Figure 5.21-merge).
Within 15 min of UCN-II treatment there was evidence of some receptor trafficking in
the cytoplasm and after 30 min of treatment intense receptor fluorescent signal was
observed in the cytoplasm indicative of substantial receptor internalization (Figure
5.21). Interestingly, receptor association with β-arrestin and clathrin was transient and 
restricted on or near to the plasma membrane since CRH-R2β receptors internalized 
without any β-arrestin or clathrin.   
Use of CRH as the receptor internalization-inducing agonist revealed important
agonist-specific temporal differences in CRH-R2β internalization kinetics; although 
CRH (100 nM) induced β-arrestin and clathrin recruitment to the plasma membrane 
after 2 min following CRH treatment (Figure 5.21) substantial CRH-R2β 
internalization was evident only after 30-45 min of treatment. Similar to UCN-II, CRH-
induced internalized CRH-R2β receptors did not co-localize with β-arrestin or clathrin.  
Further experiments were performed to characterise β-arrestin activation and 
membrane translocation in response to agonist-occupied receptor. Distribution of β-
arrestin immunoreactivity, was monitored in cell membrane fractions prepared from
st.293-R2βcells treated with either 100 nM CRH or UCN-II for various time intervals 
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(0–15 min). In resting 293-R2βcells, small amounts of β-arrestin1 (49 kDa) and β-
arrestin2 (47 kDa) were detected in the cell membrane fraction. UCN-II or CRH
treatment for 2 min resulted in a 3-4 fold increase in the membrane fraction content of
both β-arrestin1 and β-arrestin2 (Figure 5.22). This increase was transient and after 10-
15 min of UCN-II treatment, membrane levels of both β-arrestins were significantly 
reduced (by 70%). In contrast, following CRH (100 nM) treatment, substantial
membrane levels of β-arrestin1 and β-arrestin2 were observed after 15 min of treatment 
(2 and 3.5 fold above basal for β-arrestin1 and β-arrestin2, respectively).  
The retention of β-arrestin on the plasma membrane following UCN-II or CRH 
stimulation for 15-20 min was also assessed with indirect confocal microscopy (Figure
5.23). For this purpose confocal images were taken from the middle and top of the
same cell. The results revealed that β-arrestin was not present on the top of 
unstimulated cells, a weak β-arrestin signal was detected on the top of the cells treated 
with UCN-II for 15-20 min, while significant immunoreactivity corresponding β-
arrestin was observed on the top of the cells treated with CRH for 15-20 min (Figure
5.23).
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Figure 5.21. CRH-R2β, β-arrestin and clathrin subcellular distribution 
following CRH or UCN-II treatment: visualization by fluorescent confocal
microscopy. st.293-R2β were stimulated with either UCN-II or CRH (100 nM) 
for 2-30 min. CRH-R2β, clathrin and β-arrestin distribution was monitored 
over the ensuing time period by indirect triple immunofluorescence using
specific primary antibodies and Alexa-Fluor® 594 secondary antibodies for
CRH-R2β (red), Alexa-Fluor® 405 secondary antibodies for clathrin heavy 
chain (CHC) (blue) and Alexa-Fluor® 488 secondary antibody for β-arrestin 
(green). Identical results were obtained from 4 independent experiments.
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Figure 5.22. Agonist-dependent β-arrestin recruitment to the plasma 
membrane. Membrane fractions were prepared from st.293-R2β cells, 
stimulated with or without UCN-II or CRH (100 nM) for various time
intervals and proteins were resolved on SDS-PAGE gels, followed by
immunoblotting with pan-arrestin antibodies, as described in the methods.
Densitometry scanning was carried out to quantify agonist-induced β-arrestin
translocation to the plasma membrane. Top panel: representative immunoblots
and bottom panel: mean ±SEM of three independent experiments; *, P <0.05
compared with basal (Markovic D et al., 2007b)
Figure 5.23. Recruitment of β-arrestin by the agonist-activated CRH-R2β 
in st.293-R2β. Confocal microscopy was used to evaluate the interaction of
CRH-R2β (red) with β-arrestin (green). The images were taken from the 
middle and top of the same cell. The identical results were obtained from three
independent experiments.
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5.2.12 UCN-II induced MAPK activation is independent of CRH-R2β endocytosis 
Since GPCRs internalization can potentially lead to activation of the MAPK
signalling cascade, I further investigated the possibility that CRH-R2β endocytosis is 
involved in UCN-II-induced activation of ERK1/2 and p38 MAPK signalling cascades.
The receptor internalization was inhibited with conconavalin A (con A), or DN -
arrestin (319–418). Both of these approaches strongly inhibited agonist-stimulated
CRH-R2internalization (Figure 5.24.).
Figure 5.24. Effect of DN β-arrestin and conconavalin A on UCN-II 
induced CRH-R2β endocytosis in st.293-R2β cells. Cells were pre-treated
with or without concanavalin A (0.25mg/ml for 40 min) or alternatively
transfected with either 5 μg of empty pcDNA3 vector (control) or DN β-
arrestin (319–418) and the effect on UCN-II (100 nM for 30 min) induced
receptor internalization was monitored by indirect confocal microscopy.
Identical results were obtained from two independent experiments.
arr DN - +
UCN-II/30min + +
concA - +
UCN-II/30min + +
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Additionally, the receptor endocytosis was blocked with the transfection of
st.293-R2β with siRNA duplexes targeting CHC (clathrin heavy chain) (Figure 5.24), 
confirming that the internalization of CRH-R2β is a clathrin dependent process. The 
efficiency of the clathrin silencing was assessed by confocal microscopy (Figure 5.25)
and western blot analysis (Figure 5.26). Confocal microscopy revealed that the
silencing was 90% efficient; strong immunoreactivity for clathrin was present in
approximately 10% of the cells, also in those cells UCN-II induced CRH-R2β 
endocytosis was detectable (Figure 5.25, the cell pointed by the white arrow).
Figure 5.25. Effect of CHC siRNA on UCN-II induced CRH-R2β 
internalization in st.293-R2β cells. Cells were transfected with 1nmol of
CHC siRNA or scrambled oligonucleotide and the effect on UCN-II induced
internalization of CRH-R2β were monitored by indirect confocal microscopy 
using specific primary antibodies and Alexa-Fluor® 594 secondary antibody
for CRH-R2β (red) and Alexa-Fluor® 488 secondary antibody for clathrin 
heavy chain (CHC) (green). The white arrow points a cell that did not uptake
CHC siRNA. Identical results were obtained from 3 independent experiments.
At least 10 individual cells in five random fields of view were examined.
CHC siRNA
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Figure 5.26. Verification of clathrin silencing by CHC siRNA in st.293-
R2β cells. Cells were transfected with 1nmol of three pairs of CHC siRNA
(1CHC, 2CHC and 3CHC) or scrambled oligonucleotide (N/A). Equal protein
levels were confirmed by GAPDH.
Although it has been reported that UCN-I induced ERK1/2 and p38 MAPK
phosphorylation was dependent upon internalization of CRH-R1α (Punn A et al., 2006);
none of the compounds used to inhibit UCN-II induced CRH-R2β internalization did 
not exert inhibitory effects on ERK1/2 and p38MAPK activation (Figure 5.27).
Moreover, disruption of CRH-R2 internalization by -arrestin (319–418) and CHC
siRNA amplified by 70% and 30% respectively, ERK1/2 phosphorylation stimulated
by 100 nM UCN-II. Studies on UCN-II-induced p38MAPK activation showed similar
effects (Figure 5.27). These results suggested that an intact receptor endocytosis
pathway is not essential for UCN-II-induced MAPK activation.
Clathrin (160kDa)
GAPDH (37kDa)
N/A 1CHC 2CHC 3CHC
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Figure 5.27. Effect of concanavalin A, DN β-arrestin and CHC siRNA on 
UCN-II induced ERK1/2 and p38MAPK activation in 293-R2β cells. Cells
were pre-treated with or without concanavalin A (0.25mg/ml for 40 min) or
alternatively transfected with either 5 g of empty pcDNA3 vector (control) or
-arrestin (319–418) or 1nmol of CHC siRNA or scrambled oligonucleotide
and the effect on UCN-II (100 nM for 5 min) stimulation on ERK1/2 and
p38MAPK activation was determined, by measurement of ERK1/2 and
p38MAPK phosphorylation as described in the methods. Data represent the
mean ±SEM from three independent experiments. *, P <0.05 compared with
control cells.
5.2.13 UCN-II induced CRH-R2β desensitisation is dependent of the CRH-R2β 
endocytotic machinery
In order to investigate the whether the presence of β-arrestin or clathrin is 
essential for CRH-R2β desensitization, I determined agonist-induced CRH-R2β 
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desensitization in the presence of a DN β-arrestin and CHC siRNA. In st.293-R2β cells 
overexpressing DN β-arrestin, the ability of UCN-II pretreatment (100 nM for 30 min) 
to desensitize CRH-R2β responsiveness and cAMP activation was significantly 
impaired (by 50%) (Figure 5.28). Furthermore, UCN-II failed to induce CRH-R2β 
internalization (Figure 5.24), suggesting that CRH-R2β homologous internalization is 
β-arrestin–dependent. Significant inhibition by 25-35% of CRH-R2β desensitization 
was also obtained when RNA interference was employed to deplete cells from clathrin
heavy chain (CHC), and thus preventing assembly of functional clathrin-coated pits at
the plasma membrane (Figure 5.28). Reduction in CHC expression (in excess of 70%)
in siRNA transfected cells was confirmed by immunoblotting with antibodies directed
against the CHC (Figure 5.26). These data suggest that the retention of the receptor in
the plasma membrane leads to impaired receptor desensitisation.
Figure 5.28. Effect of DN β-arrestin and CHC siRNA on UCN-II induced 
CRH-R2β desensitization in st.293-R2β cells. Cells were transfected with
either 5 μg of empty pcDNA3 vector (control) or β-arrestin (319–418) or 
1nmol of CHC siRNA or scrambled oligonucleotide and the effect on CRH-
R2β homologous desensitization (induced by pretreatment with 100 nM UCN-
II for 30 min) was determined, by measurement of UCN-II-induced cAMP
production. Data represent the mean ±SEM of two estimations from three
independent experiments. *, P <0.05 compared with cells without UCN-II
pretreatment; +, P <0.05 compared with control cells.
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5.2.14 UCN-II induced ERK1/2 phosphorylation negatively regulates CRH-R2β 
endocytosis via β-arrestin1 phosphorylation 
Next, I investigated whether UCN-II activated ERK1/2 can potentially regulate
CRH-R2β internalization through a feedback mechanism previously described (Lin F-
Y et al., 1999), involving phosphorylation of β-arrestin1 at Ser412. Western blot 
analysis of cell membrane fractions using β-arrestin1 specific antibody and analysis of 
total cellular proteins using phospho-β-arrestin1 (Ser412) specific antibody was 
employed to demonstrate β-arrestin1 trafficking and phosphorylation in the presence or 
absence of U0126 (MEK inhibitor-10μM for 2 h).  
I confirmed that UCN-II ERK1/2 interactions is MEK dependent (Figure 5.29),
since U0126 pre-treatment blocked UCN-II induced ERK1/2 activation.
Figure 5.29. UCN-II induced ERK1/2 phosphorylation is MEK
dependent. Cells were pre-treated with or without U0126 (10M) for 2 h to
inhibit basal and UCN-II-dependent ERK1/2 activation, before stimulation
with UCN-II (100 nM) for various time intervals (0-10 min). The identical
results were obtained from three independent experiments.
In the section 5.2.11, I demonstrated that β-arrestin1 was recruited to the plasma 
membrane following UCN-II treatment. However, in those experiments pan-arrestin
antibody that recognises both β-arrestins, β-arrestin1 and β-arrestin2, was used (Figure 
5.22). In agreement with those results, use of β-arrestin1 specific antibody showed that 
ERK1/2-total (red)
ERK1/2-phospho (green)
0 2 5 10 0 2 5 10 time (min ) UCN-II
controlUO126
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in st.293-R2β cells treated with UCN-II for 2 min, β-arrestin1 recruitment to the plasma 
membrane was significantly increased by 70%-90% above basal. This effect was
transient and within 10 min the rise in β-arrestin1 membrane fraction was reduced by 
50% (Figure 5.30 A and C). The discrepant values for β-arrestin1 translocation to the 
plasma membrane shown on the figures 5.22 and 5.30 could be due to specificity of the
different antibodies, as well as to the detection method (ECL vs. near IR detection
system). Both basal and UCN-II induced trafficking of β-arrestin1 appeared to be 
regulated by ERK1/2, since inhibition of MEK and ERK1/2 by U0126 pretreatment
significantly increased (by 50%) basal -arrestin1 recruitment to the plasma membrane
(Figure 2.28 B). In the absence of active ERK1/2, UCN-II treatment did not
significantly alter β-arrestin1 recruitment to the plasma membrane and levels of 
membrane-bound β-arrestin1 remained unchanged for the period tested (up to 10 min) 
(Figure 5.30 C).
The purity of plasma membrane protein isolation was confirmed by probing the
PVDF membrane (from the above experiment) with GAPDH antibody. A lack of
GAPDH immunoreactive band confirms that the plasma membrane protein prep did not
contain proteins from cytoplasmic/mitochondrial fraction (Figure 2.30 A). Although
10μg of membrane proteins were separated on a 10% SDS-PAGE, the equal amount of 
proteins was confirmed by probing PVDF membranes with pan-cadherin antibody
which was also used as a plasma membrane protein marker (Figure 5.30 A).
Before focusing on β-arrestin1 phosphorylation studies, the specificity of 
phospho-β-arrestin1 (Ser412) antibody was determined. Following an incubation of a 
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PVDF membrane with alkaline phosphatase the immunoreactive band corresponding
phospho-β-arrestin1 was lost (Figure 5.29). 
Figure 5.30. Regulation of β-arrestin1 membrane translocation by 
ERK1/2 in 293-R2β cells. Cells were pre-treated with or without U0126
(10M) for 2 h to inhibit basal and UCN-II-dependent ERK1/2 activation
before stimulation with UCN-II (100 nM) for various time intervals (0-10 min).
Following cell lysis and membrane fractionation membrane-bound -arrestin1
were determined by specific antibodies and Alexa Fluor®680-conjugated goat
anti-mouse IgG using the Odyssey Infrared Imaging System. (A) top-
representative β-arrestin1 western blot of cells stimulated with the inhibitor 
and 100 nM UCN-II. middle-representative pan-cadherin western blot,
bottom-representative GAPDH western blot. (B) The effect of U0126 on basal
β-arrestin1 translocation to the membrane. (C) Quantitative representation of 
B-arrestin1 translocation. Data represent the mean ±SEM from three
independent experiments. *, P <0.05 compared with unstimulated cells.
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Fiure 5.31. Characterisation of phospho-β-arrestin1 (Ser412) antibody.
Following cell lysis in RIPA buffer, phospho-β-arrestin1 (Ser412) was 
determined by specific antibodies Alexa Fluor®680-conjugated goat anti-
mouse IgG using the Odyssey Infrared Imaging System (top blot). The
membrane was treated with alkaline phosphatase as described in the methods,
and phospho-β-arrestin1 (Ser412) and total-β-arrestin1 were determined by 
specific antibodies and IRDye™800-conjugated goat anti-rabbit IgG and/or
Alexa Fluor®680-conjugated goat anti-mouse IgG using the Odyssey Infrared
Imaging System.
Since Ser412 of β-arrestin1 is the site of ERK1/2 mediated phosphorylation (Lin 
F-Y et al., 1999), my study further investigated UCN-II induced β-arrestin1 
phosphorylation in the presence or absence of U0126. After an initial rise of 13-20%
within 2 min of UCN-II treatment, the longer exposure to the peptide led to 45-50% 
decrease below basal levels in phosphorylation of β-arrestin1 at Ser412. UCN-II 
induced phosphorylation β-arrestin1 appeared to be regulated by ERK1/2. In the 
absence of active ERK1/2, UCN-II treatment led to a significant reduction by 40%
(compared to basal) of phospho-β-arrestin1 immunoreactivity within 5 min, possibly 
due to activation of protein phosphatases (Figure 5.32).
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Figure 5.32. Regulation of β-arrestin1 phosphorylation by ERK1/2 in 293-
R2β cells. Cells were pre-treated with or without U0126 (10M) for 2 h to
inhibit basal and UCN-II-dependent ERK1/2 activation before stimulation
with UCN-II (100 nM) for various time intervals (0-10 min). Following cell
lysis in RIPA buffer phospho-β-arrestin1 were determined by specific 
antibodies and IRDye™800-conjugated goat anti-rabbit IgG using the
Odyssey Infrared Imaging System. (A) top-representative phospho-β-arrestin1 
western blot of cells stimulated with the inhibitor and 100 nM UCN-II;
bottom-GAPDH western blotto demonstrate equal loading. (B) The effect of
U0126 on basal β-arrestin1 phosphorylation. (C) Quantitative representation of 
β-arrestin1 translocation. Data represent the mean ±SEM from three 
independent experiments. *, P <0.05 compared with unstimulated cells.
5.2.15 The effect of ERK1/2 on CRH-R2β internalization 
Confocal microscopy was used to determine the effect of ERK1/2 in CRH-R2β 
internalization; in both U0126 pre-treated and control cells incubation with 100 nM
UCN-II for 15 min elicited a significant redistribution of cellular immunostaining,
indicative of receptor internalization (Figure 5.33). Quantification of red fluorescence
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in the intracellular space of 20 individual cells that were randomly selected, showed 30-
50% increased amount of red fluorescent signal throughout the intracellular space (4–
18μm) in U0126 pre-treated cells compared to control (Figure 5.33), suggesting that 
ERK1/2 inhibition was associated with increased receptor internalization.
Figure 5.33. The effect of ERK1/2 on CRH-R2β endocytocis. The effect of
U0126 on UCN-II induced CRH-R2β internalization was monitored by 
indirect fluorescent confocal microscopy using specific primary antibodies and
Alexa-Fluor 594 secondary antibody for CRH-R2 (red). For quantification of
cytoplasmic CRH-R2β distribution, 20 individual cells in five random fields of 
view were examined, and profiles of fluorescence intensity, generated. The
sum of fluorescence intensity of cytoplasmic (distance 4–18 μm) fluorescence 
along the lines was measured by using Image J software. Results are expressed
as the mean ± S.E.M of three estimations from 20 individual cells. *, p < 0.05
compared with unstimulated values.
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5.2.16 The role of C-terminus of CRH-R2β in the receptor mediated signalling 
The CRH-R1 and R2 receptors share considerable amino acid homology between
their C-terminus. A notable diversity is found within the last four amino acid residues
of the C-terminus (TAAV instead of STAV). In contrast to the CRH-R2, the CRH-R1-
MAPK interactions display different spatio-temporal characteristics involving -
arrestin-dependent pathways; therefore I explored the possibility that this amino acid
cassette plays a role in determining CRH-R2-mediated MAPK activation. I used site-
directed mutagenesis to create CRH-R2 receptors, in which the cassette TAAV was
replaced by AAAA, STAV, or deleted (DEL) (Figure 5.34). Wild-type and mutant
CRH-R2 receptors, CRH-R2(STAV), CRH-R2(4A), and CRH-R2(Del), were
transiently expressed in HEK 293 cells.
Figure 5.34. Schematic representation of the created CRH-R2β mutant 
receptors.
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Wild-type and mutant CRH-R2β receptors, CRH-R2β(STAV), CRH-R2β(4A), 
and CRH-R2β(Del), were transiently expressed in HEK293 cells. These mutant 
receptors were expressed normally at the cell membrane (Figure 5.35).
Figure 5.35. Role of CRH-R2β C-terminus amino acid cassette TAAV on 
receptor expression in the plasma membrane. Receptor (wild type or
mutant) expression was monitored by indirect fluorescent confocal microscopy
using specific primary antibodies and Alexa-Fluor® 594 secondary antibodies
for CRH-R2β (red). Identical results were obtained from 3 independent 
transfections.
5.2.16.1 The role of CRH-R2β C-terminus in UCN-II induced cAMP 
production and CRH-R2β desensitization 
All mutant receptors were able to stimulate intracellular cAMP production in
response to 100 nM UCN-II (Figure 5.34). Interestingly, although CRH-R2β(4A) and 
CRH-R2β(Del) potency in stimulating cAMP response was comparable to the wild 
type receptor, the CRH-R2β(STAV) cAMP response was 50% greater than the wild 
CRH-R2(4A)
CRH-R2(STAV) CRH-R2(DEL)
CRH-R2(w.t)
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type CRH-R2β.  Furthermore, the sensitivity of both wild type and mutant receptors to 
desensitization, induced by UCN-II (100 nM) pretreatment for 30 min, was comparable
(Figure 5.36).
Figure 5.36. Role of CRH-R2β C-terminus amino acid cassette TAAV on 
UCN-II induced cAMP production and receptor desensitization.
Transiently transfected HEK293 were stimulated with 100 nM UCN-II for 15
min, additionally the cells were pretreated with UCN-II (100 nM) for 30 min
to induce desensitization. After extensive washing, cAMP response to a
second UCN-II stimulus (100 nM for 15 min) was determined. Data represent
the mean±SEM of two estimations from three independent experiments. *, P
<0.05 compared to wild type CRH-R2 cAMP response.
5.2.16.2 The role of CRH-R2β C-terminus in UCN-II induced CRH-R2β 
internalization
The confocal microscopy studies showed that the CRH-R2β(4A) and CRH-
R2β(Del) mutant receptors exhibited an increased rate of internalization compared to 
the wild type receptor; significant receptor (red) fluorescent signal was observed in the
cytoplasm after only 5 min of UCN-II (Figure 5.37). All the mutant receptors
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substantially internalised following 30 min of UCN-II treatment. Additionally, the
internalization of all mutant receptors was β-arrestin dependent, which was evident by 
β-arrestin recruitment to the membrane (Figure 5.38) following 2 min UCN-II 
treatment. The intensity of β-arrestin recruitment was slightly impaired in the cells 
over-expressing the CRH-R2β(Del) mutant receptor. Further quantitative studies would 
be needed to confirm this.
Figure 5.37. Role of CRH-R2β C-terminus amino acid cassette TAAV on 
receptor endocytosis. Cells were also stimulated with 100 nM UCN-II for
various time intervals and CRH-R2β internalization was monitored by indirect 
confocal microscopy. Cell nuclei were stained with the DNA-specific dye DAPI
(blue). Identical results were obtained from four independent experiments.
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Figure 5.38. Role of CRH-R2β C-terminus amino acid cassette, TAAV, on 
UCN-II induced β-arrestin recruitment visualization by fluorescent
confocal microscopy. Cells were stimulated with UCN-II (100 nM) for 2 min.
CRH-R2β and β-arrestin distribution was monitored by indirect  
immunofluorescence using specific primary antibodies and Alexa-Fluor® 594
secondary antibodies for CRH-R2β (red), and Alexa-Fluor® 488 secondary 
antibody for β-arrestin (green). Cell nuclei were visualized with DAPI. 
Identical results were obtained from 4 independent experiments.
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5.2.16.3 The role of CRH-R2β C-terminus in UCN-II induced ERK1/2 
and p38 MAPK phosphorylation
The temporal characteristics of ERK1/2 and p38MAPK activation of the CRH-
R2β mutant receptors were also determined. HEK293 transiently transfected with the 
mutant receptors were stimulated with 100 nM UCN-II for 0-30 min. The western blot
analysis revealed that the CRH-R2β(STAV) mutant receptor had comparable potency 
to the wild type receptor, in activating both p38MAPK (Figure 5.39) and ERK1/2
(Figure 5.40) in response to UCN-II. However, the ability of CRH-R2β(4A), and CRH-
R2β(Del) to induced ERK1/2 and p38MAPK  activation was significantly impaired by 
35% and 20% respectively.
Figure 5.39. Time course of UCN-II stimulated p38 MAPK
phosphorylation in HEK293 cells transiently expressing wild type or
mutant CRH-R2β. HEK293 cells transiently expressing w.t and mutant CRH-
R2β receptors were treated with or without UCN-II (100 nM) for various time 
intervals to induce MAPK activation. p38 MAPK activation was determined
as described in the methods. The data represent the mean ± SEM from three
independent experiments.
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Figure 5.40. Time course of UCN-II stimulated ERK1/2 phosphorylation
in HEK293 cells transiently expressing wild type or mutant CRH-R2β.
HEK293 cells transiently expressing w.t and mutant CRH-R2β receptors were 
treated with or without UCN-II (100 nM) for various time intervals to induce
MAPK activation. ERK1/2 activation was determined as described in the
methods. The data represent the mean ± SEM from three independent
experiments.
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5.3 DISCUSSION
CRH and CRH-related peptides play a pivotal role in the body’s response to
stress by integrating and co-ordinating the activity of diverse physiological systems.
The action of CRH and CRH-related peptides is mediated though two types of CRH-
receptors (CRH-R1 and CRH-R2). The CRH-Rs transduce the signals through the cell
membrane leading to the generation of second messengers (cAMP, cGMP, DAG, IP3,
Ca2+), and activation of plethora of intracellular protein kinases and other important
molecules. Although originated from distinct genes, the two types of the receptors
share considerable sequential homology (approximately 70%). However, the CRH-R2
gene exhibits a different splicing and distribution pattern than CRH-R1, as elaborated
in the general Introduction chapter.
The aim of this part of my project was to investigate the signalling pathways and
molecules whose activation was mediated via CRH-R2β, and to determine the 
intracellular mechanisms regulating CRH-R2 responsiveness to agonist stimulation and
its potential link to activation of distinct signalling cascades. I provided novel evidence
that the CRH-R2β functional activity is sensitive to homologous desensitization 
following UCN-II binding and receptor activation. In addition, I characterised
internalization properties of CRH-R2β. Further in this section I will provide additional 
data demonstrating the variety of the signals generated upon the activation of CRH-R2β.  
These data could be use as a starting point for future studies that would focus on a
detailed investigation of individual brunches of the CRH-R2β signalling “tree”.  
One of the main intracellular mediators of CRH-R2 signalling in tissues is cAMP
(Hillhouse EW & Grammatopoulos DK, 2006). In agreement with previous studies
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(Lewis K et al., 2001), I showed that both UCN-II and UCN-I were equipotent in
inducing adenylyl cyclase activation and were 40% more potent than CRH (Figure 5.7).
Additionally, I demonstrated that CRH-R2β desensitization led to significant down-
regulation of cAMP production.  Desensitization of the CRH-R2β appears to be 
considerably rapid and exposure to UCN-II for 15 min was sufficient to diminish
receptor activity by 80-90% (Figure 5.8). This is remarkably different from the
response of the CRH-R1α, which requires agonist (CRH) treatment for 2-3 h to achieve 
a similar level of desensitization (Teli T et al., 2005). This might reflect distinct
requirements of the two CRH-Rs signal propagation in mammalian pathophysiology.
Since agonist induced GPCRs desensitization and internalization go hand in hand,
my study focused on investigations of the molecular mechanisms downstream of CRH-
R2β desensitization. The results demonstrated that UCN-II induced a rapid and 
transient recruitment of both β-arrestin1 and 2 to the plasma membrane (Figure 5.21, 
5.22, 5.23). Many other GPCRs that belong to the subfamily B1 (“brain-gut”
neuropeptide receptors) exhibit high affinity for both β-arrestin1 and 2 and although I 
did not specifically address the relative contribution of each β-arrestin isoform, it is 
possible that both β-arrestins are involved in CRH-R2β desensitization and endocytosis. 
Previous studies (Holmes KD et al., 2006) have demonstrated that the CRH-R1α 
preferentially interacts with β-arrestin2, but β-arrestin1 also translocates to the plasma 
membrane following CRH-R1α activation.  
Translocation of β-arrestin to the plasma membrane is an important step in  
receptor endocytosis. β-arrestins, by binding to clathrin, promote GPCR endocytosis 
via clathrin-coated pits (Shenoy SK & Lefkowitz RJ, 2003). The mechanism of CRH-
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R2β endocytosis also appears to require clathrin, which rapidly translocates to the 
plasma membrane following CRH-R2β activation, since depletion of clathrin 
significantly impairs CRH-R2β endocytosis. These findings suggest that CRH-R2β 
endocytosis might occur via clathrin-coated pits, similar to CRH-R1α (Perry SJ et al.,
2005). However, no receptor co-localization with β-arrestins inside the cells was 
observed, which is a characteristic of “class A” GPCRs. This is in contrast to the
“mixed” class A/class B picture previously reported for the CRH-R1α/β-arrestin 
interactions (Markovic D et al., 2006). This might have important consequences on the
fate of internalized receptor, since lack of interaction between β-arrestins and 
internalized class A GPCRs allows a more rapid recycling and resensitization by
facilitating receptor dephosphorylation (Oakley RH et al., 1999). In a resent report, Tu
H. and colleagues (Tu H et al., 2007) demonstrated that UCN uptake in HEK293
overexpressing CRH-R1 and CRH-R2 was clathrin and caveolae independent,
concluding that CRH-R1 and R2 play a facilitatory role in the non-clathrin, non-
caveolae mediated endocytosis (Tu H et al., 2007) The authors draw this conclusion
not from immunofluorescence or biochemical experiments, but solely from the use of
an inhibitor of clathrin coated pits and caveolae formation. Since this report was
published in March 2007, when my project was approaching its end, I did an additional
experiment to provide more evidence that clathrin is indeed recruited to the plasma
membrane of st.-293-R2β stimulated with UCN-II and CRH (Figure 5.41). A fraction 
of membrane protein from st.293-R2β cells treated with UCN-II and CRH for 2 min 
was made, and detection of recruited clathrin was performed as described for β-
arrestins. As shown on a western blot on the figure 5.41, stimulation of st.-293-R2β 
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cells either with 100 nM CRH or UCN-II for 2 min led to detectable clathrin
recruitment to the plasma membrane.
Figure 5.41. Agonist induced clathrin recruitment to the plasma
membrane Clathrin is recruited to the plasma membrane of st.-293-R2β 
treated with 100 nM CRH or UCN-II for 2 min.
The studies investigating CRH-R2β desensitization and endocytosis also revealed 
a number of interesting features. Firstly, the efficiency and kinetics of this process
appears to be dependent on CRH-R2β-agonist potency since CRH, which has a low 
affinity for the receptor, induced a weaker desensitization and delayed receptor
endocytosis compared to UCN-II (Figure 5.19, 5.20). The temporal characteristics of β-
arrestin translocation to the plasma membrane also appeared to be differentially
regulated by UCN-II and CRH and although both peptides induced rapid translocation
of β-arrestins and clathrin (Figure 5.21, 5.22), CRH actions led to a prolonged 
association of β-arrestins to the membrane (Figure 5.22, 5.23). At present, the precise 
functional consequences of these differences are not known, however, it is possible that
these distinct characteristics are linked to differences in receptor active conformations
in response to UCN-II or CRH that potentially lead to diverse signalling pathways in
agreement with the hypothesis of “agonist-directed trafficking” (Kenakin T, 1997).
Clathrin
(180kDa)
Basal CRH UCN-II (2min)
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I also showed that UCN-II binding to CRH-R2β led to a robust activation of 
ERK1/2 and p38MAPK (Figure 5.11-5.15), important signalling cascades for
mediating CRH-R2 physiological effects (Dermitzaki E et al., 2002, Sananbenesi F et
al., 2003, Karteris E et al., 2004). In particular, in certain cellular models, p38MAPK
but not ERK1/2, is capable of modulating CRH-R2β expression and signalling since it 
has the potential to down-regulate CRH-R2β mRNA levels (Kageyama K et al., 2005).
I have demonstrated that CRH-R2β mediated ERK1/2 and p38MAPK activation was 
characterized by:
a) a transient MAPK phosphorylation response (Figure 5.13, and 5.14),
b) a lack of association between internalized CRH-R2β receptors and phospho-
ERK1/2 or p38MAPK (Figure 5.15),
c) cytoplasmic as well as nuclear distribution of activated ERK1/2 (Figure 5.15).
Current hypotheses on GPCRs-ERK1/2 activation suggest that G protein-
dependent pathways produce a transient activation of nuclear ERK1/2 whereas β-
arrestin-dependent pathways lead to sustained activation of ERK1/2 that is localized to
the cytosol and endosomes (Luttrell DK & Luttrell LM, 2003). Thus the absence of β-
arrestin-dependent pathways in CRH-R2β mediated ERK1/2 and p38MAPK activation 
might explain the distinct spatio- temporal characteristics of CRH-R2β-mediated 
ERK1/2 phosphorylation. It has been previously reported that CRH-R1α mediates a 
sustained ERK1/2 activation, which is likely to be β-arrestin dependent, and is 
restricted primarily to the cytoplasm in stable complex formation with internalized
CRH-R1α (Punn A et al., 2006). Moreover, I have demonstrated that the inhibition of
receptor desensitization and endocytosis (by dominant negative β-arrestin and depletion 
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of clathrin) enhanced UCN-II MAPK activation, possibly due to increased amount of
accessible active receptors expressed in the cell membrane.
In addition I have provided novel evidence that ERK1/2 but not P38MAPK
activation is dependent on PKA activity. The interaction between cAMP/PKA and
ERK1/2 signalling pathways is very complex and can occur at a number of distinct
points and these effects can be tailored in a cell-specific manner (Houslay MD &
Baillie GS, 2003). The cell type specific expression of Raf-1 and B-Raf isoforms
allows increased cAMP levels to couple either negatively or positively to the activation
of ERK. Additionally, PKA catalyses phosphorylation of protein tyrosine phosphatase
(PTP) and a serine residue within a docking site on ERK2, preventing coupling
between PTP and activated ERK thus attenuates dephosphorylation of ERK (Houslay
MD & Baillie GS, 2003).
It has been reported that PKA negatively regulates CRH-R1α mediated ERK1/2 
activation, via phosphorylation of the receptor at Ser-301 (Papadopoulou N et al.,
2004). In contrast, it has been reported that in various cellular systems the CRH-R1α 
mediated ERK1/2 activation is either independent or positively regulated by PKA, but
not negatively regulated (Brar BK et al., 2004). The later report states that the same
pattern is involved in the CRH-R2 mediated ERK1/2 activation (Brar BK et al., 2004).
Data that I obtained provide a complex picture of interactions between these two
pivotal pathways in cellular functioning (Figure 5.16 and 5.17). Analysis of only one
time point (2, 5 or 10 min) of UCN-II induced ERK1/2 phosphorylation in the absence
of PKA activity can be deceptive. If one performs the experiment only at 5 min time
point, a conclusion that PKA positively regulates ERK1/2 activation can be drawn.
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However, the detailed time course experiment (Figure 5.17) demonstrated that the
interaction between the PKA and ERK1/2 signalling cascades was not a simple one. At
2 min PKA had a negative effect on ERK1/2 activation, while at 5 and 10 min the
effect was positive. This data suggest a complex regulation of ERK1/2 activation. The
simplest explanation would be that the inhibition of PKA activity accelerates UCN-II
induced ERK1/2 phosphorylation. However, the mechanisms remain unknown.
One of the main downstream targets of ERK1/2 appears to be β-arrestin1 (Lin F-
T et al., 1999, Hupfeld CJ et al., 2005). β-arrestin1 phosphorylation at Ser-412 and 
function are modulated by an ERK1/2-dependent mechanism that leads to attenuation
of GPCRs internalization. Cytosolic β-arrestin1 is phosphorylated at Ser-412, upon 
activation of GPCRs β-arrestin1 is recruited to the plasma membrane and 
dephosphorylated. Dephosphorylated β-arrestin1 targets agonist-occupied, GRK-
phosphorylated GPCR to the clathrin-coated pits for internalisation. Activated ERK1/2
phosphorylates β-arrestin1 at Ser-412, and reduces it ability to bind certain proteins 
including clathrin.
My studies suggested that UCN-II dependent ERK1/2 activation, although
endocytosis independent (and potentially β-arrestin independent), could potentially 
modulate β-arrestin1 phosphorylation and membrane translocation and ultimately 
CRH-R2β endocytosis. Experimental conditions that diminish ERK1/2 activity, 
increased accumulation of β-arrestin1 to the plasma membrane and led to rapid 
dephoshorylation, thus allowing enhanced interaction with clathrin and increased rate
of CRH-R2β endocytosis. The precise nature of the molecular determinants regulating 
β-arrestin1 dephoshorylation are unknown; previous studies have shown that protein 
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phosphatase 2A (PP2A) is found in a molecular complex with beta-arrestin1 and
phosphatase inhibitors increase Ser-412 phosphorylation (Fan GH et al., 2001). Thus it
is possible that PP2A, through induction of β-arrestin1 dephosphorylation, directly 
modulates β-arrestin1 interaction with clathrin and ultimately receptor endocytosis. 
Evidence from other GPCR systems suggest that in this signalling assembly of
GPCR/β-arrestin1, PP2A is capable of targeting multiple substrates including the 
receptor protein itself (Fan GH et al., 2001).
Interestingly, β-arrestin2 can also act as a signalling intermediate through an 
Akt/PP2A scaffold that can mediate inactivation of Akt in response to GPCR
stimulation (Beaulieu JM et al., 2005). Similarly to β-arrestin1, β-arrestin2 is also 
regulated by phosphorylation. Casein kinase phosphorylates β-arrestin2 on Thr-383 and 
Ser-361 (DeWire SM et al., 2007).
In addition, I investigated the importance of the amino acid cassette -TAAV
present at the end of the C-terminus of CRH-R2β. The cassette appears to be important 
for determining the rate of receptor endocytosis (Figure 5.37, 5.38), but not for receptor
desensitization and activation of the cAMP pathway (Figure 5.36). Interestingly, the C-
tail of CRH-R1α which exhibits a slower rate of desensitization and endocytosis, 
contains one extra Ser/Thr residue (-STAV). The mutagenesis studies suggest that lack
of potential phospho-acceptor residues in this amino acid cassette results in accelerated
receptor endocytosis. The molecular determinants of this are unknown; it is possible
that absence of Ser/Thr residues from the end of the C-tail might facilitate interaction
and association with signalling molecules involved in receptor endocytosis. Future
studies involving RGS12 will test this hypothesis. Additionally, mutant CRH-R2β 
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receptors [CRH-R2β(4A) and CRH-R2β(Del)] that showed a faster internalization rate 
exhibited a decreased MAPK response to UCN-II. The potential effect of mutating the
CRH-R2β C-tail on G-protein coupling should also be considered as a contributing 
factor to the impaired MAPK response to UCN-II.
Figure 5.42. Schematic representation of signal transduction pathways
activated by CRH-R2β. Binding of UCN-II to the CRH-R2β receptor leads to 
the activation of PKA and PI-3K which are involved in ERK1/2 activation.
Phosphorylated ERK1/2 translocates to the nucleus where it potentially
activates genes transcription, also ERK1/2 mediates phosphorylation of β-
arrestin1 at Ser-412 leading to the retention of β-arrestin1 in the cytosol. The 
p38MAPK phosphorylation was independent of PKA and PI-3K activity as
well as the receptor endocytic machinery.
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In summary, I demonstrated involvement of PKA and PI-3 kinase in UCN-II
induced ERK1/2 activation, and that the activation of p38MAPK was independent of
these two kinases. Additionally, I provided evidence that the CRH-R2β receptor 
desensitization involves β-arrestin recruitment to the plasma membrane and depends on 
the binding and signalling potency of the desensitizing agonist. Subsequently, the
receptor internalizes in a manner typical of class A GPCRs via a β-arrestin and clathrin-
dependent mechanism. The kinetics and pattern of trafficking partners differs
significantly from the corresponding mechanism regulating CRH-R1α functional 
activity, a finding that might have important implications for the elucidation of CRH
and UCNs signal propagation in mammalian pathophysiology. Furthermore, I showed
that this mechanism is not involved in the activation of ERK1/2 and p38MAPK
cascades, and this functional independence allows distinct spatio-temporal control of
MAPK activity by UCNs and CRH-R2β.The transiently and β-arrestin independently 
activated ERK1/2 translocates to the nucleus where it possibly activates genes
transcription.  Moreover, it seems that activated ERK1/2 also regulate CRH-R2β 
endocytosis via direct phosphorylation of β-arrestin1 at Ser-412 in a mechanism that 
influences rate and extent of β-arrestin1 recruitment to the plasma membrane (Figure 
5.42).
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5.3.1 FUTURE DIRECTIONS
During the course my project I also sought to investigate potential release of Ca+2
from the endoplasmic reticulum following UCN-II stimulation of st.293-R2β. Previous 
report by Karteris E et al (Karteris E et al., 2004) demonstrated an involvement of
CRH-R2 mediated signalling in the contractile pathways activated during human labour.
The authors focused on UCN-II induced myosin light chain phosphorylation mediated
via activation of a small GTPase RhoA. Moreover, it is possible that UCN-II induces
also Ca+2 release from the extracellular compartments, enhancing myosin light chain
phosphorylation.
In order to investigate potential calcium release following activation of CRH-R2β, 
I choose st.293-R2β cells, because they are the simpler and less variable model than 
primary myometrial cells. Dr Paul Squires performed experiments on st.293-R2β, and 
the results were promising (Figure 5.43). Briefly, the stimulation of st.293-R2β with 
100 μM ATP showed that the cells were responsive and able to release calcium. 
Treatment of the cells with 100 nM UCN-II led to small increase in calcium release, the
significance of the obtained results can not be concluded since the experiment was
done only once (Figure 5.43 A). However when UCN-II was added in much higher
concentration (bolus) the substantial calcium was released. The inhibition of voltage-
gated channels with varapamil (100 μM), suggested that the increased levels of calcium 
originated from the endoplasmic reticulum (Figure 5.43B).
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Figure 5. 43. The effect of UCN-II on calcium release in st.293-R2β. The
cells were loaded for 20min at 37oC with 2.5μM FURA-2/AM. The cells were 
illuminated at 340 and 380 nm, and emitted light was filtered using a 510 nm
filter. Changes in the emission intensity of FURA-2 expressed as a ratio of
dual excitation were used as an indicator of changes in Ca+2 (Squires PE et al.,
2000).
Mechanisms controlling activation of CRH-R2β are poorly understood. We still 
do not know whether the phosphorylation of the receptor by GRKs is responsible for β-
arrestin recruitment, and which would the target residues on the receptor for GRK
phosphorylation. It has been reported that GRK3 and GRK6 are important GRK forms
involved in the phosphorylation of CRH-R1α (Teli T et al., 2005). Having that on mind
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and that the CRH-R1 and R2 receptors share considerable protein sequence homology,
I performed an immuno-fluorescence experiment during which I treated st.293-R2β 
cells with CRH and UCN-II and monitor cellular localization of GRK3 (Figure 5.44).
Cellular localization of GRK6 was not monitored, since this protein is expressed in the
plasma membrane. My data demonstrated that in the cells treated with the vehicle only
(acetic acid) the GRK3 immunoreactivity was widely distributed through the cytoplasm;
however the activation of the CRH-R2β receptor with CRH or UCN-II led to robust 
GRK3 recruitment to the plasma membrane detected as punctuated staining on the
membrane and sharp edges of the cells (Figure 5.44). This GRK3 recruitment could be
of pivotal importance for the mediation of the receptors activity. However, more
detailed biochemical and mutagenesis studies are needed in order to draw an evident
conclusion. A detailed examination of the CRH-R2 receptor amino acid sequence and
identification of potential GRK3 phosphorylation sites would be of great importance in
the future studies.
Interestingly, up to date there are no data demonstrated if the CRH type 2 receptor
is a target to PKA and PKC phosphorylation. It is possible that similar mechanisms as
described for CRH-R1α (Papadopoulou N et al., 2004, Teli T et al., 2005, Markovic D
et al., 2006) govern the activity of CRH-R2β though phosphorylation of specific 
residues within the intracellular loops and cytoplasmic C-tail. It is appreciate that the
complexity of GPCR activation followed with involvement of G-proteins, generation of
various second messengers, protein kinases and phosphatases is mediated by scaffolding
proteins, such as AKAPs. These proteins represent a dynamic platform and enable
multivalent signalling from activated GPCRs (Melbon CC et al., 2004). It is well
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established that that AKAP79 and AKAP250 (gravin) translocate to the plasma
membrane and bind to a ligand occupied receptor and orchestrate the interaction of
various proteins. AKAP79 functions in switching signalling pathways of the receptor
from adenylyl cyclase to activation of the MAPK cascade (Wang H-Y et al., 2006). On
the other hand, AKAP250 is essential for the resensitization and recycling of the
receptor following agonist-induced activation, desensitization and internalization. This
AKAP has binding domains for PKA, PKC and PP2B (protein phosphatase PP2B), and
the later is crucial in dephosphorylation of the activated receptor and its recycling
(Melboun CC et al., 2004, Wang H-Y et al., 2006).
Figure 5.44. CRH and UCN-II induced recruitment to the plasma
membrane of st.293-R2β. The translocation of GRK3 was monitored by
indirect confocal microscopy using GRK3 specific antibody and
AlexaFluor®488. The nuclei were visualized with DAPI, a DNA specific dye.
I investigated the potential involvement of these two fascinating proteins in the
light of CRH-R2β activation. The immunofluorescence data provide evidence that 
5 min 10 min 15 min
CRH
UCN-II
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AKAP79 and AKAP250 are recruited to the plasma membrane following activation of
CRH-R2β with CRH and UCN-II (Figure 5.45). However, this result on its own is not 
enough to prove the interaction between CRH-R2β and AKAPs. Up to date there are no 
reports investigating interactions between the two. It would be very interesting to
deepen the observation shown on the figure 5.44, and characterize the possible
interaction by biochemical methods such as co-immunoprecipitation of CRH-R2 and
AKAPs, supported by the use of AKAP79 and AKAP250 siRNA, and mutagenesis of
potential interaction sites on the CRH-R2. The carefully planned and carried
experiments of this nature would provide novel evidence of the very likely involvement
and importance of these two scaffolding proteins in CRH-R2 mediated signalling.
The function of cytoskeletal proteins such is actin in endocytosis and protein
trafficking is complex and not fully understood. Several roles have been proposed for
actin including trapping endocytosis into restricted plasma membrane sites,
invagination of plasma membrane, vesicle fission and fusion, vesicle mobility through
the cytoplasm (Šamaj J et al., 2004). Resent evidence suggest that endocytic hot spots
act as actin filament organizing centres (Engqvist-Goldstein AEY et al., 2004).
However, there are no reports implicating the involvement of F-actin in CRH-R-
mediated signalling. Immuofluorescent studies employing co-staining of st.293-R2β 
cells with CRH-R1/2 specific antibody and Alexa Fluor®633-phalloidin (a high
affinity probe for F-actin, which specifically binds to the interface between F-actin
subunits) showed significantly increased assembly of F-actin (stress fibres) and co-
localization with the CRH-R2β receptor, following UCN-II treatment (Figure 5.46). 
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These results demonstrate for the first time the involvement of F-actin in CRH-R2
endocytotic machinery and signalling.
Figure 5.45. The recruitment of AKAPs to the plasma membrane of
st.293-R2β following stimulation with CRH and UCN-II. The translocation
of AKAP79 (top panel) and AKAP250 (bottom panel) was monitored by
indirect confocal microscopy using AKAP79 and AKAP250 specific antibody,
respectively, and AlexaFluor®488. The nuclei were visualized with DAPI, a
DNA specific dye.
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Figure 5.46. The formation of stress fibres (F-actin oligomers) in st.293-
R2β following stimulation with UCN-II. The formation of F-actin oligomers
was monitored by indirect confocal microscopy using Alexa Fluor®633-
phalloidin (red) and CRH-R1/2 specific antibody and AlexaFluor®488 (green).
The nuclei were visualized with DAPI, a DNA specific dye.
In future studies it would be interesting to investigate the connection between
increased F-actin assembly and recruitment of various proteins (AKAPs, β-arrestins, 
clathrin, GRKs) to the plasma membrane following stimulation of cells with CRH and
related peptide.
F-actin CRH-R2 merge
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UCN-II
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6 THE REGULATION OF EXPRESSION AND SIGNALLING
CHARACTERISTICS OF ENDOGENOUS CRH-Rs IN HUMAN
PREGNANT MYOMETRIAL CELLS
6.1 INTRODUCTION
Corticortopin releasing hormone (CRH), a hypothalamic stress peptide, is also
produced by placenta of pregnant primates and released into the circulation, suggesting
a potential role of the hormone in reproduction (Linton EA et al., 2001). During
gestation the uterus remains in a state of quiescence whilst the foetus matures. At term,
delivery is facilitated by cervical dilatation and a switch of the uterus from quiescence
to a state of co-ordinated contractility (Challis JRG et al., 2000). The mechanism
controlling myometrial transition from relaxation to active contractions during
pregnancy and labour are still unknown. CRH and related peptides, urocortins (UCNs)
might play an important role in foetus implantation and endocrinology of pregnancy.
CRH, produced by the trophoblast, promotes blastocyst implantation and facilitates
immune tolerance of the early pregnancy by killing maternal activated T cells (Carr BR
& Rehman KS, 2004). Placentaly derived CRH increases exponentially in maternal
plasma throughout pregnancy and peaks during labour and delivery. Levels of CRH at
term may be 50- to 100-fold higher than those in non pregnant women. There is also an
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increase in carrier protein, CRH-binding protein (CRH-BP), which binds CRH and may
blunt the increase in CRH biological activity, protecting against inappropriate
stimulation of the HPA axis. However, near the end of normal pregnancy, with the
exponential rise in plasma CRH, levels of CRH-BP fall gradually to half of those of
earlier pregnancy (Linton EA et al., 2001). Elevated levels of maternal plasma CRH
have been found in women in preterm labour who are destined to deliver within 24-48
hours, compared with those who continued pregnancy despite threatened preterm
labour. Moreover, in preterm labour and pre-eclampsia, maternal plasma CRH levels
are higher and CRH-BP levels are lower than in normal pregnancy; but in women who
deliver postdate, plasma CRH levels are lower while CRH-BP is higher than in normal
pregnancy (McLean M et al, 1995). Thus, the plasma concentrations of CRH may act
as a predictor or a “placental clock” of the duration of human gestation (McLean M et
al, 1995).
The precise biological function of CRH and UCNs during pregnancy is not well
defined but they appear to play important roles in regulation of myometrial contractility
(Grammatopoulos DK & Hillhouse EW, 1999) either directly by inducing myosin light
chain phosphorylation that could lead to increased contractility (Karteris E et al., 2004)
or indirectly by stimulating the production of prostaglandins in the decidua and fetal
membrane (Patraglia F et al., 1995; Jones SA & Challis JR, 1989). It is likely that
placental CRH influences the fetal adrenal cortex by modulating fetal pituitary-adrenal
axis (Mesiano S & Jaffe RB, 1997). It has been proposed that late in gestation, cortisol
produced by the fetal adrenal cortex blocks inhibitory effect of progesterone on
placental CRH production (Karelis K et al., 1996). As a consequence, the levels of
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placentaly produced CRH increase in the fetal compartments, leading to the further
stimulation of fetal ATCH production, which stimulates cortisol and
dehydroepiandrosterone sulphate (DHEA-S) production. These steroid hormones
produced by fetal adrenal cortex regulate intrauterine homeostasis and the maturation of
fetal organs (Karelis K et al., 1996; Mesiano S & Jaffe RB, 1997).
The human myometrium expresses a plethora of CRH and CRH-related peptides
and their respective receptors R1 and R2 (Hillhouse EW & Grammatopoulos DK, 2001).
Current evidence suggests that CRH-R1 and R2-activated signalling pathways might
exert distinct actions in the regulation of myometrial contractility. The myometrial
CRH-Rs exhibit increased affinity for CRH during pregnancy (Hillhouse EW et al.,
1993) and upon agonist activation stimulate cAMP and cGMP production and nitric
oxide synthase (NOS) up-regulation (Aggelidou E et al., 2002); thus promoting
myometrial quiescence, possibly though activation of CRH-R1 receptors. Recent
isometric contractility studies in myometrial tissue strips have confirmed CRH ability to
relax the human pregnant myometrium (Mignot TM et al., 2005). In contrast, CRH-R2-
specific agonists such as UCN-II can activate MAPK and RhoA pathways which
actively promote myometrial contractility (Karteris E et al., 2004). Furthermore,
progression of human pregnancy towards term and active labour is associated with
activation of intracellular mechanisms involving uterotonin-activated protein kinase C
(PKC) that reduce the myometrial responsiveness to CRH, an effect mediated through
phosphorylation and desensitization of specific CRH-R variants (Grammatopoulos DK
& Hillhouse EW, 1999 b, Markovic D et al., 2006).
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Furthermore, pregnant and non-pregnant myometrium have a different CRH
receptors profile. Seven subtypes of the CRH receptors were found in the human
pregnant myometrium at term before the onset of labor, R1, R1, R1c, R2, R2, and
R (Grammatopoulos DK et al., 1998), and the splice variant R1d (Grammatopoulos
DK et al., 1999), whereas only three subtypes, R1, R1 and R2were found in the
non-pregnant myometrium. This differential expression pattern of the CRH-R during
pregnancy suggests that CRH acting via different receptor subtypes might be able to
exert distinct actions on the human myometrium in the pregnant, compared to the non-
pregnant state (Grammatopoulos DK et al., 1998).
The human CRH-R1 gene spans over a 50.3-kb region and contains 14 exons
(Hillhouse EW & Grammatopoulos DK, 2006); translation of all exons results in a
human-specific, 444 amino acid 7TMD protein receptor, termed CRH-R1β, which 
exhibits impaired agonist-binding and signalling properties. Deletion of exon 6 results
in expression of CRH-R1α mRNA, which is the main functional CRH-R1 receptor 
variant and contains 415 amino acids. Therefore, the CRH-R1β can be considered as a 
“pro-CRH-R1” receptor variant. The CRH-R1 gene appears to be subject to significant
alternative splicing and a growing number of CRH-R1 mRNA splice variants have been
described, termed R1c-n (Hillhouse EW & Grammatopoulos DK, 2006). All these
variants have exon 6 spliced out together with other deletions. At least 4 distinct CRH-
R1 mRNA variants (α, β, c and d) have been identified in human myometrium during 
pregnancy (Grammatopoulos DK et al., 1998); progression towards term is associated
with altered expression of myometrial CRH-Rs and the appearance of CRH-R1 variants
such as the R1d, with reduced signalling abilities (Grammatopoulos et al., 1999). This
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might have important functional consequences by dampening tissue responsiveness to
CRH actions.
The mechanisms regulating myometrial CRH-R1 expression are not well
understood. The CRH-R1 promoter contains, amongst others, nuclear factor-kappa B
(NF-κB) putative recognition elements (κBs) elements (Parham KL et al., 2004).
Accumulating evidence points towards a role for NF-κB and its major activator IL-1β, 
in the physiology and pathophysiology of labour (Lindstrom TM & Bennett PR, 2005),
since myometrial IL-1β and NF-κB activity increases with the onset of labour and is 
central to multiple prolabour pathways by stimulating prostaglandin H synthase 2
(PGHS-2), also known as cyclooxygenase 2 (COX-2), expression and prostaglandin
(PG) synthesis (Belt AR et al., 1999).
 NF-κB is a transcription factor, composed of homo- or heterodimeres of the Rel 
family members including NF-κB1 (p50), NF-κB2 (p52), RelA (p65), RelB, and c-Rel 
(Chen FE and Ghosh S, 1999). NF-κB is sequestered in the cytoplasm of unstimulated 
cell via binding to an inhibitor protein, IκB. Following the cell stimulation, the activated 
IκB kinase (IKK) complex, predominantly acting through IKKβ in an IKKγ-dependent 
manner, catalyzes the phosphorylation of IκBα at Ser-32 and Ser-36 (DiDonato JA et al.,
1997) and NF-κB at Ser536 in p65 (Ghosh S & Karin M, 2002). The phosphorylated 
IκBα undergoes polyubiquitination and subsequent degradation by the 26S proteosome. 
The released NF-κB dimmers (most commonly p65/p50) translocate to the nucleus, 
bind DNA and regulate gene transcription (Jiang X et al., 2003).
In this part of my project, I focused my on investigations on the endogenous
CRH system in human pregnant myometrial cells. I sought to characterise the regulation
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of CRH-R1 gene expression and in particular the effects of IL-1β. In addition in this 
chapter I include data of the levels of expression of CRH-R1 and specific CRH-R1
variants by employing quantitative RT-PCR analysis from myometrial biopsies obtained
pre-term and term, before and after the onset labour. This analysis was performed by Dr
Mei Gu, Warwick Medical School.
In the second part I’ll describe some of the signalling characteristics of CRH-R
activated by UCN-II (CRH-R2 specific agonist).
METHODS
6.1.1 Subjects and myocytes preparation
Pregnant myometrial biopsies were obtained from women undergoing elective
caesarean section pre-term (30-35 weeks of gestation, n=12) or at term (>37 weeks of
gestation, n=12) before (n=6) or after (n=6) the onset of labour for non-maternal
problems. The biopsy site was standardized to the upper margin of the lower segment of
the uterus in the midline. This provides the closest approximation to the upper segment
of the uterus. The biopsies were immediately snap-frozen in liquid nitrogen and
subsequently stored at -700 C until use, or processed immediately for myocyte cell
culture as previously described (Grammatopoulos DK & Hillhouse EW, 1999 b). The
age range was 25-35 years old for both groups. Ethical approval was obtained from the
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local ethical committee and informed consent to the study was obtained from all
patients.
The myometrial smooth muscle cells (HMSM cells) were cultured in DMEM
containing 10% FCS, 1% L-glutamine, 200 IU penicillin/ml, 200 mg streptomycin/ml,
at 37oC in a humidified atmosphere of 95% air and 5% CO2 until confluency. Cells
were trypsinized in 0.25% trypsin containing 0.02% EDTA in HBSS and cultured in 12-
well plates for protein and in 6-well plates for mRNA extraction. 18 h prior to
treatments the cells were kept in DMEM without L-glutamine, FCS and antibiotics. The
following day, cells were treated with IL-1β (1 ng/ml) for various time intervals (2-18 
h). In some experiments cells with pretreated with or without specific inhibitors, as
follows: 10 μM U0126 (2 h) (U0126 inhibits both active and inactive MEK1/2), 10 μM 
SB203580 (1 h) (SB203580 is a selective inhibitor of p38MAP kinase, which acts by
competitively inhibiting ATP binding), 25 μM IKK inhibitor II, Wedelolactone (4h ) 
(IKK inhibitor II is a selective and irreversible inhibitor of IKKα and β kinase activity; 
it inhibits NF-κB-induced gene transcription by blocking the phosphorylation and 
degradation of IκBα). Proteins and RNA were harvested as described below. For 
confocal microscopy experiments, serum deprived cells were stimulated with 1 ng/ml
IL-1β for 30 and 60min. The purity of myometrial muscle cells was assessed by 
immunocytochemical staining for α-actin and vimentin (Figure 6.1) 
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Figure 6.1. The purity of smooth muscle cells was determined by
immunofluorescence. The distribution of α-actin(smooth muscle marker) and 
vimentin (fibroblast marker) in human pregnant myometrial cells was visualized
by indirect immunofluorescence confocal microscopy using specific primary
antibodies for smooth muscle α-actin and vimentin with Alexa-Fluor®488 (green) 
and Alexa-Fluor®594 secondary antibody (red), respectively, Cell nuclei were
stained with the DNA specific dye DAPI (blue).
6.1.2 RNA extraction and reverse transcription
RNA extraction was carried out by using GeneElute Mammalian Total RNA Kit
(Sigma), according to the manufacturer’s instructions. The purity and concentration of
total RNA was determined spectroscopically. 500ng of RNA was used for cDNA
synthesis, in a total volume of 50 μl reverse transcription reaction. Total RNA was 
heated up to 70°C for 5 min before the addition of random hexamers (Promega) and
reverse transcriptase containing an RNase inhibitor (Fermentas, UK). The reaction
mixture was incubated at 37°C for 60 min, followed by further 10 min incubation at
70°C. The resulting cDNA was stored at -20oC
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6.1.3 Quantitative RT-PCR analysis
Quantitative (real time) PCR of PGHS-2 was performed on a Roche Light
CyclerTM system (Roche Molecular Biochemicals, Germany). The PCR reaction was
carried in a 10 μl reaction mixture containing 5μl of PCR 2x Mastermix with 2 mM 
MgCl2, 0.5 μl of Light Cycler DNA Master SYBER®Green I, 1 μl of each primer (2 
ng/μl), and 1 μl of cDNA. The PCR protocol consisted of a denaturation step at 95oC for
15 secs, followed by 40 cycles of amplification at 95oC for 5 secs, 58oC for 10 secs, and
72oC for 15 secs, and finally by a melting curve analysis step at 95oC for 0 secs, 56oC
for 15 secs and 99oC for 0 secs. For analysis, quantitative amounts of gene of interest
were standardized against the house-keeping gene β-actin. The sequences of PGHS-2 
mRNA primers used were:
forward, 5’-TTCAAATGAGATTGTGGGAAAATTGCT-3’, and
reverse, 5’-AGATCATCTCTGCCTG AGTATCTT-3’.
The β-actin primers were: forward,  
5’-AAGAGAGGCATCCTCACCCT-3’, and
reverse, 5’-TACATGGCTGGGGTGTTGAA-5’.
As negative controls, preparations lacking RNA or reverse transcriptase were used.
RNA expression was tested in four independent experiments. The mRNA levels were
expressed as a ratio, using the “Delta-delta method” for comparing relative expression
between treatments. The PCR products were sequenced in an automated DNA
sequencer (Dept of Biological Sciences, The University of Warwick, UK) and the
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sequence data was analyzed using Blast Nucleic Acid Database Searches from the
National Centre for Biotechnology Information (NCBI).
Quantitative PCR on a TaqMan Gene Expression Assay (Applied Biosystems,
UK), was also employed to determine expression levels of various CRH-R1 mRNA
variants in human gestational myometrium and human primary myometrial cells. This
analysis was performed by Dr. Mei Gu (Warwick Medical School). Briefly, four sets of
oligonucleotide primers and four TaqMan probes specific for various human CRH-R1
mRNAs were designed from the GenBank database by mySciences (Applied
Biosystems, UK). The 1st primers/probe combination used, amplified a sequence
overlapping exons 8-9, which is present in all known CRH-R1 variants detected in the
human myometrium, R1α, R1β, R1c and R1d (Grammatopoulos DK et al., 1998).
Therefore the PCR product reflected total CRH-R1 mRNA variant expression and was
designated as CRH-R1T. In addition, primers and fluorescent probes specific for exon 6
(found in R1β mRNA variant only), were designed and the PCR amplification product 
was designated as CRH-R1β. Similarly, primers and probes overlapping exons 2-4 and 
12-14 were designed in order to amplify sequences specific for CRH-R1c and CRH-
R1d (Figure 6.2). Real-time RT-PCRs were performed using the ABI PRISM 7000
Sequence Detection System (Applied Biosystems) in a total volume of 30 µl reaction
mixture following the manufacturer’s protocol, using the SYBR Green Universal 2x
PCR Master Mix (Applied Biosystems) and 0.1 µM of each primer using the
dissociation protocol for the amplification of CRH-R1 mRNA variants. Negative
controls contained water instead of first-strand cDNA were also used. Each sample was
normalized on the basis of its 18S ribosomal RNA content (house keeping gene). The
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18S quantification was performed with a TaqMan ribosomal RNA reagent kit (Applied
Biosystems) using the manufacturer’s protocol. All samples were run in triplicate and
results were calculated with reference to the amplification of 18S rRNA using
comparative Ct method for relative quantitation (ABI Prism 7000 SDS v1.1 software).
A previous report by Sehringer and colleagues investigated the quantifying strategy on
accuracy in detecting and quantifying the CRH, CRH-BP, and CRH-Rs mRNA levels in
human gestational tissues (Sehringer B et al., 2005). The authors used the TaqMan
Gene Expression Assay, and compared the standard curve method and the comparative
Ct method (ΔΔCt or ΔCt’ method) to asses there findings. They reported that the both 
methods give consistent results, concluding that the simpler comparative Ct method is
adequate for analysis of the mRNA levels of CRH-Rs in the tissues (Sehringer B et al.,
2005).
The results were expressed as meanSE. Relative gene expression of target
mRNA was normalized to a calibrator that was chosen to be the basal condition
(untreated sample). Results were calculated with the Ct method; they were expressed
as the n-fold differences in gene expression relative to 18S rRNA and calibrator and
were determined as follows: n-fold = 2 – (Ct sample – Ct calibrator), where the parameter Ct
(threshold cycle) is defined as the fractional cycle number at which the PCR reporter
signal passes a fixed threshold. Ct values of the sample and calibrator were determined
by subtracting the average Ct value of the transcript under investigation from the
average Ct value of the 18S rRNA gene for each sample.
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Figure 6.2. Schematic diagram of CRH-R1 gene splicing pattern and the
annealing position of PCR primers and probes relative to the structure of
CRH-R1 alternative spliced variants. Arrows indicate position of primers
(Markovic D et al., 2007).
6.1.4 Qualitative RT-PCR analysis
The conditions for the conventional (qualitative) RT-PCR of CRH-R1 mRNA
were as follows: 95oC for 15 secs, 64oC for 15 secs and 72oC for 30 secs, in a total of 35
cycles with a final extension step at 72oC for 7 min. Primers sequence were: forward,
5’-CAAACAATGGCTACCGGGAG-3’, and
reverse 5’ACACCCCAGCCAATGCAGA-3’.
These primers amplified a 475bp DNA fragment present in all CRH-R1 mRNA variants
except CRH-R1α and a 538bp DNA fragment specific for CRH-R1β.  
The conditions for the conventional (qualitative) RT-PCR of CRH-R2 mRNA
were as follows: 96oC for 15 secs, 58oC for 15 secs and 72oC for 30 secs, in a total of 35
cycles with a final extension step at 72oC for 7 min. Primers sequences were: forward,
5’- CTCCTGGGCATCACCTACAT -3’, and
1 2 3 4 5 7 8 9 10 11 14
1 2 3 4 5 7 8 9 10 11 12 13 14
1 2 3 4 5 6 7 8 9 10 11 12 13 14
CRH-R1
1 2 4 5 7 8 9 10 11 12 13 14 12
Exon 6 deletion
Exon 3 deletion
CRH-R1
CRH-R1c
Exon 13 deletion
CRH-R1d
CRH-R1T
CRH-R1
real time RT-
PCR probe
qualitative RT-PCR
primers
CRH-R1c
CRH-R1d
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reverse 5’- GTCTGCTTGATGCTGTGGAA -3’.
These primers amplified a 278 bp DNA fragment present in all CRH-R2 mRNA.
Ten microliters of the reaction mixture were subsequently electrophoresed on a
1.2% agarose gel and visualized by ethidium bromide, using a 1-kb DNA ladder (Life
Technologies, Inc.) to estimate the band sizes. As a negative control for all of the
reactions, distilled water was used in place of the cDNA. The PCR products were
sequenced in an automated DNA sequencer (Dept of Biological Sciences, The
University of Warwick, UK) and the sequence data was analyzed using Blast Nucleic
Acid Database Searches from the National Centre for Biotechnology Information
(NCBI).
6.1.5 Semi-quantitative RT-PCR analysis
The conditions for the semi-quantitative RT-PCR of PGHS-2 mRNA were as
follows: 95oC for 15 secs, 64oC for 15 secs and 72oC for 30 secs, in a total of 35 cycles
with a final extension step at 72oC for 7 min. The primer sequence was same as
described in 6.1.3. As an internal standard a commercially available 18S set of primers
and competamers was used as described in manufacturer’s instruction (Ambion Inc).
Briefly, both sets of primers (PGHS-2 and 18S) were amplified in the same PCR
reaction.  Twenty μl of the reaction mixture were subsequently electrophoresed on a 
1.2% agarose gel and visualized by ethidium bromide, using a 1-kb DNA ladder (Life
Technologies, Inc.). The amount of DNA was determined by measuring intensity of
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bands using GeneDoc System. As a negative control for all of the reactions, distilled
water was used in place of the cDNA.
6.1.6 Western blot analysis
 Cells were lysed in 150μl Laemmli’s buffer. The lysates were sonicated for 30 
secs, and after boiling for 5 mins proteins were span down and 15 μl of the supernatant 
was loaded on 10% SDS-polyacrylamide gels. Gels were run at 200 V for
approximately 1h. Proteins were electrophoretically transferred to a PVDF filter at 100
V for 1 hr. The filters was initially incubated in TBS containing 0.1% Tween-20 (TBS-
T) and 5% milk (wt/vol), for 1 h at room temperature (RT) and after a brief wash with
TBS-T, were incubated with primary antisera. The primary antibodies for PGHS-2,
CRH-R1/2, RhoA, MLC, phospho-MLC, phospho-ERK1/2, total ERK1/2, phospho-
p38MAPK, and total p-38MAPK were used at a 1:1,000 dilution in TBS-T overnight at
4oC or at RT for 1 h (PGHS-2), whereas the IκBα antibody was used at a 1:500 dilution 
(overnight at 4oC). Equal protein loading was confirmed by using anti-GAPDH
antibodies (1:40,000 dilution in TBS-T at RT for 1 h). The filters were washed
thoroughly for 30 min with TBS-T, before incubation with the appropriate secondary
Abs HRP-conjugated (1:2,000) for 1 h at RT. Following a further washing step for 30
mins with TBS-T, antibody complexes were visualized using enhanced
chemiluminescence (ECL). In some experiments IκBα and GAPDH probed blots were 
incubated with goat anti-rabbit IRDye 800-conjugated IgG at 1:6000 in 10 ml of
blocking buffer with gentle agitation for 1 hour at room temperature. Finally, the blot
was washed 2 more times each with 15 ml of TBS-T, and once with TBS only. The
CHAPTER 6
244
membrane was dried between sheets of fine tissue, visualized and analysed on the
Odyssey Infrared Imaging System (LI-COR Biosciences, Cambridge, UK).
6.1.7 Glycerol-polyacrylamide gel electrophoresis
The setting was assembled the same way as for SDS-PAGE. The gel was pre-
run for 30-45min at 200V. After the samples were loaded the gel was run at 200-300V
for at least 2-3h, or until the blue dye was completely gone. The proteins were
transferred as described above.
6.1.8 RhoA activation assay
To detect RhoA translocation/activation the commercially available kit was
used (Rho activation assay, Cytoskeleton, Denver, USA). Briefly, the principle of the
assay is to detect Rho-GTP (active form). The Rho Binding Domain (RBD) of
Rhotekin has been shown to bind specifically to Rho-GTP. This allows one to “pull-
down” Rhotekin-RBD/Rho-GTP complex with glutathione-agarose beads. Before the
treatments, the cells have been starved overnight (since RhoA activation and
translocation are FCS sensitive). The assay was performed according to the
manufacturer’s instruction. The Rhotekin-RBD/Rho-GTP complex with glutathione-
agarose beads were dissolved in 2x sample buffer, boiled for 5min, span down and 10μl 
of supernatant was loaded on a 10% PAGE-SDS gel. A separate gel was loaded with
10μl of total cell lysate to demonstrate equal amount of RhoA protein in all samples. 
Following protein transfer to a PVDF membrane, the membrane was probed with
RhoA-antibody as described above.
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6.1.9 Measurement of cAMP production
Myometrial cells were plated in 12-well plates and when reached 70-80%
confluency, they were kept in DMEM for 12 hours, and treated with 1 ng/ml IL-1β for 
18 h. At the end of the incubation period, media was aspirated and cells were washed
with plain DMEM. Then, stimulation buffer (DMEM containing 10 mM MgCl2 and 1
mg/ml 3-isobutyl-1-methylxanthine- IBMX) was added and cells were incubated for 20
min at 37oC. Following washing with 1ml DMEM, cells were stimulated with 100 nM
CRH or 10 μM forskolin for 15 min. The reaction was stopped by adding 10 μl of 
concentrated HCl for 15-20 min at RT. Subsequently, cells were scraped and transferred
in 1.5 ml tubes. After a brief spin, lysates were stored at -20oC. The cAMP levels were
determined by a commercially available ELISA kit (low pH) from R&D systems
(Minneapolis, MN).
6.1.10 Confocal microscopy
Myocytes were grown on aminopropylethoxysilane (APES)-treated glass cover
slips. To monitor NF-κB(p65) and IκB translocation, serum deprived cells were treated 
with 1ng/ml IL-1β for 30-60min, and fixed with 4% PFA (paraformaldehide) in PBS. 
After permeabilization with PBS containing 0.01% Triton-x100 and 3%BSA, cells were
incubated with p65 or IκB antibody (1:100) overnight at 4oC. After 3 brief washes with
PBS, slides were incubated for 1h at RT with 1:400 anti-rabbit AlexaFluor®594. After
3 washes with PBS, the slides were mounted with VectaShield® Hard Set TM mounting
medium for fluorescence ( Vector Laboratories, Inc. Burlingame, CA) or Slowfade
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gold antifade reagent with DAPI (Invitrogen, Molecular Probes). For detection of CRH-
R, fixed cells were incubated with 1:100 CRH-R1/2 antibody overnight. The following
day the slides were washed and incubated with Alexa Fluor®594 and Alexa Fluor®488-
phalloidin. The slides were mounted as described above. The slides were examined
under an oil immersion objective (63x) using a Leica DMRE laser scanning confocal
microscope with TCS SP2 scan head (Leica Microsystems, Inc., Deerfield, IL) as
previously described (Markovic D et al., 2006).
To detect RhoA translocation, cells were fixed with 10% ice cold TCA in PBS
for 15 min at 4oC. After three 5min washes with G-PBS (30mM glycerin in PBS), the
cells were permeabilized with 0.2% Triton-x100 in G-PBS for 15min. The cells were
washes three times with G-PBS, and non-specific binding was blocked with 1% BSA
for 1h at room temperature. After a brief wash the cells were incubated overnight with
RhoA antibody (1:100) at 4oC. The following morning, the cells were washed and
incubated with donkey anti-mouse Alexa-Flour 595.
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6.2 RESULTS
THE EFFECT OF IL-1β ON MYOMETRIAL CRH-R1 SPLICE VARIANTS 
EXPRESSION
6.2.1 CRH-R mRNA and protein expression in primary myometrial smooth
muscle cells
The differential expression levels of CRH–R1 mRNA transcripts in human
myometrial biopsies during labour, was investigated in primary myometrial smooth
muscle cells. Qualitative RT-PCR studies confirmed the expression of multiple CRH-
R1 (including CRH-R1β) mRNAs (Figure 6.3 A) (Markovic D et al., 2007).
Additionally, the expression of CRH-R2 mRNA was also confirmed (Figure 6.3 B)
Moreover, indirect immunofluorescence with a CRH-R1/2-specific antibody
was used to monitor distribution of CRH-R and counterstaining with phalloidin to
detect filamentous–actin (F-actin) stress fibres and the nuclear stain DAPI. Confocal
microscopy studies demonstrated a strong CRH-R-positive immunostaining in the
plasma membrane and the cytoplasm (Figure 6.3 C); significant co-localization between
the CRH-R and F-actin immunostaining was observed in the plasma membrane (yellow
colour, Figure 6.3 C), suggestive of some common subcellular localization of CRH-R
and actin stress fibres. As shown in the chapter 4, the plasma membrane signal was not
evenly distributed in the cell membrane, and was confined in specific membrane areas
(Figure 4.1 A). No staining was detectable when cells were pre-incubated with a
specific CRH-R antibody-blocking peptide (Figure 4.1 C) (Markovic D et al., 2007).
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Figure 6.3. Detection of CRH-Rs in HMSM cells. A. RT-PCR amplification
of CRH-R1 variants sequences from RNA extracted from primary human
myometrial cell cultures. Specific primers able to amplify CRH-R1α, R1β and 
R1d mRNA were used as described in Methods. Primer sets were designed to
amplify a 475-bp fragment, present in CRH-R1α and R1d (but not R1c) 
mRNA or a 538-bp fragment, present in CRH-R1β mRNA. PCR products 
were resolved on 1.2% agarose gel and stained with ethidium bromide. The
identities of the fragments were confirmed by direct nucleotide sequencing. B.
RT-PCR amplification of CRH-R2 sequences from RNA extracted from
primary human myometrial cell cultures. The primer set was design to amplify
all three variants of CRH-R2. C. Visualization of CRH-R distribution in
human pregnant myometrial cells by indirect immunofluorescence confocal
microscopy using specific primary antibodies for CRH-R and Alexa-
Fluor®594 secondary antibody (red) and phalloidin (Alexa-Fluor®488 green)
as described in Methods. Cell nuclei were stained with the DNA specific dye
DAPI (blue). Identical results were obtained from three independent
experiments. D. Western blot analysis of HMSM cells lysates. The presence of
CRH-Rs was identified by using CRH-R1/2 antibody as described in Methods
(Markovic D et al., 2007).
CRH-R1 (475 bp)
CRH-R1 (538 bp)
A
Ladder myo st.293-R2
CRH-R2 (278 bp)
B
C
Myo 1 Myo 2 st.293-R1
GAPDH (37 kDa)
CRH-R1/2 (~60 kDa)
D
CHAPTER 6
249
Using the antibody that recognises both types of CRH-R for a Western blot
analysis, two immnuoreactive bands with approximate molecular weight of 60 kDa
were detected (Figure 6.3 D). These two bands could represent different CRH receptor
types or splice variants, but also could be a result of post-translational modifications
such are glycosylation and phosphorylation.
6.2.2 Effects of IL-1β on PGHS-2 mRNA and protein expression in primary 
myometrial smooth muscle cells.
It is well established that pro-inflammatory cytokines, especially IL-1β are 
important regulators of myometrial smooth muscle cells gene expression during
pregnancy by activating NF-κB, p38MAP, and ERK1/2 (Barlett SR et al., 1999;
Sooranna SR et al., 2005). To confirm the functional activity of IL-1β in these cells, 
experiments were carried out in cells treated with IL-1β for various time-intervals and 
expression levels of PGHS-2 mRNA and protein were determined by quantitative RT-
PCR and immunoblot and immunofluorescent analysis using a specific antibody.
Results of real-time PCR and semi-quantitative PCR analysis showed that
exposure of HMSM cells to IL-1β (1 ng/ml) significantly up-regulated PGHS-2 mRNA 
levels in a time-dependent manner (Figure 6.4). A semi-quantitative PCR analysis was
performed as described in Methods. As an internal standard primers that amplify 18S
were used (Ambion Inc.) The PCR reaction was set with both sets of the primers in the
same PCR reaction. Two bands were obtained from each PCR reaction (Figure 6.4A).
The top band of 525 bp was a product of 18S amplification and a 305 bp band was a
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product of PGHS-2 amplification. At time point 0 h the levels of PGHS-2 mRNA were
barely detectable. After 2 h of IL-1β treatment substantial levels of PGHS-2 mRNA 
were detected. The effect of IL-1β on PGHS-2 mRNA levels was more profound after 6 
and 18 h (Figure 6.4A).
These results were confirmed by quantitative real time PCR: IL-1β significantly 
increased PGHS-2 mRNA after 2 h of incubation (by 60 fold above basal), and achieved
maximal response after 18 h (300 fold above basal) (Figure 6.4 B) (Markovic D et al.,
2007).
Figure 6.4. Time course of the IL-1β effects on PGHS-2 mRNA expression.
HMSM cells isolated from myometrium of non-labouring women (n=6) were
treated with IL-1β (1 ng/ml) for various time-intervals and PGHS-2 mRNA 
analysed by semi-quantitative PCR (A) and by real-time quantitative PCR
(Lightcycler, Roche Applied Science) (B). Data are expressed as mean
values±SEM. of relative mRNA expression levels normalised against GAPDH
mRNA. *P<0·05 compared to basal.
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Additionally, the protein levels of PGHS-2 following IL-1β treatments were 
analysed by Western blot analysis (Figure 6.5). The increase in PGHS-2 protein
expression mirrored the increase in the mRNA levels. Treatment of 1 ng/ml IL-1β 
for 2 h induced significant increase in PGHS-2 protein expression (20 fold above
basal). The effect of IL-1β was maximal after 18 h when PGHS-2 protein levels 
increased by 140 fold above basal (Figure 6.5) (Markovic D et al., 2007).
The IL-1β induced PGHS-2 protein levels were also detected by indirect 
confocal microscopy studies (Figure 6.6). Prior to IL-1β stimulation, the PGHS-2 
protein could not be detected by immunofluorescence; however, after 18 h of IL-1β 
treatment significant levels of PGHS-2 proteins were detected in the cytoplasm of
HMSM cells (Figure 6.6), evident by the appearance of red signal (originated from
PGHS-2 specific antibody and Alexa-Fluor®594 secondary antibody).
Figure 6.5. Time course of the IL-1β effects on PGHS-2 protein expression.
HMSM cells isolated from myometrium of non-labouring women (n=6) were
treated with IL-1β (1 ng/ml) for various time-intervals and PGHS-2 proteins 
were analysed by Western blotting. Data are expressed as mean values ± SEM.
of relative protein expression levels normalised against GAPDH protein levels.
*P<0·05 compared to basal.
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Figure 6.6. The effect of IL-1β on PGHS-2 protein expression monitored 
by indirect immunofluorescence confocal microscopy. The cells were
grown on cover slips and treated with IL-1β (1 ng/ml) for 18 h. The PGHS-2 
protein was visualised using specific primary antibodies for PGHS-2 and
Alexa-Fluor®594 secondary antibody (red). Distribution of F-actin and stress
fibers was also monitored by double staining with Alexa Fluor®488 phalloidin
(green). Cell nuclei were stained with the DNA specific dye DAPI (blue).
Identical results were obtained from three independent experiments.
6.2.3 Effects of IL-1β on CRH-R1 mRNA and protein expression in primary 
myometrial smooth muscle cells
The effects of IL-1β treatments on CRH-R1 mRNA and protein levels were also 
investigated. The semi-quantitative analysis of CRH-R1 mRNA expression suggested
that IL-1β (1 ng/ml) treatment for 18 h affected the expression of CRH-R1α and CRH-
R1β mRNA (Figure 6.7 A). At the basal state both splice variants were expressed; 
however, following the 18 h treatment with IL-1β the CRH-R1 splice variant expression 
profile changed. The intensity of the top band, CRH-R1β, was significantly reduced, 
basal IL-1
PGHS-2
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while the intensity of the bottom band (CRH-R1α) was substantially increased (Figure 
6.7A).
Moreover, a quantitative real time PCR analysis, performed by Dr Mei Gu,
confirmed these observations. IL-1β treatment for 18 h induced myometrial cell CRH-
R1T(α) mRNA expression by 3 fold whilst significantly attenuated myometrial CRH-
R1β mRNA expression by 40% (Figure 6.7B). In contrast, IL-1β treatments for 2 or 6 h 
had no effect on myometrial cell CRH-R1 (total) and CRH-R1β mRNA expression 
levels (Figure 6.7B) (Markovic D et al., 2007).
No significant changes in CRH-R protein expression were detected following
IL-1β treatment, as demonstrated by Western blot analysis (Figure 6.8A) and 
indirect confocal microscopy studies (Figure 6.8B). The CRH-R protein levels did
not seem to be affected by IL-1β (1 ng/ml) treatment for 18 h. However, these data 
cannot be correlated to the mRNA data, due to lack of CRH-R1 splice variant
specific antibodies.
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Figure 6.7. The IL-1β effect on CRH-R1 mRNA expression. A. Qualitative
PCR analysis of IL-1β effects on CRH-R1 mRNA levels following 18 h 
treatment. B.Time course of the IL-1β effect on CRH-R1 (total) and CRH-R1β 
mRNA level in human myometrial smooth muscle cells. Cells isolated from
myometrium of nonlabouring women (n=6) were treated with IL-1β (1 ng/ml) 
for various time-intervals and target mRNA were determined by real-time
quantitative RT-PCR (Taqman, Applied Biosystems) as described in Methods.
Data are expressed as mean values±SEM. of relative mRNA expression levels
normalised against 18S RNA. *P<0·05 compared to basal (untreated). The
mean results of basal untreated mRNA concentrations were arbitrarily
assigned the value 1.
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Figure 6.8. The effect of IL-1β on CRH-R protein expression monitored 
by Western blot (A) and indirect immunofluorescence confocal
microscopy (B). A. HMSM cells isolated from myometrium of non-labouring
women (n=3) were treated with IL-1β (1 ng/ml) for 18 h and CRH-R proteins 
were analysed by Western blotting. B. The cells were grown on cover slips
and treated with IL-1β (1 ng/ml) for 18 h. The CRH-R protein was visualised 
using specific primary antibodies for CRH-R1/2 and Alexa-Fluor®594
secondary antibody (red). Distribution of F-actin and stress fibers was also
monitored by double staining with Alexa Fluor®488 phalloidin (green). Cell
nuclei were stained with the DNA specific dye DAPI (blue). Identical results
were obtained from three independent experiments.
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6.2.4 Signalling pathways mediating IL-1β effects in myometrial cells 
NF-κB is a major key intermediate of IL-1β actions in myometrial cells 
(Lindstrom TM & Bennett PR, 2005). Thus, the aim of this study was to investigate the
potential role of NF-κB on IL-1β-induced PGHS-2 and CRH-R1 mRNA variant 
expression. Confocal microscopy studies were employed using a specific p65 (RelA)
antibody to demonstrate that in untreated cells p65 immunoreactivity was exclusively
found in the cytoplasm (Figure 6.9). Exposure of myometrial cells to IL-1β (1 
ng/ml) induced nuclear translocation of p65 within 30min, this response was sustained 
for at least 1 h (Figure 6.9) (Markovic D et al., 2007).
Figure 6.9. IL-1β-induced p65 translocation. Human smooth muscle cells
isolated from myometrium of non-labouring women (n=6) were treated with
IL-1β (1 ng/ml) for various time-intervals and p65 (RelA) nuclear 
translocation was monitored by indirect immunofluorescence confocal
microscopy using specific primary antibodies for p65 and Alexa-Fluor®594
secondary antibody (red) as described in Methods. The white arrows point
towards cell nuclei (Markovic D et al., 2007).
Furthermore, IL-1β actions induced rapid phosphorylation of IκBα, indicated by 
the appearance of another immunoreactive protein with a slightly higher molecular
weight (Newton R et al., 1998) and subsequent (almost complete) degradation of IκBα, 
the cytoplasmic protein that retains NF-κB in an inactive form through association and 
IL-1β basal                                  30min    60min
CHAPTER 6
257
masking the nuclear localisation sequence (NLS) (Lindstrom TM & Bennett PR, 2005),
within 30 min (Figure 6.10) (Markovic D et al., 2007).
Figure 6.10. IL-1β-induced degradation of IκBα. Representative Western
blots of IκBα expression of cells stimulated with IL-1β (1ng/ml) for various 
time-intervals. Following cell lysis and centrifugation, supernatants were
subjected to SDS-PAGE and immunoblotted with antibodies for IκBα or 
GAPDH (protein loading control). Following incubation with HRP-conjugated
goat anti-rabbit antibody, complexes were visualized by enhanced
chemiluminescence (top panel). The data represent the mean ±SEM of 3
estimations from three independent experiments. *P<0.05 compared to basal
(Markovic D et al., 2007)
The role of the upstream IκB kinase (IKK) was evaluated by the use of a specific 
IKK inhibitor II-Wedelolactone (Pande V & Ramos MJ, 2005) and determination of
myometrial IκBα degradation following IL-1β treatment. Pretreatment of cells with 25 
μM of IKK inhibitor II-Wedelolactone for 4 h abolished IL-1β-induced IκBα 
degradation and p65 (RelA) nuclear translocation (Figure 6.11).
Most importantly, the IKK inhibitor II significantly attenuated IL-1β-induced 
up-regulation of both PGHS-2 and CRH-R1 mRNA expression (Figure 6.12). Previous
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investigations have shown that IL-1β effects on myometrial PGHS-2 up-regulation 
involve members of the family of mitogen-activated protein kinases, ERK and p38
MAPK (Sooranna SR et al., 2005). The role of these kinases on IL-1β-induced 
regulation of myometrial target gene expression was investigated by employing U0126
(a specific MEK1/2 inhibitor) and SB 203580 (a p38MAPK inhibitor). Pretreatment of
myometrial cells with each inhibitor significantly attenuated by 70-85% IL-1β-effects 
on PGHS-2 and CRH-R1 mRNA expression (Figure 6.12).
Figure 6.11. The inhibitory effect of IKK inhibitor II on IL-1β induced 
IκBα degradation and p65 translocation. The cells were pre-treated with or
without 25 μM of IKK inhibitor II- Wedelolactone for 4 h, prior to IL-1β 
addition for 1h. Identical results were obtained from four independent
experiments. A. Representative Western blots of IκBα expression of cells 
stimulated with IL-1β (1ng/ml) for 1h in the presence of the inhibitor. 
Immunoreactivity was detected by secondary antibodies conjugated to IRDye
800™ (near-IR) and the Odyssey detection system as described in Methods
(bottom panel). B. Cells were grown on cover slips and treated as above. The
translocation of p65 was detected as described at figure 6.9. (Markovic D et al.,
2007).
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Figure 6.12 Effect of IKK, ERK1/2 and p38 MAPK inhibitors on IL-1β-
induced effects on myometrial PGHS-2 and CRH-R1 gene expression.
Following pretreatment of cells with either IKK inhibitor II, U0126 and SB
203580 and stimulation with IL-1β (1ng/ml) for 18h, RNA was extracted and 
PGHS-2 and CRH-R1 mRNA levels were determined by real-time quantitative
RT-PCR (Lightcycler, Roche Applied Science and Taqman, Applied
Biosystems, respectively) as described in Methods. Data are expressed as mean
values±SEM. of relative mRNA expression levels normalised against 18S or
GAPDH mRNA. *P<0·05 compared to inhibitor-untreated values.
6.2.5 Effects of IL-1β on CRH-induced myometrial cAMP response  
The functional consequences of IL-1β-induced myometrial CRH-R1 up-regulation 
was investigated by pretreatment of cells with IL-1β for 18 h followed by determination 
of intracellular cAMP production in response to CRH stimulation. The Gsα-adenylyl 
cyclase pathway is one of the major signalling pathways mediating CRH effects in
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human myometrial cells (Grammatopoulos D and Hillhouse EW, 1999c). Surprisingly,
although IL-1β treatment increased basal and forskolin-stimulated cAMP levels (by 10x 
and 2x fold respectively), it significantly impaired CRH-induced cAMP production (by
85±7%) suggesting that myometrial CRH-R1 mRNA up-regulation was not associated
with increased functional activity and cAMP production (Figure 6.13) (Markovic D et
al., 2007).
Figure 6.13. Effect of IL-1β on CRH-induced cAMP production from 
human pregnant myometrial cells. Cells were pretreated with IL-1β (1 ng/ml) 
for 18 h, followed by incubation with 100nM CRH for 10 min at 37oC. Results
are representative of six separate cell culture preparations. Each point is the
mean±SEM of four estimates. *P<0·05 compared to basal; + P<0·05 compared
to CRH-stimulated values in cells without IL-1β pre-treatment. 
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6.2.6 Determination of myometrial CRH-R1 mRNA variant expression in
myometrial tissue
Previous RT-PCR analysis of CRH-R1 mRNA variants identified R1α, R1β, 
R1c mRNA to be present in both pre-term and term pregnant myometrium whereas R1d
mRNA only in term myometrium (Grammatopoulos DK et al., 1998). Dr Mei Gu,
performed quantitative analysis of RNA isolated from human pregnant myometrium,
amplified specific sequences present in all CRH-R1 (total) mRNA variants, and showed
a low number of threshold cycles (CT) (30-32 cycles) indicative of substantial levels of
CRH-R1T mRNA. Using specific primers and probes CRH-R1β, R1c and R1d specific 
sequences were also amplified however; the CT values of these variants mRNA
amplification were higher (33-35 cycles) suggesting lower levels of expression.
Furthermore, comparison of the mRNA concentrations showed that the expression
levels of the CRH-R1 mRNA variants relative to the total CRH-R1T mRNA levels was
4% for the R1β, 1% for the R1c and 20% for the R1d. This data suggest that the 
majority of CRH-R1T mRNA amplification signal probably reflects CRH-R1α mRNA 
levels expressed in human myometrium [CRH-R1T(α)]. These ratios cannot be used for 
an accurate quantitation of each CRH-R1 mRNA levels, but can rather provide a
relative estimation of comparative receptor variant expression (Markovic D et al., 2007).
Studies on both term groups was associated with a significant increase (by 3x and 2x
fold, respectively) of CRH-R1T(α) mRNA and CRH-R1d mRNA (by 2.5x and 3.5x fold, 
respectively). In contrast, CRH-R1β mRNA showed a significant decrease (by 40% and 
70% respectively) in labouring myometrium (both PT and T) compared to non-
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labouring myometrium, whereas no change was observed in CRH-R1c mRNA levels
(Figure 6.14B) (Markovic D et al., 2007).
Figure 6.14. Comparative studies of expression levels of CRH-R1 mRNA
variants in gestational myometrial tissues in relation to progression towards
term (A) or the onset of labour (pre-term or term) (B). Relative expression was
determined by real-time quantitative RT-PCR (TaqMan, Applied Biosystems).
Amplification runs in triplicate were performed with cDNA preparations
reversibly transcribed in the same reaction from 500 ng total RNA in each case.
Results are expressed as mean values±SEM. of relative mRNA expression
levels normalised against the levels of the house-keeping gene, 18S RNA.
*P<0·05 compared to pre-term non-labouring (A) or non-labouring
myometrium values (B). The mean results of non-labouring pre-term
myometrium (A) or non-labouring pre-term and term (B) were arbitrarily
assigned the value 1 (Markovic D et al., 2007).
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UCN-II INDUCED SIGNALLING PATHWAYS IN MYOMETRIAL
SMOOTH MUSCLE CELLS
6.2.7 The effect of UCN-II on cAMP production
As previously mentioned, one of the major signalling pathways mediating CRH
effects in human myometrial cells involves activation of the Gsα-adenylyl cyclase 
pathway which mediates myometrial relaxation (Grammatopoulos D and Hillhouse EW,
1999c). Interestingly, CRH-like peptides such as urocortin-II (a CRH-R2 specific
agonist) have been linked to activation of signalling pathways involved in myometrial
contractility. When cells were challenged with various concentrations (1 nM -100 nM)
of UCN-II no significant cAMP production was detected (Figure 6.15), suggesting that
the receptor did not couple to Gs-protein.
Figure 6.15. The effect of UCN-II on cAMP production in HMSM cells.
The cells were treated for 15 min with 1-100 nM UCN-II, supernatants were
collected and cAMP levels were determined by a commercially available
ELISA kit. The assay was performed in duplicates, from cells obtained from
three independent biopsies.
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6.2.8 The effect of UCN-II on MAPK activation
In various cellular types, another major pathway activated by UCN-II, via CRH-
R2β, is the mitogen activated protein kinase (MAPK) signalling cascade. Preliminary 
studies (Karteris E et al., 2004) have implicated the ERK pathway as a signalling
cascade mediating UCN-II effects in HSMC. My preliminary experiments confirmed
this finding and also showed that UCN-II induced p38MAPK phosphorylation.
Figure 6.15. UCN-II-induced ERK1/2 and p38MAPK phosphorylation in
HMSM cells. The cells were stimulated with 100 nM UCN-II for 5 min. Total
cellular proteins were subjected to SDS-PAGE and immunoblotted as
described in Methods.
Activated MAPKs can phosphorylate various cytoplasmic and nuclear targets,
some of which are transcription factors including Elk, c-Fos, c-Myc, NF-κB (Roux PP 
& Blenis J, 2004). Selection of targets is determined by the spatio-temporal
characteristics of MAPK activation. Since my previous studies demonstrated (section
5.2.7) that in st.293-R2β, UCN-II activated ERK1/2 translocates to the nucleus of a cell, 
I sought to investigate whether a similar spatial-temporal pattern was present in cells
that endogenously express the CRH-R2 receptor, such as HMSM cells.
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UCN-II induced ERK1/2 activation was transient and maximal stimulation was
observed after 5 min of treatment and returned to basal levels after 30 min of treatment
(Figure 6.16).
Figure 6.16. Time-dependent ERK1/2 activation by UCN-II in HMSM
cells. Top panels are representative Western blots of cells stimulated with
UCN-II (100 nM) for various time points (2-60 min). Following the treatment
the total cellular proteins were harvested and the ERK1/2 phosphorylation was
assessed using phospho-spesific-ERK1/2 antibody and GAPDH antibody and
secondary antibodies conjugated to IRDye™ 800 [near-infrared (IR)
fluorophore dyes]. Results are expressed as the means±SEM of three
independent experiments
In unstimulated HMSM cells, low levels of activated (phosphorylated) ERK1/2
were found. UCN-II treatment for 5 led to rapid increase in the amount of fluorescent
signal for phospho-ERK1/2 indicating increased activity. Phospho-ERK1/2
immunoreactive signal was wide spread throughout the cytoplasm although the majority
of the signal was localized in the cell nuclei. After 10 min of UCN-II treatment
phospho-ERK1/2 was evenly widespread throughout the cytoplasm and nucleus. In
agreement with the immunoblotting experiments suggesting transient MAPK activation,
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after prolonged treatment (30 min) with UCN-II (100 nM), only a small increase in the
amount of phospho-ERK1/2 was evident. Interestingly, most of the cell nuclei were
void of phospho-ERK1/2 immunoreactive signal, reflecting deactivation of the
signaling pathway or possible export of the MAPK outside the nucleus. After 60 min
UCN-II treatment there was no significant phospho-ERK1/2 signal in the cells (Figure
6.16).
Figure 6.16. Phospho-ERK1/2 subcellular distribution induced by UCN-II
in HMSM cells: visualization by confocal microscopy. The cells were
stimulated with or without UCN-II (100 nM) for various time intervals (5–60
min). Phospho-ERK1/2 distribution was monitored over the ensuing time
period by indirect double immunofluorescence using specific primary
antibodies for phospho-ERK1/2 and Alexa-Fluor®594 secondary antibody
(red). Identical results were obtained from two independent experiments and at
least 10 cells were examined in each experiment.
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6.2.9 CRH-R2 mediated RhoA translocation
Furthermore, I demonstrated that the treatment of myocytes with CRH also
caused a small but significant increase in RhoA translocation (by 4 fold), which was
significantly less than UCN-II-induced RhoA translocation (13 fold increase above
basal) implicating CRH-R2 mediated phenomenon. Interestingly, co-treatment of
UCN-II stimulated cells with CRH attenuated UCN-II effect on RhoA translocation to
the plasma membrane (by 30%), suggesting either desensitization of CRH-R2 or a
possible cross talk between the CRH-R1 and R2 receptors. The well-established
uterotonin, oxytocin, was used as a positive control; treatment of myocytes with
oxytocin induced RhoA translocation by 17 fold above basal (Figure 6.17).
Figure 6.17. Agonist induced RhoA translocation to the plasma
membrane in HMSM. Cells were stimulated with agonists for 5 min. The
plasma membrane fraction was separated from the cytosolic as described in
Material and Methods. The equal amount of proteins (5-10μg/lane) were 
separated by 12% SDS-PAGE and transferred to PVDF membrane. RhoA
imunoreactive band was detected as described in Methods.
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6.2.10 UCN-II induced MLC phosphorylation
As mentioned previously, Karteris et al. (Karteris E et al., 2004) have
demonstrated that in UCN-II challenged myometrial smooth muscle cells, myosin light
chain (MLC) phosphorylation is increased via an intracellular mechanism utilizing
ERK1/2-dependent RhoA activation. I confirmed that stimulation of HMSM cells for 5
min with 100 nM UCN-II led to significant mono- and di-phosphorylation of MLC
(Figure 6.18). I used urea glycerol-PAGE in order to separate differently
phosphorylated MLC forms.
Figure 6.18. UCN-II induced MLC phosphorylation. Cells were treated
with 100nM UCN-II or oxytocin (OT) for 5 min. The total proteins, collected
in urea sample buffer, were separated by glycerol-PAGE as described in
Material and Methods.(MLC-0P non-phosphorylated MLC; MLC-1P mono-
phosphorylated MLC, MLC-2P di-phosphorylated MLC).
6.2.11 Methods for monitoring UCN-II induced RhoA translocation and
activation
Previous studies suggested that the activation of ERK1/2 in HMSM cells leads to
further activation/ translocation of small GTPase, RhoA (Karteris E et al., 2004). The
activity of this protein is partially responsible for UCN-II-induced myosin light chain
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(MLC) phosphorylation, a key step in induction of contractions in a muscle cell
(Karteris E et al., 2004). In order to develop better means for a detection of RhoA
translocation to the plasma membrane of a single cell and subsequent activation, an
immunofluorescence method previously described by Hayashi K and colleagues
(Hayashi K et al., 1999) was adapted. The detailed protocol is presented in section
6.1.10. These studies showed that UCN-II treatment of HMSM cells as short as 5 min
induced a robust RhoA translocation from the cytoplasm to the plasma membrane
(Figure 6.19).
However, the translocation of RhoA to the plasma membrane is just a first step
towards the activation of RhoA. The activation of this small GTPase was monitored by
a commercially available kit (described in the section 6.1.8). The treatment of HMSM
cells with UCN-II for 5min induced significant activation of RhoA (Figure 6.20).
Use of these methods provided more conclusive evidence on the effect of UCN-II
on RhoA activation. A big advantage of these techniques over the preparation of
membrane proteins, the techniques used by Karteris E et al, is the smaller amount of
starting material, the cells. This is of pivotal importance, since the pregnant myometrial
smooth muscle cells could loose the original properties of primary cells if they are
passaged many times. A gradual loss of CRH receptors with successive passage of
cultured non-pregnant myocytes was reported, as well as reduced signalling properties
(Linton EA et al., 2001); it is possible that the same is true for cultured pregnant
myocytes.
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Figure 6.19. UCN-II induced RhoA translocation in HMSM cells. The cells
were grown on cover slips and treated with 100 nM UCN-II for 5min. The
cells were fixed with TCA as described in Methods. The identical results were
obtained from two independent experiments.
Figure 6.20. UCN-II induced RhoA activation in HMSM cells. The cells
were treated with 100 nM UCN-II for 5min and proteins were harvested and
the RhoA-GTP pull down assay was performed as described in 6.1.8. The
identical results were obtained from two independent experiments.
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6.2.12 UCN-II induced CRH-R internalization
CRH-R activity, as the activity of any other GPCR, is controlled with a fine
balance between molecular mechanisms mediating receptor signalling, desensitization,
internalization and resensitisation. Internalization (endocytosis) is an important
physiological “feedback” mechanism that protects receptor over-stimulation. As shown
on Figure 4.1A and 6.3, hot spots of CRH-R expression are present on the surface of
HMSM cells. The exposure of HMSM cells to 100 nM UCN-II for 60 mins results in
retraction of CRH-R immnunoreactive signal from the cell surface and appearance of
punctuated intracellular staining, indicative of receptor endocytosis.
Figure 6.21. UCN-II induced CRH-R internalization in HMSM cells. The
cells were treated with 100 nM UCN-II for 60 min and fixed. The CRH-R
protein was visualised using specific primary antibodies for CRH-R1/2 and
Alexa-Fluor®594 secondary antibody (red). The white arrows indicate CRH-R
immunoreactive signal on the edges of the cells.
Basal UCN-II 60 min
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6.3 DISCUSSION
CRH and UCNs are expressed in placenta and intrauterine tissues during
pregnancy and labour (Petraglia F et al., 1987). However, the precise biological
functions of CRH during human pregnancy are still unknown. There is a wealth of
evidence, including myometrial contractility studies, suggesting that CRH plays a
“protective” role for the pregnant uterus, by generating intracellular signals (cAMP,
cGMP, NO) that maintain the uterus in a state of relaxation and prevent contraction
(Grammatopoulos DK, 2007; Vatish M et al., 2006). On the other hand, increased
maternal plasma CRH levels are used as a predictor of the onset of labour (Korebrits C
et al., 1998). These two physiological roles of CRH are not necessary contradictory,
since it is possible that CRH and myometrial CRH-Rs have distinct and possible
opposite roles during different stages of pregnancy (Grammatopoulos DK, 2007). Also
it is possible, that the significantly higher levels of maternal plasma CRH in abnormal
pregnancy states might be produced in response to premature labouring process, in
order to prevent inappropriate contractions (Warren WB et al., 1995).
Human pregnancy is associated with changes in the myometrial CRH-R variant
expression profile and functional activity, consistent with the important role(s) of CRH
and CRH-related peptides in the control of myometrial transition from a state of
quiescence to one of increased contractility (Grammatopoulos D & Hillhouse EW, 1999;
Hillhouse EW et al., 1993; Grammatopoulos D et al., 1998; Grammatopoulos D et al.,
1999; Grammatopoulos D et al., 1996). Quantitative RT-PCR data shown in this chapter,
performed by Dr Mei Gu, clearly demonstrated that as pregnancy progresses towards
term, there is an increased transcription of the CRH-R1 gene in quiescent myometrial
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tissue. Most importantly, the results suggest that mechanisms activating myometrial
contractility and labour, either term or pre-term, induce increased transcription of the
CRH-R1 gene and accelerate the (unknown) splicing mechanisms involved in the
generation of downstream CRH-R1 mRNA splice variants. Analysis of the structural
characteristics of myometrial CRH-R1 variants suggests that there are at least two
distinct levels of splicing events (Figure 6.2). Use of quantitative RT-PCR probes
capable of distinguishing between different mRNA variants allowed us to investigate
expression of individual CRH-R1 mRNA variants. The finding that in labouring
myometrium there is decreased mRNA expression of the “pro-CRH-R1” variant, CRH-
R1β, with simultaneous increase of the “total”CRH-R1 mRNA (that reflects the fully-
active CRH-R1α and the signalling deficient variant CRH-R1d), suggests induction of 
the two splicing events regulating individual expression of CRH-R1 variants by
removing sequentially exons 6 and 13. These findings expand previous studies
employing a semi-quantitative RT-PCR method and showed that the CRH-R1 mRNA in
the lower myometrial segment, but not the fundus, is significantly increased in both
preterm and term labour (Stevens MY et al., 1998).
The mechanisms regulating CRH-R1 alternative splicing are largely unknown.
Studies in keratinocytes suggest that environmental stimuli such as UV irradiation as
well as intracellular messengers such as cAMP and phorbol esters can induce CRH-R1
splicing (Pisarchik A & Slominski AT, 2001). Furthermore, CRH-R heterogeneity has
been previously shown in human myometrial membrane extracts (Grammatopoulos D et
al., 1995) and the functional activity of some receptor variants appeared to be
differentially regulated by oxytocin (Grammatopoulos D & Hillhouse EW, 1999b;
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Markovic D et al., 2006). The results presented here strongly suggest that the CRH-R1
gene transcriptional activity and splicing is specifically targeted by the mechanisms
involved in the onset of labour. Unfortunately, the lack of suitable antibodies able to
distinguish between different CRH-R1 variants does not allow investigations at the level
of individual protein expression and functional response.
In order to further the investigation of the expression of CRH-R1, primary human
myometrial cell obtained from term human quiescent myometrial biopsies were used. I
was able for the first time to demonstrate un-even distribution of CRH-Rs in the plasma
membrane. This finding strongly suggests “hot spots” of receptor expression probably
reflecting “confined” CRH-R signalling networks in specific areas. These experiments
also showed significant intracellular staining for CRH-R, potentially indicated newly
synthesised unprocessed receptors, internalised mature CRH-R or cytoplasmic forms of
specific CRH-R variants (Figure 4.1A and 6.3C).
Moreover, in vitro studies in myometrial cells identified IL-1β, as a potential 
regulator of CRH-R1 gene transcription and splicing pattern. IL-1β, like many other 
pro-inflammatory cytokines, has been proposed to play important role in the onset of
labour and the pathogenesis of infection-induced preterm labour (Muhle RA et al.,
2001). My results confirmed that IL-1β induced PGHS-2 mRNA and protein expression 
is due to the activation of the NF-κB pathway (Figures 6.4-6.6, 6.9, 6.10, 6.12); but 
more importantly the data presented in this chapter suggest that IL-1β can potentially 
mediate CRH-R1 gene transcription and splicing mechanisms targeting the first splicing
step (exon 6, but not exon 13, of the CRH-R1 gene) (Figure 6.7). These interactions
appeared to involve two members of the MAPK family of proteins, ERK1/2 and p38
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MAPK (Figure 6.12). In a variety of cells these kinases exert their effects through
phosphorylation of p65 and modulation of the NF-κB transcriptional activity (Viatour P 
et al., 2005). NF-κB is a critical component of pathways mediating IL-1β-actions in 
human myometrium and other feto-maternal tissues (Soloff MS et al., 2004). Moreover,
increased p65 (RelA):p50 heterodimer DNA binding has been demonstrated in
labouring myometrium and it was linked with increased transcriptional activation to
specifically modulate changes in expression of genes critical for myometrial activation
and contraction (Chapman NR et al., 2004). My results point towards an important role
for NF-κB in IL-1β effects on CRH-R1 gene regulation and splicing. This is possible 
since the CRH-R1 promoter contains NF-κB recognition elements (Parham KL et al.,
2004). In my experimental design, I showed that, IL-1β action induced phosphorylation 
of IκBα through an IKK-mediated mechanism that releases p65 (RelA) and allows its 
translocation to the nucleus (Figures 6.9-6.11) (Lindstrom TM & Bennett PR, 2005;
Markovic D et al., 2007).
Surprisingly, increased CRH-R1 gene transcription and generation of receptor
splice variants was not associated with increased CRH-R protein levels (Figure 6.8) and
CRH signalling activity (Figure 6.13). On the contrary, prolonged exposure of cells to
IL-1β significantly impaired CRH-induced cAMP production, although the IL-1β pre-
treatment significantly augmented basal adenylyl cyclase activity, in agreement with
previous studies (Breuiller-Fouche M et al., 2005). It is likely that this is directly related
to repression of the myometrial Gαs gene by NF-κB that has been reported (Oger S et
al., 2002). The possibility that IL-1β pre-treatment might induce expression of 
signalling-deficient variants of CRH-R1 such as R1c and R1d was excluded by the real-
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time PCR experiments. Interestingly, the myometrial IL-1β/NF-κB and cAMP/PKA 
signalling pathways can interact at multiple levels; exposure of myometrial cells to IL-
1β results in a significant up-regulation of cAMP-phosphodiesterase 4 (PDE4) which is 
the predominant family of PDEs expressed in human myometrium (Breuiller-Fouche M
et al., 2005), through a mechanism involving PGE2 production and subsequent cAMP
augmentation. Also, myometrial p65 appears to be specifically associated with PKA
catalytic subunit (as well as IκBα) through an interaction that potentially involves the 
phosphorylation of p65 at serine-536 (Chapman NR et al., 2004). This association
might contributes to p65 inactive state until the cell is exposed to a p65 inducing stimuli
(e.g. IL1-β).  
One of the main actions of IL-1β in human myometrium involves the up-
regulation of PGHS-2 enzyme and increased production of prostaglandins such as PGE2
(Sooranna SR et al., 2005). The previous studies from our group have shown that short
(0.5-2hr) as well as prolonged (8-18hr) treatments with CRH can attenuate myometrial
PGE2 release and only the prolonged effect of CRH can be inhibited by co-incubation
with IL-1β (Grammatopoulos D & Hillhouse EW, 1999c). This coupled with the 
findings of the present study might suggest that IL-1β acts to diminish the CRH-induced 
cAMP response through modulation of CRH-R1 gene transcription and splicing, up-
regulation of PDE4 and/or down-regulation of Gsα, thus implicating the myometrial 
cAMP/PKA pathway in the inhibition of PGE2 synthesis and release.
In this part of my project I have provided conclusive evidence that the onset of
labour (pre-term or term) is associated with increased transcription of the myometrial
CRH-R1 gene and altered splicing events that down-regulate the pro-CRH-R1 mRNA
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encoding the R1β variant whilst up-regulating receptor variants such as CRH-R1d, 
downstream of CRH-R1α. This was confirmed in parallel experiments employing 
quantitative real time PCR by Dr. Mei Gu. Additionally, I have demonstrated that IL-1β 
appears to be one of the signals involved in the regulation of CRH-R1 gene, through a
pathway involving activation of NF-κB, the classical mediator of IL-1β intracellular 
events, as well as at least two members of the MAPK family of proteins, ERK1/2 and
p38MAPK. However, I have not been able to detect substantial changes on the CRH-R
protein levels following the IL-1β treatment. One possible explanation could be: 
because I used an antibody that recognises the C-termini of both types of CRH receptors,
R1 and R2, the possible changes in protein levels of different CRH-R1 variants could
not have been detected due to the antibody promiscuity. Another possibility is that the
changes of CRH-R1 variant mRNA levels are actually not reflected to the protein levels
(no translation). However, the most important evidence from this part of my project
was that IL-1β actions led to dampening of the CRH-induced cAMP response, an event 
that might contribute to the pro-contractile intracellular environment required for the
onset of labour. It is attractive to speculate that up-regulation of functional CRH-R1s
might lead to activation of alternative signalling cascades that might help in the
transition of the uterus from a state of quiescence to one of increased contractility and
active labour.
In the second part of this project, I focused my investigation on the identification
of signalling cascades activated by UCN-II, a CRH-R2 specific agonist. It has been
demonstrated that UCN-I acting via both types of CRH receptors, R1 and R2, can
potentially promote contractility via activation of ERK signalling cascade
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(Grammatopoulos DK et al., 2000), and that UCN-II activates MLC phosphorylation
via a pathways involving sequential activation of PKC, MEK1, ERK1/2, RhoA and
ROCK (RhoA associated kinase) (Karteris E et al., 2004). In agreement with these
observations, I have demonstrated that the activation of CRH-R2 did not lead to
production of cAMP (Figure 6.15), the main mediator of myometrial quiescence,
suggesting a potential dual role of CRH-Rs in the control of myometrial contractility.
Moreover, my data suggested that ERK1/2 and p38MAPK signalling cascades were
activated following UCN-II treatment. I particularly focused on ERK1/2 activation
since I have demonstrated that the transient activation of ERK1/2 in st293-R2β cells is 
characterised by nuclear localisation of the phospho-ERK1/2, which is of pivotal
importance for the role of ERK1/2 as a regulator of transcription factors activity. The
same spatio-temporal characteristics were detected in HMSM cells, suggesting that the
activation of endogenous CRH-R2 is important in gene transcription.
The small GTPase Rho have been reported to regulate many cellular functions
such as cell adhesion, cell contraction, cell migration and tumour cell invasion, growth
control and survival responses, phospholipids metabolism, MAP kinase activation and
gene transcription, endocytosis, exocytosis, glucose transport and ion channels
(Wettschureck N and Offermanns S, 2002). RhoA is the best characterized member of
Rho family. All members of the Rho family of proteins, like any other small GTPases,
function as molecular switches, cycling between an inactive GDP-bound state and an
active GTP-bound state (Somlyo AP and Somlyo AV, 2003). In the resting state,
RhoA-GDP exists in the cytosol tightly associated with its partner, GDP dissociation
inhibitor (RhoGDI). Activation of receptors coupled to certain trimeric G proteins such
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as Gαq, Gα12,13, and receptor tyrosine kinases lead, through activity of guanine
nucleotide exchange factors (GEFs), to the exchange of GDP for GTP on RhoA. This
causes RhoGDI dissociation and “free” RhoA-GTP translocation to the membrane
where it interacts with Rho-kinase (ROCK) to initiate a number of signalling events.
The GTP-bound form of RhoA is converted in the GDP-bound form due to its intrinsic
GTPase activity, which is stimulated by GTPase-activating proteins (Rho-GAPs).
My data suggested that the treatment of HMSM cells with CRH also led to a
small but significant increase in RhoA translocation, which was significantly less than
UCN-II-induced RhoA translocation, implicating CRH-R2 mediated phenomenon.
Interestingly, co-treatment of UCN-II stimulated cells with CRH attenuated UCN-II
effect on RhoA translocation to the plasma membrane, suggesting either desensitization
of CRH-R2 or a possible cross talk between the CRH-R1 and R2 receptors (Figure
6.17).
Since myometrial smooth muscle cells express both CRH-R1 and CRH-R2
receptor subtypes, I investigated each receptor subtype independently by using
HEK293 cells stably expressing CRH-R1α or CRH-R2β (st.293-R1α and st.293-R2β). 
HEK293 cells endogenously express RhoA and MLC, therefore, they are a suitable
model to study this system. Interestingly, treatment of st.293-R1α with CRH led to an 
80% decrease in RhoA translocation compared to basal. This effect could be mediated
by PKA. It has been demonstrated that A-kinase anchoring protein, AKAP-lbc (Ht-31)
functions as an adaptor protein to selectively couple Gα12 to RhoA (Diviani, D. et al.
2001). AKAP-lbc can function as a GEF for RhoA and thereby stimulate exchange of
GDP for GTP. The local production of cAMP activates anchored PKA, which
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phosphorylates a specific serine residue (ser1565) on AKAP-lbc, leading to the
recruitment of 14-3-3 peptide. The binding of 14-3-3 to the anchoring protein inhibits
its Rho-GEF activity, which prevents the activation of RhoA (Diviani, D. et al. 2004).
Furthermore, in st.293-R2β, CRH induced RhoA translocation to the plasma membrane 
by 10 fold. UCNII had a more dramatic effect on the translocation (more than 20 fold
increase) consistent with the higher affinity of CRH-R2β for UCNII. Interestingly, 
CRH pre-treatment of st.293-R2β reduced the UCNII effect by 35% (Figure 6.21). It is 
possible that desensitization of CRH-R2 by CRH can be accounted for the reduction of
UCNII effect. Another possibility is that CRH activation of CRH-R2 leads to
stimulation of RhoA-inhibitory proteins via a different mechanism as described above.
Figure 6.21. Agonist induced RhoA translocation to the plasma
membrane in st.293-R2β. Cells were stimulated with agonists for 5 min. The
plasma membrane fraction was separated from the cytosolic as described in
Material and Methods. The equal amount of proteins (5-10μg/lane) were 
separated by 12% SDS-PAGE and transferred to PVDF membrane. RhoA
imunoreactive band was detected as described in Methods.
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7 CHARACTERISATION OF CRH RECEPTORS SIGNALLING
AND BIOLOGICAL PROPERTIES IN BROWN ADIPOCYTES
7.1 INTRODUCTION
The critical function of CRH and UCNs in energy balance and homeostasis has
started to emerge. These peptides exert their effects through activation of two types of
CRH receptors, CRH-R1 and R2, leading to anorexia and attenuation of fasting-
induced feeding as well as increased energy expenditure through thermogenesis and
lipolysis (Spina M et al., 1996; Uehara Y et al., 1998; Kalra SP et al., 1999). Numerous
studies, primarily in vivo, demonstrated that CRH administration prevents excessive
body weight gain and stimulate sympathetic outflow, results in a decrease in basal
hyperinsulinemia, hepatic glycogen content, whilst increase brown adipose tissue (BAT)
activity (Arase K et al., 1988; Jerova D et al., 1999; Smith SR et al., 2001; Cullen MJ
et al., 2001; Tsigos C & Chrousos GP, 2002). CRH and UCNs increase BAT
thermogenesis (Rivest S et al., 1989), UCP-1 expression (Kotz CM et al., 2002), and
elevate sympathetic nerve activity to BAT (Egawa M et al., 1990a; Egawa M et al.,
1990b) in vivo. Studies investigating the role of CRH-R2 in the regulation of regional
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tissue thermogenesis and adaptive physiology using CRH-R2 knockout (KO) animal
models showed increased sympathetic nervous system (SNS) activity and basal
thermogenesis as well as elevated levels of UCP-1 in BAT. CRH-R2-mutant mice have
also smaller white and brown adipocytes indicating possible increased sympathetic tone
(Bale TL et al., 2003). These studies suggested an important role for CRH-R2 in
energy homeostasis and adaptive responses to environmental perturbations.
The appearance of BAT in early evolutionary developmental stages gave
mammals an advantage to survive and be active during periods of nocturnal or hibernal
cold and to survive the cold stress of birth (Cannon B & Nedergaard J, 2004). One of
functions of this highly specified organ is to transfer energy from food into heat, a
process known as thermogenesis. This adaptive thermogenesis is due to the action of
uncoupling protein-1, UCP-1, which functions as a mitochondrial proton translocator,
uncoupling β-oxidative phosphorylation and ATP production, resulting in heat release.  
It has been known for long time that the thermogenic process in brown
adipocytes can be mimicked by the addition of fatty acids, suggesting that lipolysis and
thermogenesis are linked processes. Indeed, all attempts to induce lipolysis in brown
adipocyes also induced thermogenesis, and no theromogenesis can be evoked without
simultaneously evoking lipolysis (Cannon B & Nedergaard J, 2004). Lipolysis is the
process of breaking down lipids which results in glycerol and fatty acids release. The
best known mechanism mediating lipolysis is the cAMP/PKA pathway. The activated
PKA catalyses phosphorylation of perilipin and hormone sensitive lipase (HSL),
leading to translocation of perilipin from the lipid droplets and HSL to the lipid
droplets, resulting in a breakdown of triglycerides and diglycerides and subsequent
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release of free fatty acids (FFA) and glycerol (Carmen G-Y & Vicror S-M, 2006). The
detailed of this pathway and involved proteins is given in the general introduction
(section 1.9).
Furthermore, brown adipocytes are also able to secrete leptin (Buyse M et al.,
2001) and other adipocytokines such as resistin and adiponectin, two adipocyte-specific
secretory factors involved in glucose and lipid metabolism (Viengchareun S et al.,
2002).
However, at the BAT level, neither the type of CRH-R expressed nor signalling
pathways employed by CRH and UCNs, in the regulation of physiological responses are
clearly characterized. To elucidate the biological properties of CRH-R and their
agonists in BAT, a brown adipocyte cell line was utilized (T37i). T37i cell line derived
from a hibernoma (malignant brown adipose tissue tumour) of the transgenic mouse
founder 37 carrying a hybrid gene composed of the human MR proximal promoter
fused to the SV40 large T antigen (Zannaro MC et al., 1998).
METHODS
7.1.1 Cell culture of T37i cells
The T37i cells were a generous gift from Dr. Lombes (Institut National de la
Santé et de la Recherche Médicale, Faculté de Médecine Xavier Bichat, Paris, France).
Cells were cultured in DMEM/F12 medium supplemented with 10% FBS, 2mM
glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin, and 15nM HEPES 
(containing 1g/l glucose) and were grown in at 37oC in a humidified atmosphere with
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5% CO2. Differentiation into adipocytes was achieved under standard conditions by
incubating subconfluent undifferentiated T37i cells with 2 nM triiodothyronine (T3) and
20 nM insulin for 8-12 days. Cell differentiation was monitored by examining cells for
lipid droplet formation under a light microscope, and staining cells with Oil Red O
(Sigma Aldrich Company Ltd (Gillingham, UK).
7.1.2 Oil Red O staining
The T37i cells grown on cover slips and differentiated for 0, 5 and 10 days, were
fixed in 4 % PFA for 10 min. The cells were washed with 60 % isopropanol and let to
dry. Oil Red O was added on cover slips for 10 min. The solution was removed and
slides were washed with distilled water. The slides were mounted and examined under
a light microscope.
7.1.3 MAPK phosphorylation assay and Western blot
For MAPK phosphorylation assays, cells were grown in 12-well plates. 18 h
prior to treatment, adipocytes were washed and kept in DMEM/F12 medium
supplemented with 0.5% fatty acids free BSA, 2 mM glutamine, 100 U/ml penicillin,
100 μg /ml streptomycin and 15 nM HEPES. Two hours prior to treatments, cells were 
washed and incubated in DMEM/F12 only. Cells were stimulated with various
concentrations of UCN-II and CRH (1-100 nM) for various time periods (0-60 minutes).
When inhibitors were used, cells were pretreated with 10 M U0126 for 40min, 1M
PKAi, 10M Ht31 peptide or 50M LY294002 for 30min prior to agonist stimulation.
At the end of the stimulation period, cells were washed with ice-cold PBS and lysed in
2x SDS-PAGE sample buffer. Solubulised material was collected, sonicated for 20sec,
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and boiled for further 5min. After a brief centrifugation step protein lysates were stored
at -20oC. Before electrophoresis, protein extracts were centrifuged at 4,000 rpm for 5
min to remove insoluble material and 15 l of the supernatant were loaded on 10%SDS-
PAGE gels. Gels were run at 200 V for approximately 1 h. Proteins were
electrophoretically transferred to PVDF membrane at 100 V for 1 h. After completion
of transfer, membranes were incubated with 8-10 ml Licor blocking buffer (LI-COR
Biosciences, Cambridge, UK) for 1 h at room temperature with gentle agitation. To
determine ERK1/2 phosphorylation, the membrane was incubated simultaneously with
the phospho-ERK1/2 (Thr202/Tyr204) antibody and total ERK2 antibody (dilutions
1:1500 and 1:2000, respectively) in 10 ml of Licor blocking buffer with gentle agitation
overnight at room temperature. The following day, membranes were washed 3 x 10
minutes with 15 ml TBS-T (TBS-0.1% Tween), before addition of secondary antibody
conjugated to a fluorescent entity: IRDye 800-conjugated goat anti-rabbit IgG and
Alexa Fluor680-conjugated goat anti-mouse IgG (dilution 1:6000) in 10 ml of Licor
blocking buffer with gentle agitation for 1 hour at room temperature. At the end of the
incubation period, membranes were washed twice with 15 ml of TBS-T, and once with
15 ml of TBS. The membrane was dried, visualized and analysed on the Odyssey
Infrared Imaging System (LI-COR Biosciences, Cambridge,UK).
To monitor p38MARK phosphorylation, membranes were incubated with Licor
buffer containing phospho-p38MAPK antibody (1:1000 dilution) with gentle agitation
overnight at 4oC. Following 3 washes with TBS-T, membranes were incubated with
goat anti-mouse Alexa®Fluor 680 conjugated IgG at 1:6000 in 10 ml of blocking buffer
with gentle agitation for 1 hour at room temperature. After visualization and analysis on
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the Odyssey Infrared Imaging System (LI-COR Biosciences, Cambridge,UK), the
membrane was striped with 25 mM glycine buffer pH2 containing 2% SDS, and
reprobed with total p38MAPK antibody (1:500 in Licor blocking buffer) with gentle
agitation overnight at room temperature.
7.1.4 CRH-R1/2 western blot analysis
10 μl of total proteins were separated on 10% SDS-PAGE. Following 
electrotransfer of proteins onto a nitrocellulose membrane, the non-specific binding
was blocked by incubating the membrane in 5% BSA in TBS-T for 1 h at room
temperature. After brief wash, the membrane was incubated with primary CRH-R1/2
(1:500) antibody in 1% BSA (in TBS-T) overnight at 4oC. Following three washes with
TBS-T the membrane was incubate with 1:5000 anti-goat antibodies (Pierce) in
1%BSA for 1h at room temperature. After two TBS-T and final PBS wash, the
immunoreactivity was detected by ECL. In some experiments prior to adding primary
CRH-R1/2 antibody to the membrane, the antibody was pre-absorbed by blocking
peptide (1:10 molar excess) overnight at 4oC.
7.1.5 cAMP assay
For cAMP assays, cells were grown and differentiated in 12 well plates. Media
was removed and cells were washed with DMEM/F12 and incubated in stimulation
buffer (DMEM/F12 containing 10 mM MgCl2 and 0.1 mg/ml 3-isobuthyl-1-
methyxanthine-IBMX) for 20 min at 37oC. Next, cells were washed with media and
stimulated with 0.1-1000nM UCN-II, CRH or 10M forskolin in stimulation buffer.
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The reaction was stopped after 15 minutes by adding 10 l of concentrated HCl. Cells
were scraped and following a brief centrifugation step stored at –20oC until assayed.
cAMP levels were determined by a commercially available ELISA Direct Cyclic AMP
kit (Assay Designs Ins., Ann Arbor, MI, USA).
7.1.6 Cell proliferation assay
Cell proliferation assay was performed on non-differentiated T37i cells grown in
96-well plate until 50% confluency. 18 h prior to stimulation the cells were kept in
DMEM/F12 containing 2% charcoal striped FBS and 2 h prior to treatment, cells were
deprived from FBS. Cells were treated with 1-100 nM UCNII or CRH for 24 and 48h.
Promega’s CellTiter 96® AQueous One Solution Cell Proliferation Assay was used to
determine cell proliferation. The assay was performed according to manufacturer’s
instructions. Briefly, 20 l of the supplied reagent was added directly to culture wells,
and incubated for 1-4 hours at 37oC. The absorbance was read at 490 nm. All
treatments were performed in quadruplets.
7.1.7 Confocal microscopy studies
T37i cells were grown and differentiated on aminopropylethoxysilane (APES)-
treated glass cover slips. To monitor ERK1/2 phosphorylation, serum-deprived cells
were treated with 100 nM UCNII for 0-30 min. Following a brief wash with ice-cold
PBS, the cells were fixed with 4% PFA (paraformaldehide) in PBS. After
permeabilization with PBS containing 0.01% Triton-x100 and 3% BSA, cells were
incubated with phospho-ERK1/2 antibody (dilution 1:100) overnight at room
temperature. Following 3 brief washes with PBS, slides were incubated for 1 h at room
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temperature with 1:400 anti-rabbit AlexaFluor®488. After 3 further washes with PBS,
slides were mounted with Slowfade gold antifade reagent with DAPI (Invitrogen,
Molecular Probes). For detection of CRH-R, perllilipin or HSL, fixed cells were
incubated overnight with appropriate antibody (dilution 1:100). The following day the
slides were washed and incubated with anti-goat Alexa Fluor®594. The specificity of
CRH-R1/2 antibody was demonstrated by preabsorbing the antibody with the blocking
peptide (1:10 molar ratio) overnight at 4oC, prior to adding the mixture to the
permeabilsed cells. The slides were mounted as described above. For dual
immunostaining of CRH-R1/2 and perilipin A, after the BSA-blocking step, slides were
incubated with perilipin A antibody (dilution 1:100) overnight at 4oC. Following three
washes with PBS, the slides were incubated with CRH-R1/2 antibody for 2 h at room
temperature. Next, slides were washed 3x with PBS, and incubated with donkey anti-
rabbit AlexaFluor®488 and donkey anti-goat AlexaFluor®594 (1:400). The slides are
mounted as described above. The slides were examined under an oil immersion
objective (63x) using a Leica DMRE laser scanning confocal microscope with TCS SP2
scan head (Leica Microsystems, Inc., Deerfield, IL). Laser 543 nm at 50% of power and
emission filter set at 555-620nm were used to examine AlexaFluor®594 staining, and
Laser 488 nm at 30% of power and emission filter set at 500-535nm was used to
examine AlexaFluor®488 staining. DAPI staining was examined with Laser 405 at 10%
of power and emission filter set at 410-450 nm. The scan speed was set at 400 Hz, and
the format was 1024x1024 pixels. For each treatment, between 10 and 15 individual
cells in three random fields of view were randomly selected and examined.
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7.1.8 Glycerol release assay
Differentiated T37i cells grown in 24-well plates were kept in DMEM/F12
containing 2% charcoal stripped FBS for 18 h. Cells were equilibrated in DMEM/F12
without phenol red for 2 h and then, pretreated with or without 1 M PKAi (30min) or
10M U0126 (40min). This was followed by stimulation for 1 or 2 h with 400 l of 1-
100 nM UCNII and CRH or 1 M isoproteranol (positive control). At the end of the
stimulation period, supernatants were collected and stored at –20oC until assayed. The
resulting cells were lysed in RIPA buffer and protein concentration was determined
using a BCATM Protein Assay Kit (Pierce, Rockford, IL, USA), in order to standardize
glycerol release. The released glycerol was measured in 30 l of supernatant using a
Randox glycerol kit (Randox. Laboratories, Co Antrim, UK), according to the
manufacturer’s instructions.
7.1.9 RNA extraction and RT-PCR
Total RNA from T37i cells was extracted by using GeneElute Mammalian Total
RNA Kit (Sigma), according to the manufacturer’s instructions. The purity and
concentration of total RNA was determined spectroscopically. 0.2-1 g RNA (1-3 l),
1.5 l random hexamers (Promega) and up to 16.5 l of molecular biology grade water,
were mixed and heated at 70oC for 5 min, and then allowed to return to room
temperature. Then, the RNA was centrifuged and the following mixture was added in: 3
l dNTP (10 mM), 6 l of 5 x buffer, 0.5 l AMV (25 u/l), 1.5 l RNasin and 2.5 l
water. For cDNA synthesis the mixture was heated to 37oC for 60 mins, 95oC for 5 mins
and 4oC for 5 mins. The resulting cDNA was stored at -20oC. CRH-R1 and CRH-R2
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PCR assays were performed as previously described (Brar BK et al., 2004). PCR for
UCP-1 and -actin were performed by using a Roche Light CyclerTM system (Roche
Molecular Biochemicals, Germany). The PCR reaction was carried in a 10 l reaction
mixture containing 5 l of PCR 2x Mastermix with 2 mM MgCl2, 0.5 l of Light Cycler
DNA Master SYBER®Green I, 1 l of each primer (2 ng/l), and 1 l of cDNA. The
PCR protocol consisted of a denaturation step at 95oC for 15 sec, followed by 40 cycles
of amplification at 95oC for 5sec, 58oC for 10sec, and 72oC for 15sec, and finally by a
melting curve analysis step at 95oC for 0 secs, 56oC for 15 secs and 99oC for 0 secs. The
UCP-1 forward primer sequence was: 5’-GGCCTCTACGACTCAGTCCA, and reverse
sequence was: 5’- TAAGCCGGC TGAGATCTTGT, with an amplified DNA fragment
of 87 bp. The -actin forward primer sequence was: 5’-
TGCGTGACATCAAAGAGAAG, and reverse was: 5’- GATGC CACAGGATTCCAT,
with an amplified DNA fragment of 197 bp.
Primary adipocytes were isolated from interscapular BAT depots using the
method of Rodbell (Rodbell M, 1964). Briefly, adipose tissue samples, 0.5-1.0 g, were
chopped finely and adipocytes isolated by collagenase digest (Hanks Balanced Salt
Solution [HBSS], containing 3 mg ml-1 collagenase [type II] and 1.5 % bovine serum
albumin) in a shaking water bath at 37 oC for up to 60 min. Mature adipocytes were
separated from the stromal vascular cells through an inert oil, Bis [3,5,5 trimethylhexyl]
phthalate (Fluka Chemicals, Gillingham, UK) according to the method of Gliemann
(Glienmann J et al., 1972). Total RNA was extracted using the Qiagen RNeasy™ Lipid
Tissue Mini Kit and reverse-transcribed into cDNA using 1 µg RNA and
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oligo(dT)B15B/random hexamers in equal concentrations as primers. The isolated RNA
from tissue was kindly provided by Dr Janet Digby.
7.2 RESULTS
7.2.1 Expression of CRH-R in brown adipocytes, T37i
In agreement with previous studies (Zannaro MC et al., 1998), preliminary
experiments confirmed that insulin and triiodothyronine (T3) treatment for more than 8
days induced T37i cells differentiation into mature brown adipocytes, and this was
accompanied by morphological and functional changes, such as accumulation of
multilocular intracytoplasmic lipid droplets, identified by Oil Red O staining (Figure 7.1)
and expression of UCP1 mRNA (Figure 7.2).
Figure 7.1. Differentiation of T37i fibroblast into adipocytes. T37i cells
were incubated with media containing 20 nM insulin and 2 nM T3 for 0-10
days. Cell differentiation was monitored by examining Oil Red O stained cells
for lipid droplet formation by a light microscope (40 x magnification) .
Day 0 Day 5 Day 10
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RT-PCR analysis showed that only differentiated cells and BAT expressed
UCP-1. Additionally both CRH-R1 and R2 mRNAs were expressed in undifferentiated
cells, T37i adipocytes and BAT (Figure 7.2).
Figure 7.2. RT-PCR analysis of CRH-Rs and UCP-1 mRNA expression.
Specific primers for CRH-R1, CRH-R2, UCP-1, and β-actin were used as 
described in methods. The PCR products were resolved on 1.2 % agarose gel,
purified and sequenced to confirm the authenticity of the products.
Furthermore, CRH-R proteins expression in T37i adipocytes was assessed by
indirect confocal microscopy and Western blotting. Western blot analysis identified
multiple bands between 64 and 115 kDa (Figure 7.3). These bands were not detected
when the antibody was preabsorbed with the blocking peptide prior to the incubation on
the membrane, demonstrating that the detection of multiple bands was not due to non-
specific interactions of the antibody and other proteins. The predicted molecular weight
of CRH-R protein is approximately 44 kDa. However, differential post-translational
glycosylation events might be responsible for the appearance of multiple bands and
increased molecular weight of the receptors in the T37i adipocytes (Figure 7.3).
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Additionally, it is possible that CRH-R could form dimmers (the band above 82 kDa) or
even trimers (the band above 115 kDa).
In confocal microscopy experiments, cells were also co-stained with the lipid
droplet-associated protein, perilipin, CRH-R1/2 and the nuclear stain DAPI. Results
showed a punctuate immunostaining pattern of CRH-R protein, which was not confined
to the cell membrane but was widely distributed in specific cytoplasmic areas (Figure
7.4). Interestingly, CRH-R-positive immunostaining was also found near the lipid
droplets as well as around the nucleus. No significant co-localization with perilipin was
observed, evident from the lack of any yellow colour in the overlap images.
No staining was detectable in cells in which the primary anti-CRH-R antibody
was omitted or when cells were preincubated with a specific CRH-R antibody-blocking
peptide (Figure 7.5).
Figure 7.3. Western blot analysis of CRH-R1/2 protein expression. Total
cellular proteins were resolved on 10 % SDS-PAGE, electrotransfered onto a
nitrocellulose membrane and incubated with CRH-R1/2 specific antibody (+:
preabsorbed with the blocking peptide or -: not preabsorbed with the blocking
peptide) as described in methods. The detection of immunoreactive band was
done using ECL reagent.
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Figure 7.4 Visualization of CRH-Rs and perilipin A in T37i adipocytes by
indirect confocal microscopy. Specific primary antibodies were used for
CRH-R and Alexa-Fluor®594 secondary antibody (red), and distribution of
perilipin A was monitored with antibody for perilipin A and Alexa-Fluor®488
secondary antibody (green). Cell nuclei were stained with the DNA specific
dye DAPI (blue). Identical results were obtained from three independent
experiments.
Figure 7.5 Validation of CRH-Rs immunoreactive in T37i adipocytes by
indirect confocal microscopy. Specific primary antibodies were used for
CRH-R1/2 perilipin overlap
CRH-R1/2
CRH-R1/2+blocking
peptide
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CRH-R and Alexa-Fluor®594 secondary antibody (red) in the presence or
absence of CRH-R blocking peptide (1 mM) as described in methods. Cell
nuclei were stained with the DNA specific dye DAPI (blue). Identical results
were obtained from three independent experiments (Markovic D et al., 2007).
7.2.2 Agonist induced cAMP production in T37i adipocytes
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Having established the presence of CRH-R in T37i cells, their functional and
signalling properties in response to CRH and the CRH-R2 specific agonist, UCN-II
were investigated. As mentioned in previous chapters, one of main signalling cascades
activated through CRH-Rs is the cAMP/PKA cascade. Exposure of differentiated T37i
cells to 0.1 or 1 nM CRH or UCN-II for 15min led to a significant increase in
intracellular cAMP levels in a dose-dependent manner (Figure 7.6). These low
concentration of agonists are close to the receptor binding affinity (Kd=1 nM). CRH
was significantly more potent that UCN-II in inducing cAMP accumulation (maximum
stimulation, 2.5 vs 0.9 fold above basal). Moreover, for both agonists the maximum
response was observed at a low concentrations of 0.1 and 1 nM and treatment of cells
with higher concentrations (10-1000 nM) resulted in small or insignificant changes in
cAMP levels. Interestingly, the higher doses of UCN-II (100 and 1000 nM) reduced
cAMP compared to the basal levels, suggesting possible coupling of CRH-R2 with Gi
protein or other pathways leading to inhibition of adenylyl cyclase activity (Figure 7.6).
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Figure 7.6. Agonist induced cAMP production in T37i adipocytes. Cells
were stimulated with various concentrations of CRH and UCN-II (0.1 to 1000
nM) for 15 min. The supernatant was collected as described in the methods
and cAMP amounts were determined by a commercially available ELISA kit.
7.2.3 Agonist induced MAPK activation in T37i adipocytes
Another pathway that was investigated was the mitogen-activated protein
kinases (MAPK) signalling cascades. I evaluated the functional coupling of CRH-R to
these cascades by determining the levels of phosphorylated ERK1/2 and p38MAPK in
response to CRH and UCN-II treatment. UCN-II induced a time- and concentration-
dependent increase in both ERK1/2 and p38MAPK phosphorylation. As seen in Figure
7.7, UCN-II effect on both ERK1/2 and p38MAPK activation was significant at
concentrations greater than 10nM and was maximal at concentrations of 100nM;
maximal ERK1/2 activation was 6 fold above basal levels, whereas maximal p38MAPK
activation was found to be 3.5-4 fold above basal. In addition, UCN-II induced ERK1/2
activation was transient and maximal stimulation was observed after 5min of treatment
and returned to near basal levels after 60 min of treatment (Figure 7.8). UCN-II effect
on p38MAPK phosphorylation showed a similar response with maximal stimulation
after 5min of treatment and return to basal levels after 30 min of treatment (Figure 7.8).
Interestingly, CRH exerted a weaker effect by 70-80% on ERK1/2 and p38MAPK
activation that reached a plateau at a concentration of 10nM (Figure 7.7).
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Figure 7.7. Agonist dose dependent MAPK activation in T37i adipocytes.
Cells were stimulated with various concentration of CRH and UCN-II (1-100
nM) for 5 min. ERK1/2 and p38MAPK phosphorylation was determined by
SDS-PAGE and immunoblotting as described in methods. Representative
Western blots are shown. Data represent the mean±SEM of three independent
experiments.
nM
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Figure 7.8. Time course of UCN-II induced MAPK activation in T37i
adipocytes. Cells were stimulated with 100 nM UCN-II for various time
periods (0-60 min). ERK1/2 and p38MAPK phosphorylation was determined
by SDS-PAGE and immunoblotting as described in methods. Representative
Western blots are shown. Data represent the mean±SEM of three independent
experiments.
To examine the spatial characteristics of ERK1/2 activation, indirect
immunofluorescence confocal microscopy was employed with phospho-specific
ERK1/2 antibodies, to monitor the relative subcellular distribution of activated MAPK
after agonist stimulation (Figure 7.9). In unstimulated T37i cells, low levels of activated
(phosphorylated) ERK1/2 were found. UCN-II treatment for 5-10 min led to rapid
increase in the amount of fluorescent signal for phospho-ERK1/2, indicating increased
activity of the kinase. Phospho-ERK1/2 immunoreactive signal was widespread
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throughout the intracellular space. Interestingly, the activation of ERK1/2 was not
consistent in all cells, in some of the cells the MAPK was not activated at all (Figure 7.9
5 and 10 min treatments). In agreement with the immunoblotting experiments
suggesting transient MAPK activation (Figure 7.8), prolonged treatment (15-30 min)
with UCN-II (100 nM), caused only a small increase in the amount of phospho-ERK1/2
reflecting deactivation of the signalling pathway (Figure 7.9).
Figure 7.9. Phospho-ERK1/2 MAPK subcellular distribution induced by
UCN-II in T37i adipocytes: visualization by confocal microscopy. Cells
were stimulated with or without UCN-II (100 nM) for various time intervals
(5–30 min). Phospho-ERK1/2 distribution was monitored over the ensuing
5 min
10 min
15 min
30 min
0 min
UCN-II
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time period by indirect immunofluorescence using specific primary antibodies
for phospho-ERK1/2 and Alexa-Fluor®488 secondary antibody (green) as
described in Method. Cell nuclei were stained with the DNA-specific dye
DAPI (blue). Identical results were obtained from two independent
experiments.
7.2.4 The involvement of PKA and PI(3)-kinase in UCN-II induced MAPK
activation
Further studies identified some of signalling molecules involved in CRH-R-
MAPK interactions. Previous studies have identified phosphatidylinositol 3-kinase,
PI(3)-kinase, as a crucial intermediate in UCN-II-induced MAPK activation (Brar BK et
al., 2004). Additionally in chapter 5, section 5.2.9, I have demonstrated that PI(3)-
kinase is involved in UCN-II induced ERK1/2 activation, but the inhibition of the
kinase did not effect UCN-II induced p38MAPK phosphorylation in st.293-R2β cells.   
The role of PI(3)-kinase in T37i adipocytes was determined by the use of a
specific PI3-K inhibitor LY294002. Pretreatment of T37i cells with LY294002 (50 μM) 
for 30 min significantly attenuated by 75% UCN-II induced ERK1/2 activation; in
contrast, UCN-II induced p38MAPK activation was augmented by 1.5 fold (Figure
7.10).
Potential cross-talk between the cAMP/PKA and MAPK signalling cascades was
also investigated by using a selective PKA inhibitor (PKA inhibitor 14-22 amide
myristoylated-PKAi) and st-Ht31 peptide which prevents binding between PKA
regulatory subunits and A-kinase anchoring proteins (AKAP). Results showed that basal
ERK1/2 and 38MAPK activity in brown adipocytes is under the negative regulation of
the PKA signalling cascade since pre-treatment with either PKAi or st-Ht31 enhanced
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phospho-ERK1/2 and 38MAPK levels by 50% and 40% respectively. In contrast, these
compounds had no effect on UCN-II induced ERK1/2 and 38MAPK phosphorylation
(Figure 7.10), which is expected, since 100 nM UCN-II fail to induce production cAMP,
the main regulator of PKA activity, in T37i adipocytes (Figure 7.6).
Figure 7.10. The role of PKA, AKAP and PI(3)-kinase on UCN-II induced
ERK1/2 and p38MAPK activation in T37i adipocytes. Cells were pretreated
with or without 1 μM PKAi, 10 μM Ht-31, or 50μM LY294002 for 30min 
prior to agonist stimulation and the effect on UCN-II (100 nM for 5 min)
stimulation on ERK1/2 and p38MAPK activation was determined, by
measuring ERK1/2 and p38MAPK phosphorylation as described in methods.
Results are expressed as arbitrary units with basal values, obtained from
control cells (no inhibitors) set as 1. Data represent the mean±SEM from three
independent experiments.
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7.2.5 Agonists induced proliferation of T37i fibroblasts
Given that one of the main biological functions of the MAPK cascade is to
promote cellular differentiation and proliferation, the role of CRH and UCN-II in T37i
fibroblasts proliferation was evaluated. Incubation of cells with UCN-II or CRH (1-
100nM) for 48h, but not 24h, significantly increased cell proliferation as assessed by the
number of viable cells; UCN-II was more potent of the two agonists used and increased
fibroblast proliferation by 50% in a dose-dependent manner (Figure 7.11), whereas
maximum CRH effect (30% increase compared to untreated) was observed at 10nM
CRH. Incubation with higher concentrations of CRH did not significantly alter this
effect (Figure 7.11).
Figure 7.11. Effect of CRH and UCN-II on T37i fibroblasts proliferation.
Cells were stimulated with various concentrations of CRH or UCN-II (1-100
nM) for 24 and 48 h. Cell proliferation was determined as described in
methods. Data represents the mean±SEM of 4 estimations from two
independent experiments.
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7.2.6 Agonist induced lipolysis in T37i adipocytes
The potential link between CRH and UCN-II induced cAMP production in
directly modulating lipolysis in T37i adipocytes was further investigated. To assess the
lipolysis rate in adipocytes in response to CRH, UCN-II or isoproteranol, which was
used as a positive control (Tebar F et al., 1996), glycerol release was measured. I
demonstrated that within 1h of isoproterenol treatment (1 μM), significant lipolysis was 
evident (Figure 7.12); this effect was time-dependent and 2h-treatment with
isoproterenol induced 2.5 fold more glycerol release. Similar results were obtained
when CRH or UCN-II were used as lipolysis-inducing agonists (Figure 7.12). Moreover,
CRH was significant more potent that UCN-II in inducing lipolysis, although both
CRH-R agonists were weaker than isoproterenol in inducing lipolysis. Analysis of the
dose-dependent characteristics of CRH/UCN-II-induced lipolysis revealed that
maximum effect was achieved at low (1nM) agonist concentrations and that the
lipolytic effect was diminished or abolished with higher (10-100nM) CRH or UCN-II
concentrations. Use of specific signalling molecule inhibitors (PKAi and U0126)
demonstrated that PKA, but not ERK1/2, was required for both CRH and UCN-II-
induced glycerol release and lipolysis (Figure 7.13).
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Figure 7.12. CRH and UCN-II induced lipolysis in T37i adipocytes. Cells
were stimulated with isoproterenol (1 μM) or various concentrations of CRH 
or UCN-II (1-100 nM) for 1 or 2 hours and released glycerol was determined
as described in methods. Data represents the mean±SEM of three estimation
from three independent experiments.
Figure 7.13. CRH and UCN-II induced lipolysis in T37i adipocytes is PKA
dependent. Cells were pretreated with 1 μM PKAi for 30min or 10 μM U0126 
for 40 min and then stimulated with isoproterenol (1 μM) or CRH or UCN-II 
(1 nM) for 2 hours and released glycerol was determined as described in
methods. Data represents the mean±SEM of three estimation from three
independent experiments.
7.2.7 The effect of CRH on perilipin and HSL translocation in T37i adipocytes
Lipolysis requires at least phosphorylation of perilipin and its translocation
from lipid droplets, and phosphorylation of HSL and translocation to the droplets. In
order to further dissect the lipolytic effect of CRH on T37i adipocytes, I investigated
the effect of 1 nM CRH on possible translocation of perilipin and HSL.
CHAPTER 7
306
Indirect confocal microscopy studies showed that prior to stimulation, perilipin
was distributed exclusively around lipid droplets, evident as a “full circle”
immunoreactive signal around the droplets. However, isoproterenol (1μM) or CRH 
(1nM) stimulation of the cells resulted in redistribution of perilipin signal from the
droplets to the cytoplasm. In addition, the perilipin signal on the droplet surface
became defuse and punctuated, suggesting redistribution of the protein. (Figure 7.14).
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Figure 7.14. Visualization of perilipin A/B distribution in T37i adipocytes by
indirect confocal microscopy. Cells were treated with 1 nM CRH or 1 μM 
isoproterenol for 15 min. Following fixation with 4 % PFA and blocking, the
specific primary antibodies were used for perilipin A/B and Alexa-Fluor®594
secondary antibody (red). Cell nuclei were stained with the DNA specific dye
DAPI (blue). Identical results were obtained from three independent experiments
basal
CRH 1 nM
iso 1 M
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The cellular distribution of HSL was also monitored by indirect confocal
microscopy. In unstimulated adipocytes, the protein was spread throughout the
cytoplasm and no staining around lipid droplets was detected. Following isoproterenol
or CRH stimulation the punctuated staining appeared around the droplets, suggesting
the translocation of HSL to the site of lipolysis (Figure 7.15).
Figure 7.15. Visualization of HSL distribution in T37i adipocytes by
indirect confocal microscopy. Cells were treated with 1 nM CRH or 1 μM 
isoproterenol for 15 min. Following fixation with 4 % PFA and blocking, the
specific primary antibodies were used for HSL and Alexa-Fluor®594
secondary antibody (red). Cell nuclei were stained with the DNA specific dye
basal
CRH 1 nM
iso 1 M
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DAPI (blue). Identical results were obtained from three independent
experiments.
In addition, western blot analysis also suggests that 15 minutes treatment with 1
nM CRH leads to phosphorylation of HSL at the Ser-563 (Figure 7.16). This residue as
well as Ser-660 are the residues primarily targeted by PKA mediated phosphorylation
and lead to the activation of HSL, and further lipolysis.
Figure 7.16. CRH induced HSL phosphorylation. Cells were stimulated
with 1 nM CRH or 1μM isoproterenol for 15min. The HSL phosphorylation on 
Ser-563 was determined by SDS-PAGE and immunoblotting using an
antibody that specifically recognizes phosphorylation event on this residue.
This experiment was performed once in duplicates and the representative
Western blot is shown.
7.3 DISCUSSION
CRH and UCNs are potent regulators of mammalian thermogenesis and their
effects on BAT have been primarily attributed to modulation of brain centres
controlling sympathetic outflow; however potentially direct effects of CRH and UCNs’
on brown adipocytes have not been investigated. In this part of my project, I
p-HSL (Ser-563)
Basal CRH (1 nM) iso (1 M)
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demonstrated for the first time that the T37i cell line, a cellular model for BAT,
expresses functional CRH-R that can influence lipolytic and other biological properties
through activation of multiple signalling cascades.
The expression of both CRH-R1 and R2 receptor mRNA in brown adipocytes
and BAT (Figure 7.2), suggests the presence of a wide receptor network that potentially
can respond to multiple agonists and modulate diverse biological functions.
Interestingly, using indirect confocal microscopy I have shown that the CRH-R
receptors are not uniformly distributed over the entire cell membrane, and their
subcellular localization is not restricted to the plasma membrane, as one might expect
from GPCR. Immunoflourescent confocal microscopy experiments showed a
punctuated pattern of extensive staining in the cytoplasm and around the nucleus
potentially indicative of newly synthesised unprocessed receptors, internalised mature
CRH-R or “cytoplasmic” forms of specific CRH-R variants (Figure 7.4).
A more detailed study employing different experimental approaches would be
appropriate to determine the real nature of the CRH-R localisation in these model cells.
The use of inhibitors of protein synthesis such is cycloheximide, would demonstrated if
perinuclear staining was indeed from newly synthesised CRH-Rs. Additionally, co-
staining and potential co-localisation of CRH-R with protein markers of various cellular
compartments would reveal the intracellular localisation of the receptor. The possibility
of constitutive CRH-R endocytosis, could be addressed by knocking down β-arrestins 
(as demonstrated in previous chapters, the internalization of both CRH-R1 and R2
requires the recruitment of β-arrestin to the plasma membrane), overexpressing 
dominant negative dynamin (K44A) which would inhibit clathrin mediated endocytosis,
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or using chemical inhibitors of internalisation such is ConconovalinA. All these three
agents would block any constitutive receptor endocytosis and keep it trapped within the
lipid bilayar of plasma membrane, which would result in increased CRH-R signal on the
membrane.
The possibility that the cytoplasmic staining comes from the soluble forms of
the CRH-Rs would be more difficult to assess because of a lack of splice variant
specific antibodies. The specific silencing of certain types of the receptors would be
possible with a careful consideration of the siRNA sequences, but a validation of
silencing on the protein levels would be impossible, at least at this moment.
One of the most interesting features of CRH-Rs is their ability to activate diverse
G-protein dependent and independent signalling pathways (Collins S et al., 2004;
Hillhouse EW & Grammatopoulos DK, 2006). My results demonstrated that in T37i
adipocytes similarly to other cellular systems, CRH-R activation leads to downstream
activation of at least two signalling cascades: the adenylyl cyclase/cAMP and the
MAPK (ERK1/2 and p38MAPK) cascades (Hillhouse EW & Grammatopoulos DK,
2006).
These results also showed that CRH-R signalling characteristics exhibit another
interesting feature not previously described: agonist concentration-dependent selectivity
of the activated signalling pathway. At low agonist concentrations (close to the receptor
binding affinity-Kd) intracellular cAMP levels are increased whereas high
concentrations prevent cAMP increase (Figure 7.6) and instead induce transient ERK1/2
and p38MAPK activation that appears to modulate primarily cytoplasmic targets
(Figure 7.7-7.9). The precise nature of the molecular mechanisms mediating this
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signalling “switch” are unknown. Given that previous studies reviewed in Hillhouse and
Grammatopoulos, 2006, have shown the potential of the receptor to activate Gi-proteins,
one can hypothesise that agonist concentrations sufficient to induce substantial CRH-R-
Gi-protein coupling might lead to inhibition of adenylyl cyclase activity and
simultaneous MAPK phosphorylation through Gi-, Gq- or other pathways. This could
be tested in future studies by implemented techniques for GPCR coupling to G-proteins.
Additionally, use of siRNA to knock down individual G-proteins or dominant negative
G-protein constructs would be an intriguing way to dissect CRH-R promiscuous
signalling properties.
In addition, the relative potencies of the CRH-R agonist tested could suggest
that the CRH-R1 is primarily responsible for cAMP production, whereas the CRH-R2 is
more efficiently linked to the MAPK pathway. An experiment utilising specific CRH-R
antagonists (Anti-Sauvagine-30 which is a CRH-R2 specific antagonist and NBI-27914,
a CRH-R1 specific antagonist) did not clarify the relative contribution of each CRH-R
subtype (Figure 7.17). The addition of the antagonists alone led to a significant increase
of cAMP production in the resting T37i adipocytes. The CRH treatment did not alter
already elevated cAMP levels. Interestingly, the identical results were obtained no
matter which of the antagonist was used, implaying equal affinities of the receptors for
CRH, which is not the case. This raises an issue of the antagonist specificity. The most
specific CRH-R1 antagonist, NBI-34041 which has been tested in clinical trials, is not
commercially available. An alternative way to avoid dealing with a problem of the
antagonist specificity is to silence the specific type of the CRH receptors, R1 or R2.
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 In mature brown adipocytes, norepinephrine interaction with β3-adrenergic 
receptor activates the adenylyl cyclase/cAMP cascade leading to activation of PKA and
consequent lipolysis (Cannon B & Nedergarrd J, 2004). Perilipin, a protein located on
the lipid droplets, is phosphorylated by PKA and translocates from the droplets. At the
same time HSL protein translocates from a cytoplasmic compartments to its site of
action, the lipid droplets (Egan JJ et al., 1992; Clifford GM et al., 2000). I have
provided evidence that both CRH and UCN-II appear to induce lipolysis in T37i
adipocytes through a PKA-dependent mechanism (Figure 7.12 and 7.13). The agonist
concentration appeared to be one of the main determinants of lipolysis induction;
however, at present the precise reason for this in not known. It is possible that this tight
regulation of lipolysis does not allow uncontrolled lipolysis and thermogenesis in
conditions of excess CRH secretion such as in response to stressful stimuli. Additionally,
the stimulation of T37i adipocytes with 1 nM CRH led to significant translocation of
perilipin from and HSL towards the lipid droplets as demonstrated by indirect confocal
microscopy (Figure 7.14 and 7.15).
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Figure 7.17. cAMP production in T37i adipocytes. Cells were stimulated
with 1 nM CRH or 1 μM isoproterenol for 15 min in the presence or absence 
of 1 μM anti-sauvagine30 (A-S-30) or 100 nM NBI-27914 (NBI) . The 
supernatant was collected as described in the methods and cAMP amounts
were determined by a commercially available ELISA kit.
Although, an accessory role of the ERK1/2 pathway has been linked to lipolysis
(Greenberg AS et al., 2001) in adipocytes, CRH-R-induced lipolysis appears to be
ERK1/2 independent since it occurs at low concentrations of the agonists, considerably
less than the concentrations required for MAPK activation.
It has been demonstrated that activation of ERK1/2 is important in cell
proliferation and differentiation (Chang L & Karin M, 2001). It would be of interest that
future studies determine the potency of CRH and UCN-II on MAPK activation during
different stages of the cell differentiation. During the course of this study, most
experiments were performed on cells composed of 85-90% adipocytes and 10-15%
fibroblasts, however the proliferation assay was performed on T37i fibroblasts. It was
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demonstrated that CRH and UCN-II were potent proliferatory agents, most likely via
activation of MAPK signalling cascade.
The data on the signalling pathways involved in T37i adipocytes CRH-R2-
MAPK interactions suggest a critical role of PI(3)-kinase, a signalling molecule
previously identified as important for CRH-R2-stimulated thermogenesis in skeletal
muscle (Solinas G et al., 2006). Use of a specific inhibitor showed that PI(3)-kinase is
involved in selective activation of ERK1/2 in T37i adipocytes. Another interesting
feature of the CRH-R2-MAPK interactions in T37i cells is that it occurs independently
of the cAMP/PKA and AKAP pathway, at the tested concentration of agonist (100 nM),
since the specific pathway inhibitors failed to alter UCN-II stimulated ERK1/2 or
p38MAPK phosphorylation, although some inhibition was seen on basal activity. For
agonist induced MAPK activation this is not surprising since the ERK1/2 and
p38MAPK activation occurs at agonist concentration that are unable to induce cAMP
production (Figure 7.10).
In summary, I have demonstrated for the first time that CRH and UCN-II can
exert direct effects in brown adipocytes to induce lipolysis, and subsequent
thermogenesis. This effect is mediated through the cAMP/PKA cascade, and involves
phosphorylation and translocation of perilipin and HSL.
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8 CONCLUSION
Beside its traditional role as an activator of the HPA axis and a coordinator of
autonomic, behavioural, emotional, immune, and cognitive responses to stress,
corticortopin releasing hormone (CRH) and the related peptides (UCN-I, UCN-II and
UCN-III) have been implicated in mediating diverse peripheral functions (i.e. in
reproduction, cancer biology, metabolism and energy homeostasis). The regulation of
these various central and peripheral functions is mediated via activation of one or both
CRH receptors, R1 and R2. In many tissues, endogenously expressing CRH-R
stimulation of the receptor by CRH or CRH-related peptides leads to the activation of
adenylyl cyclase (AC) and increases cAMP levels. However, others signalling cascades
such is MAPK signalling pathway, are also targeted by CRH-R activation. The distinct
response of CRH-R activation has been attributed to differential and multiple G-protein
activation. The peripheral expression of CRH-R1 and R2 exhibits a species dependent
pattern with R2 receptor as the main functional receptor in animal peripheral tissues,
most peripheral human tissues express both types of CRH receptors, indicating higher
levels of complexity and more subtle roles for CRH and UCNs in human physiology. I
CONCLUSION
307
have demonstrated that although bearing 70% sequence homology, the CRH-R1 and
R2 receptors have different desensitization, internalization and signalling
characteristics. Desensitization of CRH-R2 is remarkably different from the response
of the CRH-R1α, which requires CRH treatment for 2-3 h to achieve a similar level of 
desensitization as CRH-R2β after just 15 min. This might reflect distinct requirements 
of the two CRH-Rs signal propagation in mammalian pathophysiology. Moreover, this
could be of pivotal importance in physiological conditions accompanied by the changes
in receptors expression pattern (i.e. in uterus during pregnancy). In addition, the co-
expression studies I have provided evidence that the co-expression of CRH-R1d does
have an effect on UCN-II induced CRH-R2β activation. This is of potential importance 
in understanding how the action of urocortins via activation of CRH-R2 are controlled
in peripheral tissues, such are skin, muscle, adipose tissue, that express both types of
receptors.
Tissue sensitivity to agonists is determined by the availability of receptor in the
plasma membrane. The immunofluorescence studies investigating the cellular
expression of CRH-R1 variants have provided novel evidence that in HEK293 over-
expressing CRH-R1α and R1β, the receptor protein is localised in the plasma 
membrane, while another splice variant CRH-R1d is primarily expressed
intracellularly.
The mechanisms regulating CRH-R1 alternative splicing are largely unknown.
In vitro studies in myometrial cells identified IL-1β, a pro-inflammatory cytokines 
implicated in the onset of labour and the pathogenesis of infection-induced preterm
labour, as a potential regulator of CRH-R1 gene transcription and splicing pattern.
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However, increased CRH-R1 gene transcription and generation of receptor splice
variants was not associated with increased CRH-R protein levels and CRH signalling
activity, implicating a complex regulation of CRH biological action.
CRH and UCNs are potent regulators of mammalian thermogenesis and their
effects on BAT have been primarily attributed to modulation of brain centers
controlling sympathetic outflow; however direct effects of CRH and UCNs on brown
adipocytes have not been investigated. During the course of this study I demonstrated
that both types of CRH-Rs are expressed in mice BAT and T37i cells. CRH-R
activation led to downstream activation of at least two signalling cascades: the adenylyl
cyclase/cAMP/PKA and the MAPK (ERK1/2 and p38MAPK) cascades. CRH mediated
activation of PKA led to lipolysis in adipocytes; on the other hand, UCN-II stimulation
of T37i preadipocytes led to increased proliferation. The relative potencies of the CRH-
R agonist tested could suggest that the CRH-R1 is primarily responsible for cAMP
production, whereas the CRH-R2 is more efficiently linked to the MAPK pathway. It
would be intriguing to determine if CRH-Rs are expressed and functional in human
infant BAT, and to investigate potential link between increased maternal CRH levels
and newborn BAT activity.
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